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My PhD research plan concerns the exploration of the structural requirements 
determining TRPM8 modulation. We prepared a series of N-substituted 
tryptamines and identified two compounds acting, respectively, as an activator 
(21) or an inhibitor (12) of calcium influx in HEK293 cells. To develop more 
potent and selective derivatives we designed and synthetized new series of 
potential tetrahydroisoquinoline- and tetrahydro-β-carboline-based TRPM8 
modulators. The synthetic approach used for the preparation of these compounds 
led to indole-fused aminoacetal derivatives. Optimization of reaction conditions 
allow us to obtain ring-fused aminals, which could be useful for preparing 
analogues of biologically active natural and synthetic products. 
At the same time I worked on the synthesis of potential varicella zoster virus 
replication inhibitors: tryptamine derivative 17a was found to have a selective 
activity against this herpesvirus family member. A second part of my PhD was 
dedicated to the identification of small heterocyclic compounds as GRK2 
inhibitors. 
Lastly, I spent an abroad semester in the University of Graz, where I collaborated 
to the development of a continuous flow difluoromethylation protocol employing 
fluoroform as reagent. The protocol is applicable for the direct Cα-
difluoromethylation of protected α-amino acids, and enables a highly atom 


































1.1 Introduction: TRP, an overview  
Transient receptor potential channels (TRP) play critical roles in the responses to 
all major classes of external stimuli, including light, sound, chemicals, 
temperature, and touch. TRP channels also imbue individual cells with the ability 
to sense changes in the local environment, such as alterations in osmolarity. 
Voltage and pH interact allosterically with temperature to activate the channel.
1
 
TRP genes were first described in the fruit fly Drosophila melanogaster. In some 
of these flies, prolonged exposure to light induced transient photoreceptor 
depolarisation, whereas in the wild type the response was sustained. This 
difference was attributed to mutant TRP gene expression. Genetic ablation studies 
in worms, flies and mice indicate that TRPs serve as sensors to elicit responses to 
a variety of stimuli, ranging from temperature, osmotic pressure, olfaction, taste, 
mechanical stress, light and injury-induced inflammation mediating pain.
2 
Currently, more than 100 TRP genes have been identified in various animals 
(Table 1). Human TRP genes are diverse in length and range between 11.4 and 
about 911 kb. The overall protein sequence homology between subfamily 
























TRPC 3 3 8 8 8 7 6 
TRPV 3 5 2 4 4 6 6 
TRPM 1 4 2 6 6 8 8 
TRPA 4 2 4 1 2 1 1 
TRPN 1 1 1 - 1 - - 
TRPML 4 1 9 2 2 3 3 
TRPP 1 1 1 4 4 3 3 
Total 17 17 27 25 27 28 27 
aTRP channel in the fruit fly Drosophila melanogaster, the worm Caenorhabditis elegans, the sea squirt 
Ciona intestinalis, the puffer fish Fugu rubripes, the zebrafish Danio rerio, mouse and human. The numbers 
correspond to proteins with distinct channel properties within each subfamilies. 
3 
 
Based on protein homology, members of the TRP channel family can be seen to 
fall into seven subfamilies: TRPC, TRPV, TRPM, TRPA, TRPP, TRPML e 
TRPN. The number of channels within each subfamily varies across species 
(Figure 1), while the transmembrane segments tend to share the greatest homology 







Figure 1. TRP subfamilies. (Adapted from Nilius et al., 
2011). 
 
The TRPV, TRPM, TRPA, and TRPN subfamilies are so called based on the 
original name of the initially described member of each subfamily. TRPVs 
(‘vanilloid’) are named after a founding member vanilloid receptor 1 (now 
TRPV1). The TRPM subfamily groups, with eight members (TRPM1–8), named 
after the original member, melastatin (now TRPM1). All members of the TRPA 
subfamily are nociceptive channels characterized by the presence of about 14 
ankyrin repeats. The TRPN subfamily is named after the ‘NO-mechano-potential 
C’ (NOMP-C) channel of Caenor-habditis elegans. The TRPC subfamily 
(‘canonical’) comprises closest homologs of Drosophila TRP channels. TRPMLs 
and TRPPs include mucolipins and polycystins, respectively. The structure of the 
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integral channel endows the receptor with its characteristic nonselective cationic 
behavior and also potentially defines the outwardly rectifyingcurrent-voltage 
profile noted for many of these channels.
5
  
All members of TRP family share a similar molecular architecture, most likely 
consisting of a symmetrical arrangement of four subunits, each of six 
transmembrane-spanning domains (TM1–TM6) and cytosolic N- and C-terminal 
tails that tetramerize to form a functional channel. TM5, TM6 and the connecting 
pore loop form the central cation-conducting pore, whereas TM1–TM4 and the 
cytoplasmic N- and C-terminal parts are thought to contain the regulatory 
domains that control channel gating.
6
 
Compared with the six TM channels, TRP channels can have extremely long 
cytoplasmic N- and C-terminal tails containing several regulatory modules and, as 
in TRPM2, TRPM6 and TRPM7, can even contain entire functional enzymes. The 





Figure 2. TRP channel.  
 
The heat-activated TRPV1 was first among a group of eight temperature-activated 
TRP ion channels called thermoTRPs (Figure 3). TRPV1 could be activated by 
elevated temperatures with a discrete threshold near 43°C.
8
 Three other TRPV 
channels TRPV2 (also known as VRL-1), TRPV3, and TRPV4 (also known as 
5 
 
VROAC or OTRPC4) have been cloned and characterized as heat or warm 
thermosensors.
7-9
 In addition, two TRPM channels (TRPM4 and TRPM5) have 
been recently reported to be thermosensitive.
10
 The threshold temperatures for the 
activation of these channels range from relatively warm (TRPV3, TRPV4, 
TRPM4, and TRPM5) to extremely hot (TRPV2). In contrast to these warmth- or 
heat-activated TRP channels, two other TRP channels TRPM8 and TRPA1 are 
activated by cold stimuli. All eight, when expressed in native cells (human 
embryonic kidney cells, chinese hamster ovary cells, Xenopus oocytes) have the 
property of rendering the cells temperature sensitive. Each one has unique 
characteristics, highlighted by distinct temperature thresholds of activation. 
Sensitization or desensitization to repeated thermal stimuli and the ability to be 

















1.2 TRPM8: features, structure and localization 
Transient receptor potential melastatin type 8 (TRPM8) is a non-selective Ca
2+
 
permeable channel, that behaves as a polymodal receptor and exhibits highly 
complicated gating behavior that is regulated by a variety of factors.
3
 It has been 
demonstrated that cool temperature opens TRPM8 channels localized on the 
membranes of somatic sensory nerves, causing sensory nerve excitation. TRPM8 
was the first cold-activated ion channel to be identified and it established the 
general role for TRP ion channels in thermosensation. When expressed on 
heterologous cell systems, cooling temperatures below 24–28°C start to evoke 
depolarizing currents. TRPM8-mediated currents increase with decreasing 
temperatures and reach maximum currents near 10°C.
5
  
Electrophysiological studies have indicated that TRPM8 activation results in a 
large increase of intracellular Ca
2+
 levels through both Ca
2+ 
entry from 
extracellular sites and Ca
2+
 release from intracellular Ca
2+
 stores. TRPM8 is 




The human TRPM8 polypeptide consists of 1104 amino acids.
14
 The channel is 
formed by four identical subunits. Each subunit shows 6 transmembrane domains 
(S1-S6) that surround the central pore, with S5 and S6 forming the gate and 
selective filter, while the S1–S4 transmembrane domains exhibit weak voltage-
sensing properties. The N- and C-terminal domains are in the cytoplasmic side.
15
 
The C-terminal domain, which confers temperature sensitivity on TRPM8, 
appears involved in tetramer stabilization since some mutations within the coiled 
region of C-terminus (978–1104) markedly reduce the ability of the TRPM8 
monomers to form oligomeric channels. Single-point mutation in this region, Leu-
1089 into Pro, disrupts this interaction and reduces oligomerization and surface 
expression of TRPM8, without affecting total protein. The "TRP box", in common 
with all the TRP family members, and a binding site for phosphatidylinositol 4,5-
bisphosphate, are located in this C-terminal tail. Functional TRPM8 channels 
require the presence of the C-terminal as well as the region compromised between 
amino acids 40 to 86 of the N-terminal which are essential for the localization to 
the plasma membrane.
16
 On the other hand, N-terminus should not play a 
7 
 
significant role in tetramerization since the analysis of deletion mutants shows 
that the transmembrane domain is sufficient for TRPM8 assembly into tetramers 
(Figure 4).
17
   
The protein shows 8 putative glycosylation sites and an immunogenic epitope that 
will facilitate the future design of peptide vaccination.
16
 
The first four helices (S1–S4) constitute the voltage sensor module and include 
the binding sites for activators as menthol and icilin, although they do not fully 
overlap, since most residues involved in menthol recognition are located in S2, 
whereas icilin interacts also with residues of S3.
18
  
The last two TM helices (S5–S6) constitute the pore module, which is 
characterized by a highly conserved hydrophobic region and a conserved aspartate 
residue, whose neutralization results in a non-functional channel. Moreover, the 
S6 helix is responsible for the ion selectivity of TRPM8 since the introduction of 







Figure 4. Schematic representation of TRPM8 protein. 




TRPM8 is expressed mainly in a subpopulation of primary afferent neurons from 
both, dorsal root and trigeminal ganglia, and in the nodose and geniculate ganglia 
in the peripheral nervous system. The protein has been also identified in prostate 
and genitourinary tract, bladder, sperm, vascular smooth muscle, liver, lung and 
odontoblasts. Moreover the channel is expressed in the plasma membrane, in the 




1.3 TRPM8: physiopathological role 
 
1.3.1 TRPM8 and cancer 
The role of TRP channels in cancer is highly heterogeneous, ranging from the 
control of Ca
2+
 homeostasis to regulation of tumourigenic and metastatic events. 
Tumour progression can be generally associated with misregulation of either one 
or more TRP channels. 
TRPM8 is overexpressed in many prostate, breast, colon, lung and skin cancers,
21
 
and this behaviour makes it an attractive target for cancer modulation.
22
 




Several studies suggest that TRPM8 expression is regulated by androgens, thus 
the channel levels  decrease when prostate cancer cells become androgen-
independent. This has been confirmed in recent more direct experiments which 
reported androgen-dependent TRPM8 expression in the androgen-responsive 
LNCaP (androgen-sensitive human prostate adenocarcinoma cells) cell line, but 
not in the androgen-unresponsive PC-3 cell line.
25
  
It has been recognized that the androgen receptor (AR)2 protein is an important 
transcription factor for TRPM8 expression in prostate cells.
26
 In general, 
androgens are important regulators of reproductive organs and are also involved 
in the pathogenesis of prostate cancer, including progression and metastasis.
27
 An 
intensive colocalization pattern of the TRPM8 protein with endogenous androgens 
in human prostate tissues obtained from healthy individuals and patients with 
prostate cancer at various stages of the disease, as well as in cultured cells, was 
9 
 
detected, suggesting possible interactions. Co-immunoprecipitation experiments 
performed using cultured prostate epithelial cells, prostate cancer cells, and HEK-
293 cells stably expressing TRPM8 further confirmed direct binding of the steroid 
hormone, testosterone, to the TRPM8 protein, suggesting that testosterone-
induced TRPM8 could be an important regulator of Ca
2+
 homeostasis in prostate 
cells. In this view, TRPM8 would be an important channel to control cell cycling, 
including growth, proliferation, and apoptosis and down-regulation of plasma 
membrane TRPM8 activity could have an impact on cancer development.
28
 
1.3.2 TRPM8 and  pain 
The use of cooling to produce analgesia is described since Hippocrates and 
Galen.
29
 Preparations containing menthol, which produces a cool sensation, are 
used topically to relieve neuralgia in traditional chinese and european medicine.
30
 
Several clinical trials show beneficial effects of cooling on chronic back pain, 
dental pain, postoperative pain, and muscle injuries but no definitive mechanism 
has been established for cool-induced analgesia.
31 
All these data greatly promote 
the progress in exploring the relationship between temperature and pain. 
TRPM8 seems the best candidate for being the mediator of cooling-induced 
analgesia. Mouse knockout studies have revealed that TRPM8 is required for cold 
sensation over a broad range of innocuous and noxious cold temperatures.
32
 A 
central spinal mechanism of analgesia is suggested, because cutaneous cooling 
can prevent pain produced by afferent stimulation. In addition several studies 
demonstrated marked analgesic effects of peripherally or centrally applied 
TRPM8 activators (such as icilin or menthol), or mild cooling of the skin, in a 
model of neuropathic pain.  The channel response to agonists depends on their 
concentration, as low doses of menthol induce a sensation of cooling and 
analgesia in inflammatory and neuropathic pain models. Much higher doses of 
menthol induce a noxious cold sensation, although it is not clear if TRPM8 is 
specifically being targeted at such doses.
29b
 
An increased expression of these channels or an alteration in their functional 
properties could lead to the lower thresholds for cold pain and increased 
sensitivity to cold seen in neuropathic pain states.
33
 Moreover several studies have 
10 
 
shown that levels of TRPM8 protein and RNA were both increased in rats with 
chronic neuropathic pain. In addition, inflammatory factors such as H+,
34
 
bradykinin and phospholipase  can affect the activation of TRPM8. 
35,36
 Several 
studies also showed that TRPM8 plays a role in amplifying pain sensation after 
injury, especially in models of neuropathic pain. Whereas hypersensitivity to cold 
is a common feature of individuals with neuropathies, these data suggest that 




1.3.3 TRPM8 in overactive bladder and painful bladder syndrome 
TRPM8 is widely expressed in the urothelium and suburothelial sensory fiber and 
seems to be implicated in the bladder cooling reflex.
38,39
 The expression of 
TRPM8 is consistent with a role in the initiation of pain or the micturition reflex, 
with message being concentrated in the urothelium lining the bladder as well as in 
the dorsal root ganglia (DRG). Studies in a variety of animal models have shown 
that either cold or intravesical menthol induced micturition or increase bladder 
contraction frequency in a spontaneously contracting bladder.
40
 
Recent studies showed that the density of TRPM8 channels is elevated in bladder 
afferent nerve fibers of overactive bladder syndrome (OAB) patients, with an even 
higher density in patients with bladder pain. The positive correlation between the 
density of TRPM8 in the bladder mucosa and increased TRPM8 expression in 
patients with bladder pain, led to the suggestion that this channel was involved in 
the symptomatology and pathophysiology of these disorders.
41
 These observations 
suggest that a blocker of the TRPM8 channel could be effective for treatment of 










1.4 TRPM8 modulation 
 
1.4.1 TRPM8 activators 
The activity of TRPM8 was shown to depend on a variety of stimuli.  
Phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] in cellular systems activates 
this channel through interactions with positively charged residues in the 
cytoplasmic tails.
42
 In addition, several studies has examined the role of 
phospholipase A2 (PLA2) in the activation of TRPM8. All PLA2 enzymes 
hydrolyze the sn-2 ester of glycerophospholipids to release a free polyunsaturated 
fatty acid (PUFA) and a lysophospholipid (LPL). Two main groups of 
intracellular PLA2 enzymes exist, cytosolic PLA2 (cPLA2) and calcium-
insensitive PLA2 (iPLA2), also called group IV and group VI PLA2, respectively. 
Although cPLA2 is selective for phospholipids with arachidonic acid in the sn-2 
position, this is not the case for iPLA2, which releases other fatty acids as well. 
Recently has been reported that lysophospholipids, produced by PLA2 activity, 
positively modulate TRPM8 and can act as endogenous agonists to activate the 
channel at normal physiological temperatures. In contrast, PUFAs such as 
arachidonic, eicosapentaenoic, and docosahexaenoic acid inhibit TRPM8. 
Although the two groups of PLA2 products exert opposing modulatory effects on 
TRPM8, the net balance of equimolar concentrations of the PLA2 products favors 
TRPM8 activation. These data introduce lysophospholipids as novel modulators 
of thermosensitive TRP channel activity.
43  
TRPM8 can also be activated by menthol, the active ingredient of pepper mint, 
and by other cooling compounds as eucalyptol (the active ingredient in eucalyptus 
oil), the super-cooling AG-3-5 (also known as icilin), geraniol, hydroxycitronellal, 
linalool, PMD38, WS-3, and WS-23.
44
 Of these AG-3-5 bears little structurally 
resemblance to menthol and is more potent and effective than menthol in 
activating TRPM8.
45
 Interestingly, the mechanism whereby AG-3-5 activates 
TRPM8 is different than that of menthol or cold. AG-3-5 requires a coincident 
rise in cytoplasmic calcium, either via permeation through the channel or by 
release from intracellular stores, in order to evoke TRPM8 currents, suggesting 
that the channel can be activated by multiple mechanisms. 
12 
 
 In addition mutational studies identified a critical amino acid (Gly805): when 
mutated, it makes AG-3-5 unable of activating TRPM8.
46
 This residue was 
located between the second and third transmembrane domains of the channel, a 




Figure 5. TRPM8 chemical activators. 
 
 
1.4.2 TRPM8 inhibitors 
Despite different positive modulators of TRPM8, a large class of inhibitors are 
subject to intense studies.  
Endogenous antagonists comprise bradykinin, a proinflammatory agent, 
significantly downregulate TRPM8 in a PKC-dependent manner.
48,49
 Moreover 
several synthetic and natural antagonists have been identified, including BCTC 
(4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1 




 The antifungal medication clotrimazole has strong TRPM8 
antagonistic activity, but also activates TRPV1 and TRPA1, actions consistent 
with the commonly reported side effects of irritation and burning.51 SKF96365, a 
non-specific blocker of several types of calcium channels, receptor-operated 
channels and inwardly rectifying potassium channels, also inhibits TRPM8 in 
vitro.
52 Certain tryptamine derivatives that are ligands for 5-benzyloxytryptamine 
13 
 
receptors also act as TRPM8 antagonists.
53
 Lastly, ethanol, at concentrations of 1–
3%, inhibits TRPM8 channel function by disrupting interactions with the 
membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2), an obligate 
molecule for TRPM8 channel function.
54
  
Several structural classes of nanomolar TRPM8 antagonists have been reported, 
including substituted 4-benzyloxy-phenylmethylamides (M8-B) benzyloxy-
benzoic acid amides (AMTB), (1-phenylethyl-4-(benzyloxy)-3-methoxybenzyl(2-
aminoethyl)carbamate (PBMC) and benzyloxy-phenylmethylureas.
50
 Some of 
these compounds are patented for the treatment of urological disorders, although 
there are no data available on the in vivo efficacy of any of these compounds in 
animal models of these diseases. High affinity antagonists M8-B, AMTB and 
PBMC have been used as selective pharmacological probes of TRPM8 to explore 
the range of therapeutic applications resulting from blockade of this receptor, such 
as the regulation of deep body temperature, treatment of urological disorders and 
cold hypersensitivity associated with inflammatory and neuropathic conditions.
55
 
In vitro, PBMC is the most potent TRPM8 antagonist reported to date and inhibits 
channel activation to both chemical and thermal stimuli. Using calcium 
microfluorimetry and whole cell electrophysiology, PBMC was found to reduce 
TRPM8 activity in a dose-dependent manner and unlike other TRPM8 








Figure 6. TRPM8 chemical inhibitors. 
 
Indeed, many of these compounds also antagonize the heat-gated channel TRPV1. 
Thus, there is significant pharmacologically overlap between the two channels,
57
 
which suggests a conserved mechanism for ligand activation of the 
thermosensitive TRP proteins. These results complicate the search for selective 














2.1 Tryptamine-based derivatives as TRPM8 channel modulators: 
Background 
Because of its above described role as cellular sensor, TRPM8 represents a good 
target for therapeutic intervention. Actually, most of current TRPM8 inhibitors 
showed also agonistic/antagonistic properties towards other receptors and have 
side effects that justify the need for new, more selective compounds.  
The design and synthesis of new TRPM8 modulators is a central goal of my PhD 
programme because of their potential therapeutic applications in cancer and pain 
process.  
Recently, some indole compounds have been identified as potent and selective 
TRPM8 antagonists. Voacangine (1), an iboga-type indole alkaloid, is found in 
the root bark of Voacanga africana Stapf ex Scott-Elliot (Apocynaceae) and it is 
characterized by the presence of an isoquinuclidine ring. This compound acts as 
modulators for TRPV1, TRPM8, and TRPA1. Voacangine showed TRPA1 
agonistic and notable TRPM8 antagonistic activity.
58
 
Also 5-substituted tryptamines have been studied as potent TRPM8 blockers and a 
structure-activity study described some important determinants of TRPM8 
activity. In detail, the phenyl ring and ethylamine side-chain were found to be 







Figure 7. Indole-based TRPM8 modulators. 
 
In addition, the most potent natural TRPM8 activator, icilin, is characterized by 
the presence of a central tetrahydropyrimidine-2-one ring and several other 
analogues, based on the tetrahydropyrimidine-2-one moiety, have been described 





The need for a heterocyclic ring to elicit efficient interactions with TRPM8 is also 
demonstrated by the isolation of the potent cooling agent α-ketoenamine from 
roast malt extract; however, these molecules are penalized by their instability to 
oxidation. Therefore, different heterocyclic moieties have been utilized as 
chemical scaffolds for the synthesis of new TRPM8 modulators; these include 
benzimidazole-based, as well as fused oxazole and thiazole.
60
  
On the basis of these findings, we chose the tryptamine nucleus as template for 
the design of a small library of TRPM8 modulators and considered of interest to 
introduce different substituents on the side chain of the starting tryptamine and to 
derivatize the N-1 position of the indole scaffold.  
Derivatives in this series, compared to the above cited tryptamine-based 
modulators, are modified at different positions and have a reduced scaffold 

















2.2 Synthesis of 1st series  
Derivatives 4−12 were prepared applying the synthetic route shown in Scheme 1. 
A subset of compounds (4−7) were prepared from the N-1 substituted 
intermediates 2 and 3. Reaction of 3-(2- bromoethyl)-1H-indole (1) with methyl 
iodide or 4-phenylbenzyl iodide in DCM/DMF using NaH as a base led to 
derivatives 2 and 3 with 67% and 61% yields, respectively. The 4-phenylbenzyl 
iodide (3a) used in the formation of intermediate 3, was previously prepared from 
the corresponding biphenyl-4-carboxylic acid as shown in Scheme 2. Nucleophilic 
displacement of the bromine atom of 1, 2, and 3 by different commercially 
available amines was performed in THF/TEA using palladium acetate as a 
catalyst. The final compounds 4−12 were obtained in 55−75% yield under 
microwave conditions. 
 












Derivatives 14−22 were prepared using an alternative synthetic route as shown in 
Scheme 3. Tryptamine (13) has been used as starting material. Compound 14 was 
obtained as racemic mixture by nucleophilic substitution reaction of the tosyl 
derivative of the (1,2,3,4-tetrahydronaphthalen-4-yl)methanol (6a) with 
tryptamine (13). The intermediate 6a has been synthesized by reducing the 
1,2,3,4-tetrahydronaphthalene-1-carboxylic acid with lithium aluminum hydride, 
followed by tosylation with 4-methylbenzene-1-sulfonyl chloride (Scheme 4). 
Reductive amination of different commercially available aldehydes with the 
tryptamine, using sodium triacetoxyborohydride as reductive agent, gave the final 
compounds 15−21 in 51−85% yields (Scheme 3). Finally, treatment of derivative 
21 with methyl iodide using NaH as a base allowed us to obtain the dimethyl 





















Scheme 4: Synthesis of intermediate 1,2,3,4 tetrahydronaphthalen-4-












2.3 Activity and binding evaluation of the N-substituted tryptamines 
synthesized 
 
2.3.1 Screening of the activity of the 1st series by Ca2+-Imaging experiments on 
TRPM8 
The synthesized compounds were examined, in the  nstitute of Molecular and 
Cellular  iology of   niversity Miguel  ern nde  of  lche  for their modulating 
activity on TRPM8 channels. The results obtained are summarized in Figure 8. 
All synthesized derivatives were tested at three different concentrations (0.5, 5, 
and 50 μM) by in vitro Ca
2+
 fluorometric assays experiments using Fluo4-NW in 
HEK293 cells stably expressing mouse TRPM8 channels. The results obtained are 
normali ed to the effects prompted by 100 μM canonical agonist menthol
62
 or by 
10 μM TRPM8 antagonist AMT  + 100 μM menthol 
63
 whose effects were 
reported as +100% (activation) or −100% (inhibition)  respectively.  
Derivatives 4 and 5 showed agonist activity at high concentration (50 μM)  being 
about 2-fold more effective than menthol. At the same concentration, the presence 
of the sterically hindered biphenyl ethyl group on the amine moiety (6) led to 
slight loss of efficacy in comparison to 4 and 5, maintaining an efficacy similar to 
menthol. Interestingly, introduction of a sterically hindered group at N-1 indole 
position, such as a biphenyl methyl group, together with increased flexibility of 
the substituent on the amine moiety (7 versus 4 or 5), maintained agonistic 
efficacy. 
The nonsubstituted  N-1 indole derivatives (8−21) were quite productive. A direct 
linkage of the amine moiety with different bulky aromatic groups, such as 
naphthalene and quinolines, gives compounds 8−11 unable to act as TRPM8 
modulators (Figure 8A and Figure 8B). By contrast, the tertiary amine obtained by 
derivatization of tryptamine with a benzyl moiety (12) proved to be an effective 
and potent antagonist. Introduction of a methylene spacer between the amine 
group and the bulky aryl moiety in 8 led to the potent agonist 15, which was 
shown to be 3-fold more effective than menthol at 50 μM.  ntroduction of 
substituents at position 2 of the naphthalene ring, such as OMe (16) and OH (17), 
induced a shift from agonist to antagonistic activity for these derivatives at high 
21 
 
concentration (50 µM). A similar effect was observed when the bicyclic system 
modification involved changes in the electronic nature of the ring (14) or an 
increase in ring size (18). In addition, tryptamine benzyl derivatives 19 and 20 lost 
the agonistic activity shown by the methylated analogue 4. Notably, compound 21 
bearing a p-methoxybenzyl group showed significant agonist activity at 0.5 μM  
with an efficacy similar to that of menthol. At 50 μM  the efficacy of derivative 21 
was nearly 3-fold higher than that of menthol. Conversion of this compound to its 
N-methyl-2-(1-methyl-1H-indol-3-yl)derivative (22) shifted the agonistic activity 
to antagonism, with an efficacy comparable to that of derivative 12, at all tested 




Figure 8. Efficacy of synthesized compounds as TRPM8 agonists (A) or 
antagonists ( ) at three different increasing concentrations (0.5 μM  5 μM  









2.3.2 Screening of the activity of the 1st series by Ca2+-Imaging experiments on 
TRPA1 and  TRPV1 
We decided to evaluate the activity of the synthetized compounds on other 
members of TRP family, in detail TRPV1 and TRPA1, because their 
physiopathological pathways are deeply connected.
64,65,66
 
The most active derivatives, in detail two TRPM8 antagonists (12, 22) and one 
agonist (21), were  tested in calcium fluorometric experiments in SH-SY5Y cells 
stably expressing mouse TRPV1 channels and in IMR90 cells natively expressing 
mouse TRPA1 channels to investigate the ability  to interfere with the activity of 
other TRP channels.  
In these experiments, the canonical TRPV1 agonist (capsaicin, 10 μM) or 
antagonist (ruthenium red  10 μM) as well as the canonical TRPA1 agonist 
(AITC, 500 μM) or antagonist (ruthenium red  10 μM) were used as controls. The 
values obtained for the tested compounds were normalized to the effects exerted 
by canonical agonists or agonist + antagonist coexposure. 
The performed Ca
2+
-imaging experiments showed a weak activity of compound 
12 on TRPV1 only at the highest concentration (50 µM) and unremarkable 
activity on TRPA1 at all concentrations, suggesting a selective TRPM8 
antagonism. The TRPM8 agonist 21 behaved, instead, as an antagonist on both 
TRPV1 and TRPA1 receptors, showing in both full antagonist ability at the 
highest concentrations (50 μM). Compound 22 appeared less selective, acting as 
an antagonist of both TRPV1 and TRPA1 channels with potency comparable to 
that on TRPM8 at all concentrations, and was therefore not further investigated. 
Whereas these results the most interesting synthetized derivatives are compounds 











Figure 9. Efficacy of synthesized compounds at three different increasing 
concentrations (0.5 μM  5 μM  and 50 μM) as modulators of TRPV1 (vs capsaicin 
and capsaicin + ruthenium red) (A) and TRPA1 (vs AITC and AITC + ruthenium 



































2.3.3 Patch-Clamp Electrophysiology of the 1st series 
To corroborate the activity of derivatives 21 and 12, these compounds were tested 
in patch-clamp assays in the Department of Medicine and Health Science V. 
Tiberio, University of Molise.  
The assays were performed in single HEK293 cells transiently expressing the rat 
TRPM8 isoform by patch-clamp recordings using a 100 ms voltage ramp ranging 
from −100 mV to +100 mV delivered every 4 s. Perfusion with 500 μM menthol 
activated a large, strongly outwardly rectifying current ( +80mV/ −80mV was 90 
± 25; n = 39) reversing at a potential near 0 mV (−1.3 ± 0.7 mV; n = 10) (Figure 
10A and Figure 10B). No currents were activated when menthol was perfused in 
nontransfected cells (0 pA/pF at +80 mV; n = 4). The dose-response curve for 
menthol-evoked currents (Figure 10C) at +80 mV showed an EC50 of 75 ± 4 μM  
a value close to those reported for rat
67
 and mouse isoforms.
34,68
 
Perfusion of derivative 21 (100 μM) in rat TRPM8-transfected HEK-293 cells 
also triggered the appearance of large outwardly rectifying currents, reversing 
around 0 mV (−1.1 ± 0.3 mV; n = 10; Figure 10D and Figure 10E). By contrast, 
perfusion of derivative 12 (100 μM) failed to activate TRPM8 currents. When 
compared to menthol, derivative 21 displayed a significantly higher potency 
( C50 was 40 ± 4 μM; n = 3−10) and a similar efficacy (current density at +80 
mV was 134 ± 13 and 140 ± 7 for derivative 21 and menthol, respectively; p > 
0.05) (Figure 10F).  
To investigate possible antagonistic effects exerted by the new synthesized 
compounds, we investigated their ability to inhibit menthol-evoked responses. As 
previously reported, the canonical TRPM8 antagonist  CTC (3 μM) produced a 
fast and complete inhibition of menthol-gated TRPM8 currents, which largely 
recovered after drug washout (Figure 11A and Figure 11B). Similarly, perfusion 
with the same concentration (3 μM) of derivative 12 produced a complete 
inhibition of menthol-induced TRPM8 currents at +80 mV (Figure 11C and 
Figure 11D), with slower kinetics when compared to those of BCTC. TRPM8 
block by derivative 12 appeared concentrationdependent, with an IC50 of 367 ± 24 





These effects were largely reversible upon drug washout (Figure 11C), although 





Figure 10. Menthol- and derivative 21-induced currents in HEK293 cells expressing 
TRPM8. (A, D) Representative traces of currents evoked by a 100 ms voltage ramp 
ranging from −100 mV to +100 mV applied every 4 s in control solution (CTL  black 
trace; A, D), during application of menthol (green trace; A) or derivative 21 (grey 
trace; D) or after washout (W, red trace; A, D). (B, E) Time-course of currents 
recorded at +80 mV (blue symbols) or −80 mV (red symbols) in single   K293 cells 
transiently expressing TRPM8 upon exposure to menthol (500 μM;  ) or derivative 
21 (100 μM;  ). The duration of compounds exposure is indicated by the bar on top 
of the traces. (C, F) Concentration−response curves for TRPM8 current activation by 
menthol (C) or derivative 21 (F). Peak current data were expressed as pA/pF (to 
facilitate comparison among cells of different size) and expressed as a function of 
agonist concentrations. The solid lines represent fits of the experimental data to the 
following binding isotherm: y = max/(1 + x/EC50)n, where x is the drug 
concentration and n the Hill coefficient. The fitted values for n were 0.97 ± 0.05 or 
3.0 ± 0.6 for menthol or derivative 21, respectively. Each point is the mean ± SEM of 







Figure 11. BCTC and derivative 12 block TRPM8-mediated 
responses evoked by menthol in TRPM8 expressing HEK293 
cells. (A, C) Time-course of currents recorded at +80 mV or 
−80 mV in   K293 cells transiently expressing TRPM8 upon 
application of 500 μM menthol (A  C)  500 μM menthol + 3 μM 
 CTC (A) or 500 μM menthol + 3 μM derivative 12 (C). (   D) 
 −V curves obtained in   K293 cells expressing TRPM8 and 
exposed to control solution (CTL  black trace;    D)  500 μM 
menthol (green trace;    D)  500 μM menthol + 3 μM  CTC 
(red trace;  )  or 500μM menthol + 3 μM derivative 12 (red 
trace; D). Traces shown in parts B and D correspond to the 
currents measured at the time points shown in colors (green or 











2.3.4 Molecular modeling studies 
To study the exact binding mode and to better rationalize the reasons behind the 
activity of our N-substituted tryptamines, molecular docking studies were carried 
on derivatives 21 and 12, which are the most potent TRPM8 agonist and 
antagonist, respectively. To investigate the binding characteristics of newly 
synthesized TRPM8 modulators with particular attention to the difference 
between agonist and antagonist binding which might be indicative of the residues 
involved in TRPM8 gating, we ran a series of molecular dynamic simulations 
using a homology model of a rat TRPM8 subunit. The homology model is based 
on the experimentally solved structures of TRPV1 (PDB code 3J5P).
71
 Notably, 
human, rat, and mouse TRPM8 amino acid sequences are highly similar within 
the modeled regions; the percent of overall identity/similarity is 93.8%/97.4% 
(human versus mouse), 93.8%/97.3% (human versus rat), and 98.6%/99.5% 
(mouse versus rat). More importantly, some of the critical residues involved in 
drug binding (namely, Leu697, Ile710, Tyr754, Leu843, Glu1004, and Arg1008) 
are strictly conserved among the three species. Overall, these data strongly 
suggest a high level of structural similarity in the binding sites for the described 
modulators among TRPM8 receptors belonging to humans, rats, and mice. By 
SiteMap
70
 calculations on the whole monomer the best site identified was BP1. It 
has a volume of 791 Å and a site score of 1.093 (the cutoff value generally used to 
distinguish between drug-binding and nondrug-binding sites is 0.80) and is 
located between S1, S2, S3, and S4 helices, while at the bottom it is delimited by 
residues 990−1010. Recently Taberner et al. reported the central role of S6-TRP 
box linker (amino acids 980−992 in rat TRPM8) in the gating mechanism of 
TRPM8 channel and showed that mutations in the 986–990 region had a deep 
impact on channel gating by voltage and menthol.
71
 The proximity of the binding 
site to the 980−992 region suggests that the binding of a molecule to BP1 might 
influence the conformation of this linker region in the TRP domain and, as a 
result, the pore opening. 
Molecular docking simulations have been performed to predict the binding mode 
into BP1 of the most potent antagonist (12) and agonist (21) in our series. The 
best docked models were then submitted to molecular dynamics simulations to 
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analy e protein−ligand contacts and protein conformational rearrangements at the 
level of BP1 and of the 980−992 region.  P1−12 and  P1−21 complexes are 
stabilized by similar interactions, such as hydrophobic contacts with Leu843, 
Ile701, Leu697  π−π stacking with Tyr754, and electrostatic interactions with the 
Glu1004 side chain. Apart from these similar interactions, the antagonist and the 
agonist also show different interactions that could be responsible for different 
conformational rearrangements of the 980−992 region.  n particular, 21 makes a 
hydrogen bond with the phenoxyl group of Tyr754 by its amino linker and a 
second hydrogen bond, with the backbone of Arg1008, provided by the indole 
NH. The different interaction of 12 or 21 to TRPM8 possibly brings differences in 
the conformation of BP1, regarding in particular Arg1008. Upon 21 binding 
Arg1008 side chain appears projected outside BP1 (Figure 12A), with the ligand 
indole ring claiming its space and hydrogen-binding to Arg1008 backbone. In the 
case of 12 binding, Arg1008 is instead pointing toward the BP1 cavity, keeping its 
interaction with Glu1004 (Figure 12B). Moreover, compound 12 establishes a 
wider hydrogen bonding network, interacting even with Gln1003 and Glu662, 
possibly stabilizing the TRP domain helix which might be responsible for its 
antagonistic nature. We used the predicted bioactive conformations of 12 and 21 
to summarize the most stable interactions involved in the binding of these ligands 
as representative antagonists and agonists of this tryptamine-based series (Figure 
12). The pharmacophore model for tryptamine-based agonists accounts for the 
interaction with Ile837, Leu806, Ile701 (H1), Leu697, Leu843, Ile844 (H2), 
Glu1004 (D2/P1), Arg1008 (D3), Tyr754 (D1/R1), and Leu757, and Met758 
(R1). On the other hand, the antagonist model accounts for the interaction with 
Ile701, Leu751, Leu697, Leu843 (R1), Glu1004 (P1/D1), Val800 (H1), Arg1008 
(R2), and Tyr754 (R1/R2). The two pharmacophore models might help to 
understand which chemical features are required to endow a ligand with agonist or 
antagonist capabilities. Despite binding to the same site, the two models present in 
fact substantial differences that may cause the observed differences induced in 







Figure 12. Pharmacophore models for tryptamine-based TRPM8 agonists (A) and 
antagonists (B). Chemical features are depicted as spheres and color-coded as follows: 
yellow, H = hydrophobic; blue, P = positive charge; green, D = HB donor; orange, R = 
































3.1 Tetrahydro-β-carboline and tetrahydroisoquinoline-based TRPM8 
modulators (series III, IV, V): Background and design 
The aim of my second year of PhD was to identify new potent and selective 
TRPM8 modulators. Based on the structural requirements of our previous series 
(12) and taking into account the tetrahydroisoquinoline derivatives described in 
literature.72 (series I and II) as potent TRPM8 antagonists, we developed two new 
series of derivatives using the tetrahydro-β-carboline (T βC  series     and  V) 
and tetrahydroisoquinoline (TIQ, series V) scaffolds  (Figure 13). These templates 
could be considered as the conformationally rigid analogues of triptamine and 
dopamine, respectively. 
Pictet−Spengler reaction  which involves the condensation of β-arylethylamine 
with an aldehyde or its synthetic equivalent, is one of the most convenient 
methods to obtain tetrahydro-β-carboline and tetrahydroisoquinoline derivatives. 
In this synthetic strategy, the stereogenic C-1 center is generated during the ring 
closure in a one-pot process.
73
 This condensation also occurs with aminoacids 
such as tryptophan and 3,4-dihydroxyphenylalanine (Dopa), chosen as starting 
materials, because of  the easy derivatization procedure of the carboxylic 
functional group. This feature may be exploited to synthetize the corresponding 
hydantoin-fused tetrahydro-β-carboline or tetrahydroisoquinoline scaffold as 
shown in Figure 13. 
 
 
Figure 13. TRPM8 identified antagonists (A) and new 
designed modifications (B). 
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3.2 Synthesis of series III-V 
The tetrahydro-β-carboline nucleus was obtained by a Pictet-Spengler 
condensation starting from L-Trp-OCH3 (23) and differently substituted aromatic 
aldehydes, in methanol, in the presence of trifluoroacetic acid as catalyst and 
using microwave irradiation (Scheme 5). Using these reaction conditions means 
exploiting the power of the pseudo three-component reactions to obtain the 
1,2,3,4-tetrahydro-β-carboline-1,3-disubstituted as a mixture of diasteroisomers 
(24a/b and 25a/b) in a short time with a very high yield (87%). Compounds thus 
obtained were then easily separated by flash chromatography and the single 
diastereoisomers were reacted with triphosgene and an alkyl or aryl amine leading 
to the formation of ureidic intermediates 26a/b, 27a/b and 28.  Cyclization of 
26a/b, 27a/b and 28 in MeOH and TEA furnished the final hydantoin-fused 
tetrahydrobetacarboline derivatives 29a/b, 30a/b and 31. 




The tetrahydro-β-carbolines 35a/b were obtained using an alternative synthetic 
pathway  as shown in Scheme 6. Coupling of Nα-Boc-L-tryptophan (32) with 4-
fluorobenzylamine, using HOBt, HBTU and Dipea as base, gave the intermediate 
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33. The cleavage of Boc protecting group in acid conditions, led to the formation 
of 34. Final condensation of 34 with 4-chlorobenzaldehyde via Pictet-Spengler 
reaction, provided 35a/b, as a diasterosomeric mixture. 
 




Tetrahydroisoquinoline derivatives 41 and 42a/b were obtained using the 
synthetic strategy previously described for the derivatives 29a/b, 30a/b and 31 
(Scheme 7). In this case, Pictet-Spengler reaction of L-Dopa-OMe (36) with 
formaldehyde or 4-chlorobenzaldehyde yield the intermediate 37 or 38a/b as a 
mixture of diasteroisomers, respectively. Reaction of isoquinoline-based 
compounds with triphosgene and 4-fluorobenzylamine, using TEA as base, led to 
the formation of derivatives 39 and 40a/b. The final cyclization in methanol and 
TEA, at reflux temperature, provided the final hydantoin-fused 
































3.3 Activity evaluation of series III-V 
 
3.3.1 Screening of the activity of series III-V by Ca2+-Imaging experiments on 
TRPM8  
The tetrahydro-β-carbolines 29a/b, 30a/b, 31, 35a/b and the 
tetahydroisoquinolines 41, 42a/b were tested for their modulating activity on 
TRPM8 channels at the  nstitute of Molecular and Cellular  iology of   niversity 
Miguel  ern nde  of  lche. 
At 50 μM  compound 30a showed higher agonist activity than menthol. At the 
same concentration, the trans diastereoisomer 30b completely lost efficacy. The 
introduction of a sterically hindered group at N-hydantoin nucleus (31), as well as 
the presence of a substituent at C-1 tetrahydroisoquinoline scaffold (42a/b) led to 
uneffective derivatives. Compounds 29a/b, 35a, and, particularly, the trans 
diastereoisomer 35b and the unsubstitued hydantoin-fused tetrahydroisoquinoline 
41  showed antagonistic activity at the tested concentration (Figure 14).  
 
 
Figure 14. Efficacy of synthesized compounds as TRPM8 agonists or 
antagonists at the concentration of 50 μM. Values are expressed as the mean ± 
SEM of three independent measurements. 
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3.3.2 Patch-Clamp Electrophysiology of series III-V 
To provide evidence of the activity of derivatives 35b and 41, the compounds 
were tested in single HEK293 cells transiently expressing the rat TRPM8 isoform 
by patch-clamp recordings, using a 100 ms voltage ramp ranging from −100 mV 
to +100 mV delivered every 4 s. To test possible antagonistic effects exerted by 
the newly synthesized compounds, we investigated their ability to inhibit 
menthol-evoked responses and compared the results with the activity of the 
canonical TRPM8 antagonist BCTC (Figure 15A). Perfusion with 50 µM 
concentration of derivative 35b and 100 µM concentration  of 41 produced a 
complete inhibition of menthol-induced TRPM8 currents at +80 mV (Figure 15B 
and Figure 15C). Derivatives 35b and 41 showed an IC50 of 10.7±0.6 µM and 
30.3±0.7 µM, respectively, values higher than that reported for BCTC (475 nM) 
and for derivative 12 (367 nM). 
 
 
Figure 15. BCTC, derivatives 35b and 41 block TRPM8-mediated responses evoked 
by menthol in TRPM8 expressing HEK293 cells (A, C). Time-course of currents 
recorded at +80 mV or −80 mV in   K293 cells transiently expressing TRPM8 upon 
application of 500 μM menthol + 3 μM  CTC (A) or 500 μM menthol + 50 μM 
derivative  35b (B) or 500 μM menthol + 100 μM derivative 41 (C). 
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4.1 Tetrahydro-β-carboline and tetrahydroisoquinoline-based TRPM8 
modulators (series III, IV, V, and VI): Background and design 
The pharmacological results obtained from the THC/TIC series provided us 
some interesting data about the structural requirements important for TRPM8 
modulation. With regards to antagonistic effect of derivatives 35b and 41 and 
bearing in mind the potent and selective activity of compound 12, we decided to 
deepen the study of the structure-activity relationships of the series III, IV and V. 
Thus, we have modified the nature of substituents at C-1 and N-2 in series III, at 
C-1 and N-hydantoin in series IV and V. In addition, we modified the nature and 
dimension of cycle by introducing a diketopiperazine (series VI) or diaza-bridged 
moieties. 
Hence, we designed and synthetized new potential TRPM8 antagonists as 











4.2 Synthesis of series III- VI  
Derivatives 43-45a/b and 46 were prepared using the synthetic route shown in 
Scheme 8, starting from Nα-Boc-L-tryptophan (32). Reaction with 4-
fluorobenzylamine gave the amide intermediate 33. Deprotection by 
trifluoroacetic acid in dichloromethane provided the intermediate 34, which was 
subsequently reacted with formaldehyde or isovaleraldehyde or methyl 5-
oxopentanoate or 5-oxopentanoic acid to form derivative 46 and diastereoisomeric 
mixtures of tetrahydrobetacarbolines 43-45a/b. 
 




Derivatives 52-55a/b and 56 were prepared from L-Trp-OMe applying the 
synthetic route shown in Scheme 9. The reaction between 23 and different 
aromatic and aliphatic aldehydes in methanol containing trifluoroacetic acid, 
yielded in short time the mixtures of diastereoisomers of 1,3-disubstituted-1,2,3,4-
tetrahydro-β-carbolines 47-51a/b and the enantiomeric derivative 51. Ureas were 
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made by coupling the tetrahydrobetacarboline intermediates with triphosgene and 
an alkyl or aryl amine. The spontaneous cyclization of intermediate ureas 
furnished the final hydantoin-fused tetrahydrobetacarboline derivatives 52-55a/b 
and 56. 
 




Tetrahydrobetacarboline derivatives 63 and 65-67a/b were prepared as shown in 
Scheme 10. Starting with L-tryptophan methyl ester (23), reaction with 
isovaleraldheyde or 4-chlorobenzaldehyde or formaldehyde gave and the 
diastereoisomeric mixtures 57-58a/b, and intermediate 59. Treatment of 57-58a/b 
with Boc-L-phenylalanine or Boc-L-glycine under coupling conditions gave 
intermediates 60-61a/b. Intermediate 59 underwent the same reaction using Boc-
L-glycine and Boc-beta-alanine, furnishing compounds 62 and 64. The removal of 
the protecting group using a mixture of DCM and trifluoroacetic acid provided the 





















All the synthetized compounds were characterized by ROESY experiments to 
assign the absolute configuration. The ROESY and 
1
H NMR spectra of 
derivatives 67a/b are shown (Figure 19, 21). 
The configuration at C-6 asymmetric center of  67a was assigned as S on the basis 
of an NOE effect between H-6 and H-12a observed in the 2D ROESY spectra, 
indicating a cis disposition between these protons (Figure 19). The R 
configuration assigned to chiral centre 6 of 67b is justified by the absence of 
correlation between H-6 and H-12a (Figure 21). The absolute configuration of 
67a/b as 6S,12aS and 6R,12aS, respectively, was determined by hypothesizing the 























Figure 21. ROESY NMR spectrum of compound 67b. 
 
Tetrahydroisoquinoline derivatives 71a/b were prepared as shown in Scheme 11. 
Starting from L-Dopa methyl ester (68), reaction with 4-fluorobenzaldehyde gave 
the diastereoisomeric mixture 69a/b. Treatment with triphosgene and 4-
chlorobenzylamine and  the subsequent cyclization  provided  the final hydantoin-
fused tetrahydroisoquinolines. 
 






Derivatives 73a/b were synthetized as shown in Scheme 12. The Pictet-Spengler 
reaction between L-tryptophan methyl ester and benzaldheyde furnished 
intermediates 72a/b as diastereoisomeric mixture which was separated by flash 
chromatography. Then the nucleophilic displacement of bromine atom of benzyl 
bromide by the isolated diastereoisomers led to the final compounds 73a/b. 
 




Compound 78 was synthetized using an alternative synthetic route as shown in 
Scheme 13. The first step involved the Weinreb amidation of Boc-L-phenilalanine 
and N,O-dimethylhydroxylamine; the subsequent treatment of this species with an 
excess of lithium aluminum hydride led to the aldehyde 76, which was used to 
perform a Pictet-Spengler reaction  using L-tryptophan methyl ester. The obtainad 
diastereoisomeric mixture 77a/b was separated by flash chromatography; the final 
deprotection of the isolated intermediates using a mixture DCM/TFA led to the 
indole-fused bicycle 78 as single diastereoisomer (1S,2S,5S). The cyclization of 
the derivative with configuration 1R,2S,5S was not observed, as previously 
















Derivative 80 was synthetized according to Scheme 14. Intermediate 59, 
synthetized as previously described, was used as starting material and coupled 
with Boc-L-phenylalanine to obtain 79. Deprotection by trifluoroacetic acid in 
dichloromethane provided the derivative 80.  
 









4.3 Activity evaluation of the series III-VI 
All the synthesized derivatives are current in the process of biological assays to 
test their activity on TRPM8 channels. 
5.1 Conclusions 
In this chapter, we report the synthesis and pharmacological evaluation of a small 
library of derivatives based on the tryptamine scaffold designed as potential 
TRPM8 modulators. Two of the synthesized derivatives, compounds 12 and 21 
were shown to be efficient and potent TRPM8 antagonist and agonist, 
respectively. In detail, 12 showed a potency higher than that one reported for the 
wellknown TRPM8 antagonist BCTC. Meanwhile the agonist 21 showed a 
potency and efficacy significantly higher than menthol. In addition, compound 12 
showed unremarkable activity on TRPV1 and TRPA1 at different concentrations. 
Computational studies allowed us to hypothesize a binding site and two 
pharmacophore prototypes for this series of tryptamine-based TRPM8 
modulators. Moreover we designed and synthetized new potential modulators, 
using as scaffold tetrahydrobetacarboline and  tetrahydroisoquiniline nucleus. The 
preliminary biological evaluation of this new class of compound didn’t lead to an 
activity increase. Further studies to investigate the potential activity of the new 













Reagents, starting materials, and solvents were purchased from Sigma-Aldrich 
(Milan, Italy) and used as received. Reactions were carried out with magnetic 
stirring in round-bottomed flasks unless otherwise noted. Moisture-sensitive 
reactions were conducted in oven-dried glassware under a positive pressure of dry 
nitrogen, using predried, freshly distilled solvents. Microwave assisted reactions 
were performed in a Biotage Initiator+ reactor. Analytical thin layer 
chromatography (TLC) was performed on precoated glass silica gel plates 60 
(F254, 0.25 mm, VWR International). Purifications were performed by flash 
column chromatography on silica gel (230−400 mesh  Merck Millipore). NMR 
spectra were recorded on Varian Mercury-400 apparatus. 
1
H NMR and 
13
C NMR 
spectra were recorded with a Varian-400 spectrometer, operating at 400 and 100 
M    respectively. Chemical shifts are reported in δ values (ppm) relative to 
internal Me4Si, and J values are reported in hertz (Hz). The following 
abbreviations are used to describe peaks: s (singlet), d (doublet), dd (double 
double), t (triplet), q (quadruplet), and m (multiplet). ESI-MS experiments were 
performed on an Applied Biosystem API 2000 triple-quadrupole spectrometer. 
Combustion microanalyses were performed on a Carlo Erba CNH 1106 analyzer, 
and results were within 0.4% of calculated values and confirmed >95% purity for 
the final products. Analytical RP-HPLC was performed on a Phenomenex Synergi 
Fusion RP-80A (75 mm × 4.6 mm  4 μm)  with a flow rate of 1 mL/min  using a 
tunable UV detector at 254 nm. Mixtures of CH3CN and 0.05% TFA in H2O 
were used as mobile phase. 
General Procedure for the Synthesis of Derivatives 2 and 3. 
3-(2-Bromoethyl)indole (1, 1.0 equiv) was dissolved in a mixture of anhydrous 
DCM/DMF (2/1 v/v) under magnetic stirring, and the temperature was set to 0 °C. 
To this solution, an amount of 1.5 equiv of NaH was added portionwise and the 
mixture was allowed to react for 30 min. Then, an amount of 1.5 equiv of alkyl 
iodide [methyl iodide or 4-[phenyl]iodomethylbenzene (3a)] in DCM was added 
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dropwise and the reaction was warmed to room temperature and maintained under 
stirring for further 12 h. Then, reaction was quenched by 10% aqueous solution of 
citric acid and washed with brine. Organic layer was separated, dried over 
anhydrous Na2SO4, filtered, and evaporated in vacuo. Crude products were 
purified by column chromatography using n-hexane/ethyl acetate (4:1 v:v) as 
mobile phase. 
3-(2-Bromoethyl)-1-methyl-1H-indole (2).  
Yield 67%. 
1
H NMR (400 MHz,CDCl3) δ 3.39−3.46 (m  4   C 2); 3.79 (s  3   
CH3); 6.97 (s, 1H); 7.20 (t, 1H, J = 7.6 Hz); 7.28 (d, 1H, J = 8.0 Hz); 7.34 (t, 1H, 
J = 8.0 Hz); 7.62 (d, 1H, J = 8.0 Hz). ESIMS m/z calcd for C11H12BrN, 237.02; 
found 238.11[(M + H)
+
]. 
Synthesis of 1-(Iodomethyl)-4-phenylbenzene (3a).  
To 1 equiv of biphenyl-4-carboxylic acid (1a) dissolved in dry THF was added 
portionwise LiAlH4 (3.0 equiv), under stirring at room temperature. After 2 h the 
solution was washed three times with HCl 2 N and then water and the organic 
layer was dried over anhydrous Na2SO4, filtered, and concentrated. The resultant 
4-biphenylmethanol (2a) was purified by flash chromatography using ethyl 
acetate as solvent and was obtained as oil. 
Yield 89%. 
1
H NMR (400 MHz,CDCl3) δ 2.98 (bs  1   O ); 4.70 (s, 2H, CH2); 
7.33−7.43 (m  5   aryl); 7.59−7.61 (m  4   aryl). 
Then, treatment of 2a with triphenylphosphine and I2 in dry DCM according to 
the procedure previously described27 gave the title compound. 
Yield 65%. 
1
H NMR (400 MHz,CDCl3) δ 4.53 (s  2   CH2); 7.15 (d, 2H, J = 8.0 
  ); 7.24 (d  2   J = 8.0   ); 7.43−7.55 (m  5 ). 
1-(Biphenyl-4-ylmethyl)-3-(2-bromoethyl)-1H-indole (3). 
Prepared from intermediate 3a and 3-(2-bromoethyl)indole as described above. 
Yield 61%. 
1
H NMR (400 MHz, CD3OD) δ 3.27 (t  1   J = 7.4     C 2); 
3.38−3.46 (m  2   C 2); 3.81 (t  1   J = 7.6     C 2); 5.35 (s  2   C 2); 7.07 
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General Procedure for the Synthesis of Derivatives 4−12. 
One equivalent of 3-(2-bromoethyl)indole (1) or intermediate 2 or 3 was dissolved 
in THF and 1.5 equiv of the proper amine, 1.5 equiv of TEA, 1.5 equiv of NaI, 
and 0.3 equiv of (CH3COO)2Pd were added to this solution (Scheme 1). The 
reaction was conducted under μW  at 100 °C  for 20 min. The resulting mixture 
was filtered through Celite, dried in vacuo, and reconstituted in DCM. The 
organic phase was washed with water (3 × 50 mL), dried over anhydrous Na2SO4, 
filtered, concentrated, and purified by column chromatography using 
DCM/MeOH as mobile phase. 
N-(4-Methoxybenzyl)-2-(1-methyl-1H-indol-3-yl)ethanamine (4). 
Synthesized starting from 3 and 4-methoxybenzylamine, yield 71%. 
1
H NMR 
(400 M   CDCl3) δ 2.92 (t  2   J = 7.6     C 2); 3.19 (t  2   J = 7.6     C 2); 
3.49 (s  6   2C 3); 3.72 (s  2   C 2); 6.81 (s  1 ); 7.07−7.15 (m  3 ); 7.20 (t  
1   J = 6.8   ); 7.24−7.30 (m  3 ); 7.52 (d  1   J = 8.0   ). 
13
C NMR (100 
MHz, CDCl3) δ 22.7, 41.6, 50.8, 57.1, 109.1, 110.0, 112.4, 118.6, 118.8, 121.4, 
121.9, 124.2, 126.4, 128.0, 128.3, 135.3, 199.8. ESIMS m/z calcd for C19H22N2O, 




Synthesized starting from 3 and 4-chlorobenzylamine, yield 69%. 
1
H NMR (400 
MHz,CDCl3) δ 2.93−3.00 (m  4   2C 2); 3.74 (s  3   C 3); 3.77 (s  2   C 2); 
6.87 (s  1 ); 7.10 (t  1   J = 8.0   ); 7.20−7.30 (m  6 ); 7.58 (d  1   J = 8.0   ). 
13
C NMR (100 MHz, CDCl3) δ 25.57  32.56  49.40  53.06  109.2  110.0  112.3  
118.7, 118.9, 121.6, 126.7, 127.8, 128.4, 129.4, 132.5, 137.1, 138.7. ESIMS m/z 








Synthesized starting from 3 and 2-(4-biphenyl)-ethylamine, yield 65%. 
1
H NMR 
(400 MHz,CD3OD) δ 3.03 (t  2   J = 8.8     C 2); 3.17 (t  2   J = 8.6     C 2); 
3.32−3.37 (m  4   C 2); 3.76 (s  3   C 3); 7.06−7.11 (m  2 ); 7.20 (t  1   J = 
7.2   ); 7.31−7.44 (m  6 ); 7.56−7.60 (m  5 ). 
13
C NMR (100 MHz, CD3OD) δ 
22.0, 31.7, 48.4, 109.4, 118.0, 119.0, 121.8, 126.7, 127.3, 127.5, 128.7, 129.1, 





Synthesized starting from 3 and 3,4-dimethoxyphenthylamine, yield 75%. 
1
H 
NMR (400 MHz,CD3OD) δ 2.91 (t  2   J = 7.2     C 2); 3.17−3.26 (m  4   
CH2); 3.34 (t, 2H, J = 7.4 Hz, CH2); 3.77 (s, 3H, OCH3); 3.79 (s, 3H, OCH3); 
5.39 (s  2   C 2); 6.83−6.87 (m  2 ); 7.09 (t  1   J = 8.0   ); 7.11−7.24 (m  
5 ); 7.37−7.41 (m  4 ); 7.50−7.55 (m  4 ); 7.62 (d  1   J = 8.0   ). 
13
C NMR 
(100 MHz, CD3OD) δ 22.1  31.7  48.8  49.2  55.2  109.2  110.1  112.1  112.3  
118.3, 119.3, 120.9, 112.0, 126.7, 126.9, 127.0, 127.2, 127.4, 127.7, 128.7, 129.0, 
137.3, 140.7, 148.6 149.6. ESIMS m/z calcd for C33H34N2O2, 490.26; found 
491.31 [(M + H)+]. 
N-[2-(1H-Indol-3-yl)ethyl]naphthalen-1-amine (8). 
Synthesized starting from 1 and 1-naphthalenamine, yield 55%. 
1
H NMR (400 
MHz, CDCl3) δ 3.26 (t  2   J = 8.0     C 2); 3.64 (t  2   J = 8.2     C 2); 6.70 
(d  1   J = 7.8   ); 7.06 (s  1 ); 7.20 (t  1   J = 7.2   ); 7.25−7.27 (m  2 ); 
7.37−7.43 (m  4 ); 7.66 (d  1   J = 7.6   ); 7.72 (d  1   J = 8.0   ); 7.80 (d  1   
J = 8.2 Hz); 7.98 (s, 1H, NH). 
13
C NMR (100 MHz, CDCl3) δ 25.1; 44.3; 104.7  
111.5; 113.6; 117.5, 119.0, 119.8, 120.1, 122.3; 122.5; 123.7; 124.8, 125.9, 126.9; 
127.6; 128.9; 133.4; 136.7, 143.7. ESI-MS m/z calcd for C20H18N2, 286.15; found 








Synthesized starting from 1 and 2-naphthalenamine, yield 58%. 
1
H NMR (400 
MHz, CDCl3) δ 3.16 (t  2   J = 7.8    C 2); 3.58 (t  2   J = 8.0     C 2); 
6.81−6.85 (m  2 ); 7.08 (s  1 ); 7.12−7.24 (m  4 ); 7.33−7.40 (m, 3H); 7.59 (d, 
1H, J = 8.4 Hz); 7.64 (d, 1H, J = 8.2 Hz); 8.07 (s, 1H, NH). 
13
C NMR (100 MHz, 
CDCl3) δ 25.1; 44.1; 104.8  111.4  118.4  119.0  119.7 122.1  122.3; 122.4; 123.0; 
126.1; 126.5; 126.8; 127.4; 127.8; 129.1; 133.7; 136.5; 146.0. ESI-MS m/z calcd 




Synthesized starting from 1 and 5-aminoquinoline, yield 63%. 
1
H NMR (400 
MHz, CDCl3) δ 3.26 (t  2   J = 8.0     C 2); 3.62 (t  2   J = 8.2     C 2); 6.82 
(d  1   J = 7.6   ); 7.12−7.48 (m  7 ); 7.69 (d  1   J = 7.8   ); 8.15 (s  1   
NH); 8.37 (d, 1H, J = 4.0 Hz); 9.13 (d, 1H, J = 4.0 Hz). 
13
C NMR (100 MHz, 
CDCl3) δ 24.9; 44.1; 107.9; 111.6; 113.0; 113.6, 116.2; 118.9; 119.4; 119.8, 
122.3; 122.6; 127.4; 128.4; 136.5; 138.7; 141.9; 146.6, 153.0. ESI-MS m/z calcd 




Synthesized starting from 1 and 5-aminoisoquinoline, yield 67%. 
1
H NMR (400 
MHz, CDCl3) δ 3.23 (t  2   J = 6.4     C 2); 3.61 (t  2   J = 6.2     C 2); 7.82 
(d  1   J = 8.0   ); 7.15−7.54 (m  7 ); 7.71 (d  1   J = 8.0   ); 8.11 (s  1   
NH); 8.39 (d, 1H, J = 7.2 Hz); 9.17 (s,1H). 
13
C NMR (100 MHz, CDCl3) δ 25.9; 
49.9; 111.4; 114.9; 116.9, 119.0, 119.5, 122.3, 122.4, 127.0; 127.3; 127.5; 127.7; 
130.1; 134.7; 134.9; 135.4; 136.6; 143.3; 153.2. ESIMS m/z calcd for C19H17N3 
287.14; found 288.24 [(M + H)
+
]. 
N,N-Dibenzyl-2-(1H-indol-3-yl)ethanamine (12).  
Synthesized starting from 1 and dibenzylamine, yield 73%. 
1
H NMR (400 MHz, 
CDCl3) δ 2.84 (t  2   J = 5.6     C 2); 3.01 (t  2   J = 6.0     C 2); 3.73 (s  4   
2CH2); 6.90 (s, 1H); 7.06 (t, 1H, J = 8.2 Hz, aryl); 7.18 (t, 1H, J = 8.0 Hz); 7.26 





NMR (100 MHz, CDCl3) δ 23.3; 54.1; 58.5; 111.2; 114.8; 119.1  119.3  121.6  
122.0 127.0; 127.8; 128.4; 129.0; 136.4; 140.1. ESI-MS m/z calcd for C24H24N2, 




yl)ethanamine. (14) (1,2,3,4-Tetrahydronaphthalen-1-yl)methyl 4-
Methylbenzenesulfonate (6a). 
(1,2,3,4-Tetrahydronaphthalen-1-yl)methanol (5a) was synthesized by reduction 
of 1,2,3,4-tetrahydronaphthalenecarboxylic acid (4a) following the procedure 
described for intermediate 2a. Yield 95%. 
1
H NMR (400 MHz,CDCl3) δ 
1.80−1.89 (m  2   C 2); 2.02−2.11 (m  2   C 2); 2.79−2.90 (m  3   C 2 and 
C ); 3.90−3.96 (m  2   C 2O); 7.12−7.23 (m  4 ). 
Then, to a solution of 5a in DCM was added Cl-Tos (2.0 equiv), TEA (2.0 equiv), 
and DMAP (0.7 equiv). After 2 h at room temperature, the solution was washed 
with brine. The organic layer was dried over anhydrous Na2SO4, filtered, 
concentrated, and purified with flash chromatography in n-hexane/ethyl acetate 
30:20. 
The title compound 6a was obtained in 61% yield. 
1
  NMR (400 M    CDCl3) δ 
1.67−1.73 (m  2   C 2); 1.85−1.91 (m  2   C 2); 2.48 (s  3   C 3); 2.68−2.74 
(m, 2H, CH2); 3.18 (t, 1H, J = 8.0 Hz, CH); 4.07 (t, 1H, J = 7.8 Hz, CH2O); 
4.21−4.26 (m  1   C 2O); 7.05−7.13 (m  4 ); 7.36 (d  2   J = 8.0     tosyl); 
7.86 (d, 2H, J = 8.0 Hz, tosyl). 
N-[(1,2,3,4,Tetrahydronaphthalen-1-yl)methyl]-2-(1H-indol-3-yl)ethanamine 
(14). 
A 10 mL sealable flask, equipped with a stir bar, was charged with 1 equiv of 
tosylate 6a and 2.6 equiv of tryptamine dissolved in THF. The flask was sealed, 
heated to 60−70 °C  and allowed to stir at that temperature overnight. 
The resulting slurry was cooled to room temperature, added to DCM, and washed 
with brine. The organic layer solvents was dried over Na2SO4, filtered, and 
evaporated under vacuum. The resulting mixture was separated by silica gel 





H NMR (400 MHz, CDCl3) δ 1.68−1.71 (m  2   C 2); 1.82−1.85 
(m  2   C 2); 2.65−2.68 (m  2   C 2); 3.02−3.05 (m  2   C 2); 3.25−3.29 (m  
5   C  and 2C 2); 6.96 (d  1   J = 8.0   ); 7.00−7.14 (m  5 ); 7.21 (t  1   J = 
8.4 Hz); 7.36 (d, 1H, J = 8.2 Hz); 7.62 (d, 1H, J = 8.4 Hz); 8.08 (s, 1H, NH); 
13
C 
NMR (100 MHz, CDCl3) δ 19.2; 22.8; 26.1; 29.3; 36.0; 49.1; 54.1; 111.6; 113.0; 
118.8, 120.0, 122.9, 123.1, 126.2, 126.8, 127.5, 128.7, 129.8; 136.0; 136.9, 143.7. 
ESIMS m/z calcd for C21H24N2, 304.19; found 305.43 [(M + H)
+
]. 
General Procedure for the Synthesis of Derivatives 15−22. 
Tryptamine (1.0 equiv) was dissolved in a solution of DCM/CH3COOH (5:1 v/v) 
at room temperature. To this solution an amount of 2.0 equiv of the proper 
aldehyde was added and the mixture was warmed to reflux for 1.5 h. Then, an 
amount of 1.8 equiv of sodium triacetoxyborohydride was added portionwise and 
the mixture was allowed to reflux for further 3−5 h. After cooling to room 
temperature, NaOH 1 N was added. The organic phase was separated and 
extracted one more time with the alkaline solution. Then it was dried over 
Na2SO4, filtered, and concentrated in vacuo. The crude products were purified by 
column chromatography using mixtures of DCM/MeOH as eluent. 
2-(1H-Indol-3-yl)-N-(naphthalen-1-ylmethyl)ethanamine (15). 
Synthesized starting from 13 and 1-naphthaldehyde, yield 75%. 
1
H NMR (400 
MHz,CDCl3) δ 3.05 (t  2   J = 6.8     C 2); 3.13 (t  2   J = 6.8     C 2); 4.27 
(s  2   C 2); 6.97 (s  1 ); 7.20 (t  1   J = 7.2   ); 7.33−7.48 (m  4 ); 7.64 (d  
1H, J = 7.8 Hz); 7.74 (d, 1H, J = 8.2 Hz); 7.84 (d, 1H, J = 7.8 Hz); 8.00 (d, 2H, J = 
4.0 Hz). 
13
C NMR (100 MHz, CDCl3) δ 25.7  49.8  51.4  111.1  113.9  118.9  
119.3, 121.9, 122.0, 123.5, 125.4, 125.5, 125.9, 126.0, 127.4, 127.7, 128.7, 131.7, 
133.8, 135.7. ESIMS m/z calcd for C21H20N2, 300.16; found 301.18 [(M + H)
+
]. 
2-(1H-Indol-3-yl)-N-[(2-methoxynaphthalen-1-yl)methyl]-ethanamine (16).  
Synthesized starting from 13 and 2-methoxy-1-naphthaldehyde, yield 63%. 
1
H 
NMR (400 MHz, CDCl3) δ 3.05−3.09 (m  4   C 2); 3.61 (s  3   C 3); 4.35 (s  
2   C 2); 7.01−7.19 (m  3 ); 7.28−7.44 (m  6 ); 7.76 (d  1   J = 7.8   ); 7.90 
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(d, 1H, J = 7.0 Hz); 8.14 (s, 1H, NH). 
13
C NMR (100 MHz, CDCl3) δ 25.1; 42.6; 
48.1; 56.0; 94.6, 111.4; 112.7; 119.0, 119.6, 122.3, 122.7, 122.9; 123.6; 127.3; 
128.8; 129.9; 130.7; 131.7; 136.5, 142.8. ESIMS m/z calcd for C21H20N2O 




Synthesized starting from 13 and 2-hydroxy-1-naphthaldehyde, yield 51%. 
1
H 
NMR (400 MHz, CDCl3) δ 3.05−3.09 (m  4   2C 2); 4.41 (s  2   C 2); 
7.07−7.14 (m  3 ); 7.20 (t  1   J = 7.0   ); 7.26−7.42 (m  3 ); 7.60 (d  1   J = 
8.0 Hz); 7.65 (d, 1H, J = 8.0 Hz); 7.73 (d, 2H, J = 8.0 Hz); 8.08 (s, 1H, NH). 
13
C 
NMR (100 MHz, CDCl3) δ 25.2; 47.4; 48.7; 111.4; 111.5; 112.8; 113.0; 118.9  
119.6, 119.7, 121.1, 122.5; 122.6; 126.6; 127.5; 128.6; 129.0; 129.3; 131.9; 137.4, 




Synthesized starting from 13 and 10-methyl-9-anthracenecarbaldehyde, yield 
58%. 
1
H NMR (400 MHz, CDCl3) δ 3.04−3.07 (m  4   2C 2); 3.26 (t  2   J = 
6.4 Hz, CH2); 3.48 (s, 3H, CH3); 6.92 (s, 1H); 7.10 (t, 1H, J = 8.0 Hz); 7.20 (t, 
1H, J = 8.0 Hz); 7.32 (d, 1H, J = 8.0 Hz); 7.39 (t, 2H, J = 7.8 Hz); 7.46 (t, 2H, J = 
8.0 Hz, aryl); 7.56 (d,1H, J = 8.0 Hz); 7.95 (s, 1H, NH); 8.19 (d, 2H, J = 8.0 Hz); 
8.29 (d, 2H, J = 8.0 Hz). 
13
C NMR (100 M    CDCl3) δ 17.1; 25.5; 45.6; 49.7; 
111.4; 111.5;112.2; 113.0; 119.7, 122.2, 122.4, 124.6; 125.0; 125.7; 125.9; 136.5; 




Synthesized starting from 13 and vanillin, yield 58%. 
1
H NMR (400 MHz, 
CD3OD) δ 2.84 (t  2   C 2  J = 7.4   ); 2.92 (t  2   C 2  J = 7.4   ); 3.59 (s  
2H, CH2); 3.67 (s, 3H, CH3); 6.61 (d, 1H, J = 8.0 Hz); 6.71 (s, 1H); 6.73 (d, 1H, J 
= 8.0   ); 6.94−6.98 (m  2 ); 7.05 (t  1   J = 8.0   ); 7.31 (d  1   J = 8.0   ); 
7.48 (d, 1H, J = 8.0 Hz). 
13
C NMR (100 MHz, CD3OD) δ 24.7  48.6  52.8  55.1  
111.2, 111.8, 112.1, 115.0, 118.2, 121.2, 121.3, 122.4, 122.5, 127.4, 130.1, 137.0, 






Synthesized starting from 13 and 3,4-dimethoxybenzaldehyde, yield 72%. 
1
H 
NMR (400 MHz, CDCl3) δ 3.01−3.15 (m  4   2C 2); 3.80 (s  2   C 2); 3.82 (s  
6H, 2CH3); 6.75 (d, 1H, J = 8.0 Hz); 6.81 (d, 1H, J = 8.0 Hz); 6.88 (s, 1H); 7.03 
(s, 1H); 7.10 (t, 1H, J = 4.0 Hz); 7.18 (t, 1H, J = 4.0 Hz); 7.35 (d, 1H, J = 8.0 Hz); 
7.58 (d, 1H, J = 8.0 Hz); 8.10 (s, 1H, NH). 
13
C NMR (100 MHz, CDCl3) δ 25.4; 
49.0; 53.5; 56.0; 111.0, 111.4; 111.5; 112.7; 119.0, 119.5, 120.8, 122.3; 122.4; 
127.4; 130.1; 137.0; 145.9, 147.9. ESIMS m/z calcd for C19H22N2O2, 310.17; 




Synthesized starting from 13 and 4-phenoxybenzaldehyde, yield 83%. 
1
H NMR 
(400 MHz, CD3OD) δ 3.12 (t  2   C 2  J = 8.8   ); 3.24 (t  2   C 2  J = 8.4 
  ); 4.08 (s  2   C 2); 6.95−7.05 (m  5 ); 7.10−7.18 (m  3 ); 7.31−7.42 (m, 
5H); 7.53 (d, 1H, J = 8.0 Hz). 
13
C NMR (100 MHz, CD3OD) δ 24.5; 50.7; 52.7; 
111.4; 113.4; 119.8; 120.6; 120.9, 121.3, 123.6, 124.9; 125.9; 128.8; 129.0; 131.9; 
133.4; 139.2; 158.8, 160.8. ESIMS m/z calcd for C23H22N2O, 342.17; found 




Compound  21 (1 equiv) was dissolved in a mixture of anhydrous DCM/DMF 
(2/1 v/v) under magnetic stirring, and the temperature was set to 0 °C. To this 
solution, an amount of 3 equiv of NaH was added portionwise, and the mixture 
was allowed to react for 30 min. Then, an amount of 3 equiv of methyl iodide in 
dry DCM was added dropwise and the reaction was warmed to room temperature 
and maintained under stirring for further 12 h. Then, reaction was quenched by 
10% aqueous solution of citric acid and washed with brine. Organic layer was 
separated, dried over anhydrous Na2SO4, filtered, and evaporated in vacuo. Crude 
product was purified by column chromatography using DCM/MeOH (9:1 v:v) as 





H NMR (400 MHz, CDCl3) δ 3.14−3.18 (m  5   C 3 and C 2); 
3.78 (s, 3H, CH3); 3.84 (t, 2H, J = 8.0 Hz, CH2); 4.99 (s, 2H, CH2); 6.95 (d, 2H, J 
= 8.0   ); 7.05 (d  2   J = 8.0   ); 7.17 (t  1   J = 7.6   ); 7.18−7.24 (m  4 ); 
7.35 (t, 2H, J = 8.0 Hz); 7.59 (d, 3H, J = 8.0 Hz). 
13
C NMR (100 M    CDCl3) δ 
19.3, 32.8, 49.7, 63.7, 67.0, 109.5, 118.2, 118.4, 119.3, 119.9, 120.7, 121.9, 124.5, 
126.9, 128.2, 130.0, 134.8, 136.8, 155.4, 159.9. ESIMS m/z calcd for C25H26N2O, 
370.49; found 371.55 [(M + H)
+
]. 
General procedure for the synthesis of derivatives 29a/b, 30a/b, 31 
p-Cl benzadehyde or o-NO2 benzaldheyde (1.5 eq) was added to a solution of L-
Trp-OMe (23) dissolved in methanol and TFA (1.5eq).  The reaction mixture was 
heated to 110 °C for 30 min in a microwave reactor (Scheme 1). The combined 
organic layer was concentrated, diluted with dichloromethane and washed with 
water (3 x 20 mL). The combined organic layer was dried over anhydrous sodium 
sulfate, filtered, concentrated and purified by flash chromatography in n-hexane/ 
ethyl acetate (40:10 ratio) to separate the diasteroisomeric mixture (yield 87%). 
To a solution of 24 and 25 as singles diasteroisomers dissolved in DCM, 0.4 eq of 
triphosgene, 1.2 eq of TEA and 1.2 eq of proper amine were added. The reaction 
was mixed at room temperature for 20 minutes. Then the solution was washed 
with water (3 x 20 mL). The combined organic layer was dried over anhydrous 
sodium sulfate, filtered, concentrated and purified by flash chromatography in 
30:20 n-hexane/ethyl acetate (yield: 65%). Final compounds 29a/b, 30a/b, 31 
were obtained by refluxing intermediates 26a/b, 27a/b and 28 in MeOH/TEA for 
10 minutes. The crude was concentrated in vacuo, washed with water (3 X 20 
mL), dried over anhydrous sodium sulfate, filtered, concentrated and purified by 
flash chromatography in 75:25 n-hexane/ethyl acetate. For compounds 29a/b 
ethyl acetate was used as mobile phase. The final compounds are obtained as two 
diasteroisomers; the TRANS isomer 41 was obtained in such small quantities that 





imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione (29a).  
Overall yield 46%. 
1
H NMR (400 MHz, CDCl3) δ 2.83 (t, 1H, J = 7.6 Hz, H-11’); 
3.47 (dd, 1H, J’ = 5.6, J “ =  15.6 Hz, H-11”); 4.28 (dd  1   J’ = 5.2, J “ =  10.8 
Hz, H-11a); 4.58 (d, 1H, CH2a, J = 14.4 Hz); 4.68 (d, 1H, CH2b, J = 14.4 Hz); 6.24 
(s, 1H, H-5); 6.97 (t, 2H, J = 8.0 Hz aryl); 7.17-7.31 (m, 7H, aryl); 7.37 (t, 2H, J = 
8.0 Hz aryl); 7.54 (d, 1H, J = 8.0 Hz, aryl); 7.86 (s, 1H, NH). 
13
C NMR (100 
MHz, CDCl3) δ 23.5, 41.9, 51.6, 53.4, 108.5, 111.5, 115.7, 115.9, 118.7, 120.5, 
123.3, 126.2, 129.6, 129.8, 130.7, 130.8, 132.0, 135.2, 136.8, 137.6, 154.7, 163.9, 
172.4. HR-MS m/z calcd for C26H20ClFN3O2 [(M + H)]
+
: 460,1223; found 
460,1236. 
(1R,3S)5-(4-chlorophenyl)-2(4-fluorobenzyl)-5,6,11,11a-tetrahydro-1H-
imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione (29b).  
Overall yield 32%. 
1
H NMR (400 MHz, CDCl3) δ 3.05 (t, 1H, J = 7.6 Hz, H-11’); 
3.47 (dd, 1H, J’=6.0 Hz, J’’=11.6 Hz, H-11”); 4.36 (dd  1   J’ = 5.4, J “ =  11.2 
Hz, H-11a); 4.51 (d, 1H, J = 14.0 Hz CH2a); 4.68 (d, 1H, J = 14.0 Hz, CH2b); 5.78 
(s, 1H, H-5); 6.98 (t, 2H, J = 7.6 Hz, aryl); 7.18-7.31 (m, 6H, aryl); 7.38 (t, 2H, J 
= 7.6 Hz, aryl); 7.58 (d, 2H, J = 8.0 Hz, aryl). 
13
C NMR (100 MHz, CDCl3) δ 
24.7, 52.4, 52.8, 54.4, 109.7, 111.1, 116.5, 117.2, 118.4, 119.1, 121.0, 127.5, 
128.8, 129.8, 130.3, 131.1, 132.4, 134.9, 137.2, 137.8, 152.2, 164.4, 173.5. HR-
MS m/z calcd for C26H20ClFN3O2 [(M + H)]
+
: 460,1223; found 460,1239. 
(1S,3S)2-(3-aminopropyl)-5-(2-nitrophenyl)-5,6,11,11a-tetrahydro-1H-
imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione (30a).  
Overall yield 66%. 
1
H NMR (400 MHz, CDCl3) δ: 1.70-1.72 (m, 2H, CH2); 3.04-
3.13 (m, H, H-11’ and CH2); 3.48-3.58 (m, 3H, H-11” and CH2); 4.46 (d, 1H, J = 
12.0 Hz, H-11a); 6.48 (s, 1H, H-5); 7.16-7.32 (m, 4H, aryl); 7.40 (t, 1H, J = 8.0 
Hz, aryl); 7.47 (t, 1H, J = 8.0 Hz, aryl); 7.57 (d, 1H, J=8.0 Hz, aryl); 7.92 (d, 1H, 
J = 8.0 Hz, aryl); 8.51 (s, 1H, NH).  
13
C NMR (100 MHz, CDCl3) δ 22.6  29.9  
36.0; 37.3, 50.4, 58.3, 107.6, 111.6, 118.7, 120.5, 126.3, 128.7, 129.0, 130.5, 
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134.1, 134.7, 135.3, 137.1, 155.8, 173.5. HR-MS m/z calcd for C22H22N5O43 [(M 
+ H)]
+
: 420,1666; found  420,1684. 
(1R,3S)2-(3-aminopropyl)-5(2-nitrophenyl)-5,6,11,11a-tetrahydro-1H-
imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione (30b).  
Overall yield 31%. 
1
H NMR (400 MHz, CDCl3) δ: 1.73 (t  2   J = 8.0 Hz, CH2); 
2.66-2.69 (m, 3H, H-11’ and CH2); 2.90 (t, 1H, J = 12.0 Hz, H-11”); 3.57-3.64 
(m, 2H, CH2); 4.56 (dd, 1H, J’ = 5.4, J “ =  11.2 Hz, H-11a); 6.81 (s, 1H, H-5); 
7.15-7.35 (m, 5H, aryl); 7.49 (t, 1H, J = 8.0 Hz, aryl); 7.55 (t, 1H, J = 8.0 Hz, 
aryl); 7.93 (d, 1H, J = 8.0 Hz, aryl); 8.42 (s, 1H, NH). 
13
C NMR (100 MHz, 
CDCl3) δ 23.3, 31.5, 36.4, 38.9, 47.5, 55.2, 107.4, 111.6, 118.7, 120.5, 123.4, 
124.9, 126.1, 129.4, 129.6, 130.0, 133.9, 134.0, 135.1, 136.9, 155.6, 172.9. HR-
MS m/z calcd for C22H22N5O4 [(M + H)]
+
: 420,1666; found  420,2851. 
2-(naphthalen-1-yl)-5(2-nitrophenyl)-5,6,11,11a-tetrahydro-1H-
imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione (31).  
Overall yield 31%. 
1
H NMR (400 MHz, CDCl3) δ: 3.37 (t, 1H, J  = 11.6 Hz, H-
11’); 3.76 (t  1   J  = 14.8 Hz, H-11”); 4.73 (dd  1   J’ = 4.4, J “ =  11.6 Hz, H-
11a); 6.64 (s, 1H, H-5); 7.19-7.26 (m, 4H, aryl); 7.32-7.45 (m, 4H, aryl); 7.65 (d, 
2H, J = 8.0 Hz, aryl); 7.86-7.92 (m, 5H, aryl); 8.58 (s, 1H, NH). 
13
C NMR (100 
MHz, CDCl3) δ 23.4  50.8  58.6  104.3  111.7  118.8  120.6  122.3  123.5  124.7, 
125.4, 126.7, 127.1, 127.5, 128.7, 129.1, 130.3, 133.9, 134.2, 134.8, 136.4, 142.3, 




General procedure for the synthesis of derivatives 35a/b. 
To a solution of Nα-Boc-L-Tryptophan (32), dissolved in DCM/DMF (ratio 9:1), 
1.2 eq of HOBt, 1.2 eq of HBTU and 2.4 eq of Dipea at room temperature were 
added. After 30 min 1.2 eq of 4-fluorobenzylamine were added and the reaction 
was mixed at room temperature over night. Than the crude was washed with water 
(3 x 20 mL), 10% aqueous solution of citric acid (3 X 20 mL) and saturated 
aqueous solution of sodium bicarbonate (3 x 20 mL). The combined organic layer 
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was dried over anhydrous sodium sulfate, filtered, concentrated and purified by 
flash chromatography in 30:20 n-hexane/ethyl acetate. The removal of the 
protecting group, using a solution of DCM/TFA in ratio 3:1 (9:3 mL), led to 
intermediate 34 after treatment with saturated aqueous solution of sodium 
bicarbonate (3 x 20 mL). Final compounds 35a/b were obtained performing a 
Pictet-Spengler reaction. To a solution of derivative 34 dissolved in methanol and 
1.5 eq of TFA, p-Cl benzadehyde (1.5 eq) was added. The reaction mixture was 
heated to 110 °C for 30 min in a microwave reactor. Then the solution was 
washed with water (3 x 20 mL). The combined organic layer was dried over 
anhydrous sodium sulfate, filtered, concentrated and purified by flash 
chromatography using ethyl acetate as mobile phase to separate the 
diasteroisomeric mixture.  
(1S,3S)1-(4-chlorophenyl)-N-(4-fluorobenzyl)-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxamide (35a).  
Overall yield 66%. 
1
H NMR (400 MHz, CDCl3) δ 2.88 (t  1   J  = 11.6 Hz, H-
11’); 3.43 (dd  1   J’ = 4.0, J’ = 16.2 Hz,  H-11”); 3.81 (dd  1   J’ = 3.6, J’ = 
11.4 Hz, H-11a); 4.41 (dd, 1H, J’ =4.0, J ’= 12.0 Hz, CH2a); 4.48 (dd, 1H, J’ =4.0, 
J ’= 12.0 Hz, CH2b); 5.20 (s, 1H, H-5); 7.01 (t, 2H, J  = 8.0 Hz, aryl); 7.13-7.22 
(m, 7H, aryl); 7.35 (d, 2H, J = 8.0 Hz, aryl); 7.57 (d, 1H, J = 7.8 Hz, aryl).  
13
C 
NMR (100 MHz, CDCl3) δ 24.8  42.7; 52.6  54.0  110.9  111.1, 115.8, 118.8, 
120.0, 122.7, 127.2, 129.0, 129.7, 130.1, 132.6, 134.2, 136.4, 139.8, 163.9, 172.8. 
HR-MS m/z calcd for C25H22ClFN3O [(M + H)]
+
: 434,1430; found 434,1472. 
(1R,3S)1-(4-chlorophenyl)-N-(4-fluorobenzyl)-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxamide (35b).  
Overall yield 54%. 
1
H NMR (400 MHz, CDCl3) δ 2.93 (dd  1   J’ = 10.0, J” = 
16.0 Hz, H-11’); 3.34 (dd  1   J’=4.8, J”=16.0 Hz, H-11”); 3.61 (dd  1   J’ = 5.2, 
J” = 10.0 Hz , H-11a); 4.41 (dd, 1H, J’ = 5.6, J ’= 15.0 Hz, CH2a); 4.48 (dd, 1H, 
J’ =5.6, J ’= 15.0 Hz, CH2b); 5.21 (s, 1H, H-5); 7.00 (t, 2H, J  = 8.0 Hz, aryl); 
7.12-7.28 (m, 9H, aryl); 7.58 (d, 1H, J = 8.0 Hz, aryl); 7.79 (s, 1H, NH).
 13
C NMR 
(100 MHz, CDCl3) δ 25.7  42.7; 52.6  55.0  110.9  111.1, 115.5, 115.8, 118.7, 
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120.1, 122.6, 127.3, 128.8, 129.9, 129.5, 129.6, 129.8, 130.1, 132.6, 134.3, 136.5, 




General procedure for the synthesis derivatives 41, 42a/b. 
Intermediates 37 and 38a/b were obtained adding p-chlorobenzadehyde or 
formaldehyde (1.5 eq) to a solution of L-Dopa methyl ester (1 eq) dissolved in 
methanol and TFA (1.5eq) and heating the reaction mixture to 110 °C for 30 min 
in a microwave reactor. Then the solution was concentrated in vacuo, diluted with 
DCM (10 mL) and washed with water (3 x 20 mL). The combined organic layer 
was dried over anhydrous sodium sulfate, filtered, concentrated and purified by 
flash chromatography in n-hexane/ethyl acetate 50:50 to separate the 
diasteroisomeric mixture of 38a/b (yield 82%), while compound 37 was obtained 
without further purification steps. To a solution of obtained 
tetrahydroisoquinolines dissolved in DCM, 0.4 eq of triphosgene, 1.2 eq of TEA 
and 1.2 eq of 4-fluorobenzylamine were added. The reaction was mixed at room 
temperature for 20 minutes. Then the combined organic layer was washed with 
water (3 x 20 mL), dried over anhydrous sodium sulfate, filtered, concentrated 
and purified by flash chromatography in 50:50 n-hexane/ethyl acetate. 
Intermediates 39, 40a/b were refluxed in MeOH/TEA for 10 minutes. The solvent 
was removed in vacuo and the crude was diluted with DCM, washed with water, 
dried over anhydrous sodium sulfate, filtered, concentrated and purified by flash 
chromatography in 75:25 n-hexane/ethyl acetate to obtain derivatives 42a/b. The 
purification of compound 41 was allowed using ethyl acetate as mobile phase. 
2-(4-fluorobenzyl)-7,8-dihydroxy-10,10a-dihydroimidazo[1,5-b]isoquinoline-
1,3(2H,5H)-dione (41).  
Overall yield 52%. 
1
H NMR (400 MHz, CDCl3)  2.70 (t, 1H, J = 11.6 Hz, H-
10’); 3.13 (dd  1   J’ = 2.8, J” = 14.0 Hz, H-10”); 4.06 (dd  1   J’ = 4.4, J” = 
10.8 Hz, H-10a); 4.27 (d, 1H, J = 16.0 Hz, CH2a); 4.71 (s, 2H, H-5); 4.82 (d, 1H, J 
= 16.0 Hz, CH2b); 6.71 (s, 1H, aryl); 6.73 (s, 1H, aryl); 7.01-7.07 (m, 2H, aryl); 
7.44-7.50 (m, 2H, aryl). 
13
C NMR (100 MHz, CDCl3) δ 28.5  40.3; 47.8  55.9  
113.1, 116.2, 118.6, 126.9, 127.4, 129.4, 130.7, 133.5, 140.8, 142.4, 145.7, 155.1, 
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173.7. HR-MS m/z calcd for C18H16FN2O4 [(M + H)]
+
: 343,1089; found 
343,1105. 
(1S,3S)5-(4-chlorophenyl)-2-(4-fluorobenzyl)-7,8-dihydroxy-10,10a-
dihydroimidazo[1,5b] isoquinoline-1,3 (2H,5H)-dione (42a).  
Overall yield 50%. 
1
H NMR (400 MHz, CDCl3)  2.72 (t, 1H, J = 10.8 Hz, H-
10’); 3.11 (dd  1   J’ = 4.0, J’’ = 12.2 Hz, H-10”); 4.10 (dd  1   J’ = 5.2, J’’ = 
11.6 Hz, H-10a); 4.53, (d, 1H, J = 16.0 Hz, CH2a); 4.61 (d, 1H, J=16.0 Hz, CH2b); 
6.00 (s, 1H, H-5); 6.39 (s, 1H, aryl); 6.67 (s, 1H, aryl); 6.93-6.99 (m, 2H, aryl); 
7.13 (d, 2H, J = 8.0 Hz, aryl); 7.24 (d, 2H, J = 8.0 Hz, aryl); 7.31-7.36 (m, 2H, 
aryl). 
13
C NMR (100 MHz, CDCl3) δ 29.6  41.5; 52.9  55.0  115.8  116.0  116.7  
117.4, 123.7, 125.4, 129.2, 130.1, 131.2, 131.7, 134.8, 140.2, 143.4, 144.0, 154.8, 
172.9. HR-MS m/z calcd for C24H19ClFN2O4 [(M + H)]
+
: 453,1012; found 
453,1016. 
(1R,3S)5-(4-chlorophenyl)-2-(4-fluorobenzyl)-7,8-dihydroxy-10,10a-
dihydroimidazo[1,5b] isoquinoline-1,3 (2H,5H)-dione (42b).  
Overall yield 35%. 
1
H NMR (400 MHz, CDCl3) δ 2.74 (t  1   J = 10.8 Hz, H-
10’); 3.12 (dd  1   J’ = 4.4, J’’ = 11.4 Hz, H-10”); 4.11 (dd  1   J’ = 5.2, J’’ = 
11.6 Hz, H-10a); 4.54, (d, 1H, J = 14.4 Hz, CH2a); 4.62 (d, 1H, J=14.4 Hz, CH2b); 
6.02 (s, 1H, H-5); 6.39 (s, 1H, aryl); 6.69 (s, 1H, aryl); 6.94-7.00 (m, 2H, aryl); 
7.16 (d, 2H,  J = 8.0 Hz, aryl); 7.26 (d, 2H, J = 8.0 Hz, aryl); 7.30-7.37 (m, 2H, 
aryl). 
13
C NMR (100 MHz, CDCl3) δ 30.1  41.9  52.7  54.3, 115.0, 115.4, 115.7, 
115.9, 123.9, 125.5, 129.2, 129.9, 130.8, 131.9, 134.3, 140.4, 143.3, 143.9, 154.8, 
172.7. HR-MS m/z calcd for C24H19ClFN2O4 [(M + H)]
+
: 453,1012; found 
453,1097. 
General procedure for the synthesis of derivatives 43a/b-46. 
To a solution of Nα-Boc-L-Tryptophan (32), dissolved in DCM/DMF (ratio 9:1), 
1.2 eq of HOBt, 1.2 eq of HBTU and 2.4 eq of Dipea at room temperature were 
added. After 30 min 1.2 eq of 4-fluorobenzylamine were added and the reaction 
was mixed at room temperature over night. Than the crude was washed with water 
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(3 x 20 mL), 10% aqueous solution of citric acid (3 X 20 mL) and saturated 
aqueous solution of sodium bicarbonate (3 x 20 mL). The combined organic layer 
was dried over anhydrous sodium sulfate, filtered, concentrated and purified by 
flash chromatography in 30:20 n-hexane/ethyl acetate. The removal of the 
protecting group, using a solution of DCM/TFA in ratio 3:1 (9:3 mL), led to 
intermediate 34 after treatment with saturated aqueous solution of sodium 
bicarbonate (3 x 20 mL). Final compounds 43-45a/b and 46 were obtained 
performing a Pictet-Spengler reaction. To a solution of derivative 34 dissolved in 
methanol and 1.5 eq of TFA, formaldehyde, isovaleraldehyde, methyl 5-
oxopentanoate or 5-oxopentanoic acid (1.5 eq) was added. The reaction mixture 
was heated to 110 °C for 30 min in a microwave reactor. Then the solution was 
washed with water (3 x 20 mL). The combined organic layer was dried over 
anhydrous sodium sulfate, filtered, concentrated and purified by flash 
chromatography using ethyl acetate as mobile phase to separate the 
diasteroisomeric mixture.  
(1S,3S)-N-(4-fluorobenzyl)-1-isobutyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxamide (43a). 
Overall yield 61%. 
1
H NMR (400 MHz, CDCl3) δ: 0.92 (d  3H, J = 8.0, CH3); 
0.96 (d, 3H, J = 8.0, CH3); 1.41-1.48 (m, 1H, CH2a); 1.61-1.67 (m, 1H, CH2b); 
1.91-1.99 (m, 1H, CH); 2.66 (dd, 1H, J’=4.2, J”= 12.6 Hz, H-4’); 3.29 (dd  1   J’ 
= 4.2, J”= 15.6 Hz, H-4”); 3.52 (dd  1   J’=4.0, J”=8.4 Hz, H-3); 4.08 (dd, 1H, J’ 
= 4.4, J”= 12.2 Hz, H-1); 4.42 (d, 2H, J’ = 4.2, Hz, CH2); 6.97 (t, 2H, J  = 8.0 Hz, 
aryl); 7.01-7.10 (m, 2H, aryl); 7.21-7.26 (m, 2H, aryl); 7.38 (t, 1H, J = 8.0 Hz, 
aryl); 7.43 (d, 1H, J = 8.0 Hz, aryl); 7.75 (s, 1H, NH).
 13
C NMR (100 MHz, 
CDCl3) δ 21.9  23.8  25.5  30.9  42.4  44.2  51.9  57.9  109.0  110.8  115.4  115.6  
118.2, 119.7, 121.9, 127.4, 129.4, 134.3, 135.9, 136.5, 163.4, 172.9. HR-MS m/z 
calcd for C23H27FN3O [(M + H)]
+
: 380.2133; found 380.2142. 
(1R,3S)-N-(4-fluorobenzyl)-1-isobutyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxamide (43b). 
Overall yield 49%. 
1
H NMR (400 MHz, CDCl3) δ: 0.90 (d  3   J = 8.0, CH3); 
0.93 (d, 3H, J = 8.0, CH3); 1.40-1.48 (m, 1H, CH2a); 1.59-1.69 (m, 1H, CH2b); 
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1.83-1.91 (m, 1H, CH); 2.77 (dd, 1H, J’=11.6, J”= 16.0 Hz, H-4’); 3.21 (dd  1   
J’ = 4.4, J”= 15.6 Hz, H-4”); 3.71 (dd  1   J’=4.0, J”=8.4 Hz, H-3); 4.05 (dd, 1H, 
J’ = 4.4, J”= 12.2 Hz, H-1); 4.36 (dd, 1H, J’ = 7.8, J”= 15.6 Hz, CH2a); 4.43 (dd, 
1H, J’ = 7.8, J”= 15.6 Hz, CH2a); 6.95 (t, 2H, J  = 8.0 Hz, aryl); 7.02-7.11 (m, 2H, 
aryl); 7.08-7.24 (m, 2H, aryl); 7.39 (t, 1H, J = 8.0 Hz, aryl); 7.45 (d, 1H, J = 8.0 
Hz, aryl); 7.62 (s, 1H, NH).
 13
C NMR (100 MHz, CDCl3) δ 22.0  23.5  24.6  25.1  
42.5, 43.8, 49.5, 52.7, 108.3, 110.6, 115.4, 115.6, 118.3, 119.6, 121.2, 129.4, 






Overall yield 55%. 
1
H NMR (400 MHz, CDCl3) δ: 1.98-2.14 (m, 2H, CH2); 2.49-
2.69 (m, 2H, CH2); 2.80 (dd, 1H, J’=15.6, J”= 19.8 Hz, H-4’); 3.30 (dd  1   J’ = 
4.6, J”= 19.4 Hz, H-4”); 3.67 (s  3   CH3); 3.73 (dd, 1H, J’= 8.0, J”= 16.0  Hz, 
H-3); 4.06 (dd, 1H, J’ = 4.4, J”= 12.2 Hz, H-1); 4.45 (dd, 1H, J’ = 7.8, J”= 18.8 
Hz, CH2a); 4.54 (dd, 1H, J’ = 7.8, J”= 18.8 Hz, CH2a); 7.05 (t, 2H, J  = 8.0 Hz, 
aryl); 7.10-7.18 (m, 2H, aryl); 7.21-7.39 (m, 3H, aryl); 7.53 (d, 1H, J = 8.0 Hz, 
aryl); 8.21 (s, 1H, NH).
 13
C NMR (100 MHz, CDCl3) δ 24.7  29.6  31.3  43.0  
51.3, 51.8, 52.6, 108.7, 110.8, 115.4, 118.4, 119.6, 122.1, 127.1, 129.5, 135.2, 
136.0, 163.4, 172.7, 174.4. HR-MS m/z calcd for C23H25FN3O3 [(M + H)]
+
: 
410.1874; found 410.1888. 
methyl 3-((1S,3S)-3-((4-fluorobenzyl)carbamoyl)-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indol-1-yl)propanoate (44b). 
Overall yield 48%. 
1
H NMR (400 MHz, CDCl3) δ: 1.80-1.90 (m, 1H, CH2); 2.23-
2.31 (m, 1H, CH2); 2.29-2.54 (m, 2H, CH2); 2.64-2.72 (m, 1H, H-4’); 3.25 (dd  
1H, J’ = 4.8, J”= 12.0 Hz, H-4”); 3.53-3.58 (m, 4H, CH3 and H-3); 4.12 (dd, 1H, 
J’= 4.2, J”= 8.6  Hz, H-1); 4.41 (d, 2H, J = 7.8 Hz, CH2); 6.97 (t, 2H, J  = 8.0 Hz, 
aryl); 7.04 (t, 1H, J  = 8.0 Hz, aryl); 7.10 (t, 1H, J  = 8.0 Hz, aryl); 7.21-7.27 (m, 
3H, aryl); 7.43 (d, 1H, J = 8.0 Hz, aryl); 8.00 (s, 1H, NH).
 13
C NMR (100 MHz, 
CDCl3) δ 25.4  29.2  30.3  42.5  51.8  53.5  57.8  109.5  111.0  115.5  115.7  
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118.4, 119.8, 122.2, 127.2, 129.5, 129.6, 134.2, 136.1, 161.0, 163.4, 172.5, 174.2. 
HR-MS m/z calcd for C23H25FN3O3 [(M + H)]
+
: 410.1874; found 410.1879. 
3-((1R,3S)-3-((4-fluorobenzyl)carbamoyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indol-1-yl)propanoic acid (45a). 
Overall yield 42%. 
1
H NMR (400 MHz, CD3OD) δ: 2.03-2.06 (m, 1H, CH2); 
2.12-2.15 (m, 1H, CH2);  2.47 (t, 2H, J = 8.0 Hz, CH2); 2.90 (dd, 1H, J’=8.6, J”= 
12.4 Hz, H-4’); 3.10 (dd  1   J’ = 4.4, J”= 11.6 Hz, H-4”); 3.90 (dd  1   J’= 4.0, 
J”= 8.0  Hz, H-3); 4.20 (dd, 1H, J’ = 4.4, J”= 8.2 Hz, H-1); 4.45 (s, 2H, CH2a); 
6.96-7.09 (m, 4H, aryl); 7.29-7.35 (m, 3H, aryl); 7.42 (d, 1H, J = 8.0 Hz, aryl). 
13
C NMR (100 MHz, CD3OD) δ: 24.4  31.0  34.8  41.8  51.2  52.5  106.1  110.4  
114.6, 114.8, 117.1, 118.2, 120.7, 126.9, 128.9, 129.0, 134.7, 135.6, 136.5, 163.2, 
174.1. HR-MS m/z calcd for C22H23FN3O3 [(M + H)]
+
: 396.1718; found 
396.1725. 
3-((1S,3S)-3-((4-fluorobenzyl)carbamoyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indol-1-yl)propanoic acid (45b). 
Overall yield 33%. 
1
H NMR (400 MHz, CD3OD) δ: 1.92-2.02 (m, 1H, CH2); 
2.38-2.40 (m, 3H, CH2);  2.74-2.77 (m, 1H, H-4’); 3.09 (dd  1   J’ = 4.4, J”= 
11.6 Hz, H-4”); 3.61 (dd  1   J’= 4.0, J”= 12.6  Hz, H-3); 4.18 (dd, 1H, J’ = 4.2, 
J”= 8.4 Hz, H-1); 4.47 (s, 2H, CH2a); 6.98 (t, 1H, J = 8.0 Hz, aryl); 7.04-7.10 (m, 
3H, aryl); 7.31 (d, 1H, J = 8.0 Hz, aryl); 7.38-7.45 (m, 3H, aryl). 
13
C NMR (100 
MHz, CD3OD) δ 25.6  30.8  33.7  41.8  53.0  57.7  107.1  110.6  114.6  114.8  
117.0, 118.3, 120.6, 127.1, 129.1, 134.7, 135.7, 136.6, 160.8, 163.3, 174.6, 181.2 . 
HR-MS m/z calcd for C22H23FN3O3 [(M + H)]
+
: 396.1718; found 396.1729. 
(S)-N-(4-fluorobenzyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-
carboxamide (46). 
Overall yield 55%. 
1
H NMR (400 MHz, CDCl3) δ 2.68 (dd  1   J’ = 8.0, J” = 
16.0 Hz, H-4’); 2.90 (dd  1   J’=4.6, J”=16.0 Hz, H-4”); 3.47-3.52 (m, 1H, H-3); 
3.95 (s, 2H, H-1); 4.32 (d, 2H, J’ =4.2, Hz, CH2); 6.94 (t, 1H, J  = 8.0 Hz, aryl); 
6.99 (t, 1H, J  = 8.0 Hz, aryl); 7.14 (t, 2H, J  = 8.0 Hz, aryl); 7.26-7.39 (m, 3H, 
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aryl); 8.46 (t, 1H, J = 8.0 Hz, aryl); 10.38 (s, 1H, NH).
 13
C NMR (100 MHz, 
CDCl3) δ 25.2  41.7  42.4  57.0  106.9  111.6  113.1  115.3  115.5  117.7  118.8  
120.8, 125.9, 129.8, 134.3, 135.0, 136.2, 173.2. HR-MS m/z calcd for 
C19H19FN3O [(M + H)]
+
: 324.1507; found 324.1516. 
General procedure for the synthesis derivatives 52a/b-56. 
p-fluorobenzadehyde, isovaleraldehyde or formaldehyde (1.5 eq) was added to a 
solution of L-Trp-OMe (23) dissolved in methanol and TFA (1.5eq).  The reaction 
mixture was heated to 110 °C for 30 min in a microwave reactor (Scheme 1). The 
combined organic layer was concentrated, diluted with dichloromethane and 
washed with water (3 x 20 mL). The combined organic layer was dried over 
anhydrous sodium sulfate, filtered, concentrated and purified by flash 
chromatography in n-hexane/ethyl acetate (3:2 ratio) to separate the 
diasteroisomeric mixture. To a solution of  47-50a/b as singles diasteroisomers, 
and 51 dissolved in DCM, 0.4 eq of triphosgene, 1.2 eq of TEA and 1.2 eq of 
proper amine were added. The reaction was mixed at room temperature for 20 
minutes. Then the solution was washed with water (3 x 20 mL). The combined 
organic layer was dried over anhydrous sodium sulfate, filtered, concentrated and 
purified by flash chromatography in 30:20 n-hexane/ethyl acetate. Final 
compounds 52-55a/b and 56 were obtained by refluxing urea intermediates in 
MeOH/TEA for 10 minutes. The crude was concentrated in vacuo, washed with 
water (3 X 20 mL), dried over anhydrous sodium sulfate, filtered, concentrated 
and purified by flash chromatography in 80:20 n-hexane/ethyl acetate. For 
compound 56 n-hexane/ethyl acetate (70:30 ratio) was used as mobile phase. The 
final derivatives 52-55a/b were obtained as two diasteroisomers. 
(5S,11aS)-2-benzyl-5-(4-fluorophenyl)-5,6,11,11a-tetrahydro-1H-
imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione (52a). 
Overall yield 66%. [α]
25
D : -124.615 ± 0.162. 
1
H NMR (400 MHz, CDCl3) δ: 2.80 
(dd, 1H, J’ = 15.4, J” = 19.6 Hz, H-11’); 3.45 (dd  1   J’= 8.4, J”= 19.8 Hz, H-
11”); 4.30 (dd  1   J’ = 8.0, J” = 16.4 Hz, H-11a); 4.63 (d, 1H, J  = 20.0 Hz, 
CH2’); 4.75 (d, 1H, J  = 20.0 Hz, CH2”); 6.30 (s, 1H, H-5); 7.06 (t, 2H, J  = 8.0 Hz, 
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aryl); 7.17-7.35 (m, 8H, aryl); 7.41-7.44 (m, 2H, aryl); 7.54 (d, 1H, J  = 8.0 Hz, 
aryl); 7.75 (s, 1NH).
 13
C NMR (100 MHz, CDCl3) δ 23.4, 42.4, 51.3, 53.2, 108.3, 
111.2, 116.0, 118.5, 120.3, 123.1, 128.0, 128.7, 130.1, 134.9, 136.0, 136.6, 154.6, 
161.7, 164.2, 172.3. HR-MS m/z calcd for C26H20FN3O2 [(M + H)]
+
: 425.1540; 
found 425.1549.  
(5R,11aS)-2-benzyl-5-(4-fluorophenyl)-5,6,11,11a-tetrahydro-1H-
imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione (52b). 
Overall yield 52%. [α]
25
D : -53.529 ± 0.182 (c = 0.10, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 2.87 (dd, 1H, J’ = 15.4, J” = 19.6 Hz, H-11’); 3.65 (dd, 1H, J’= 
8.4, J”= 19.8 Hz, H-11”); 4.42 (dd, 1H, J’ = 8.0, J” = 16.4 Hz, H-11a); 4.73 (d, 
1H, J  = 20.0 Hz, CH2’); 4.75 (d, 1H, J  = 20.0 Hz, CH2”); 6.30 (s, 1H, H-5); 7.16 
(t, 2H, J  = 8.0 Hz, aryl); 7.17-7.45 (m, 8H, aryl); 7.41-7.48 (m, 2H, aryl); 7.54 (d, 
1H, J  = 8.0 Hz, aryl); 7.77 (s, 1NH).
 13
C NMR (100 MHz, CDCl3) δ 23.4  42.4  
51.3, 53.2, 108.3, 111.2, 116.0, 118.5, 120.3, 123.1, 128.0, 128.7, 130.1, 134.9, 
136.0, 136.6, 154.6, 161.7, 164.2, 172.3. HR-MS m/z calcd for C26H20FN3O2 [(M 
+ H)]
+
: 425.1540; found 425.1552.  
(5S,11aS)-5-isobutyl-2-(4-methoxybenzyl)-5,6,11,11a-tetrahydro-1H 
imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione (53a). 
Overall yield 63%. [α]
25
D : -98.563 ± 0.158 (c = 0.10, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 0.98 (d  3   J  = 8.8 Hz, CH3); 1.17 (d, 3H, J  = 8.8 Hz, CH3); 
1.64-1.74 (m, 2H, CH2); 1.78-1.86 (m, 1H, CH); 2.75 (dd, 1H, J’ = 8.2, J” = 11.4 
Hz, H-11’); 3.36 (dd  1   J’= 4.8, J”= 12.6 Hz, H-11”); 3.79 (s  3   CH3); 4.31 
(dd, 1H, J’ = 4.0, J” = 8.0 Hz, H-11a); 4.63 (d, 1H, J  = 16.0 Hz, CH2’); 4.75 (d, 
1H, J  = 16.0 Hz, CH2”); 5.30-5.34 (m, 1H, H-5); 6.86 (d, 2H, J  = 8.0 Hz, aryl); 
7.15 (t, 1H, J  = 8.0 Hz, aryl); 7.22 (t, 1H, J  = 8.0 Hz, aryl); 7.28-7.39 (m, 3H, 
aryl); 7.47 (d, 1H, J  = 8.0 Hz, aryl); 7.88 (s, 1NH).
 13
C NMR (100 MHz, CDCl3) 
δ 22.2  23.5  23.6  25.0  41.8  45.8  46.9  52.9  55.2  105.7  111.0  114.1  118.2  
120.1, 122.6, 126.3, 128.5, 130.0, 133.1, 136.2, 155.3, 159.3, 172.9. HR-MS m/z 
calcd for C25H28N3O3 [(M + H)]
+






Overall yield 52%. [α]
25
D : -42.360 ± 0.179 (c = 0.10, MeOH). 
1
H NMR (400 
MHz, CDCl3) δ 1.08 (d, 3H, J  = 8.8 Hz, CH3); 1.23 (d, 3H, J  = 8.8 Hz, CH3); 
1.65-1.78 (m, 2H, CH2); 1.81-1.88 (m, 1H, CH); 2.77 (dd, 1H, J’ = 8.2, J” = 11.4 
Hz, H-11’); 3.38 (dd, 1H, J’= 4.8, J”= 12.6 Hz, H-11”); 3.81 (s, 3H, CH3); 4.33 
(dd, 1H, J’ = 4.0, J” = 8.0 Hz, H-11a); 4.74 (d, 1H, J  = 16.0 Hz, CH2’); 4.77 (d, 
1H, J  = 16.0 Hz, CH2”); 5.36-5.44 (m, 1H, H-5); 6.86 (d, 2H, J  = 8.0 Hz, aryl); 
7.15 (t, 1H, J  = 8.0 Hz, aryl); 7.22 (t, 1H, J  = 8.0 Hz, aryl); 7.32-7.39 (m, 3H, 
aryl); 7.47 (d, 1H, J  = 8.0 Hz, aryl); 7.92 (s, 1NH).
 13
C NMR (100 MHz, CDCl3) 
δ 22.2  23.5  23.6  25.0  41.8  45.8  46.9  52.9  55.2  105.7  111.0  114.1  118.2  
120.1, 122.6, 126.3, 128.5, 130.0, 133.1, 136.2, 155.3, 159.3, 172.9. HR-MS m/z 
calcd for C25H28N3O3 [(M + H)]
+
: 418.2125; found 418.2139.  
(5S,11aS)-5-(4-chlorophenyl)-2-(3-(trifluoromethyl)phenyl)-5,6,11,11a-
tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione (54a). 
Overall yield 37% [α]
25
D : -1.000 ± 0.001 (c = 0.10, MeOH). 
1
H NMR (400 MHz, 
CDCl3) δ 3.12 (dd, 1H, J’ = 8.4, J” = 12.0 Hz, H-11’); 3.58 (dd  1   J’= 4.6, J”= 
12.2 Hz, H-11”); 4.52 (dd  1   J’ = 4.4, J” = 10.2 Hz, H-11a); 5.85 (s, 1H, H-5); 
6.97 (t, 2H, J  = 8.0 Hz, aryl);
 
7.10-7.21 (m, 4H, aryl); 7.24-7.30 (m, 2H, aryl); 
7.45-7.59 (m, 3H, aryl); 7.68 (s, 1H, aryl).
 13
C NMR (100 MHz, CDCl3) δ 22.7  
56.4, 57.9, 107.2, 110.0, 111.3, 116.0, 116.2, 118.6, 120.5, 122.8, 123.2, 124.7, 
126.1, 129.1, 129.5, 129.8, 132.0, 132.8, 133.9, 136.8, 153.2, 161.6, 164.0, 169.9. 
HR-MS m/z calcd for C26H18ClF3N3O2 [(M + H)]
+
: 496.1034; found 496.1042.   
(5R,11aS)-5-(4-chlorophenyl)-2-(3-(trifluoromethyl)phenyl)-5,6,11,11a-
tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione (54b). 
Overall yield 25% [α]
25
D : -166.0 ± 0.1 (c = 0.10, MeOH). 
1
H NMR (400 MHz, 
CDCl3) δ 3.00 (dd, 1H, J’ = 12.2, J” = 16.0 Hz, H-11’); 3.54 (dd  1   J’= 4.2, J”= 
12.2 Hz, H-11”); 4.41 (dd  1   J’ = 8.6, J” = 12.4 Hz, H-11a); 6.32 (s, 1H, H-5); 
7.12-7.30 (m, 7H, aryl); 7.49-7.60 (m, 3H, J  = 8.0 Hz, aryl); 7.62 (d, 1H, J  = 8.0 
Hz, aryl);
 
7.69 (s, 1H, aryl); 7.71 (s, 1NH).
 13
C NMR (100 MHz, CDCl3) δ 23.6  
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51.7, 53.1, 108.4, 111.3, 118.6, 120.5, 122.8, 123.3, 124.8, 126.0, 129.0, 
129.5,129.8, 132.1, 135.3, 136.7, 137.0, 153.2, 170.9. HR-MS m/z calcd for 
C26H18ClF3N3O2 [(M + H)]
+
: 496.1034; found 496.1048.  
(5S,11aS)-2-(3-aminopropyl)-5-(4-fluorophenyl)-5,6,11,11a-tetrahydro-1H-
imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione (55a). 
Overall yield 52%. [α]
25
D : -107.83 ± 0.21 (c = 0.10, MeOH). 
1
H NMR (400 MHz, 
CD3OD) δ 1.71-1.80 (m, 2H, CH2); 2.61 (t, 2H, J  = 8.0 Hz, CH2) 2.80 (dd, 1H, J’ 
= 12.0, J” = 16.0 Hz, H-11’); 3.43 (dd  1   J’= 8.2, J”= 20.2 Hz, H-11”); t  2   J  
= 8.0 Hz, CH2) 4.46 (dd, 1H, J’ = 8.4, J” = 16.2 Hz, H-11a); 6.30 (s, 1H, H-5); 
7.03-7.15 (m, 4H, aryl); 7.26 (d, 1H, J  = 8.0 Hz, aryl); 7.29-7.39 (m, 2H, aryl); 
7.52 (d, 1H, J  = 8.0 Hz, aryl).
 13
C NMR (100 MHz, CD3OD) δ 22.6  30.7  35.5  
38.0, 51.4, 53.2, 106.6, 110.9, 115.3, 117.7, 119.0, 121.8, 126.0, 129.8, 129.9, 
130.3, 135.9, 137.2, 155.1, 161.5, 163.9, 173.6. HR-MS m/z calcd for 
C22H22FN4O2 [(M + H)]
+
: 393.1721; found 393.1729.  
(5R,11aS)-2-(3-aminopropyl)-5-(4-fluorophenyl)-5,6,11,11a-tetrahydro-1H-
imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione (55b). 
Overall yield 44%. [α]
25
D : -37.500 ± 0.075 (c = 0.10, MeOH). 
1
H NMR (400 
MHz, CD3OD) δ 1.73-1.82 (m, 2H, CH2); 2.66 (t, 2H, J  = 8.0 Hz, CH2) 2.82 (dd, 
1H, J’ = 12.0, J” = 16.0 Hz, H-11’); 3.45 (dd, 1H, J’= 8.2, J”= 20.2 Hz, H-11”); t  
2H, J  = 8.0 Hz, CH2) 4.47 (dd, 1H, J’ = 8.4, J” = 16.2 Hz, H-11a); 6.33 (s, 1H, 
H-5); 7.06-7.17 (m, 4H, aryl); 7.26 (d, 1H, J  = 8.0 Hz, aryl); 7.29-7.39 (m, 2H, 
aryl); 7.53 (d, 1H, J  = 8.0 Hz, aryl).
 13
C NMR (100 MHz, CD3OD) δ 22.6  30.7  
35.5, 38.0, 51.4, 53.2, 106.6, 110.9, 115.3, 117.7, 119.0, 121.8, 126.0, 129.8, 
129.9, 130.3, 135.9, 137.2, 155.1, 161.5, 163.9, 173.6. HR-MS m/z calcd for 
C22H22FN4O2 [(M + H)]
+








Overall yield 55%. 
1
H NMR (400 MHz, CDCl3) δ 2.80 (dd  1   J’ = 12.0, J” = 
16.0 Hz, H-11’); 3.40 (dd  1   J’=8.2, J”=16.4 Hz, H-11”); 4.25 (dd  1   J’ =8.2, 
J” = 12.4 Hz, H-11a); 4.39 (d, 1H, J = 12.0, Hz, H-5’); 4.73 (s  2   CH2); 5.10 (d, 
1H, J = 12.0, Hz, H-5”); 7.02 (t  2   J  = 8.0 Hz, aryl); 7.16 (t, 1H, J  = 8.0 Hz, 
aryl); 7.21 (t, 1H, J  = 8.0 Hz, aryl); 7.34 (d, 1H, J  = 8.0 Hz, aryl); 7.43-7.46 (m, 
2H, aryl); 7.50 (d, 1H, J = 8.0 Hz, aryl); 8.15 (s, 1H, NH).
 13
C NMR (100 MHz, 
CDCl3) δ 23.1, 37.8, 41.7, 55.3, 106.2, 111.0, 115.5, 115.7, 120.1, 122.6, 130.5, 
136.5, 155.1, 161.3, 163.7, 172.5. HR-MS m/z calcd for C20H17FN3O2 [(M + H)]
+
: 
350.1299; found 350.1307. 
General procedure for the synthesis of derivatives 63, 65 and 66-67a/b. 
p-chlorobenzadehyde, isovaleraldehyde or formaldehyde (1.5 eq) was added to a 
solution of L-Trp-OMe (23) dissolved in methanol and TFA (1.5eq).  The reaction 
mixture was heated to 110 °C for 30 min in a microwave reactor (scheme 1). The 
crude was concentrated, diluted with dichloromethane and washed with water (3 x 
20 mL). The combined organic layer was dried over anhydrous sodium sulfate, 
filtered, concentrated and purified by flash chromatography in n-hexane/ethyl 
acetate (70:30 ratio) to separate the diasteroisomeric mixtures of 57-58a/b, while 
intermediate 59 was obtained with no further purification. To 1 mmol of the 
isolated intermediate dissolved in DCM/DMF (10/1) 1.2 eq of PyBOP and 2.4 eq 
of Dipea at room temperature were added. After 30 min 1.2 eq of the proper L-
aminoacids were added and the reaction was mixed at room temperature over 
night. Then the crude was washed with water (3 x 20 mL), 10% aqueous solution 
of citric acid (3 X 20 mL) and saturated aqueous solution of sodium bicarbonate 
(3 x 20 mL). The combined organic layer was dried over anhydrous sodium 
sulfate, filtered, concentrated and purified by flash chromatography in 40:10 n-
hexane/ethyl acetate, providing intermediates 60-61a/b, 62 and 64. The removal 
of the protecting group, using a solution of DCM/TFA in ratio 3:1 (9:3 mL) and 
treatment with saturated aqueous solution of sodium bicarbonate (3 x 20 mL) led 




b]indole-1,4(6H,7H)-dione (63).  
Overall yield 65%.   
1
H NMR (CDCl3  400 M  ) : δ: 2.79 (dd  1    -12’  J’ = 
12.0, J” = 16.0 Hz);  3.03 (dd, 1H, CH2 benzyl, J’ = 8.0, J” = 12.0 Hz); 3.32 (d, 
1H, CH2 benzyl,  J = 4.0 Hz);  3.40 (dd, 1H, H-12’   J’ = 4.0, J” = 24.0 Hz);  3.67 
(dd, 1H, H-12a,  J’ = 4.0, J” = 8.0 Hz);  4.02 (dd, 1H, H-6’  J’ = 4.0, J” = 16.0 
Hz); 4.32 (dd, 1H, H-3, J’ = 4.0, J” = 8.0 Hz);  5.49 (d, 1H, H-6”  J = 16.0 Hz);  
7.04 (t, 1H, aryl, J = 8.0 Hz); 7.12 (t, 1H, aryl, J = 8.0 Hz); 7.16-7.24 (m, 6H, 
aryl); 7.37 (d, 1H, aryl, J = 8.0 Hz); 7.82 (s, 1NH); 
13
C NMR (CDCl3, 100 MHz) 
δ: 28.0  41.4  42.1  56.8  56.9, 108.4, 112.0, 119.3, 121.0, 123.4, 127.3, 128.7, 
129.2, 130.2, 130.77, 136.1, 137.3, 163.9, 166.1.     
HR-MS m/z calcd for C21H20N3O2 [(M + H)]
+





H NMR (CD3OD  400 M  ) : δ: (A) 2.54-2.65 (m, 2H, CH2); 2.86-
2.91 (m, 2H, CH2); 3.01 (dd, 1H, H-6’  J’ = 8.0 and J” = 16.0 Hz);  3.42 (d, 1H, 
H-6”  J =16.0 Hz);  3.52 (s, 3H, CH3);  4.24 (d, 1H, H-2’  J = 16.0 Hz); 5.04 (d, 
1H, H-2”  J = 16.0 Hz); 5.16 (d, 1H, H-5, J = 4.0 Hz); 6.90 (t, 1H, aryl, J = 8.0 
Hz); 6.97 (d, 1H, aryl, J = 8.0 Hz); 7.18 (t, 1H, aryl, J = 8.0 Hz); 7.31 (d, 1H, aryl, 
J = 8.0 Hz); 
13
C NMR (CD3OD  100 M  ) δ: 22.8  35.4  36.8  38.3  51.0  54.8  
104.9, 110.0, 116.8, 118.0, 120.6, 126.4, 128.5, 137.2, 171.4, 173.5.   
1
H NMR (CD3OD  400 M  ): δ: (B) 2.54-2.65 (m, 2H, CH2); 2.86-2.91 (m, 3H, 
CH2 and H-6’); 3.36 (d  1    -6”  J =16.0 Hz);  3.50 (s, 3H, CH3);  4.63 (d, 1H, 
H-2’  J = 16.0 Hz); 4.81 (d, 1H, H-2”  J = 16.0 Hz); 5.74 (d, 1H, H-5, J = 4.0 Hz); 
6.90 (t, 1H, aryl, J = 8.0 Hz); 6.97 (d, 1H, aryl, J = 8.0 Hz); 7.18 (t, 1H, aryl, J = 
8.0 Hz); 7.31 (d, 1H, aryl, J = 8.0 Hz); 
13
C NMR (CD3OD, 100 MHz) (A + B) δ: 
21.8, 35.4, 36.8, 40.8 , 51.0, 50.5, 104.9, 110.0, 116.8, 118.0, 120.6, 137.2, 128.5, 
126.4. 171.4, 173.5. 
HR-MS m/z calcd for C16H20N3O3, [(M+H)
+





Overall yield 53%. 
1
H NMR (400 MHz, CDCl3) δ 0.78 (d  3   J = 8.2 Hz, CH3); 
1.01 (d, 3H, J = 8.2 Hz, CH3); 1.47-1.55 (m, 2H, CH2); 1.74-1.76 (m, 1H, CH); 
2.80 (dd, 1H, J’ = 11.6, J” = 15.8 Hz, H-12’); 2.94 (dd  1   J’= 12.0, J”= 16.0 
Hz, CH2’); 3.51 (dd, 1H, J’= 4.0, J”= 16.0 Hz, CH2”); 3.64 (dd, 1H, J’= 4.0, J”= 
12.0 Hz, H-12”); 3.98 (dd  1   J’= 4.0, J”= 11.6 Hz, H-3); 4.14 (dd, 1H, J’ = 4.6, 
J” = 11.4 Hz, H-12a); 5.45 (dd, 1H, J’= 4.4, J”= 8.8 Hz, H-6); 5.67 (s, 1NH); 
7.07-7.16 (m, 2H, aryl);
 
7.19 (d, 2H, J  = 8.0 Hz, aryl);
 
7.25 (d, 1H, J  = 8.0 Hz, 
aryl);
 
7.31 (t, 3H, J  = 8.0 Hz, aryl);
 
7.50(d, 1H, J  = 8.0 Hz, aryl); 7.95 (s, 1NH).
 
13
C NMR (100 MHz, CDCl3) δ 21.7  22.1  23.8  30.9  37.2  45.9  51.2  55.0  56.1  
107.0, 111.2, 118.2, 120.2, 122.2, 126.1, 127.7, 129.1, 129.4, 134.3, 135.8, 168.2, 
169.1 HR-MS m/z calcd for C25H28N3O2 [(M + H)]
+
: 402.2176; found 402.2190.  
(3S,6R,12aS)-3-benzyl-6-isobutyl-2,3,12,12a-
tetrahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4(6H,7H)-dione (66b). 
Overall yield 42%. 
1
H NMR (400 MHz, CD3OD) δ 1.02 (d  3   J = 8.2 Hz, CH3); 
1.14 (d, 3H, J = 8.2 Hz, CH3); 1.60-1.80 (m, 4H, H-12’  CH and CH2); 3.11 (dd, 
1H, J’ = 4.6, J” = 11.6 Hz, H-12”); 3.18 (d  2   J = 4.8 Hz, CH2); 4.30 (dd, 1H, 
J’= 8.0, J”= 12.0 Hz, H-3); 4.43-4.46 (m, 1H, H-12a); 5.98-6.00 (m, 1H, H-6); 
6.26 (s, 1NH); 7.12-7.24 (m, 7H, aryl);
 





C NMR (100 MHz, CD3OD) δ 22.4  23.2  25.2  27.2  41.7  43.6  47.8  
52.3, 56.9, 106.6, 110.8, 118.2, 119.9, 122.3, 126.4, 127.5, 129.0, 129.8, 132.7, 
135.0, 135.9, 164.2, 167.5 HR-MS m/z calcd for C25H28N3O2 [(M + H)]
+
: 







Overall yield 66%.   [α]
25
D : -79+ 0.01.  
1
H NMR (CDCl3  400 M  ) : δ: 3.26 (dd  
1H, H-12’  J’ = 12.0, J” = 4.0 Hz);  3.77 (dd, 1H, H-12”  J’ = 4.0, J” = 16.0 Hz); 
4.06 (dd, 2H, H-3’ and  -3”  J’ = 20.0, J” = 36 Hz);  4.40 (dd, 1H, H-12a, J’ = 
4.0, J” = 12 Hz); 6.22 (s, 1NH, H-2);   6.26 (s, 1H, aryl); 7.16-7.32 (m, 7H, aryl); 
7.63 (d, 1H, aryl, J = 8.0 Hz); 7.92 (s, 1NH). 
13
C NMR (CDCl3, 100 MHz) δ: 
23.4, 45.3, 55.8, 56.3, 109.6, 111.3, 118.6, 120.3, 122.8, 126.2, 128.6, 128.9, 
132.2, 133.7, 136.6, 139.8, 167.1, 168.5.    
HR-MS m/z calcd for C20H17ClN3O2 [(M + H)]
+
: 366.1004; found 366.1009.  
(6R,12aS)-6-(4-chlorophenyl)-2,3,12,12a-
tetrahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4(6H,7H)-dione (67b). 
Overall yield 59%. [α]
25
D : -244 + 0.2.  
1
H NMR (CDCl3  400 M  ): δ: 2.96 (dd  
1H, H-12’  J’ = 12.0, J” = 4.0 Hz);  3.46 (dd, 1H, H-12”  J’ = 4.0, J” = 16.0 Hz); 
4.05 (dd, 2H, H-3’ and  -3”  J’ = 16.0, J” = 36 Hz);  4.18 (dd, 1H, H-12a, J’ = 
4.0, J” = 12 Hz); 6.67 (s, 1NH, aryl);   6.97 (s, 1H, aryl); 7.08-7.26 (m, 7H, aryl); 
7.48 (d, 1H, aryl, J = 8.0 Hz); 8.00 (s, 1NH). 
13
C NMR (CDCl3, 100 MHz) δ: 
22.7, 44.8, 51.5, 52.3, 109.1, 111.2, 118.5, 120.3, 123.0, 126.2, 129.1, 129.2, 
130.1, 134.9, 136.4, 136.7, 161.8, 167.5.    
HR-MS m/z calcd for C20H17ClN3O2, 366.1004; found 366.1011.  
General procedure for the synthesis derivatives 71a/b. 
Intermediates 69a/b were obtained adding 4-fluorobenzadehyde (1.5 eq) to a 
solution of L-Dopa methyl ester (1 eq) dissolved in methanol and TFA (1.5eq) 
and heating the reaction mixture to 110 °C for 30 min in a microwave reactor. 
Then the solution was concentrated in vacuo, diluted with DCM (10 mL) and 
washed with water (3 x 20 mL). The combined organic layer was dried over 
anhydrous sodium sulfate, filtered, concentrated and purified by flash 
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chromatography in n-hexane/ethyl acetate 50:50 to separate the diasteroisomeric 
mixture. To a solution of isolated tetrahydroisoquinolines dissolved in DCM, 0.4 
eq of triphosgene, 1.2 eq of TEA and 1.2 eq of 4-chlorobenzylamine were added. 
The reaction was mixed at room temperature for 20 minutes. Then the combined 
organic layer was washed with water (3 x 20 mL), dried over anhydrous sodium 
sulfate, filtered, concentrated and purified by flash chromatography in 60:40 n-
hexane/ethyl acetate. Intermediates 70a/b were refluxed in MeOH/TEA for 10 
minutes. The solvent was removed in vacuo and the crude was diluted with DCM, 
washed with water, dried over anhydrous sodium sulfate, filtered, concentrated 




Overall yield 45%. [α]
25
D : -148.20 ± 0.35 (c = 0.10, MeOH). 
1
H NMR (400 MHz, 
CDCl3) δ: 2.70 (dd, 1H, J’ = 12.2, J” = 16.6 Hz, H-10’); 3.10 (dd  1   J’= 4.2, 
J”= 16.6 Hz, H-11”); 4.06 (dd  1   J’ = 4.0, J” = 12.0 Hz, H-10a); 4.48 (d, 1H, J  
= 16.0 Hz, CH2’); 4.56 (d, 1H, J  = 16.0 Hz, CH2”); 5.99 (s, 1H, H-5); 6.36 (s, 1H, 
aryl); 6.65 (s, 1H, aryl); 6.93 (t, 2H, J  = 8.0 Hz, aryl); 7.13-7.25 (m, 8H, aryl).
 13
C 
NMR (100 MHz, CDCl3) δ: 30.0  41.7  52.4  54.0  115.0  115.3  115.6  115.9  
124.0, 125.9, 128.9, 129.9, 134.4, 142.9, 143.7, 172.6. HR-MS m/z calcd for 
C24H18ClFN2O4 [(M + H)]
+
: 452.0939; found 452.0944.  
(5R,10aS)-2-(4-chlorobenzyl)-5-(4-fluorophenyl)-7,8-dihydroxy-10,10a-
dihydroimidazo[1,5-b]isoquinoline-1,3(2H,5H)-dione (71b). 
Overall yield 34%. [α]
25
D : -102.36 ± 0.24 (c = 0.10, MeOH). 
1
H NMR (400 MHz, 
CDCl3)δ 2.73 (dd, 1H, J’ = 12.2, J” = 16.6 Hz, H-10’); 3.12 (dd, 1H, J’= 4.2, J”= 
16.6 Hz, H-11”); 4.10 (dd, 1H, J’ = 4.0, J” = 12.0 Hz, H-10a); 4.50 (d, 1H, J  = 
16.0 Hz, CH2’); 4.58 (d, 1H, J  = 16.0 Hz, CH2”); 6.02 (s, 1H, H-5); 6.39 (s, 1H, 
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aryl); 6.67 (s, 1H, aryl); 6.95 (t, 2H, J  = 8.0 Hz, aryl); 7.15-7.27 (m, 8H, aryl).
 13
C 
NMR (100 MHz, CDCl3) δ: 30.0  41.7  52.4  54.0  115.0  115.3  115.6  115.9  
124.0, 125.9, 128.9, 129.9, 134.4, 142.9, 143.7, 172.6. HR-MS m/z calcd for 
C24H18ClFN2O4 [(M + H)]
+
: 452.0939; found 452.0948.  
General procedure for the synthesis derivatives 73a/b. 
Benzadehyde (1.5 eq) was added to a solution of L-Trp-OMe (23) dissolved in 
methanol and TFA (1.5eq). The reaction mixture was heated to 110 °C for 30 min 
in a microwave reactor. The combined organic layer was concentrated, diluted 
with dichloromethane and washed with water (3 x 20 mL). The combined organic 
layer was dried over anhydrous sodium sulfate, filtered, concentrated and purified 
by flash chromatography in n-hexane/ethyl acetate (30:20 ratio) to separate the 
diasteroisomeric mixture. The isolated tetrahydrobetacarbolines were dissolved in 
dichloromethane, then 1.2 eq of NaH and 1.2 eq of benzyl bromide were added. 
The reaction mixtures were heated to 120 °C for 30 min in a microwave reactor. 
The obtained crudes were washed with water (3 X 20 mL), dried over anhydrous 
sodium sulfate, filtered, concentrated and purified by flash chromatography in n-
hexane/ethyl acetate (45:5 ratio). 
(1S,3S)-methyl 2-benzyl-1-phenyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-
3-carboxylate (73a). 
Overall yield 58%. [α]
25
D : 135.18 ± 0.25 (c = 0.10, MeOH) 
1
H NMR (400 MHz, 
CDCl3) δ: (dd, 1H, J’ = 4.4, J” = 15.6 Hz, H-4’); 3.31 (s  3   CH3);  dd, 1H, J’ = 
7.8, J” = 15.6 Hz, H-4” ) 87 (t  1   J = 8.0 Hz, H-3); 3.92 δ d  1   J  = 16.0 Hz, 
CH2) 4.08 (d, 1H, J  = 16.0 Hz, CH2) 4.97 (s, 1H, H-1); 7.11-7.23 (m, 2H, aryl); 
7.24-7.37 (m, 11H, aryl); 7.55 (d, 1H, J  = 8.0 Hz, aryl).
 13
C NMR (100 MHz, 
CDCl3) δ 22.7  51.4 57.2  61.0  61.8  107.2  110.8  118.4  119.5  121.8  126.8  
127.1, 128.0, 128.5, 129.3, 133.2, 136.4, 138.2, 140.2, 173.5. HR-MS m/z calcd 
for C26H25N2O2 [(M + H)]
+





Overall yield 55%. [α]
25
D : -101.16 ± 0.17 (c = 0.10, MeOH). 
1
H NMR (400 MHz, 
CDCl3) δ (d, 2H, J  = 4.8, H-4’ and  -4”); 3.55 (s  3   CH3); δd, 2H, J = 11.8, 
CH2) δ 81-3.88 (m, 1H, H-3); 5.39 (s, 1H, H-1); 6.99-7.03 (m, 2H, aryl); 7.04 (d, 
1H, J  = 8.0 Hz, aryl); 7.10-7.29 (m, 6H, aryl); 7.38 (d, 2H, J  = 8.0 Hz, aryl); 7.42 
(d, 2H, J  = 8.0 Hz, aryl); 7.44 (d, 1H, J  = 8.0 Hz, aryl).
 13
C NMR (100 MHz, 
CDCl3) δ 24.5  51.4  54.4  56.1  60.9  106.4  110.8  118.2  119.3  121.6  127.0  
127.1, 128.1, 128.3, 128.6, 128.8, 128.9, 135.0, 136.5, 139.4, 142.2, 173.5. HR-
MS m/z calcd for C26H25N2O2 [(M + H)]
+
: 397.1911; found 397.1918.  
Synthesis of derivative 78. 
To a solution of, Boc-L-Phe-OH (1 mmol) dissolved in DCM/DMF (10/1) 1.2 eq 
of HOBt, 1.2 eq of HBTU and 2.4 eq of Dipea at room temperature were added. 
After 30 min 1.2 eq of N,O-dimethylhydroxylamine were added and the reaction 
was mixed at room temperature over night. Then the crude was washed with water 
(3 x 20 mL), 10% aqueous solution of citric acid (3 X 20 mL) and saturated 
aqueous solution of sodium bicarbonate (3 x 20 mL). The combined organic layer 
was dried over anhydrous sodium sulfate, filtered, concentrated and purified by 
flash chromatography in 40:10 n-hexane/ethyl acetate. 
The N-methoxy-N-methylcarbamoyl derivative (1 mmol; 88 % yield) was 
dissolved in dry THF and mixed at 0°C under nitrogen atmosphere. Then 2.5 eq of 
LiAlH4 ( 1 M in THF) were added and the reaction was mixed at 0°C for 6 
minutes. The crude was washed with 10% aqueous solution of citric acid (3 X 20 
mL), the combined organic layer was dried over anhydrous sodium sulfate, 
filtered and concentrated. No further purification was performed. The obtained 
intermediate (1.5 eq) was added to a solution of L-Trp-OMe dissolved in MeOH 
and TFA (1.5 eq). The reaction mixture was heated to 110 °C for 30 min in a 
microwave reactor. Then the crude was concentrated, diluted with 
dichloromethane and washed with water (3 x 20 mL). The combined organic layer 
was dried over anhydrous sodium sulfate, filtered, concentrated and purified by 
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flash chromatography in n-hexane/ethyl acetate (30:20 ratio) to separate the 
diasteroisomeric mixture. The removal of the protecting group using a mixture 
DCM/TFA 3/1 provided the indole-fused bicycle 78 as single diastereoisomer. 
(1S,2S,5S)-2-benzyl-2,3,5,6-tetrahydro-1H-1,5-epiminoazocino[4,5-b]indol-
4(11H)-one (78). 
Overall yield 35%. 
1
H NMR (400 MHz, CD3OD) δ: dd  1   J’ = 12.0, J” = 16.0 
Hz, CH2); δ: d, 1H, J  = 12.0 Hz, H-6’) δ: 20 (dd  1   J’ = 4.6, J” = 16.2 Hz, H-
6”); 3.28-3.37 (m, 1H, CH2); δ: d  1   J  = 8.0 Hz, H-5) δ: 4.28 (dd  1   J’ = 4.4, 
J” = 8.6 Hz, H-2); 4.41 δ: d  1   J  = 4.4 Hz, H-1) δ: 7.04 (t  1   J  = 8.0 Hz, 
aryl); 7.15 (t, 1H, J  = 8.0 Hz, aryl); 7.26-7.31 (m, 3H, aryl); 7.35-7.39 (m, 3H, 
aryl); 7.47 (d, 1H, J  = 8.0 Hz, aryl).
 13
C NMR (100 MHz, CD3OD) δ 26.0  38.3  
49.2, 52.6, 59.0, 107.2, 110.8, 117.4, 118.7, 121.4, 126.2, 126.6, 126.8, 128.8, 
129.6, 136.6, 174.5, 183.6. HR-MS m/z calcd for C20H19N3O [(M + H)]
+
: 
318.1601; found 318.1619.  
Synthesis of derivative 80. 
Intermediate 59, synthetized as previously described, was added to a solution of 
Boc-L-Phe-OH (1 mmol) dissolved in DCM/DMF (10/1), HOBt (1.2 eq), HBTU 
(1.2 eq) and Dipea (2.4 eq) and the reaction was mixed at room temperature over 
night. Then the crude was washed with water (3 x 20 mL), 10% aqueous solution 
of citric acid (3 X 20 mL) and saturated aqueous solution of sodium bicarbonate 
(3 x 20 mL). The combined organic layer was dried over anhydrous sodium 
sulfate, filtered, concentrated and purified by flash chromatography in 30:20 n-
hexane/ethyl acetate. The removal of the protecting group using a mixture of 







b]indole-1,4(6H,7H)-dione (80).  
Overall yield 31%. 
1
H NMR (CDCl3  400 M  ) : δ: 2.79 (dd  1    -12’  J’ = 
12.0, J” = 16.0 Hz);  3.03 (dd, 1H, CH2 benzyl, J’ = 8.0, J” = 12.0 Hz); 3.32 (d, 
1H, CH2 benzyl,  J = 4.0 Hz);  3.40 (dd, 1H, H-12’   J’ = 4.0, J” = 24.0 Hz);  3.67 
(dd, 1H, H-12a,  J’ = 4.0, J” = 8.0 Hz);  4.02 (dd, 1H, H-6’  J’ = 4.0, J” = 16.0 
Hz); 4.32 (dd, 1H, H-3, J’ = 4.0, J” = 8.0 Hz);  5.49 (d, 1H, H-6”  J = 16.0 Hz);  
7.04 (t, 1H, aryl, J = 8.0 Hz); 7.12 (t, 1H, aryl, J = 8.0 Hz); 7.16-7.24 (m, 6H, 
aryl); 7.37 (d, 1H, aryl, J = 8.0 Hz); 7.82 (s, 1NH); 
13
C NMR (CDCl3, 100 MHz) 
δ: 28.0  41.4  42.1  56.8  56.9  108.4  112.0  119.3  121.0  123.4  127.3  128.7, 
129.2, 130.2, 130.77, 136.1, 137.3, 163.9, 166.1.    
HR-MS m/z calcd for C21H20N3O2 [(M + H)]
+














6.2 Pharmacology and molecular modeling 
Cell Culture and Transfections 
For fluorescence assays, cells stably expressing TRP channels (SH-SY5Y for 
TRPV1, HEK for TRPM8, and IMR90 for TRPA1) were cultured in a monolayer 
at 37 °C in a humidified atmosphere of 5% CO2 in  arle’s minimum essential 
medium with  arle’s salts supplemented with 10% fetal calf serum  1% 
nonessential amino acids, 2 mM L-glutamine  100 μg of streptomycin/mL  100   
penicillin/mL, and the correspondent antibiotic for each stable cell line (0.4 
μg/mL puromycin for Sh-SY5Y and 400 μg/mL G418 for   K-CR1). 
For electrophysiological experiments, HEK293 cells were grown in 100 mm 
plastic Petri dishes in Dulbecco’s modified  agle medium containing 10% fetal 
bovine serum, penicillin (100 U/mL), and streptomycin (100 U/mL) in a 
humidified atmosphere at 37 °C with 5% CO2. The cells were seeded on glass 
coverslips (Carolina Biological Supply Company, Burlington, NC) and 
transfected the next day with 3.6 μg of rat TRPM8 receptor cDNA (a gift from Dr. 
Felix Viana, Alicante Institute of Neuroscience, Elche, Spain) using 
Lipofectamine 2000 (Invitrogen, Milan, Italy). A plasmid encoding for the 
Enhanced Green Fluorescent Protein (Clontech, Palo Alto, CA) was used as a 




For fluorescence assays, the cells were seeded in 96-well plates (Corning 
Incorporated, Corning, NY) at a cell density of 40 000 cells 2 days before 
treatment. On the day of treatment the medium was replaced with 100 μL of the 
dye loading solution Fluo-4 NW supplemented with probenecid 2.5 mM. Then the 
tested molecules dissolved in DMSO were added at the desired concentrations and 
the plates were incubated in darkness at 37 °C in a humidified atmosphere of 5% 
CO2 for 60 min. The fluorescence was measured using instrument settings 
appropriate for excitation at 485 nm and emission at 535 nm (POLARstar Omega 
BMG LABtech). A baseline recording of four cycles was recorded prior to 
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stimulation with the agonist (10 μM capsaicin for TRPV1  100 μM menthol for 
TRPM8  and 100 μM A TC for TRPA1).  ach antagonist (10 μM ruthenium red 
for TRPV1 and TRPA1  10 μM AMT  for TRPM8) was added to the medium 
containing the corresponding agonist to induce channel blockade. The changes in 
fluorescence intensity were recorded during 15 cycles more. The higher 
concentration of DMSO used in the experiment was added to the control wells. 
The cells’ fluorescence was measured before and after the addition of various 
concentrations of test compounds (λ X = 488 nm  λ M = 516 nm). The 
fluorescence values obtained are normalized to that prompted by the 
corresponding agonist (for channel activating compounds) or upon agonist + 
antagonist coexposure (for channel blocker compounds). 
Whole-Cell Electrophysiology  
Macroscopic currents from transiently transfected HEK293 cells were recorded at 
room temperature 1 day after transfection, with an Axopatch 200B amplifier 
(Molecular Devices, Union City, CA) using the whole-cell configuration of the 
patch-clamp technique  with glass micropipettes of 3−5 MΩ resistance. The 
extracellular solution contained the following (mM): 138 NaCl, 5.4 KCl, 2 CaCl2, 
1 MgCl2, 10 glucose, and 10 HEPES, pH 7.4 with NaOH. The pipet (intracellular) 
solution contained the following (mM): 140 CsCl, 1 EGTA, 10 HEPES, and 5 
Mg-ATP  p  7.3−7.4 with CsO . The pCLAMP software (version 10.2; 
Molecular Devices) was used for data acquisition and analysis. Linear cell 
capacitance (C) was determined by integrating the area under the whole-cell 
capacity transients  evoked by short (5−10 ms) pulses from −80 to −75 mV with 
the whole-cell capacitance compensation circuit of the Axopatch 200B turned off. 
Data were acquired at 5 k   and filtered at 1−5 k   with the four-pole low-pass 
Bessel filter of the amplifier. No corrections were made for liquid junction 
potentials. Currents were evoked by consecutive voltage ramps from −100 to 
+100 mV in 100 ms, delivered every 4 s. Current densities (expressed in pA/pF) 





l-Menthol and BCTC were purchased from Applichem Panreac (Barcelona, 
Spain) and Tocris Bioscience (Bristol, U.K.), respectively. AITC, capsaicin, and 
ruthenium red were purchased from Sigma-Aldrich (St. Louis, MO, USA). These 
compounds were dissolved in DMSO (final concentration  ≤1%).  n each 
experiment, the same volume of solvent used for tested drugs was added to the 
control solution. Fast solution exchanges (<1 s) were achieved by means of a 




Molecular Modeling. Protein and Ligands Preparations 
The TRPM8 homology model was prepared using the Protein Preparation 
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utility in order  to obtain satisfactory starting structures for the following studies. 
This utility is meant to ensure chemical correctness and to optimize protein 
structures for further analysis. In particular, Epik
78
 was then used to predict 
ionization and tautomeric states for the ligands using a pH of 7 ± 1. Successively, 
optimization of the hydrogen-bonding network was obtained by reorienting 
hydroxyl and thiol groups, amide groups of Asn and Gln, and His rings. The 
ionization and tautomeric states of His, Asp, Glu, Arg, and Lys were adjusted to 
match a pH of 7.4. The structure was finally submitted to a restrained 
minimization (OPLS2005 force field) that was stopped when rmsd of heavy atoms 
reached 0.30 Å. 
Ligands were sketched using the Maestro,
79
 interface and 3D coordinates were 
generated using LigPrep.
80
 Ionization/tautomeric states were predicted for a pH 
range of 7 ± 1 using Epik
78
 The most populated ionization state for each ligand 
was retained. 
In order to investigate the potential usefulness of the described TRPM8 rat 
homology model also for the results obtained in other species, pairwise 
alignments were performed among the rat, human, and mouse TRPM8 sequences 





All TRPM8 atoms were considered in the identification the top ranking potential 
binding sites. Each site was required to have at least five site points and was 
cropped at 4 Å from the nearest site point. The definition of hydrophobicity was 
set to “restrictive’’. 
Molecular Docking 
Docking of 12 and 21 was performed using Glide SP44−46 and XP47 in a 
stepwise manner. The docking spaces were defined as a 50 Å3 cubic box, while 
the diameter midpoint of docked ligands was required to remain within a smaller, 
nested 30 Å3 cubic box centered on the centroid of BP1 site points. Receptor OH 
and SH groups were set free to rotate. Two docking grids were used for SP and 
XP docking, differing for the scaling of vdW radii for nonpolar receptor atoms 
only. For SP a coefficient of  0.85 was used, while no scaling was used for XP. At 
most 10 poses for each ligand were retrieved from the SP docking, discarding as 
duplicates poses that showed both rms deviation less than 1.5 Å and maximum 
atomic displacement less than 2.0 Å. These poses were then refined, rescored, and 
minimized using Glide XP. The best scoring XP pose for each ligand was then 
retained for the MD simulations. 
Molecular Dynamics Simulation 
MD simulations of TRPM8/12 and TRPM8/21 complexes were set and run using 
Desmond MD system 
81
. The simulated environment was built using the system 
builder utility, with the structures being neutralized by Cl− ions. The small 903−
924 fragment was removed. With the exception of the 954−1016 fragment, which 
was unconstrained, the protein backbone was constrained by a 1 kcal/mol force. 
Octanol was used as explicit solvent. Before performing the simulations, a series 
of minimizations and short MD simulations were carried out to relax the model 
system by means of a relaxation  protocol consisting of six stages: (i) 
minimization with the solute restrained; (ii) minimization without restraints; (iii) 
simulation (12 ps) in the NVT ensemble using a Berendsen thermostat (10 K) 
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with non-hydrogen solute atoms restrained; (iv) simulation (12 ps) in the NPT 
ensemble using a Berendsen thermostat (10 K) and a Berendsen barostat (1 atm) 
with non-hydrogen solute atoms restrained; (v) simulation (24 ps) in the NPT 
ensemble using a Berendsen thermostat (300 K) and a Berendsen barostat (1 atm) 
with non-hydrogen solute atoms restrained; (vi) unrestrained simulation (24 ps) in 
the NPT ensemble using a Berendsen thermostat (300 K) and a Berendsen 
barostat (1 atm). At this point, 12 ns long MD simulations were carried out at a 
temperature of 300 K in the NPT ensemble using a Nose−Hoover chain thermostat 
and a Martyna−Tobias−Klein barostat (1.013 25 bar). Trajectory analyses were 
performed using the Desmond simulation event analysis tool for the rmsd 
calculations, Desmond Simulation Interaction diagram tool for the ligand 
interaction analysis, and Schrodinger clustering of conformers script for the bound 
conformation analysis. 
Pharmacophore Modeling 
Docking/MD predicted bound conformations were used to manually build the 
pharmacophore models summarizing the chemical feature of tryptamine based 
agonists and antagonists. Models were built using the software Phase. Features 
and their coordinates were automatically detected using the ligand-based option of 
Phase and were then edited in freestyle modes according to the ligand−protein 
interaction detected by the Simulation. Interaction diagram tool. In particular, H1 
and H2 features were previously detected as aromatic features but were changed 
to hydrophobic since during the MD trajectories they interacted with nonaromatic 
hydrophobic residues only. For the same reason, the R3 feature of the antagonist 
model was changed to H1. After the model generation, a refinement phase was 
used to evaluate the fitness of the tryptamine based agonists and antagonists on 
the two models. 
Statistical Analysis  
Data are expressed as the mean ± SEM. Statistically significant differences were 
evaluated with the Student t test or with ANOVA followed by the Student−




































While synthesizing compound 80 (Chapter I, paragraph 4.2), we found that the 
reduced yields in the desired product were due to the simultaneous formation of a 
side product. In order to rationalize this unprecedented reaction pathway, this side 
product was isolated and characterized by NMR spectroscopy leading to the 
identification of the aminoacetal derivative 81 (Scheme 1), as suggested by its 
1
H 
NMR spectra showing both the methyl ester signal (δ= 3.60) and a singlet at 5.84 
ppm, compatible with the aminoacetal CH proton (Figure 1). 
 
Scheme 1. Cyclization of 79 leading to 2,5-diketopiperazine 80 and aminoacetal 










H NMR of derivative 81. 
 
Aminoacetal derivatives of tetrahydrobetacarbolines are endowed with potential 
pharmacological activities.
82
 This structural motif finds applications in medicinal 
chemistry due to various valuable biological activities such as anti-cancer, anti-
microbial and anti-malarial. In addition many alkaloids contain the aminoacetal 
moiety.
83
 This is the reason why the central goals of this part of my PhD 
programme were the full characterization of this new chemical entity and the 
design and optimization of an efficient method for the preparation of ring-fused 
aminals by a mild functionalization of nitrogen heterocycles, extending the 







2. Chemistry and computational studies 
N-Acyliminium ions are powerful reactive species for the formation of carbon–
carbon and carbon–heteroatom bonds. Strategies relying on intramolecular 
reactions of N-acyliminium intermediates have been employed for the 
construction of structurally diverse scaffolds, ranging from simple bicyclic 
skeletons to complex polycyclic systems and natural-product-like compounds.
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Based on the evidence that the formation of tetrahydro-β-carbolines occurs 
through the Pictet−Spengler reaction 
73, 85 
we envisaged that the regeneration of 
the latent N-acyliminium ion ( ′) in type A′ dipeptides could provide access to the 










Structure and relative stereochemistry of 81 were determined by analysis of 1D 
and 2D NMR data, including COSY, qDEPT, HSQC, HMBC, and ROESY. The 
configuration at C-11b asymmetric center was assigned as S on the basis of an 
NOE effect between H-2 and H-11b observed in the 2D ROESY spectra, 
indicating a cis disposition between these protons. The absolute configuration of 
81 as 2S,5S,11bS was determined by hypothesizing the retention of configuration 







Figure 2. ROESY NMR spectrum and NOE correlations related to 
compound 81. 
 
The proposed stereochemical behavior of the reported reaction was corroborated 




H NMR chemical shifts and the 
corresponding calculated values at the density functional theory level (DFT). 
NMR parameters were predicted at the density functional theory level for 81 and 
the other hypothetical diastereoisomer 81’, specifically differ from 81 for the R 
configuration at C-11b in order to confirm the proposed stereochemical 
























C (orange bars) and 
1
H (green bars) mean absolute errors 
(MA ) histograms related to compounds 81/81’. 
 
 
To find suitable reaction conditions for the formation of 81, we investigated the 
influence of both redox and acid mediums on the cyclization of 79. Initially, we 
decided to explore the use of a weak oxidant agent as promoter of the H-
abstraction of C-H adjacent to nitrogen in acid medium.
86a, 88
 Treatment of 79 with 
0.2 equiv of TEMPO in 3/1 DCM/TFA led to the enantiomerically pure 
(2S,5S,11bS)-methyl 2-benzyl-3-oxo-(2,3,5,6,11,11b)-hexahydro-1H-
imida o[1′ 2′:1 2]pyrido[3 4-b]indole-5-carboxylate (81) and to the 2,5-
diketopiperazine 80 in 48% and 20% yield, respectively. Use of O2 (Table 1, entry 
2) or perbenzoic acid (1 equiv, entry 3) exclusively afforded the aminoacetal in 
82−85% isolated yield. Treatment of 79 with perbenzoic acid in a MeOH/37% 
HCl solution leads to 81 with lower yields (Table 1, entry 4). The lack of an 
oxidizing agent (Table 1, entry 5) also favors the nucleophilic attack of amine on 
the carbonyl group and formation of 80, which was obtained with 31% yield. 
Inorganic oxidizing agents were less effective in promoting cyclization to 81 












 redox cond. yields (%) 
80 81 
1 3/1 DCM/TFA TEMPO (0.2 eq) 20 48 
2 3/1 MeOH/TFA O2 - 85 
3 3/1 DCM/TFA Perbenzoyc acid (1eq) - 82 
4 MeOH/37%HCl Perbenzoyc acid (1eq) - 65 
5 3/1 DCM/TFA _ 31 29 
6 1/1/2 MeOH/H2O/TFA Oxone 19 27 
7 1/1/2 MeOH/H2O/TFA KMnO4 26 19 
8 1/1/2 MeOH/H2O/TFA K2Cr2O7 18 14 
9 1/1/2 MeOH/H2O/TFA HIO4 30 22 
10 1/1/2 MeOH/H2O/TFA FeCl3 12 15 
 aReactions were performed for 2 h on a 1.0 mmol scale. b“− = no redox reagents used. 
 
 
In order to verify the importance of the amide group in the mechanism of 
aminocetal formation via N-acyliminium generation, we performed the reaction 
using the Boc-Phe-Tpi(OMe)-reduced analogue 82 (Scheme 3) in the optimized 
conditions (Table 1, entry 3); using 82 as starting material we observed the 
cycli ation to the corresponding hexahydropyra ino[1′ 2′:1,6]-pyrido[3,4-
b]indole-4-one (83) in 88% yield. 
89
According to the literature, the protonation of 
the tertiary amine of intermediate 82 could cause ring opening and formation of a 
carbocation intermediate,
85a,90 
incompatible with the formation of the 
corresponding aminal derivatives. 
Additionally intramolecular cyclization of 2-(3-Boc-aminopropanoyl)-Tpi-OMe 
intermediate 64 did not occur, while the linear compound 65 was isolated in 79% 










Various other Tpi derivatives and amino acids were used for the preparation of 
functionalized polycyclic indole derivatives (Table 2). Cyclization of L- or D-N-
acyl-Tpi using 1 equiv of perbenzoic acid gave the corresponding (2S,5S 11bS) 
(106−108) or (2R,5S,11bS) (109) derivatives in high yields (Table 2  entries 1−4). 
Reactions of intermediates containing different N-protecting groups (Table 2, 
entries 5 and 6) led to N-protected aminals 110 and 111 in lower yields, perhaps 
due to the steric hindrance of the reactive nitrogen. When D-Tpi-OMe (entry 7), 
Tpi (entry 8), Tpi-NHCH2CH3 (entry 9), or tryptamine (entry 10) were used as 
starting compounds, no significant differences in the corresponding yields of 112 
(2S,5R,11bR), 113 (2S,5S,11bS), 114 (2S,5S,11bS), or 115 (2S,11bS) 
aminoacetal were evidenced in comparison with Tpi-OMe. 
Interestingly, the total stereoselectivity observed in the cyclization reaction using 
an intermediate not substituted at the C-1 position (106−115) was completely lost 
with substituted intermediates at C-1. Cyclization of the 1-(S or R)-substituted 
tetrahydro-β-carboline glycil or phenylalanil derivatives to the corresponding 
aminals resulted in the formation of a mixture of (5S,11bS) and (5S,11bR) 
diastereoisomers (Table 2  entries 11−13  116/117, 118/119, and 120/121 in a 1:1 
ratio; entry 14, 122/123 in a 3:2 ratio), as strongly confirmed by the comparison of 
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H chemical shift data and by the analysis of the 
most energetically favored conformers of 116 and 117. Furthermore, the absence 
of the stereoselectivity in the formation of the products (116 and 117) was 
investigated through the analysis of the energy diagrams, again confirming that 
the cyclization is kinetically and thermodynamically driven. The reported data 
indicate the steric hindrance at C-11 on the final products as a key factor in 
determining the stereoselectivity of the cyclization reaction, as confirmed by the 
smaller difference of the energies of the species at the transition state for the 
formation of 116 and 117.  
 





















































































































































































An efficient method for the preparation of ring-fused aminals by a mild 
functionalization of nitrogen heterocycles, extending the structural diversity of 
indole-based chemotypes, has been described. Some of the reported compounds 
could be useful for preparing analogues of biologically active natural and 
synthetic products. The observed stereoselectivity has been rationalized by means 
of DFT calculations, providing useful information for future investigations about 
the quantitative prediction of the products. Studies aimed at increasing the scope 
of this cyclization are ongoing. Moreover, the synthesized compounds are 
attractive templates for drug discovery. Several cyclic aminals have been proposed 
as antitumor agents
82d, 82h-j
 and PDE5 inhibitors.
91
 Moreover, cyclic aminals are 
involved in Transient Receptor Potential (TRP) channel modulations.
92
 
Preliminary in silico assays on synthesized compounds are ongoing, using a 
previously described model.
93
 Finally, computational investigation of the 
molecular docking models between 81 and microsomal prostaglandin E2 synthase-
1 (mPGES-1) highlighted the presence of several key interactions that could be 
responsible of the inhibitory activity towards of the reported compounds with the 
investigated target suggesting further studies for assessing their use as new anti-











Figure 4. 3D docking model of the interaction between 81 and 
mPGES-1 target. Specifically, 81 establishes a wide set of 
interaction with the receptor counterpart, making contacts with 
key residues in the ligand binding site (LBD). In details, 81 
establishes: a) hydrogen bonds with A:Ser127, A:Thr131, 
B:Gln36 (represented with dotted green lines); b) edge to face 
interactions with B:Phe44; c) polar contacts with B:Asn46, 




























Reagents, starting materials, and solvents were purchased from Sigma-Aldrich 
(Milan, Italy) and used as received. Reactions were carried out with magnetic 
stirring in round-bottomed flasks unless otherwise noted. Purifications were 
conducted on the Biotage Isolera One flash purification system, using prepacked 
KP-sil columns, (Biotage, Uppsala, Sweden). Microwave-assisted closed vessel 
reactions were performed in a  iotage  nitiator+ reactor using 10−20 mL vials and 
an external temperature sensor. Analytical TLC was performed on precoated glass 
silica gel plates 60 (F254, 0.25 mm, VWR International). 1D and 2D NMR 
spectra were recorded on a Bruker Avance (400 MHz) spectrometer, at room 





C) or methanol (3.31 ppm, 
1
H; 49.15 ppm, 
13
C). Chemical shifts are 
reported in δ values (ppm) relative to internal Me4Si, and J values are reported in 
hertz (Hz). The following abbreviations are used to describe peaks: s (singlet), d 
(doublet), dd (double doublet), t (triplet), q (quartet), and m (multiplet). HR-MS 
experiments were performed using an LTQ-Orbitrap-XL-ETD mass spectrometer 
(Thermo Scientific, Bremen, Germany) using electrospray ionization. Optical 
rotations were measured on an Atago Polax 2-L polarimeter at a concentration of 
0.1 g/100 mL. 
General Procedure for the Synthesis of Derivatives 59 and 84−91. 
Compounds 59, and 84−91 were obtained by microwave-assisted Pictet−Spengler 
reactions, starting from tryptophan derivatives or tryptamine and differently 
substituted aldehydes, according to the procedure previously described.
95
 NMR 
and mass spectra are in accordance with literature data. 
General Procedure for the Synthesis of Derivatives 79, 64, 92−99, and 
101−103.  
To a solution of the corresponding tetrahydro-β-carboline (4 mmol) in 
dichloromethane (25 mL) were successively added different N-protected amino 
96 
 
acids (4.4 mmol), PyBop (4.8 mmol), and DIPEA (8.8 mmol). Stirring was 
continued at room temperature for 12 h. Afterward, the reaction mixture was 
diluted with dichloromethane (20 mL), and the resulting solution was washed 
successively with 10% citric acid (2 × 25 mL), 10% NaHCO3 (2 × 25 mL), and 
water (2 × 25 mL), dried over Na2SO4, and evaporated to dryness. Flash 
chromatography of the residues, using different eluent systems, yielded, in each 
case, the corresponding N-protected aminoacyl derivatives 64, 79, 90−97, and 





H NMR (CDCl3, 400 MHz): (A) : 1.45 (s, 9H, Boc); 2.70-2.78 (m, 
1H, CH2a); 2.97 (dd, 1H, H-4b, J’ = 8.0, J” = 12.0 Hz); 3.08-3.15 (m, 1H, CH2b); 
3.34 (d, 1H, H4a, J = 12.0 Hz); 3.61 (s, 3H, CH3); 4.73 (d, 1H, H1a, J = 16.0 Hz); 
4.97-5.13 (m, 2H, H-1b and H-2’); 5.48 (d  1   N  oc  J = 8.0 Hz);  5.87 (d, 1H, 
H-3, J = 8.0 Hz); 7.12 (t, 1H, H-7, J = 8.0 Hz); 7.18 (t, 1H, H-6, J = 8.0 Hz); 7.23-
7.32 (m, 6H, H-8 and aryl); 7.45 (d, 1H, H-5, J = 8.0 Hz); 8.48 (s, 1H, NH); (B) : 
1.43 (s, 9H, Boc); 2.41 (dd, 1H, CH2a, J’ = 8.0, J” = 16.0 Hz); 3.23 (dd, 1H, H-
4b, J’ = 4.0, J” = 16.0 Hz); 3.08-3.15 (m, 1H, CH2b); 3.28 (d, 1H, H4a, J = 12.0 
Hz); 3.60 (s, 3H, CH3); 4.53 (d, 1H, H1a, J = 16.0 Hz); 4.97-5.13 (m, 3H, H-3, H-
1b and H-2’); 5.48 (d  1   N  oc  J = 8.0 Hz); 7.12 (t, 1H, H-7, J = 8.0 Hz); 7.18 
(t, 1H, H-6, J = 8.0 Hz); 7.23-7.32 (m, 6H, H-8 and aryl); 7.45 (d, 1H, H-5, J = 
8.0 Hz); 8.45 (s, 1H, NH); 
13
C NMR (CDCl3, 100 MHz) (A + B) : 22.5; 22.7; 
23.4; 28.3; 31.6; 38.7; 39.0; 40.3; 41.4; 51.1; 52.3; 52.5; 52.8; 53.3; 80.1; 105.2; 
106.6; 111.0; 118.0; 118.2; 119.6; 121.9; 122.1; 126.5; 126.9; 127.1; 127.7; 
128.4; 128.7; 128.9; 129.4; 129.6; 136.1; 136.5; 155.0; 155.5; 170.6; 171.3; 
172.2; 172.6. HR-MS m/z: calcd for C27H32N3O5, [(M+H)
+










H NMR (CDCl3, 400 MHz) : (A): 1.46 (s, 9H, Boc); 2.66-2.75 (m, 
2H, H-2’); 3.05-3.18 (m, 1H, H-4a); 3.46-3.57 (m, 3H, H-4b and H-3’); 3.64 (s  
3H, CH3);  4.80 (dd, 2H, H-1, J ‘= 16.0  J “= 16.8   ); 5.32 (d  1   N  oc  J = 
8.0 Hz);  5.93 (d, 1H, H-3, J = 4.0 Hz); 7.15 (t, 1H, H-7, J = 8.0 Hz); 7.21 (t, 1H, 
H-6, J = 8.0 Hz); 7.35 (d, 1H, H-8, J = 8.0 Hz); 7.53 (d, 1H, H-5, J = 8.0 Hz); 
7.95 (s, 1NH); (B) : 1.60 (s, 9H, Boc); 2.55-2.62 (m, 1H, H-2’a); 3.05-3.18 (m, 
2H, H-4a and H-2’b); 3.46-3.57 (m, 3H, H-4b and H-3’); 3.66 (s  3   CH3); 4.44 
(d, 1H, H-1a, J = 16.0 Hz); 4.98 (d, 1H, H-3, J = 4.0 Hz); 5.27 (d, 1H, H-1b, J = 
16.0 Hz); 5.32 (d, 1H, NHBoc, J = 8.0 Hz); 7.15 (t, 1H, H-7, J = 8.0 Hz); 7.21 (t, 
1H, H-6, J = 8.0 Hz); 7.35 (d, 1H, H-8, J = 8.0 Hz); 7.53 (d, 1H, H-5, J = 8.0 Hz); 
8.00 (s, 1NH);  
13
C NMR (CDCl3, 100 MHz) (A + B) : 22.9; 23.9; 28.4; 34.0; 
34.2; 36.2; 39.0; 41.4; 50.6; 52.5; 52.8; 54.8; 79.6; 110.9; 118.09; 118.3; 118.6; 
119.5; 119.8; 122.1; 122.3; 126.6; 128.1; 136.5; 170.8; 171.4. HR-MS m/z calcd 
for C21H28N3O5, 402.2023; [(M+H)
+





H NMR (CDCl3, 400 MHz): (A) : 1.50 (s, 9H, Boc); 3.10-3.16 (m, 
1H, H-4a); 3.48 (d, 1H, H-4b, J = 16.0 Hz); 3.62 (s, 3H, CH3); 4.12 (dd, 1H, H-
2’a  J’ = 4.0, J” = 8.0 Hz); 4.23-4.26 (m, 1H, H-2’b); 4.65 (d  1    -1a, J = 12.0 
Hz); 4.76 (d, 1H, H-1b, J = 12.0 Hz); 5.59 (d, 1H, NHBoc, J = 8.0 Hz); 5.86 (d, 
1H, H-3, J = 4.0 Hz); 7.12-7.23 (m, 2H, H-6 and H-7); 7.28-7.37 (m, 1H, H-8); 
7.50-7.53 (m,1H, H-5); 8.42 (s, 1H, NH); (B) : 1.51 (s, 9H, Boc); 3.10-3.16 (m, 
1H, H-4a); 3.50 (d, 1H, H-4b, J = 16.0 Hz); 3.65 (s, 3H, CH3); 4.20 (dd, 1H, H-
2’a  J’ = 4.0, J” = 8.0 Hz); 4.23-4.26 (m, 1H, H-2’b); 4.51 (d  1    -1a, J = 12.0 
Hz); 4.78 (d, 1H, H-3, J = 4.0 Hz); 5.23 (d, 1H, H-1b, J = 12.0 Hz); 5.57 (d, 1H, 
NHBoc, J = 8.0 Hz); 7.12-7.23 (m, 2H, H-6 and H-7); 7.28-7.37 (d, 1H, H-8); 
7.50-7.53 (d, 1H, H-5); 8.42 (s, 1H, NH);
13
C NMR (CDCl3, 100 MHz) (A + B) : 
22.8; 23.8; 28.4; 28.4; 39.5; 40.5; 43.0; 51.2; 52.6; 52.9; 54.1; 80.1; 105.0; 106.7; 
98 
 
111.01; 111.06; 118.0; 118.2; 119.64; 119.75; 122.1; 122.3; 126.5; 127.5; 128.8; 
136.5; 155.8; 169.2; 170.4; 171.3. HR-MS m/z: calcd for C20H26N3O5, [(M+H)
+
]: 





H NMR (CDCl3, 400 MHz): (A) : 1.42-1.50 (m, 12H, Boc and CH3); 
2.85 (dd, 1H, H-4a, J’ = 4.0 and J” = 16.0 Hz); 3.36 (d, 1H, H-4b, J = 16.0 Hz); 
3.65 (s, 3H, CH3); 4.81-4.91 (m, 2H, H1a and H-2’); 5.00 (d  1    -1b, J = 16.0 
Hz); 5.58 (d, 1H, NHBoc, J = 8.0 Hz); 5.89 (d, 1H, H-3, J = 4.0 Hz); 7.12-7.18 
(m, 2H, H-6 and H-7); 7.21 (d, 1H, H-8, J = 8.0 Hz); 7.49 (d, 1H, H-5, J = 8.0 
Hz); 8.17 (s, 1H, NH); (B) : 1.42-1.50 (m, 12H, Boc and CH3); 3.18 (dd, 1H, H-
4a, J’ = 8.0 and J” = 16.0 Hz); 3.57 (d, 1H, H-4b, J = 16.0 Hz); 3.63 (s, 3H, CH3); 
4.54 (d, 1H, H1a, J = 16.0 Hz); 4.71-4.74 (m, 1H, H-2’); 5.11 (d  1    -3, J = 4.0 
Hz); 5.20 (d, 1H, H-1b, J = 16.0 Hz); 5.56 (d, 1H, NHBoc, J = 8.0 Hz); 7.12-7.18 
(m, 2H, H-6 and H-7); 7.23 (d, 1H, H-8, J = 8.0 Hz); 7.51 (d, 1H, H-5, J = 8.0 
Hz); 8.16 (s, 1H, NH); 
13
C NMR (CDCl3, 100 MHz) (A + B) : 18.6; 19.7; 22.5; 
24.1; 28.4; 39.7; 41.3; 47.0; 51.1; 52.5; 52.84; 54.87; 80.0; 110.9; 118.2; 119.7; 
122.2; 126.5; 127.6; 136.4; 136.5; 155.3; 171.3; 173.5. HR-MS m/z: calcd for 
C21H28N3O5, [(M+H)
+





H NMR (CDCl3, 400 MHz): (A) : 1.43 (s, 9H, Boc); 1.79-1.87 (m, 
3H, CH2 and H-4a); 1.98-2.11 (m, 2H, CH2 );  2.84 (d, 1H, H-4b, J = 16.0 Hz); 
3.46 (s, 3H, CH3); 3.50-3.64 (m, 2H, CH2  H1a  J = 16.0 Hz ); 
4.80-4.87 (m, 2H, H-1b, and H-2’); 5.49 (d  1    -3, J = 8.0 Hz); 6.97-7.10 (m, 
2H, H-6 and H-7); 7.23-7.30 (m, 1H, H-8); 7.46 (d, 1H, H-5, J = 8.0 Hz); 8.08 (s, 
1H, NH); (B) : 1.43 (s, 9H, Boc); 1.67-1.75 (m, 2H, CH2 ); 2.12-2.20 (m, 2H, 
CH2 ); 2.96 (dd, 1H, H-4a, J’ = 4.0, J “ = 16.0 Hz); 3.40-3.56 (m, 6H, CH3 H-4b, 
CH2 ); 4.44 H1a  J = 16.0 Hz ); 4.70 (m, 1H, H-2’); 4.93 H1b  J 
= 16.0 Hz ); 5.87 (d, 1H, H-3, J = 8.0 Hz); 6.97-7.10 (m, 2H, H-6 and H-7); 7.23-
99 
 
7.30 (m, 1H, H-8); 7.40 (d, 1H, H-5, J = 8.0 Hz); 8.33 (s, 1H, NH);; 
13
C NMR 
(CDCl3, 100 MHz) (A + B) : 21.2; 22.8; 23.5; 24.0; 28.3; 28.4; 29.0; 30.0; 41.1; 
41.3; 46.3; 46.6; 46.9; 50.9; 51.1; 52.2; 52.4; 52.7; 57.1; 57.4; 79.8; 80.2; 106.2; 
108.4; 111.1; 117.9; 118.2; 119.0; 119.7; 121.7; 122.2; 126.4; 127.2; 128.1; 









H NMR (CDCl3, 400 MHz): (A) : 1.50 (s, 9H, Boc); 2.94-3.05 (m, 
3H, H-4a and CH2); 3.42 (d, 1H, H-4b, J = 12.0 Hz); 3.60 (s, 3H, CH3); 4.37 (d, 
1H, H1a, J = 16.0 Hz); 4.69 (d, 1H, H-1b, J = 16.0 Hz); 4.98-5.02 (m, 1H, H-2’); 
5.61 (d, 1H, NHBoc, J = 8.0 Hz);  5.86 (d, 1H, H-3, J = 4.0 Hz); 7.01 (t, 1H, H-7, 
J = 8.0 Hz); 7.11-7.21 (m, 4H, H-6 and aryl); 7.24-7.32 (m, 3H, H-8 and aryl); 
7.50 (d, 1H, H-5, J = 8.0 Hz); 7.96 (s, 1H, NH); (B) : 1.48 (s, 9H, Boc); 2.94-
3.05 (m, 2H, CH2); 3.16-3.21 (m, 1H, H-4a); 3.51 (d, 1H, H-4b, J = 12.0 Hz); 
3.58 (s, 3H, CH3); 4.51 (d, 1H, H1a, J = 16.0 Hz); 4.98-5.02 (m, 1H, H-2’); 5.35 
(t, 1H, H-3, J = 4.0 Hz); 5.38 (d, 1H, H-1b, J = 16.0 Hz); 5.61 (d, 1H, NHBoc, J = 
8.0 Hz);  6.86 (t, 1H, H-7, J = 8.0 Hz); 7.11-7.21 (m, 4H, H-6 and aryl); 7.24-7.32 
(m, 3H, H-8 and aryl); 7.50 (d, 1H, H-5, J = 8.0 Hz); 8.57 (s, 1H, NH); 
13
C NMR 
(CDCl3, 100 MHz) (A + B) : 22.9; 24.4; 28.3; 28.4; 38.7; 39.4; 40.7; 41.2; 51.1; 
51.9; 52.3; 52.5; 52.8; 55.0; 80.0; 105.3; 106.4; 110.9; 111.0; 118.04; 118.08; 
119.51; 119.54; 121.91; 122.05; 126.5; 126.7; 126.8; 127.9; 128.2; 128.5; 129.1; 











H NMR (CDCl3, 400 MHz): (A) : 1.00 (d, 3H, CH3, J = 8.0 Hz); 
1.07 (d, 3H, CH3, J = 8.0 Hz);1.57-1.71 (m, 2H, CH2); 1.84-1.87 (m, 1H, CH); 
2.70 (dd, 1H, H-4a, J’ = 4.0, J” = 16.0 Hz); 3.25 (d, 1H, H-4b, J = 16.0 Hz); 3.60 
(s, 3H, CH3); 4.85 (d, 1H, H1a, J = 12.0 Hz); 4.96 (t, 1H, H-2’  J = 12.0 Hz); 
100 
 
5.05-5.18 (m, 3H, H-1b and CH2 benzyl); 5.77 (d, 1NH, J = 12.0 Hz); 5.87 (d, 1H, 
H-3, J = 4.0 Hz); 7.11-7.20 (m, 2H, H-6 and H-7); 7.24 (d, 1H, H-8, J = 8.0 Hz); 
7.29-7.38 (m, 5H, aryl); 7.44 (d, 1H, H-5, J = 8.0 Hz); 8.56 (s, 1H, NH); (B) : 
1.00 (d, 3H, CH3, J = 8.0 Hz); 1.07 (d, 3H, CH3, J = 8.0 Hz);1.57-1.71 (m, 2H, 
CH2); 1.84-1.87 (m, 1H, CH); 3.18 (dd, 1H, H-4a, J’ = 4.0, J” = 16.0 Hz); 3.59-
3.65 (m, 4H, H-4b and CH3); 4.52 (d, 1H, H1a, J = 16.0 Hz); 4.84-4.87 (m, 1H, 
H-2’); 5.05-5.18 (m, 3H, H-1b and CH2 benzyl); 5.21 (d, 1H, H-3, J = 4.0 Hz); 
5.77 (d, 1NH, J = 12.0 Hz); 7.11-7.20 (m, 2H, H-6 and H-7); 7.24 (d, 1H, H-8, J = 
8.0 Hz); 7.29-7.38 (m, 5H, aryl); 7.52 (d, 1H, H-5, J = 8.0 Hz); 8.37 (s, 1H, NH); 
13
C NMR (CDCl3, 100 MHz) (A + B) : 21.9; 22.3; 22.4; 23.19; 23.26; 24.0; 
24.7; 39.9; 41.3; 41.8; 43.1; 49.9; 50.1; 51.1; 52.5; 52.8; 55.0; 60.4; 67.00; 67.16; 
105.1; 106.6; 111.0; 118.03; 118.15; 119.51; 119.63; 122.02; 122.09; 126.5; 
127.6; 127.97; 128.02; 128.14; 128.19; 128.5; 129.2; 136.1; 136.6; 156.3; 156.6; 











H NMR (CDCl3, 400 MHz): (A) : 2.98 (dd, 1H, H-4a, J’ = 4.0, J” = 
16.0 Hz); 3.27-3.34 (m, 2H, CH2a,b ); 3.45 (d, 1H, H-4b, J = 16.0 Hz); 3.63 (s, 
3H, CH3); 4.17-4.24 (m, 1H, CHFmoc); 4.38-4.47 (m, 2H, CH2Fmoc); 4.77 (d, 
1H, H1a, J = 12.0 Hz); 5.02-5.14 (m, 1H, H-1b); 5.19 (q, 1H, H-2’); 5.96 (d  2   
H-3 and NHFmoc, J = 8.0 Hz); 7.11-7.50 (m, 15H, H-6, H-7, H-8 and aryl); 7.61 
(t, 1H, aryl, J = 8.0 Hz); 7.78 (d, 1H, H-5, J = 8.0 Hz); 8.29 (s, 1H, NH); (B) : 
2.40 (dd, 1H, H-4a, J’ = 4.0, J” = 16.0 Hz); 3.07 (dd, 1H, CH2a, J’ = 8.0, J” = 
16.0 Hz); 3.15-3.19 (m, 1H, CH2b,); 3.27-3.34 (m, 1H, H-4b); 3.56 (s, 3H, CH3); 
4.17-4.24 (m, 1H, CHFmoc); 4.30 (q, 2H, CH2Fmoc); 4.53 (d, 1H, H1a, J = 12.0 
Hz); 4.93 (d, 1H, H-3, J = 4.0 Hz); 5.02-5.14 (m, 2H, H-1b and H-2’); 5.87 (d  1  
NHFmoc, J = 8.0 Hz); 7.11-7.50 (m, 15H, H-6, H-7, H-8 and aryl); 7.56 (t, 1H, 
aryl, J = 8.0 Hz); 7.80 (d, 1H, H-5, J = 8.0 Hz); 8.23 (s, 1H, NH); 
13
C NMR 
(CDCl3, 100 MHz) (A + B) : 22.7; 23.3; 31.6; 38.6; 40.0; 40.2; 41.5; 47.05; 
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47.08; 50.8; 51.3; 52.5; 52.67; 52.72; 52.86; 55.4; 65.9; 67.2, 105.2; 106.8; 
110.96; 110.99; 118.06; 118.22; 119.62; 119.71; 120.00; 122.04; 122.26; 125.09; 
125.14; 125.21; 126.5; 127.08; 127.12; 127.27; 127.7; 128.5; 128.8; 129.4; 129.7; 
135.8; 136.5; 141.3; 143.9; 155.6; 155.9; 170.5; 171.2; 171.8; 172.3. HR-MS m/z: 
calcd for C37H34N3O5, [(M+H)
+





H NMR (CDCl3, 400 MHz): (A) : 1.50 (s, 9H, Boc); 2.94-3.05 (m, 
3H, H-4a and CH2); 3.42 (d, 1H, H-4b, J = 12.0 Hz); 3.60 (s, 3H, CH3); 4.37 (d, 
1H, H1a, J = 16.0 Hz); 4.69 (d, 1H, H-1b, J = 16.0 Hz); 4.98-5.02 (m, 1H, H-2’); 
5.61 (d, 1H, NHBoc, J = 8.0 Hz);  5.86 (d, 1H, H-3, J = 4.0 Hz); 7.01 (t, 1H, H-7, 
J = 8.0 Hz); 7.11-7.21 (m, 4H, H-6 and aryl); 7.24-7.32 (m, 3H, H- 
8 and aryl); 7.50 (d, 1H, H-5, J = 8.0 Hz); 7.96 (s, 1H, NH); (B) : 1.48 (s, 9H, 
Boc); 2.94-3.05 (m, 2H, CH2); 3.16-3.21 (m, 1H, H-4a); 3.51 (d, 1H, H-4b, J = 
12.0 Hz); 3.58 (s, 3H, CH3); 4.51 (d, 1H, H1a, J = 16.0 Hz); 4.98-5.02 (m, 1H, H-
2’); 5.35 (t  1    -3, J = 4.0 Hz); 5.38 (d, 1H, H-1b, J = 16.0 Hz); 5.61 (d, 1H, 
NHBoc, J = 8.0 Hz);  6.86 (t, 1H, H-7, J = 8.0 Hz); 7.11-7.21 (m, 4H, H-6 and 
aryl); 7.24-7.32 (m, 3H, H-8 and aryl); 7.50 (d, 1H, H-5, J = 8.0 Hz); 8.57 (s, 1H, 
NH); 
13
C NMR (CDCl3, 100 MHz) (A + B) : 22.9; 24.4; 28.29; 28.42; 38.7; 
39.4; 40.7; 41.2; 51.1; 51.8; 52.3; 52.5; 52.8; 55.0; 80.0; 105.3; 106.4; 110.9; 
111.0; 118.04; 118.08; 119.51; 119.54; 121.91; 122.05; 126.5; 126.73; 126.83; 
127.9; 128.2; 128.5; 129.1; 129.5; 135.8; 136.4; 155.2; 170.6; 171.0; 171.7; 
172.21. HR-MS m/z: calcd for C27H32N3O5, [(M+H)
+
]:  478.2336; found 
478.2325.  
(S)-2-((S)-2-((tert-butoxycarbonyl)amino)-3-phenylpropanoyl)-2,3,4,9-
tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid (99). 
63% yield. 
1
H NMR (CDCl3, 400 MHz): (A) : 1.36 (s, 9H, Boc); 2.80-2.88 (m, 
2H, H-4a and CH2a); 3.06-3.15 (m, 1H, CH2b); 3.29-3.41 (m, 1H, H-4b); 4.62 (d, 
1H, H-1a, J = 12.0 Hz); 4.96-5.08 (m, 2H, H1b and H-2’); 5.56 (d  1   N  oc  J 
= 8.0 Hz);  5.87 (d, 1H, H-3, J = 4.0 Hz); 7.06-7.29 (m, 8H, H-6, H-7, H-8 and 
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aryl); 7.46 (d, 1H, H-5, J = 8.0 Hz); 8.49 (s, 1H, NH); (B) : 1.23 (s, 9H, Boc); 
2.37-2.44 (m, 1H, CH2a); 2.94-3.03 (m, 1H, H-4a); 3.06-3.15 (m, 1H, H-4b); 
3.29-3.41 (m, 1H, CH2b); 4.40 (d, 1H, H-1a, J = 12.0 Hz); 4.96-5.08 (m, 3H, H-
1b, H-3 and H-2’); 5.63 (d  1   N  oc  J = 8.0 Hz); 7.06-7.29 (m, 8H, H-6, H-7, 
H-8 and aryl); 7.40 (d, 1H, H-5, J = 8.0 Hz); 8.19 (s, 1H, NH); 
13
C NMR (CDCl3, 
100 MHz) (A + B) : 22.6; 23.2; 28.3; 28.3; 29.7; 38.4; 39.8; 40.1; 41.4; 51.2; 
53.4; 55.3; 60.5; 80.5; 105.3; 106.5; 111.03; 111.09; 118.02; 118.12; 119.47; 
119.53; 121.8; 122.1; 126.5; 126.8; 127.1; 127.9; 128.25; 128.35; 128.58; 128.64; 
129.1; 129.37; 129.46; 129.7; 135.8; 136.36; 136.53; 155.37; 155.55; 172.3; 
172.9; 174.0; 175.2; 176.38. HR-MS m/z: calcd for C26H29N3O5, [(M+H)
+
]: 
464.2180; found 464.2185.  
Synthesis of tert-butyl ((S)-1-((S)-3-(ethylcarbamoyl)-3,4-dihydro-1H-
pyrido[3,4-b]indol-2(9H)-yl)-1-oxo-3-phenylpropan-2-yl)carbamate (100). 
Acid intermediate 99 (2 mmol) was dissolved in 10 mL of DCM/DMF (7:3 v:v) 
and ethylamine hydrochloride (2.4 mmol), PyBop (2.4 mmol) and DIPEA (4.4 
mmol) were successively added. Stirring was continued at room temperature for 
12 h. Afterward, the reaction mixture was concentrated in vacuo, diluted with 
dichloromethane (20 mL), and washed successively with 10% citric acid (2 x 25 
mL), 10% NaHCO3 (2 x 25 mL), and water (2 x 25 mL), dried over Na2SO4 and 
evaporated to dryness. Flash chromatography of the residues with ethyl acetate 
yielded 100 as rotamers mixture. 
59% yield. 
1
H NMR (CDCl3, 400 MHz): (A) : 1.10 (t, 3H, CH3, J = 8.0 Hz); 1.46 
(s, 9H, Boc); 1.66 (dd, 1H, H-4a, J’ = 8.0, J” = 16.0 Hz); 2.97-3.11 (m, 2H, H-3’a 
and H-3’b); 3.15-3.28 (m, 2H, CH2); 3.32 (d, 1H, H4b, J = 16.0 Hz); 4.09 (d, 1H, 
H-1a, J = 20.0 Hz); 4.78 (d, 1H, H-3, J = 8.0 Hz); 4.84 (q, 1H, H-2’); 5.45 (d  1   
H1b, J = 16.0 Hz); 5.60 (d, 1H, NHBoc, J = 8.0 Hz); 7.04-7.23 (m, 8H, H-6, H-7, 
H-8 and aryl); 7.40 (d, 1H, H-5, J = 8.0 Hz); 7.53 (t, 1H, NH, J = 8.0 Hz); 8.64 (s, 
1NH). (B) : 0.97 (t, 3H, CH3, J = 8.0 Hz); 1.46 (s, 9H, Boc); 2.89 (dd, 1H, H-4a, 
J’ = 8.0, J” = 16.0 Hz); 2.97-3.11 (m, 2H, H-3’a and  -3’b); 3.15-3.28 (m, 2H, 
CH2); 3.37 (d, 1H, H4b, J = 16.0 Hz); 4.50 (d, 1H, H-1a, J = 16.0 Hz); 5.07 (d, 
1H, H1b, J = 16.0 Hz); 5.13 (q, 1H, H-2’); 5.57 (d  1   N  oc  J = 8.0 Hz); 5.70 
103 
 
(d, 1H, H-3, J = 8.0 Hz); 7.04-7.23 (m, 8H, H-6, H-7, H-8 and aryl); 7.46 (d, 1H, 
H-5, J = 8.0 Hz); 7.53 (t, 1H, NH, J = 8.0 Hz); 8.85 (s, 1NH). 
13
C NMR (CDCl3, 
100 MHz) (A + B) : 14.4; 14.7; 21.4; 22.1; 28.31; 28.38; 34.6; 35.0; 38.63; 
38.80; 39.4; 41.7; 52.4; 56.1; 65.9; 80.2; 80.7; 106.5; 110.8; 111.0; 118.09; 
118.16; 119.1; 119.3; 121.5; 121.8; 126.6; 127.1; 127.4; 127.90; 127.97; 128.47; 
128.58; 129.0; 129.2; 129.5; 135.4; 136.5; 155.3; 156.2; 168.3; 169.5; 172.4; 
172.6. HR-MS m/z: calcd for C28H35N4O4, [(M+H)
+





H NMR (CDCl3, 400 MHz) : (A): 1.44 (s, 9H, Boc); 2.72-2.80 (m, 
2H, H-4a,b); 2.95-3.12 (m, 2H, CH2a,b); 3.64-3.71 (m, 1H, H-3a);  3.95-4.01 (m, 
1H, H-3b); 4.68 (d, 1H, H-1a, J = 16.0 Hz);  4.85 (d, 1H, H-1b, J = 16.0 Hz); 5.04 
(q, 1H, H-2’); 5.44 (d  1   N  oc  J = 8.0 Hz); 7.07-7.35 (m, 8H, H-6, H-7, H-8 
and aryl); 7.43 (d, 1H, H-5, J = 8.0 Hz); 7.94 (s, 1H, NH); (B) : 1.60 (s, 9H, 
Boc); 2.39-2.46 (m, 2H, H-4a,b); 2.95-3.12 (m, 2H, CH2a,b); 3.42-3.49 (m, 1H, 
H-3a); 3.79-3.85 (m, 1H, H-3b); 4.53 (d, 1H, H-1a, J = 16.0 Hz);  4.85 (d, 1H, H-
1b, J = 16.0 Hz); 4.90 (q, 1H, H-2’); 5.55 (d  1   N  oc  J = 8.0 Hz); 6.97 (t, 1H, 
H-7, J = 8.0 Hz); 7.07-7.35 (m, 7H, H-6, H-8 and aryl); 7.47 (d, 1H, H-5, J = 8.0 
Hz); 7.75 (s, 1H, NH); 
13
C NMR (CDCl3, 100 MHz) (A + B) : 20.8; 21.7; 28.4; 
40.4; 40.70; 40.75; 43.2; 43.8; 51.7; 52.1; 79.6; 110.1; 118.0; 119.7; 120.1; 122.0; 
127.0; 128.3; 128.5; 129.25; 129.43; 136.1; 136.3; 171.0; 171.4. HR-MS m/z 
calcd for C25H30N3O3, [(M+H)
+





H NMR (CDCl3, 400 MHz) : (A) : 1.49 (s, 9H, Boc); 2.97 (dd, 1H, 
H-4a, J’ = 8.0, J” = 16.0 Hz); 3.64 (d, 1H, H-4b, J = 16.0 Hz); 3.80 (s, 3H, CH3); 
4.10 (d, 1H, H-2’a  J” = 12.0 Hz); 4.24 (d, 1H, H-2’b  J” = 12.0 Hz); 4.65 (d, 1H, 
H-3, J = 8.0 Hz); 5.28 (s, 1H, NH-Boc); 6.81 (s, 1H, H-1); 7.18-7.32 (m, 7H, H-6, 
H-7, H-8 and aryl); 7.55 (d, 1H, H-5, J = 8.0 Hz); 8.03 (s, 1H, NH-9). (B) : 1.58 
(s, 9H, Boc); 2.55 (dd, 1H, H-4a, J’ = 8.0, J” = 16.0 Hz); 3.25-3.30 (m, 1H, H-
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4b); 3.72 (s, 3H, CH3); 4.14 (d, 1H, H-2’a  J” = 12.0 Hz); 4.21 (d, 1H, H-2’b  J” 
= 12.0 Hz); 4.48 (d, 1H, H-3, J = 8.0 Hz); 5.33 (s, 1H, NH-Boc); 6.83 (s, 1H, H-
1); 7.18-7.32 (m, 7H, H-6, H-7, H-8 and aryl); 7.59 (d, 1H, H-5, J = 8.0 Hz); 8.03 
(s, 1H, NH-9). 
13
C NMR (CDCl3, 100 MHz) (A + B) : 22.1; 22.2; 28.55; 28.63; 
43.1; 52.7; 53.2; 58.1, 58.7; 62.1; 80.0; 106.5; 111.2; 113.6; 118.0; 119.2; 121.6; 
126.4; 130.2; 130.8; 136.8; 139.3; 157.5; 168.0; 170.4. HR-MS m/z: calcd for 
C26H29ClN3O5, [(M+H)
+





H NMR (CD3OD, 400 MHz) : (A) : 1.39 (s, 9H, Boc); 3.14 (dd, 1H, 
H-4a, J’ = 8.0, J” = 16.0 Hz); 3.72-3.75 (m, 4H, CH3 and H-4b); 3.99 (d, 1H, H-
2’a  J = 16.0 Hz); 4.10 (d, 1H, H-2’b  J = 16.0 Hz); 5.02-5.06 (m, 1H, H-3); 5.59 
(s, 1H, NH-Boc); 6.08 (s, 1H, H-1); 7.11-7.28 (m, 7H, H-6, H-7, H-8 and aryl); 
7.49 (d, 1H, H-5, J = 8.0 Hz); 8.04 (s, 1H, NH-9). (B) : 1.41 (s, 9H, Boc); 3.07 
(dd, 1H, H-4a, J’ = 8.0, J” = 16.0 Hz3.72-3.75 (m, 4H, CH3 and H-4b); 4.03 (d, 
1H, H-2’a  J = 16.0 Hz); 4.25 (d, 1H, H-2’b  J = 16.0 Hz); 5.02-5.06 (m, 1H, H-
3); 5.66 (s, 1H, NH-Boc); 6.21 (s, 1H, H-1); 7.11-7.28 (m, 7H, H-6, H-7, H-8 and 
aryl); 7.54 (d, 1H, H-5, J = 8.0 Hz); 8.10 (s, 1H, NH-9). 
13
C NMR (CDCl3, 100 
MHz) (A + B) : 23.4; 23.6; 28.33; 28.39; 43.1; 52.4; 56.0; 57.2; 80.1; 107.1; 
110.6; 114.2; 118.5; 119.1; 121.8; 127.5; 128.9; 130.0; 136.4; 138.9; 155.1; 
170.3; 172.1. .HR-MS m/z: calcd for C26H29ClN3O5, [(M+H)
+
]: 498.1790, 






H NMR (CDCl3, 400 MHz) : : 1.46 (s, 9H, Boc); 3.05 (dd, 1H, H-
4a, J’ = 8.0, J” = 16.0 Hz); 3.10 (s, 3H, OCH3); 3.68 (d, 1H, H-4b, J = 16.0 Hz); 
3.78 (s, 3H, CH3); 4.12 (d, 1H, H-2’a  J” = 12.0 Hz); 4.25 (d, 1H, H-2’b  J” = 
12.0 Hz); 4.73 (d, 1H, H-3, J = 8.0 Hz); 5.63 (s, 1H, NH-Boc); 6.79 (d, 2H, aryl, J 
= 8.0 Hz); 6.94 (s, 1H, H-1); 7.16-7.24 (m, 4H, H-6, H-7 and aryl); 7.29 (d, 1H, 
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H-8, J = 8.0 Hz); 7.62 (d, 1H, H-5, J = 8.0 Hz); 7.80 (s, 1H, NH-9). 
13
C NMR 
(CDCl3, 100 MHz) : 21.6; 28.4; 43.1; 51.6; 51.9; 52.3; 55.3; 79.8; 107.5; 111.0; 
113.5; 118.6; 119.8; 122.5; 126.4; 129.9; 130.8; 136.4; 155.7; 159.4; 168.7; 170.0. 
HR-MS m/z: calcd for C27H32N3O6,
 [(M+H)
+






H NMR (CDCl3, 400 MHz) : (A) : 1.43 (s, 9H, Boc); 3.26 (dd, 1H, 
H-4a, J’ = 8.0, J” = 16.0 Hz); 3.65-3.70 (m, 4H, OCH3 and H-4b); 3.78 (s, 3H, 
CH3); 4.08-4.16 (m, 1H, H-2’a and  -2’b); 5.10-5.14 (m, 1H, H-3); 5.48 (s, 1H, 
NH-Boc); 5.96 (s, 1H, H-1); 6.84 (d, 2H, aryl, J = 8.0 Hz); 7.11-7.19 (m, 2H, H-6, 
and H-7); 7.23-7.27 (m, 3H, H-8 and aryl); 7.54 (d, 1H, H-5, J = 8.0 Hz); 7.86 (s, 
1H, NH-9). (B) : 1.43 (s, 9H, Boc); 3.26 (dd, 1H, H-4a, J’ = 8.0, J” = 16.0 Hz); 
3.65-3.70 (m, 4H, OCH3 and H-4b); 3.78 (s, 3H, CH3); 4.08-4.16 (m, 1H, H-2’a 
and H-2’b); 4.94-4.97 (m, 1H, H-3); 5.48 (s, 1H, NH-Boc); 6.08 (s, 1H, H-1); 
6.84 (d, 2H, aryl, J = 8.0 Hz); 7.11-7.19 (m, 2H, H-6, and H-7); 7.23-7.27 (m, 3H, 
H-8 and aryl); 7.54 (d, 1H, H-5, J = 8.0 Hz); 7.86 (s, 1H, NH-9).  
13
C NMR 
(CDCl3, 100 MHz) (A + B) : 22.5; 28.3; 43.9; 50.9; 52.4; 55.3; 56.8; 79.6; 108.5; 
111.1; 114.8; 118.4; 119.9; 122.5; 126.3; 127.9; 136.7; 155.6; 171.2; 171.5. HR-
MS m/z: calcd for C27H32N3O6,
 [(M+H)
+
]: 494.2286; found 494.2272.  
General procedure for the synthesis of derivatives 104 and 105. 
A solution of N-Boc-L-Phe-OH (8.0 mmol), 2-chloro-1-methylpyridinium iodide 
(Mukayiama reagent, 8.0 mmol) and triethylamine (8.0 mmol) in dichloromethane 
(50 mL) was refluxed for 15 min. Then  (1S,3S)/(1R,3S)-methyl 1-(4-
methoxyphenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate (4 
mmol) or (1S,3S)/(1R,3S)-methyl 1-isobutyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole-3-carboxylate (4 mmol) was added. Stirring was continued for 24 h. 
Afterward, the reaction mixture was diluted with dichloromethane (20 mL), and 
the resulting solution was washed successively with 10% citric acid (2 x 25 mL), 
10% NaHCO3 (2 x 25 mL), and water (2 x 25 mL), dried over Na2SO4 and 
106 
 
evaporated to dryness. Flash chromatography of the residues, using n-
hexane/ethyl acetate 2/1 v/v as eluent, yielded, the corresponding N-protected 






H NMR (CDCl3, 400 MHz) : (A) : 1.35 (s, 9H, Boc); 2.10-2.18 (m, 
1H, H-4a); 2.87-3.03 (m, 5H, CH2a benzyl, CH2b benzyl and OCH3); 3.34 (d, 1H, 
H-4b, J = 16.0 Hz); 3.65 (s, 3H, CH3); 4.63-4.67 (m, 1H, H-3); 4.92-4.95 (m, 1H, 
H-2’); 5.45 (d  1   N -Boc, J = 8.0 Hz); 6.76 (s, 1H, H-1); 6.65 (d, 2H, aryl, J = 
8.0 Hz); 6.81 (d, 1H, aryl, J = 8.0 Hz); 6.90-7.24 (m, 9H, H-6, H-7, H-8 and aryl); 
7.44 (d, 1H, H-5, J = 8.0 Hz); 7.79 (s, 1H, NH-9). (B)  1.34 (s, 9H, Boc); 2.67 
(dd, 1H, CH2a benzyl, J’ = 8.0, J” = 12.0 Hz); 2.87-3.03 (m, 4H, CH2b benzyl and 
OCH3); 3.17 (d, 1H, H-4b, J = 16.0 Hz); 3.44 (dd, 1H, H-4a, J’ = 4.0, J” = 12.0 
Hz); 3.68 (s, 3H, CH3); 4.63-4.67 (m, 1H, H-3); 5.02-5.06 (m, 1H, H-2’); 5.58 (d  
1H, NH-Boc, J = 8.0 Hz); 6.51 (s, 1H, H-1); 6.70 (d, 2H, aryl, J = 8.0 Hz); 6.88 
(d, 1H, aryl, J = 8.0 Hz); 6.90-7.24 (m, 9H, H-6, H-7, H-8 and aryl); 7.44 (d, 1H, 
H-5, J = 8.0 Hz); 7.69 (s, 1H, NH-9).. 
13
C NMR (CDCl3, 100 MHz) (A + B) : 
28.1; 28.3; 29.7; 31.4; 40.5; 41.7; 51.7; 52.1; 55.2; 52.4; 55.7; 57.7; 79.7; 80.1; 
107.5; 113.4; 114.2; 118.4; 118.56; 119.7; 122.3; 126.4; 127.0; 127.3; 128.0; 
128.24; 128.36; 128.; 128.89; 129.1; 129.42; 129.58; 129.61; 130.0; 130.3; 130.9; 
131.3; 136.0; 136.7; 154.8; 159.2; 170.12; 172.15; 172.27; 173.0. HR-MS m/z: 
calcd for C34H38N3O6, [(M+H)
+






H NMR (CDCl3, 400 MHz) : (A) : 1.42 (s, 9H, Boc); 2.77 (dd, 1H, 
H-4a, J’ = 4.0, J” = 12.0 Hz); 2.97-3.07 (m, 1H, H- CH2a benzyl and CH2b 
benzyl); 3.25-3.33 (m, 1H, H-4b); 3.58 (s, 3H, OCH3); 3.79 (s, 3H, CH3); 4.81 (d, 
1H, H-2’  J = 4.0 Hz); 4.85-4.91 (m, 1H, H-3); 5.44 (t, 1H, NH-Boc, J = 8.0 Hz); 
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6.03 (s, 1H, H-1); 6.74 (d, 1H, aryl, J = 8.0 Hz); 6.79-6.85 (m, 2H, aryl); 7.01 (d, 
2H, aryl); 7.07-7.32 (m, 7H, H-6, H-7, H-8 and aryl); 7.54 (d, 1H, H-5, J = 8.0 
Hz); 7.75 (s, 1H, NH-9). (B) : 1.46 (s, 9H, Boc); 2.84-2.92 (m, 2H, CH2a benzyl 
and H-4a); 2.97-3.07 (m, 1H, CH2b benzyl); 3.44 (d, 1H, H-4b, J = 16.0 Hz); 3.70 
(s, 3H, OCH3); 3.77 (s, 3H, CH3); 4.02 (d, 1H, H-3, J = 8.0 Hz); 5.12-5.17 (m, 
1H, H-2’); 5.44 (t  1   N -Boc, J = 8.0 Hz); 5.82 (s, 1H, H-1); 6.79-6.85 (m, 2H, 
aryl); 6.91 (d, 1H, aryl, J = 8.0 Hz); 7.01 (d, 2H, aryl); 7.07-7.32 (m, 7H, H-6, H-
7, H-8 and aryl); 7.47 (d, 1H, H-5, J = 8.0 Hz); 7.75 (s, 1H, NH-9). 
13
C NMR 
(CDCl3, 100 MHz) (A + B) : 28.11; 28.20; 39.8; 40.7; 52.1; 52.3; 52.6; 53.0; 
53.2; 53.4; 55.3; 56.6; 57.3; 61.2; 79.6; 80.0; 110.2; 111.0; 113.7; 114.1; 118.1; 
118.4; 119.8; 122.1; 122.5; 126.1; 126.4; 128.0; 128.5; 128.9; 129.3; 129.7; 
130.3; 131.0; 134.1; 134.3; 135.6; 136.4; 136.6; 158.7; 159.6; 171.5; 172.2; 
174.3; 174.4. HR-MS m/z: calcd for C34H38N3O6, [(M+H)
+






H NMR (CDCl3, 400 MHz) : (A) : 0.95 (d, 3H, CH3, J = 8.0 Hz); 
1.02 (d, 3H, CH3, J = 8.0 Hz); 1.33-1.43 (m, 11H, Boc and CH2); 1.70-1.77 (m, 
1H, CH); 2.06 (dd, 1H, H-4a, J’ = 8.0, J” = 16.0 Hz); 2.86-2.97 (m, 1H, CH2a 
benzyl); 3.15-3.20 (m, 2H, H-4b and CH2b benzyl); 3.57 (s, 3H, CH3); 4.62 (d, 
1H, H-3, J = 8.0 Hz); 4.88-4.98 (m, 1H, H-2’); 5.42 (d  1   N -Boc, J = 8.0 Hz); 
5.57 (t, 1H, H-1, J = 8.0 Hz); 7.01-7.12 (m, 3H, aryl and H-6); 7.17-7.26 (m, 5H, 
aryl, H-7 and H-8); 7.35 (d, 1H, H-5, J = 8.0 Hz); 7.70 (s, 1H, NH-9). (B) : 0.76 
(d, 3H, CH3, J = 8.0 Hz); 0.80 (d, 3H, CH3, J = 8.0 Hz); 1.18-1.23 (m, 11H, Boc 
and CH2); 1.53-1.60 (m, 1H, CH); 2.86-2.97 (m, 2H, CH2a benzyl and H-4a); 
3.15-3.20 (m, 1H, CH2b benzyl); 3.26 (dd, 1H, H-4b, J’ = 8.0, J” = 12.0 Hz); 3.59 
(s, 3H, CH3); 4.88-4.98 (m, 2H, H-3 and NH-Boc); 5.33 (t, 1H, H-2’  J = 8.0 Hz); 
5.48 (t, 1H, H-1, J = 8.0 Hz); 7.01-7.12 (m, 3H, aryl and H-6); 7.17-7.26 (m, 5H, 
aryl, H-7 and H-8); 7.43 (d, 1H, H-5, J = 8.0 Hz); 7.99 (s, 1H, NH-9). 
13
C NMR 
(CDCl3, 100 MHz) (A + B) : 21.8; 22.1; 22.7; 23.47; 23.65; 24.8; 25.9; 28.18; 
28.36; 40.6; 44.9; 45.5; 48.6; 51.1; 51.75; 51.83; 52.2; 52.4; 52.6; 53.5; 79.7; 
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80.1; 105.0; 110.7; 111.0; 118.1; 118.3; 119.68; 119.79; 122.1; 126.4; 126.8; 
127.0; 128.4; 128.6; 129.4; 129.9; 132.9; 134.0; 136.0; 136.8; 154.8; 171.08; 
172.25. HR-MS m/z: calcd for C31H40N3O5, [(M+H)
+





H NMR (CDCl3, 400 MHz) : (A) δ: 0.89 (d  3   CH3, J = 8.0 Hz); 
1.05 (d, 3H, CH3, J = 8.0 Hz); 1.44-1.49 (m, 11H, Boc and CH2); 1.81-1.86 (m, 
1H, CH); 2.85-2.92 (m, 1H, CH2a benzyl); 2.98-3.04 (m, 1H, H-4a); 3.12-3.23 (m, 
2H, H-4b and CH2b benzyl); 3.77 (s, 3H, CH3); 4.17-4.21 (m, 1H, H-3); 4.57 (t, 
1H, H-1, J = 8.0 Hz); 4.83-4.93 (m, 1H, H-2’); 5.34-5.42 (m, 1H, NH-Boc); 6.81 
(t, 2H, aryl, J = 8.0 Hz), 7.01 (d, 2H, aryl, J = 8.0 Hz); 7.06-7.21 (m, 3H, aryl, H-7 
and H-6); 7.26-7.34 (m, 1H, H-8); 7.48 (d, 1H, H-5, J = 8.0 Hz); 7.58 (s, 1H, NH-
9). (B) δ: 0.83 (d  3   CH3, J = 8.0 Hz); 1.10 (d, 3H, CH3, J = 8.0 Hz); 1.26-1.31 
(m, 11H, Boc and CH2); 1.61-1.70 (m, 1H, CH); 2.48 (dd, 1H, H-4a, J’ = 8.0, J” 
= 16.0 Hz); 2.85-2.92 (m, 1H, CH2a benzyl); 2.98-3.04 (m, 1H, CH2b benzyl); 
3.30 (d, 1H, H-4b, J = 12.0 Hz); 3.43 (s, 3H, CH3); 4.37-4.40 (m, 1H, H-3); 4.69-
4.77 (m, 1H, H-2’); 5.34-5.42 (m, 1H, H-1); 5.54 (d, 1H, NH-Boc, J = 8.0 Hz); 
6.72 (t, 2H, aryl, J = 8.0 Hz), 7.06-7.21 (m, 3H, aryl, H-7 and H-6); 7.26-7.34 (m, 
3H, H-8 and aryl); 7.43 (d, 1H, H-5, J = 8.0 Hz); 8.23 (s, 1H, NH-9). 
13
C NMR 
(CDCl3, 100 MHz) (A + B) : 22.1; 22.9; 23.0; 23.4; 25.1; 26.1; 29.1; 29.9; 41.6; 
44.3; 46.1; 49.6; 50.9; 51.3; 52.0; 52.6; 53.3; 53.6; 80.1; 81.3; 107.0; 110.5; 
111.1; 118.3; 120.4; 121.7; 122.7; 125.8; 126.1; 126.4; 128.1; 129.7; 130.0; 
130.5; 133.4; 134.2; 136.7; 137.0; 155.1; 171.5; 172.8. HR-MS m/z: calcd for 
C31H40N3O5, [(M+H)
+







Methods for the synthesis of (2S, 5S, 11bS)-methyl2-benzyl-3-oxo-
2,3,5,6,11,11b-hexahydro-1H-imidazo[1',2':1,2] pyrido[3,4-b]indole-5-
carboxylate (81) and (3S,12aS)-3-benzyl-2,3,12,12a-tetrahydropyrazino 
[1',2':1,6] pyrido[3,4-b]indole-1,4(6H,7H)-dione (80).  
Method A: Cyclization under redox (TEMPO) and acidic conditions (TFA) 
Intermediate 79 (1.0 mmol) was dissolved in 20 mL of DCM/TFA (3:1 v:v, Table 
1 entry 1). Triethylsylane. (0.25 mmol) and (2,2,6,6-Tetramethylpiperidin-1-
yl)oxyl (TEMPO) were added.  Reactions were stirred at room temperature for 2 
hours. Then, the solvent was evaporated in vacuo, the crude product was 
reconstituted in DCM (30 mL) and washed with water and 3M NaOH solution 
adjusting the pH to 7. The organic phase was washed with brine (2x 25 mL), dried 
over Na2SO4 and evaporated to dryness. Final compounds were isolated by flash-
chromatography using ethyl acetate as solvent.   
Method B: Cyclization under oxygen flush and acidic conditions (TFA) 
Intermediate 79 (1.0 mmol) was dissolved in 20 mL of MeOH/TFA (3:1 v:v, 
Table 1 entry 2) and added with 0.25 mmol of triethylsylane. In a separate round-
bottomed flask, hydrogen peroxide solution (12.5 ml, 30 % w/w in water) 
acidified with H2SO4 (0.15 mmol, 7.9 ml) was added dropwise with aqueous 
KMnO4 (0.05 mol, 12.5 mL) for 20 minutes. The oxygen thus generated was 
bubbled in the solution containing intermediate 79 that was maintained under 
stirring at room temperature for 2 hours. The mixture was then subjected to the 
same work up procedure described for method A.  
Method C: Cyclization under redox (Perbenzoyc acid) and acidic conditions 
(TFA) 
Intermediate 79 (1.0 mmol) was dissolved in 20 mL of DCM/TFA (3:1 v:v, Table 
1 entry 3) Then 0.25 mmol of triethylsylane.and 1.0 mmol of perbenzoyc acid 
were added.  Reactions were stirred at room temperature for 2 hours and treated as 
described for method A.   
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Method D: Cyclization under redox (Perbenzoyc acid) and acidic conditions 
(37%HCl) 
Intermediate 79 (1.0 mmol) was dissolved in 20 mL of aqueous HCl 
(37%)/MeOH (9.8:0.2 v:v, Table 1, entry 4). Then 0.25 mmol of 
triethylsylane.and 1.0 mmol of perbenzoyc acid were added.  Reactions were 
stirred at room temperature for 2 hours and treated as described for method A.   
Method E: Cyclization under acidic conditions 
Intermediate 79 (1.0 mmol) was dissolved in a 20 mL volume consisting of 
DCM/TFA (3:1 v:v, Table 1 entry 5) and added with 0.25 mmol of triethylsylane. 
Reaction was stirred at room temperature for 2 hours and treated as described for 
method A.   
Method F: Cyclization using inorganic oxidating reagents (oxone, KMnO4, 
K2Cr2O7, HIO4, FeCl3) 
Intermediate 79 (1.0 mmol) was dissolved in a 10 mL MeOH (Table 1 entry 6-10) 
and added with a solution of oxidating agent (2.0 mmol) in H2O/TFA (1/2 v/v, 30 
mL) and 0.25 mmol of triethylsylane. Reaction was stirred at room temperature 
for 2 hours and treated as described for method A.   
 
(2S,5S,11bS)-methyl-2-benzyl-3-oxo-2,3,5,6,11,11b-hexahydro-1H-
imidazo[1',2':1,2]pyrido[3,4-b] indole-5-carboxylate (81). 
Obtained from intermediate 79 using methods A, B, C, D and E.  
For the obtained yield see table 1. [α]
25
D : 84.00 ± 0.08 (c = 0.10, MeOH). 
1
H 
NMR (CD3OD  400 M  ) : δ: 2.68 (dd  1   CH2
’
, J’ = 8.0 and J” = 12.0 Hz);  
2.92 (dd, 1H, H-6’  J’ = 8.0, J” = 16.0 Hz);  3.06 (dd, 1H, CH2
”
, J’ = 4.0 and J” = 
16.0 Hz); 3.25-3.30 (m, 1H, H-6”); 3.60 (s  3   CH3);  3.98 (dd, 1H, H-2,  J’ = 
4.0, J” = 12.0 Hz); 5.19 (d, 1H, H-5,  J = 8.0 Hz); 5.84 (s, 1H, H-11b); 6.93-6.99 
(m, 2H, H-8 and aryl); 7.03-7.07 (m, 3H, H-9 and aryl); 7.15 (d, 2H, aryl, J = 8.0 
Hz); 7.26 (d, 1H, H-10, J = 8.0 Hz); 7.34 (d, 1H, H-7, J = 8.0 Hz);  
13
C NMR 
(CD3OD  100 M  ) δ: 24.7 (C-6); 38.4 (CH2); 52.4 (C-5); 53.3 (CH3); 63.4 (C-2); 
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67.9 (C-11b); 107.1 (C-6a); 112.5 (C-10); 119.4 (C-7); 120.4 (C-8); 123.5 (C-9); 
127.6 (aryl); 138.5 (C- 10a); 129.3 (aryl);130.55 (aryl), 131.9 (C-11a), 127.7 (C-
6b), 139.1 (aryl), 172.4 (C=O); 176.0 (C-3).  HR-MS m/z: calcd. for C22H22N3O3, 
[(M+H)
+
]: 376.1656; found 376.1662. 
(3S,12aS)-3-benzyl-2,3,12,12a-tetrahydropyrazino[1',2':1,6]pyrido[3,4-
b]indole-1,4(6H,7H)-dione (80). 
Obtained from intermediate 79 using method A and E.  
For the obtained yield see table 1. [α]
25
D : -68.000 ± 0.00108 (c = 0.10, MeOH). 
1
H NMR (CD3OD  400 M  ) : δ: 0.80 (t  1    -12’  J = 16 Hz);  2.65 (dd, 1H, 
H-12”  J’ = 4.0, J” = 16.0 Hz); 2.90 (dd, 1H, CH2 benzyl,  J’ = 4.0, J” = 12.0 Hz);  
3.27 (dd, 1H, CH2 benzyl,  J’ = 4.0, J” = 16.0 Hz);  3.98 (dd, 1H, H-12a,  J’ = 4.0, 
J” = 12.0 Hz);  4.24 (d, 1H, H-6’  J = 16.0 Hz); 4.40 (t, 1H, H-3, J = 4.0 Hz);  
5.42 (d, 1H, H-6”);  6.89 (t  1    -9, J = 8.0 Hz); 6.94-7.01 (m, 6H, H-10 and 
aryl); 7.10 (d, 1H, H-8, J = 8.0 Hz); 7.20 (d, 1H, H-11, J = 8.0 Hz); 
13
C NMR 
(CD3OD  100 M  ) δ: 27.4 (C-12); 41.1 (CH2 benzyl and C-6); 50.5 (C-12a); 
57.6 (C-3); 107.3 (C-11b); 112.0 (C-11); 118.6 (C-10); 120.1 (C-9); 122.6 (C-8); 
127.9 (C-6a); 128.5 (aryl); 129.4 (C-7a); 129.7, 131.6 (aryl); 136.5 (C-11a); 138.1 
(aryl); 166.5 (C-4); 169.5 (C-1).  HR-MS m/z: calcd. for C21H20N3O2, [(M+H)
+
]: 
346.1550; found 346.1556. 
Synthesis of (S)-methyl 2-((S)-2-((tert-butoxycarbonyl)amino)-3-
phenylpropyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate (82). 
Derivative 82 was obtained by reductive amination reaction starting from 59 (4.0 
mmol), wich was reacted under reflux with Boc-L-Phenylalanilal (6.0 mmol) in 
ethanol (20 mL) for 3 hours. The reaction was then cooled to room temperature 
and NaBH4 (12 mmol) was added portionwise. The mixture was allowed to react 
for 1hour, then 10% citric acid was added portionwise till pH 7, ethanol was 
evaporated under vacuum and 25 mL of dichloromethane were added. The 
organic phase was wash twice with water (25 mL), dried over Na2SO4 and 
evaporated to dryness. The crude product was purified by flash chromatography 




H NMR (CDCl3  400 M  ): δ: 1.34 (s  9    oc); 2.58 (dd  1   CH2a, J’ = 8.0, 
J” = 12.0 Hz); 2.80-2.85 (m, 3H, H-4a, H-1’a and CH2b); 3.03-3.06 (m, 2H, H-
1’b and  -4b); 3.55 (s, 3H, CH3); 3.77 (t, 1H, H-3, J = 8.0 Hz); 3.89-3.93 (m, 2H, 
H-1a and H-2’); 4.00 (d  1    -1b, J = 16.0 Hz); 4.84-4.88 (m, 1H, NHBoc); 
6.99-7.15 (m, 5H, H-6, H-7 and aryl); 7.17-7.24 (m, 3H, H-8 and aryl); 7.39 (d, 
1H, H-5, J = 8.0 Hz); 7.68 (s, 1H, NH); 
13
C NMR (CDCl3  100 M  ) δ: 22.6; 
23.6; 28.4; 31.6; 46.4; 50.9; 51.6; 60.8; 77.3; 110.7; 117.8; 199.4; 121.6; 126.3; 
128.3; 129.6; 136.1; 137.9; 155.7; 173.1. HR-MS m/z: calcd for C27H34N3O4, 
[(M+H)
+
]: 464.2544; found 464.2551.  
(3S,12aS)-3-benzyl-3,4,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-
b]indol-1(2H)-one (83). 
Obtained from intermediate 82 using method C. 
88% yield. [α]
25
D : -82.0 + 0.33 (c = 0.10, MeOH). 
1
H NMR (CDCl3, 400 MHz) : 
δ: 2.82 (dd  1    -4’  J = 12 Hz);  2.88-2.97 (m, 2H, H-4” and  -12’); 3.01 (d  
2H, CH2 benzyl,  J = 8.0 Hz);  3.25 (dd, 1H, H-12a,  J’ = 4.0, J” = 12.0 Hz);  3.40 
(dd, 1H, H-12”   J’ = 4.0, J” = 16.0 Hz);  3.60-3.63 (m, 1H, H-3); 3.71 (d, 1H, H-
6’  J = 12.0 Hz);  3.96 (d, 1H, H-6”  J = 12.0 Hz); 5.93 (s, 1NH); 7.10 (t, 1H, H-
10, J = 8.0 Hz); 7.13-7.18 (m, 3H, H-9 and aryl); 7.24 (t, 1H, aryl, J = 8.0 Hz); 
7.29-7.33 (m, 3H, H-8 and aryl); 7.51 (d, 1H, H-11, J = 8.0 Hz);  
13
C NMR 
(CDCl3  100 M  ) δ: 25.0 (C-12); 42.1 (CH2 benzyl); 52.0 (C-6); 53.0 (C-3); 53.6 
(C-4); 62.0 (C-12a); 108.7 (C-11b); 110.9 (C-8); 118.5 (C-11); 120.1 (C-10); 
122.1 (C-9); 124.5 (C-7a); 127.3; 129.1; 129.5 (aryl); 130.5 (C-6a); 136.3 (C-
11a); 137.8 (aryl); 171.3 (C-1).   HR-MS m/z: calcd for C21H22N3O, [(M+H)
+
]: 
332.1757; found 332.1750. 
(S)-methyl 2-(3-aminopropanoyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-
3-carboxylate (65). 
Obtained from intermediate 64 using method C.  
79% yield.
 1
H NMR (CD3OD, 400 MHz) : δ: (A) 2.54-2.65 (m, 2H, CH2); 2.86-
2.91 (m, 2H, CH2); 3.01 (dd, 1H, H-6’  J’ = 8.0 and J” = 16.0 Hz);  3.42 (d, 1H, 
H-6”  J =16.0 Hz);  3.52 (s, 3H, CH3);  4.24 (d, 1H, H-2’  J = 16.0 Hz); 5.04 (d, 
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1H, H-2”  J = 16.0 Hz); 5.16 (d, 1H, H-5, J = 4.0 Hz); 6.90 (t, 1H, H-8, J = 8.0 
Hz); 6.97 (d, 1H, H-10, J = 8.0 Hz); 7.18 (t, 1H, H-9, J = 8.0 Hz); 7.31 (d, 1H, H-
7, J = 8.0 Hz); 
13
C NMR (CD3OD, 100 MHz) δ: 22.8 (C-6); 35.4 (CH2); 36.8 
(CH2); 38.3 (C-2); 51.0 (CH3); 54.8 (C-5); 104.9 (C-6a); 110.0 (C-8); 116.8 (C-7); 
118.0 (C-8); 120.6 (C-10), 126.4 (C- 10a); 128.5 (C-11a), 137.2 (C-6b), 171.4, 
173.5 (C=O). 
   
1
H NMR (CD3OD, 400 MHz) : δ: (B) 2.54-2.65 (m, 2H, CH2); 2.86-2.91 (m, 3H, 
CH2 and H-6’); 3.36 (d  1    -6”  J =16.0 Hz);  3.50 (s, 3H, CH3);  4.63 (d, 1H, 
H-2’  J = 16.0 Hz); 4.81 (d, 1H, H-2”  J = 16.0 Hz); 5.74 (d, 1H, H-5, J = 4.0 Hz); 
6.90 (t, 1H, H-8, J = 8.0 Hz); 6.97 (d, 1H, H-10, J = 8.0 Hz); 7.18 (t, 1H, H-9, J = 
8.0 Hz); 7.31 (d, 1H, H-7, J = 8.0 Hz); 
13
C NMR (CD3OD, 100 MHz) (A + B) δ: 
21.8 (C-6); 35.4 (CH2); 36.8 (CH2); 40.8 (C-2); 51.0 (CH3); 50.5 (C-5); 104.9 (C-
6a); 110.0 (C-8); 116.8 (C-7); 118.0 (C-8); 120.6 (C-10), 137.2 (C- 10a); 128.5 
(C-11a), 126.4 (C-6b), 171.4, 173.5 (C=O). 
HR-MS m/z calcd for C16H20N3O3, [(M+H)
+
]: 302.1499; found 302.1503. 
(5S,11bS)-methyl-3-oxo-2,3,5,6,11,11b-hexahydro-1H-
imidazo[1',2':1,2]pyrido[3,4-b]indole-5-carboxylate (106). 
Obtained from intermediate 92 using method C.  
70% yield. [α]
25
D : 56.00 ± 0.030 (c = 0.10, MeOH). 
1
H NMR (CDCl3, 400 MHz) 
: δ: 3.19 (dd  1    -6’  J’ = 4.0 and J” = 16.0 Hz);  3.39 (d, 1H, H-6”  J =16.0 
Hz);  3.52 (d, 1H, H-2’  J = 16.0 Hz); 3.66 (d, 1H, H-2”  J = 16.0 Hz); 3.67 (s, 3H, 
CH3);  5.28 (d, 1H, H-5,  J = 4.0 Hz); 6.05 (s, 1H, H-11b); 7.13 (t, 1H, H-8, J = 
8.0 Hz); 7.20 (t, 1H, H-9, J = 8.0 Hz); 7.35 (d, 1H, H-10, J = 8.0 Hz); 7.50 (d, 1H, 
H-7, J = 8.0 Hz); 8.32 (s, 1NH, H-11); 
13
C NMR (CDCl3  100 M  ) δ: 23.6 (C-
6); 50.3 (C-2); 50.6 (C-5); 52.7 (CH3); 68.3 (C-11b); 107.9 (C-6a); 111.4 (C-10); 
118.9 (C-7); 120.2 (C-8); 136.6 (C- 10a); 126.3 (C-9); 129.9 (C-11a), 126.3 (C-
6b), 172.2 (C=O); 173.7 (C-3). HR-MS m/z: calcd. for C15H16N3O3, [(M+H)+]: 





imidazo[1',2':1,2]pyrido[3,4-b] indole-5-carboxylate (107). 
Obtained from intermediate 93 using method C.  
79% yield. [α]
25
D : 125 ± 20 (c = 0.10, MeOH). 
1
H NMR (CD3OD  400 M  ) : δ: 
1.33 (d, 3H, CH3, J = 4.0 Hz); 3.16 (dd, 1H, H-6’  J’ = 8.0 and J” = 16.0 Hz);  
3.46 (d, 1H, H-6”  J =16.0 Hz); 3.70 (s, 3H, CH3);  3.83 (q, 1H, H-2); 5.27 (d, 1H, 
H-5,  J = 8.0 Hz); 5.94 (s, 1H, H-11b); 7.04 (t, 1H, H-8, J = 8.0 Hz); 7.16 (t, 1H, 
H-9, J = 8.0 Hz); 7.38 (d, 1H, H-10, J = 8.0 Hz); 7.48 (d, 1H, H-7, J = 8.0 Hz); 
13
C NMR (CDCl3  100 M  ) δ: 16.5 (CH3); 24.1 (C-6); 50.6 (C-5); 52.9 (CH3); 
56.9 (C-2); 66.3 (C-11b); 107.6 (C-6a); 111.6 (C-10); 119.1 (C-7); 120.4 (C-8); 
123.4 (C-9); 129.6 (C-11a), 126.5 (C-6b), 136.7 (C- 10a); 171.2 (C=O); 175.1 (C-
3).   HR-MS m/z: calcd. for C16H18N3O3, [(M+H)
+
]:  300.1343; found 300.1347. 
(3aS,6S,12bS)-methyl-4-oxo-2,3,3a,4,6,7,12,12b-octahydro-1H-
pyrrolo[1'',2'':3',4']imidazo[1',2':1,2] pyrido [3,4-b]indole-6-carboxylate 
(108). 
Obtained from intermediate 94 using method C.  
72% yield. [α]
25
D : 180.00 ± 0.36 (c = 0.10, MeOH). 
1
H NMR (CDCl3, 400 MHz) 
: δ: 1.71-1.79 (m, 2H, H-2’ and  -2”); 2.13-2.26 (m, 3H, H-1’   -1” and  -3’); 
2.64-2.69 (m, 1H, H-3”); 3.11 (dd  1    -7’  J’ = 4.0, J” = 12.0 Hz); 3.47 (d, 1H, 
H-7”  J =16.0 Hz); 3.64 (s, 3H, CH3); 4.08 (dd, 1H, H-3a, J’ = 4.0, J” = 8.0 Hz); 
5.22 (d, 1H, H-6,  J = 8.0 Hz); 6.18 (s, 1H, H-12b); 7.14 (t, 1H, H-9, J = 8.0 Hz); 
7.23 (t, 1H, H-10, J = 8.0 Hz); 7.35 (d, 1H, H-11, J = 8.0 Hz); 7.52 (d, 1H, H-8, J 
= 8.0 Hz); 8.83 (s, 1NH, H-12).  
13
C NMR (CDCl3  100 M  ) δ: 24.1 (C-7); 24.5 
(C-2); 25.6 (C-1); 47.8 (C-3); 50.6 (C-6); 52.7 (CH3); 66.3 (C-3a); 69.5 (C-12b); 
108.8 (C-7a); 111.4 (C-11); 118.8 (C-8); 120.0 (C-9); 123.2 (C-10); 136.7 (C- 
11a); 127.1 (C-12a), 126.2 (C-7b), 170.9 (C=O); 174.5 (C-4).   HR-MS m/z: calcd 
for C18H20N3O3, [(M+H)
+





imidazo[1',2':1,2]pyrido[3,4-b] indole-5-carboxylate (109). 
Obtained from intermediate 95 using method C.  
81% yield.  [α]
25
D : 40.00 ± 0.01 (c = 0.10, MeOH). 
1
H NMR (CDCl3, 400 MHz) : 
δ: 3.01 (dd  1   CH2
’
, J’ = 8.0 and J” = 16.0 Hz);  3.13 (dd, 1H, CH2
”
, J’ = 4.0, J” 
= 16.0 Hz);  3.19 (d, 1H, H-6’  J = 8.0 Hz); 3.25 (d, 1H, H-6”  J = 16.0 Hz); 3.59 
(s, 3H, CH3);  3.69 (dd, 1H, H-2,  J’ = 4.0, J” = 8.0 Hz); 5.25 (d, 1H, H-5,  J = 8.0 
Hz); 5.84 (s, 1H, H-11b); 7.05 (t, 1H, H-8, J = 8.0 Hz); 7.13 (t, 1H, H-9, J = 8.0 
Hz); 7.19-7.30 (m, 6H, aryl and H-10); 7.42 (d, 1H, H-7, J = 8.0 Hz); 8.22 (s, 
1NH, H-11);  
13
C NMR (CDCl3  100 M  ) δ: 23.4 (C-6); 36.4 (CH2); 51.1 (C-5); 
52.6 (CH3); 61.3 (C-2); 66.6 (C-11b); 107.6 (C-6a); 111.3 (C-10); 118.7 (C-7); 
120.0 (C-8); 123.0 (C-9); 123.2 (aryl); 136.3 (C- 10a); 128.7 (aryl); 129.4 (aryl), 
130.3 (C-11a), 126.4 (C-6b), 137.1 (aryl), 170.0 (C=O); 175.10 (C-3).   HR-MS 
m/z: calcd for C22H22N3O3, [(M+H)
+
]:  376.1656; found 376.1660. 
(2S,5S,11bR)-1-benzyl-5-methyl-2-isobutyl-3-oxo-2,3,5,6-tetrahydro-1H-
imidazo[1',2':1,2]pyrido[3,4-b]indole-1,5(11H,11bH)-dicarboxylate (110). 
Obtained from intermediate 96 using method C.  
40% yield. [α]
25
D : +2.0 ± 0.20 (c = 0.10, MeOH). 
1
H NMR (CDCl3, 400 MHz) : 
δ: 0.63 (d  3   CH3, J = 4.0 Hz); 0.66 (d, 3H, CH3, J = 4.0 Hz);1.51-1.60 (m, 2H, 
CH2); 1.67-1.71 (m, 1H, CH); 3.16 (dd, 1H, H-6’  J’ = 4.0 and J” = 8.0 Hz);  3.39 
(d, 1H, H-6”  J =16.0 Hz); 3.67 (s, 3H, CH3); 4.37 (dd, 1H, H-2, J’ = 4.0 and J” = 
8.0 Hz); 5.29 (q, 2H, CH2); 5.48 (d, 1H, H-5,  J = 8.0 Hz); 6.59 (s, 1H, H-11b); 
7.09 (t, 1H, H-8, J = 8.0 Hz); 7.21 (t, 1H, H-9, J = 8.0 Hz); 7.35-7.38 (m, 6H, H-
10 and aryl); 7.49 (d, 1H, H-7, J = 8.0 Hz); 9.19 (s, 1NH, H-11). 
13
C NMR 
(CDCl3  100 M  ) δ: 22.1 (CH3); 23.2 (CH3); 23.3 (C-6); 24.1 (CH); 40.9 (CH2); 
51.3 (C-5); 52.8 (CH3); 57.9 (C-2); 66.4 (C-11b); 68.4 (CH2); 106.5 (C-6a); 111.6 
(C-10); 118.8 (C-7); 119.7 (C-9); 123.0 (C-8); 136.1 (C- 10a); 128.3 (aryl); 128.7 
(aryl) 130.0 (C-11a), 135.3 (aryl); 125.9 (C-6b), 156.3 (C=O); 170.4 (C-3); 170.4 
(C=O). HR-MS m/z: calcd for C27H30N3O5, [(M+H)
+







Obtained from intermediate 97 using method C.  
28% yield. [α]
25
D : +207.00 ± 0.43 (c = 0.10, MeOH). 
1
H NMR (CDCl3, 400 
M  ) : δ: 2.17-2.23 (m, 2H, CH2
’
 benzyl and H-6’); 2.68 (d  1   CH2
” 
benzyl, J’ 
= 16.0 Hz);  2.86 (d, 1H, H-6”  J =16.0 Hz); 3.56 (s, 3H, CH3); 4.19 (d, 1H, H-2, J 
= 8.0 Hz); 4.32 (t, 1H, CH Fmoc, J = 4.0 Hz); 4.80 (dd, 1H, CH2 Fmoc, J’ = 4.0, 
J” = 12.0 Hz); 5.11-5.15 (m, 2H, CH2 Fmoc and H-5); 6.27-6.35 (m, 3H, H-11b 
and aryl); 7.02 (t, 1H, H-9, J = 8.0 Hz); 7.14-7.19 (m, 2H, H-7 and H-8); 7.24-
7.39 (m, 6H, H-10 and aryl); 7.62 (d, 2H, aryl, J = 8.0 Hz); 7.69-7.74 (m, 4H, 
aryl); 8.57 (s, 1NH, H-11). 
13
C NMR (CDCl3  100 M  ) δ: 22.9 (C-6); 35.3 (CH2 
benzyl); 47.5 (CH-Fmoc); 51.0 (C-5); 52.7 (CH3); 60.5 (C-2); 65.9 (C-11b); 67.0 
(CH2 Fmoc); 106.2 (C-6a); 111.1 (C-10); 118.4 (C-7); 119.2 (C-9); 120.1 (aryl); 
122.5 (C-8); 124.2 (aryl); 124.7 (aryl); 135.7 (C- 10a); 127.3 (aryl); 127.6 (aryl), 
128.1 (aryl), 129.0 (C-11a); 129.5 (aryl); 133.9 (aryl), 126.1 (C-6b); 141.8 (aryl); 
143.3 (aryl); 155.5 (C=O); 169.0 (C-3); 170.3 (C=O).   HR-MS m/z: calcd for 
C37H32N3O5, [(M+H)+]:  598.2336; found 598.2336. 
(2S,5R,11bR)-methyl-2-benzyl-3-oxo-2,3,5,6,11,11b-hexahydro-
1Himidazo[1',2':1,2]pyrido[3,4-b]indole-5-carboxylate (112).  
Obtained from intermediate 98 using method C.  
65% yield. [α]
25




C NMR and mass 
spectra are as for derivative 109. 
(2S,5S,11bS)-2-benzyl-3-oxo-2,3,5,6,11,11b-hexahydro-1H-
imidazo[1',2':1,2]pyrido[3,4-b]indole-5-carboxylic acid (113). 
Obtained from intermediate 99 using method C.  
69% yield. [α]
25
D : -15.0 ± 0.7 (c = 0.10, MeOH). 
1
H NMR (CD3OD, 400 MHz) : 
δ: 2.66 (dd  1   CH2, J’ = 8.0 and J” = 12.0 Hz);  2.86 (dd, 1H, H-6’  J’ = 8.0, J” 
= 16.0 Hz);  3.10 (dd, 1H, CH2, J’ = 4.0 and J” = 16.0 Hz); 3.40 (d, 1H, H-6”  J = 
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16.0 Hz ); 3.98 (dd, 1H, H-2,  J’ = 4.0, J” = 8.0 Hz); 4.96 (d, 1H, H-5,  J = 8.0 
Hz); 5.91 (s, 1H, H-11b); 6.91 (t, 1H, H-9, J = 8.0 Hz); 6.98-7.02 (m, 2H, H-8 and 
aryl); 7.07 (t, 2H, aryl, J = 8.0 Hz); 7.16 (d, 2H, aryl, J = 8.0 Hz); 7.21 (d, 1H, H-
10, J = 8.0 Hz); 7.34 (d, 1H, H-7, J = 8.0 Hz); 
13
C NMR (CD3OD  100 M  ) δ: 
25.5 (C-6); 38.4 (CH2); 49.2 (C-5); 63.8 (C-2); 68.2 (C-11b); 108.5 (C-6a); 112.5 
(C-10); 119.6 (C-7); 120.3 (C-9); 123.3 (aryl); 127.8 (C-8); 138.6 (C- 10a); 129.6 
(aryl); 130.6 (aryl), 132.1 (C-11a), 128.3 (C-6b), 139.5 (aryl); 175.7 (C-3); 177.0 
(C=O). HR-MS m/z: calcd. for C21H20N3O3, [(M+H)
+




Obtained from intermediate 100 using methods A (entry 3, table 1, 57% yield). 
[α]
25
D : +13.00 ± 0.06 (c = 0.10, MeOH). 
1
H NMR (CDCl3, 400 MHz) : δ: 1.09 (t  
3H, CH3, J = 8.0 Hz); 2.69 (dd, 1H, CH2
’ 
benzyl, J’ = 8.0 and J” = 12.0 Hz);  2.97 
(dd, 1H, H-6’  J’ = 8.0, J” = 16.0 Hz);  3.19-3.26 (m, 3H, CH2
” 
benzyl and  CH2); 
3.42 (d, 1H, H-6”  J = 16.0 Hz ); 3.98 (dd, 1H, H-2,  J’ = 4.0, J” = 8.0 Hz); 5.08 
(d, 1H, H-5,  J = 8.0 Hz); 5.83 (s, 1H, H-11b); 5.86 (s, 1NH, H-1); 7.08-7.24 (m, 
7H, H-8, H-9 and aryl); 7.30 (d, 1H, H-10, J = 8.0 Hz); 7.47 (d, 1H, H-7, J = 8.0 
Hz); 
13
C NMR (CDCl3  100 M  ) δ: 15.0 (CH3); 22.3 (C-6); 34.9 (CH2); 37.5 
(CH2); 51.7 (C-5); 62.1 (C-2); 66.7 (C-11b); 108.0 (C-6a); 111.5 (C-10); 119.2 
(C-7); 120.2 (C-8); 123.2 (C-9); 136.7 (C- 10a); 127.2, 128.7; 129.3 (aryl); 129.7 
(C-11a); 126.8 (C-6b), 137.2 (aryl); 169.3 (C=O); 174.9 (C-3).    
HR-MS m/z: calcd for C23H25N4O2, [(M+H)
+
]: 389.1972; found 389.1975.  
(2S,11bS)-2-benzyl-5,6,11,11b-tetrahydro-1H-imidazo[1',2':1,2]pyrido[3,4-
b]indol-3(2H)-one (115). 
Obtained from intermediate 101 using method C.  
39% yield. [α]
25
D : 29.0 ± 0.3 (c = 0.10, MeOH). 
1
H NMR (CDCl3  400 M  ) : δ: 
2.69 (dd, 1H, CH2, J’ = 8.0 and J” = 12.0 Hz); 2.79-2.83 (m, 2H, H-6’ and  -6”); 
3.14-3.18 (m, 1H, H-5’);  3.26 (dd  1   CH2, J’ = 4.0 and J” = 12.0 Hz); 3.91 (dd, 
1H, H-2, J’ = 4.0 and J”= 8.0 Hz ); 4.46 (dd, 1H, H-5”   J’ = 8.0, J” = 20.0 Hz); 
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5.66 (s, 1H, H-11b); 7.08-7.22 (m, 7H, H-8, H-9 and aryl); 7.33 (d, 1H, H-10, J = 
8.0 Hz); 7.47 (d, 1H, H-7, J = 8.0 Hz); 8.13 (s, 1NH, H-11).
13
C NMR (CDCl3, 
100 M  ) δ: 21.2 (C-6); 37.6 (C-5); 38.2 (CH2); 62.4 (C-2); 68.2 (C-11b); 110.2 
(C-6a); 111.5 (C-10); 119.1 (C-7); 120.3 (C-8); 123.2 (C-9); 136.6 (C- 10a); 
127.0, 128.7 and 129.3 (aryl); 130.9 (C-11a), 126.8 (C-6b), 137.5 (aryl); 173.5 (C-
3). HR-MS m/z: calcd. for C20H20N3O, [(M+H)+]: 318.1601; found 318.1603. 
(5S,11bR)-methyl 11b-(4-chlorophenyl)-3-oxo-2,3,5,6,11,11b-hexahydro-1H-
imidazo[1',2':1,2]pyrido [3,4-b]indole-5-carboxylate (116). 
Obtained from intermediate 102a or 102b using method C.  
25% yield). [α]
25
D : -8.00 ± 0.08 (c = 0.10, MeOH).  
1
H NMR (CDCl3, 400 MHz) 
: δ: 2.93 (dd  1    -6’  J’ = 8.0, J” = 16.0 Hz);  3.16 (d, 1H, H-2’  J = 16.0 Hz);  
3.44- 3.48 (m, 1H, H-6” ); 3.70 (d  1    -2”  J = 16.0 Hz);  3.84 (s, 3H, CH3); 
3.93 (dd, 1H, H-5, J’= 8.0  J” = 12.0 Hz);  7.15 (t, 1H, H-9, J = 8.0 Hz); 7.26 (t, 
1H, H-8, J = 8.0 Hz); 7.36 (d, 2H, aryl, J = 8.0 Hz); 7.42 (d, 1H, H-10, J = 8.0 
Hz); 7.51-7.54 (m, 3H, H-7 and aryl); 8.65 (s, 1NH, H-11); 
13
C NMR (CDCl3, 100 
M  ) δ: 21.7 (C-6); 48.9 (C-2); 52.6 (CH3);52.9 (C-5); 80.1 (C-11b); 111.5 (C-
10), 111.9 (C-6a); 119.0 (C-7); 120.3 (C-9); 123.3 (C-8); 136.7 (C-10a); 128.3 
(aryl); 129.3 (aryl), 132.3 (C-11a), 135.7 (aryl), 126.7 (C-6b), 138.7 (aryl), 169.7 
(C=O); 176.8 (C-3).   HR-MS m/z: calcd. for C21H19ClN3O3, 396.1109, 398.1080, 
[(M+H)
+
]: found 396.1114, 398.1086. 
(5S,11bS)-methyl11b-(4-chlorophenyl)-3-oxo-2,3,5,6,11,11b-hexahydro-1H-
imidazo[1',2':1,2]pyrido [3,4-b]indole-5-carboxylate (117). 
Obtained from intermediate 102a or 102b  using method C.  
26% yield. [α]
25
D : +30.00 ± 0.03 (c = 0.10, MeOH). 
1
H NMR (CDCl3, 400 MHz) 
: δ: 3.17 (s  3   CH3); 3.20 (dd, 1H, H-6’  J’ = 8.0, J” = 16.0 Hz);  3.29 (dd, 1H, 
H-6”  J’ = 4.0, J” = 16.0 Hz); 3.46 (d, 1H, H-2’   J = 20.0 Hz);  3.97 (d, 1H, H-2”   
J = 20.0 Hz);  5.19 (dd, 1H, H-5,  J’ = 4.0, J” = 8.0 Hz);  7.15-7.19 (m, 3H, H-9 
and aryl); 7.24-7.28 (m, 3H, H-8 and aryl); 7.39 (d, 1H, H-10, J = 8.0 Hz); 7.56 
(d, 1H, H-7, J = 8.0 Hz); 
13
C NMR (CDCl3  100 M  ) δ: 20.3 (C-6); 49.2 (C-2); 
50.4  (C-5); 52.0 (CH3); 78.7 (C-11b); 109.4 (C-6a); 111.5 (C-10); 119.1 (C-7); 
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120.3 (C-9); 123.2 (C-8); 136.1 (C-10a); 128.5 (aryl); 128.9 (aryl), 132.2 (C-11a), 
135.3 (aryl), 126.6 (C-6b), 139.4 (aryl), 170.4 (C=O); 174.6 (C-3).   HR-MS m/z: 
calcd. for C21H19ClN3O3, 396.1109, 398.1080, [(M+H)
+]
: found 396.1112, 
398.1074. 
(5S,11bR)-methyl-11b-(4-methoxyphenyl)-3-oxo-2,3,5,6,11,11b-hexahydro-
1H-imidazo[1',2':1,2] pyrido [3,4-b]indole-5-carboxylate (118). 
Obtained from intermediate 103a or 103b using method C.  
37% yield. [α]
25
D : -89.0 ± 0.9 (c = 0.10, MeOH).  
1
H NMR (CD3OD, 400 MHz) : 
δ: 2.83 (dd  1    -6’  J’ = 4.0, J” = 16.0 Hz);  3.05 (d, 1H, H-2’  J = 16.0 Hz);  
3.24-3.29 (m, 1H, H-6” ); 3.67 (d  1    -2”  J = 16.0 Hz);  3.73 (s, 6H, OCH3 and 
CH3); 3.96 (dd, 1H, H-5, J ‘= 4.0  J” = 8.0 Hz);  6.88 ( d, 2H, aryl, J = 8.0 Hz); 
6.98 (t, 1H, H-9, J = 8.0 Hz); 7.10 (t, 1H, H-8, J = 8.0 Hz); 7.34 (d, 1H, H-10, J = 
8.0 Hz); 7.39-7.43 (m, 3H, aryl and H-7); 
13
C NMR (DMSO  100 M  ) δ: 21.3 
(C-6); 48.3 (C-2); 51.9 (CH3); 52.1 (C-5); 55.2 (OCH3); 81.0 (C-11b); 108.8 (C-
6a); 111.5 (C-10); 113.7 (aryl); 118.2 (C-7); 118.7 (C-9); 121.8 (C-8); 134.4 (C-
10a); 128.4 (aryl); 132.5 (C-11a), 125.8 (C-6b), 136.4 (aryl), 159.5 (aryl), 169.7 





1H-imidazo[1',2':1,2] pyrido[3,4-b]indole-5-carboxylate (119). 
Obtained from intermediate 103a or 103b using method C.  
37% yield. [α]
25
D : +42.0 ± 0.35 (c = 0.10, MeOH). 
1
H NMR (CDCl3, 400 MHz) : 
δ: 3.01 (s  3   CH3); 3.05 (d, 1H, H-6’  J = 4.0 Hz);  3.28 (d, 1H, H-6”  J = 16.0 
Hz);  3.40 (d, 1H, H-2’  J = 12.0 Hz); 3.69 (s, 3H, OCH3); 3.99 (d, 1H, H-2”   J = 
12.0 Hz);  5.16 (d, 1H, H-5,  J = 4.0); 6.77 (d, 2H, aryl, J = 8.0 Hz); 7.00 (t, 1H, 
H-9, J = 8.0 Hz); 7.06 (d, 2H, aryl, J = 8.0 Hz); 7.09 (t, 1H, H-8, J = 8.0 Hz); 7.31 
(d, 1H, H-10, J = 8.0 Hz); 7.47 (d, 1H, H-7, J = 8.0 Hz); 
13
C NMR (CDCl3, 100 
M  ) δ: 21.5 (C-6); 50.5 (C-2); 51.4 (C-5); 52.6 (CH3); 55.9 (OCH3); 81.0 (C-
11b); 108.9 (C-6a); 112.7 (C-10); 114.6 (aryl); 119.5 (C-7); 120.5 (C-9); 123.5 
(C-8); 138.3 (C-10a); 130.4 (aryl); 134.2 (C-11a), 134.7 (aryl), 127.7 (C-6b), 
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161.6 (aryl), 172.0 (C=O); 176.8 (C-3). HR-MS m/z: calcd. for C22H22N3O4, 
[(M+H)
+
]: 392.1605; found 392.1609. 
(2S,5S,11bR)-methyl 2-benzyl-11b-(4-methoxyphenyl)-3-oxo-2,3,5,6,11,11b-
hexahydro-1H-imidazo[1',2':1,2]pyrido[3,4-b]indole-5-carboxylate (120). 
Obtained from intermediate 104a or 104b using method C.  
29% yield. [α]
25
D : -33.00 ± 0.01 (c = 0.10, MeOH).  
1
H NMR (CDCl3, 400 MHz) 
: δ: 2.93 (dd  1    -6’  J’ = 4.0, J” = 16.0 Hz); 3.00 (dd, 1H, CH2a benzyl, J’ = 
4.0, J” = 12.0 Hz); 3.42-3.53 (m, 2H, H-6” and CH2b benzyl); 3.48 (t, 1H, H-2, J 
= 4.0 Hz);  3.77 (s, 3H, OCH3); 3.80 (dd, 1H, H-5, J ‘= 4.0  J” = 12.0 Hz);  3.91 
(s, 3H, CH3); 6.67 (d, 2H, aryl, J = 8.0 Hz); 6.72 (d, 2H, aryl, J = 8.0 Hz); 7.18 (t, 
1H, H-8, J = 8.0 Hz); 7.26-7.30 (m, 3H, H-9 and aryl); 7.42-7.44 (m, 3H, H-10 
and aryl); 7.55 (d, 1H, H-7, J = 8.0 Hz); 8.51 (s, 1H, NH-11). 
13
C NMR (CDCl3, 
100 M  ) δ: 21.8 (C-6); 35.3 (CH2 benzyl); 52.4 (CH3); 52.5 (C-5); 55.3 (OCH3); 
59.7 (C-2); 79.5 (C-11b); 111.3 (C-6a); 111.4 (C-10); 114.0 (aryl); 118.9 (C-7); 
120.1 (C-9); 123.0 (C-8); 126.8 (C10a); 127.4, 128.2, 129.0; 130.1 (aryl); 135.7 
(C-11a); 136.4 (C-6b); 160.2 (aryl); 169.8 (C=O); 177.4 (C-3). HR-MS m/z: 
calcd. for C29H28N3O4, [(M+H)
+
]: 482.2074; found 482.2080. 
(2S,5S,11bS)-methyl 2-benzyl-11b-(4-methoxyphenyl)-3-oxo-2,3,5,6,11,11b-
hexahydro-1H-imidazo[1',2':1,2]pyrido[3,4-b]indole-5-carboxylate (121). 
Obtained from intermediate 104a or 104b using method C.  
32% yield. [α]
25
D : 19.00± 0.09 (c = 0.10, MeOH).  
1
H NMR (CDCl3, 400 MHz) : 
δ: 2.38 (dd  1   CH2a benzyl, J’ = 12.0, J” = 16.0 Hz); 2.92-3.03 (m, 5H, CH2b 
benzyl, H-6’ and CH3); 3.26 (d, 1H, H-6”  J = 16.0 Hz);  3.67 (s, 3H, OCH3 ); 
4.35 (dd, 1H, H-2, J ‘= 4.0  J” = 8.0 Hz);  5.15 (dd, 1H, H-5, J ‘= 4.0  J” = 8.0 
Hz); 6.68 (d, 2H, aryl, J = 8.0 Hz); 6.90-6.96 (m, 1H, aryl); 6.99-7.09 (m, 6H, 
aryl); 7.11 (t, 1H, H-8, J = 8.0 Hz); 7.21 (t, 1H, H-9, J = 8.0 Hz); 7.34 (d, 1H, H-
10, J = 8.0 Hz); 7.47 (d, 1H, H-7, J = 8.0 Hz); 8.04 (s, 1H, NH-11). 
13
C NMR 
(CDCl3, 100 M  ) δ: 20.4 (C-6); 39.3 (CH2 benzyl); 50.0 (C-5); 51.9 (CH3); 55.3 
(OCH3); 61.1 (C-2); 77.4 (C-11b); 108.1 (C-6a); 111.3 (C-10); 113.4 (aryl); 119.0 
(C-7); 120.0 (C-8); 127.8 (C-9); 126.4 (aryl); 126.8 (C10a); 128.1; 128.8; 129.3, 
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133.5 (aryl); 134.0 (C-11a); 136.2 (C-6b); 137.8 and 160.0 (aryl); 170.3 (C=O); 
174.5 (C-3). HR-MS m/z: calcd. for C29H28N3O4, [(M+H)
+




Obtained from intermediate 103a or 103b using method C.  
33% yield. [α]
25
D : -39.00 ± 1.00 (c = 0.10, MeOH).  
1
H NMR (CDCl3, 400 MHz) 
: δ: 0.69 (d, 3H, CH3, J = 8.0 Hz); 0.73 (d, 3H, CH3, J = 8.0 Hz); 1.09-1.13 (m, 
1H, CH); 1.64 (dd, 2H, CH2, J ‘= 8.0  J” = 16.0 Hz); 2.92 (dt, 2H, H-6’and CH2a 
benzyl, J’ = 4.0, J” = 16.0 Hz); 3.21 (dd, 1H, CH2b benzyl, J’ = 8.0, J” = 16.0 
Hz); 3.35-3.39 (m, 2H, H-2 and  6”); 3.83 (s  3   CH3 ); 4.06 (dd, 1H, H-5, J ‘= 
4.0, J” = 12.0 Hz); 7.03 (t, 1H, H-9, J = 8.0 Hz); 7.12 (t, 1H, H-8, J = 8.0 Hz); 
7.22-7.28 (m, 6H, H-10 and aryl); 7.41 (d, 1H, H-7, J = 8.0 Hz); 8.04 (s, 1H, NH-
11). 
13
C NMR (CDCl3  100 M  ) δ: 21.7 (C-6); 23.1 (CH); 23.4 (CH3); 25.0 
(CH3); 35.1 (CH2 benzyl); 45.7 (CH2); 52.4 (CH3); 53.3 (C-5); 58.7 (C-2); 78.5 
(C-11b); 109.8 (C-6a); 111.4 (C-10); 118.8 (C-7); 120.0 (C-9); 122.9 (C-8); 126.8 
(C10a); 127.4; 128.9; 129.8; 130.0 (aryl); 135.8 (C-11a); 136.2 (C-6b); 169.6 






Obtained from intermediate 105a or 105b using method C.  
24% yield. [α]
25
D : 26.00 ± 1.1 (c = 0.10, MeOH).  
1
H NMR (CDCl3, 400 MHz) : 
δ: 0.75 (d  3   CH3, J = 8.0 Hz); 0.90 (d, 3H, CH3, J = 8.0 Hz); 1.19-1.23 (m, 1H, 
CH); 1.77 (t, 2H, CH2, J = 12.0 Hz); 2.45 (dd, 1H, CH2a benzyl, J’ = 8.0, J” = 
12.0 Hz); 3.06-3.13 (m, 2H, CH2b benzyl and H-6’); 3.70 (s  3   CH3 ); 4.04-4.09 
(m, 1H, H-2); 5.13 (dd, 1H, H-5, J ‘= 4.0  J” = 8.0 Hz); 7.03-7.17 (m, 7H, aryl, H-
8 and H-9); 7.29 (d, 1H, H-10, J = 8.0 Hz); 7.43 (d, 1H, H-7, J = 8.0 Hz); 8.04 (s, 
1H, NH-11). 
13
C NMR (CDCl3  100 M  ) δ: 21.2 (C-6); 22.7 (CH); 24.2 (CH3); 
24.4 (CH3); 37.9 (CH2 benzyl); 48.8 (CH2); 50.3 (C-5); 52.6 (CH3); 60.3 (C-2); 
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76.7 (C-11b); 105.6 (C-6a); 111.3 (C-10); 118.7 (C-7); 120.1 (C-9); 122.6 (C-8); 
126.3 (C10a); 126.6; 128.4; 129.0; (aryl); 134.9 (C-11a); 135.4 (C-6b); 136.5 
(aryl); 171.3 (C=O); 178.8 (C-3). HR-MS m/z: calcd. for C26H30N3O3, [(M+H)
+
]: 































4.2  Computational details 
Preparation of the chemical structures  
The chemical structures of compounds 81, 81’ were built with Maestro 10.5,
96
 and 
optimized with MacroModel 11.1
96
 with the OPLS force field
97
 and the Polak-
Ribier conjugate gradient algorithm (PRCG, maximum derivative less than 0.001 
kcal/mol).  
Molecular dynamics simulations  
Molecular dynamics simulations were performed at 450 K, with a time step of 1.5 
fs, an equilibration time of 0.5 ns, a simulation time of 100 ns, using MacroModel 
11.1, and saving 2000 conformers for each compound.  
DFT calculations 
About compounds 81, 81’ conformational search rounds were performed with 
MacroModel 11.1 at the empirical molecular mechanics (MM) level, with Monte 
Carlo Multiple Minimum (MCMM) method and Low mode Conformational 
Search (LMCS) method. Also, molecular dynamic simulations were performed at 
450, 600, 700, 750 K, with a time step of 2.0 fs, an equilibration time of 0.1 ns, 
and a simulation time of 10 ns. All the produced conformers were then analyzed, 
and non-redundant conformers were selected by using the “Redundant Conformer 
Elimination” module of Macromodel 11.1.  
QM calculations were performed using Gaussian 09 software package.
98 
The 
obtained conformers were energy and geometry optimized at QM level by using 
the M062X functional and the 6-311+G(d,p) basis set. For the above mentioned 
compounds, the selected conformers were accounted for the subsequent 




H NMR chemical shifts, using the MPW1PW91 




H NMR spectra 
were built considering the influence of each conformer on the total Boltzmann 
distribution and taking into account the relative energies previously determined 














C (excluding carbonyl carbons) and 
1
H chemical 





H data using tetramethylsilane as reference.  




H NMR chemical shifts were compared 
computing the Δδ parameter (compounds 81/81’): 
 
Δδ = |δexp - δcalc| 
 




H experimental and calculated 
chemical shifts, respectively. 
The mean absolute errors (MAEs) for the diastereoisomeric pairs 81/81’ were 
computed: 
MA  = ∑(Δδ)/n 
defined as the summation through n of the absolute error values (difference of the 




H chemical shifts), 
normalized to the number of the chemical shifts considered (n). 
The energy diagrams for the reactions leading to 81/81’ diastereoisomeric pairs 
were built computing the free energies (G) of the three main species involved: a) 
reactant (N-acyliminium ion); b) unstable chemical species at the transition state; 
c) product (aminoacetal derivatives species protonated at N1). In particular, for a) 
and c) steps, conformational searches were performed following the above 
reported workflow. Then, the produced conformers were optimized at the 
M062X/6-311+G(d,p) functional/basis set level of theory and, in order to 
reproduce the experimental environment, conformers showing intramolecular H-
bonds were discarded. On the selected conformers, force constants and the 
resulting vibrational frequencies (Freq Gaussian keyword) were computed at the 
M062X/6-311+G(d,p) level of theory.  
Furthermore, for each compound, a starting guess geometry model representing 
the transition state (step b) was built and optimized at the QM level (M062X/6-
311+G(d,p) level of theory), using the Berny algorithm followed by vibrational 
frequency calculations (TS, CalcAll, Freq keywords for Gaussian calculations). 
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Analysis of the vibrational frequencies showed that the optimized structure was 
correctly associated to the transition state, since an imaginary frequency was 
detected and the vibration between C11b and N1 involved in the chemical bond 
leading to the formation of the aminoacetal species was correctly visualized.  
Molecular docking 
Docking calculations were performed using Glide software (version 7.0  
Schr dinger package).
100
 Glide docking experiments were performed using the 
crystal structure of mPGES-1 co-complexed with the potent inhibitor LVJ (PDB 
code: 4BPM), generating a receptor grid focused on the ligand binding site. 
Molecular docking calculations were performed using the XP (Extra Precision) 
Glide mode, sampling ligands as flexible. 20 maximum output structures were 
saved for the ligand; a post-docking optimization of the obtained docking outputs 
was performed, accounting 20 maximum number of poses. Docking results were 
analyzed with Maestro (version 10.5). Illustrations of the 3D models were 


































Indole-based derivatives as 


















1.1  Introduction 
The discovery and development of new antiviral drugs are of great interest for 
global human health, particularly as new pathogens emerge and old ones evolve to 
evade current therapeutic agents. Viruses are intracellular pathogens that have 
developed many strategies to evade host immune responses. Combating viral 
diseases with vaccines or antiviral drugs, or both, is a constant challenge. Even 
when successful strategies are discovered and employed, the high rate of genetic 
change exhibited by many viruses, particularly RNA viruses, often enables drug 
resistance or vaccine escape. 
101
 Among the viruses which are able to develop 
resistance to drug treatment Varicella zoster virus infection is one of the 
worldwide distributed and virulent.                                                 
Varicella-zoster virus (VZV) is an ubiquitous human alphaherpesvirus, which 
causes varicella (chicken pox) and herpes zoster (shingles). Varicella results from 
primary VZV infection; it is a common childhood illness associated with fever 
and a generalized pruritic vesicular rash. Herpes zoster is a localized, painful, 
vesicular rash involving one or adjacent dermatomes and caused by VZV 




1.2 Pathogenesis of Varicella-Zoster Virus 
Humans are infected with varicella-zoster virus when the virus comes in contact 
with the mucosa of the upper respiratory tract or the conjunctiva. The virus 
disseminates throughout the bloodstream to the skin in mononuclear cells, causing 
the generalized rash of varicella.
103
 The average incubation period for varicella is 
14 days; almost all cases occur from 10 to 20 days after exposure. Other organs 
are infected, including the central nervous system. As is characteristic of the 
alphaherpesviruses, VZV establishes latency in cells of the dorsal root ganglia 
after primary infection.
104 When viral replication is reactivated, VZV reaches the 
skin via anterograde axonal transport to cause the symptoms of zoster, which is 
characterized by a vesicular rash in the dermatome. Both varicella and zoster skin 
lesions contain high concentrations of infectious virus and are thus responsible for 
transmission to susceptible individuals. It has been difficult to verify individual 
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steps in viral pathogenesis because VZV is a highly human-specific virus that has 
little or no capacity to infect other species.
105
  
1.3 Epidemiology of Varicella-Zoster Virus 
Over 95% of immunocompetent individuals aged at least 50 years are seropositive 
for VZV and are, therefore, at risk of developing Herpes zoster (HZ).
106
 VZV-
specific cell-mediated immunity declines with age concomitantly with the rise in 
the incidence of HZ and its complications that occurs at about 50 years of age. 
107
 
The estimated average overall incidence of HZ is about 3.4–4.82 per 1000 person 
per year which increases to more than 11 per 1000 person years in those aged at 
least 80 years. The overall incidences of medically attended HZ and HZ-related 
outpatient visits and hospitalizations were reported to increase with age.
108.109
 HZ-




1.4 Treatment and resistance 
In immunocompetent children, varicella zoster infections can cause severe 
morbidity and mortality, as well as in patients with impaired cell-mediated 
immune responses. In addition, complications of herpes zoster in 
immunecompetent hosts include post-herpetic neuralgia (PHN), a persistent pain 
syndrome, which is the most challenging complication particularly in older 
individuals.
111,112
 The dramatically improving of herpes zoster infections, 
especially in immunocompromised patients, led scientific research to develop safe 
and effective antiviral drugs. Vidarabine and interferon-α have been used in the 
treatment of severe VZV infection, but because their modest efficacy and 
substantial toxicity have been replaced by antiviral agents with enhanced in vitro 
activity, improved pharmacokinetic properties and safety profiles. Most of the 
approved compounds for the treatment of VZV infections are nucleoside 
analogues which require phosphorylation by the viral thymidine kinase. Three 
oral guanine-based antivirals are approved worldwide for the treatment of VZV-
associated diseases: acyclovir, valacyclovir, and famciclovir.
113
 Acyclovir and its 
analogues are converted to their monophosphate by virus-encoded thymidine 
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kinase (TK). Cellular enzymes catalyze the subsequent diphosphorylation and 
triphosphorylation steps which yield high concentrations of the triphosphate 
derivative in VZV-infected cells. The triphosphate derivative inhibits viral DNA 
synthesis by competing with deoxyguanosine triphosphate as a substrate for viral 
DNA polymerase. Incorporation into viral DNA results in obligate chain 
termination since the molecule lacks the 3-hydroxyl group required for further 
DNA chain elongation. Viral DNA polymerase is tightly associated with the 
terminated DNA chain and is functionally inactivated.
114
 Among the nucleoside 
analogues that have been pursued for the treatment of VZV infections, one of the 
most potent inhibitors of in vitro VZV replication is brivudine. Brivudine is an 




One of the limitations of the use of nucleoside derivatives is the emergence of 
single and multiple drug resistance linked to mutations in TK gene of VZV.
116
 
Three distinct classes of acyclovir-resistant TK mutants have been identified: TK-
negative (TKN), TK-partial (TKP), and TK-altered (TKA) mutants. TKN mutants 
lack TK activity, whereas TKP mutants express reduced levels of TK activity. 
TKA mutants phosphorylate thymidine but not acyclovir. Mutants with altered 
DNA polymerase have also been identified,
117
 although these are infrequently 
reported.
118
 A drug of choice for treatment of acyclovir-resistant VZV disease is 
foscarnet. It is a pyrophosphate analogue, which binds reversibly near the 
pyrophosphate-binding site of DNA polymerase without requiring further 
modification. After binding, the drug blocks the cleavage of the pyrophosphate 
moiety from deoxynucleotide triphosphates, halting DNA chain elongation.
119
 In 
addition, several small molecules have been identified and reported as potent and 
selective VZV inhibitors with different mechanisms of action. Some examples are 
the 4-oxo-dihydroquinoline and 4-oxo-dihydrothieno[2,3-b]pyridine derivatives as 
inhibitors of the viral DNA polymerases, the oxadiazolephenyl derivative 
(ASP2151) as a helicase-primase inhibitor,
120
 and N-α-methylbenzyl-N’-
arylthiourea derivatives that interfere with the function of the viral ORF54 
protein, impairing morphogenesis of the capsid.
121
 Finally, a series of 4-
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benzyloxy-γ-sultone derivatives has been also reported as non-selective VZV 

























2.1 Background and design: 1st series 
Given the difficulty of identifying initial hit compounds in this field, we 
considered of interest to use a privileged scaffold as effective starting point in the 
search for anti-VZV ligands.
122
 Indole scaffold is widely used in antiviral 
research. Examples of marketed indole-containing antiviral drugs include Arbidol 
and Delavirdine. Meanwhile, a number of indole derivatives are actively 
undergoing different phases of clinical evaluation, such as Atevirdine, 
GSK2248761 (IDX-12899), Golotimod, Panobinostat (LBH589), BILB 1941, 
BMS-791325, MK-8742 and Enfuvirtide.
123
 With the aim to identify small 
molecules able to inhibit VZV replication we decided to explore the minimum 
structural requirements for anti-VZV activity starting from this scaffold. We 
synthesized a first series of derivatives based on substituted indoles (A, B) and 





Figure 1. Indole-containing antiviral compounds. Structure of indole (A, B) and 









2.2 Synthesis of 1st series  
Compounds 4a-d were prepared starting from indole 1 according to Scheme 1. N-
1 alkylation of 1 with propyl iodide or 4-phenylbenzyl iodide in DCM/DMF using 
NaH as base, gave the corresponding intermediates 2 and 3, respectively. The 3-
acyl derivative 4a was obtained from 2 by Friedel-Crafts acylation, using 4-
chlorobenzoyl chloride and AlCl3 in acetonitrile (32% yield). Functionalization of 
2 and 3 through a Mannich reaction, using formaldehyde and piperidine/or 
biphenyl ethyl amine, and TFA as catalyst, led to 3-methylamine derivatives 4b-d 
(25-38% yield). 
 




The 5-substituted indole derivatives (8a-c) were synthesized using the indole-5-
carboxyaldehyde (5) and the 5-aminoindole (9) as starting material and following 
the two-synthetic strategy indicated in Scheme 2. 5 was first N-alkylated (6) and 
then subjected to a Mannich reaction to obtain the corresponding aldehydes 7a 
and 7b, as described above. Treatment of these intermediates with 4-chloroaniline 
and sodium triacetoxyborohydride in reductive amination conditions, led to final 
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products 8a and 8b in 24% and 30% yield, respectively. On the other hand, 
reaction of 9 with benzoic acid using HOBt/HBTU as coupling agents gave N-
(1Hindol-5-yl)benzamide 10 in 63% yield. N-alkylation of 10 with n-propyl 
iodide followed by Mannich reaction with formaldehyde and piperidine afforded 
final compound 8c. 
 




The tryptamine-based derivatives 15, 16a-i were prepared following Scheme 3. N-
alkylation of 3-(2-bromoethyl)-1H-indole (12) with methyl iodide or 4-
phenylbenzyl iodide led to derivatives 13 and 14 in 67% and 61% yield, 
respectively. Nucleophilic displacement of the bromine atom in these 
intermediates by different commercially available amines was performed under 
microwave conditions, using palladium acetate as catalyst, obtaining the 
compounds 15, 16a-i in 38-75% yield. Treatment of compound 16a with acetyl 



























Biological evaluation  
3.1 Antiviral activity against Varicella zoster virus: 1st series 
All the synthetized derivatives were examined in the Department of Microbiology 
and Immunology of the Rega Institute for Medical Research, for their ability to 
inhibit the replication of VZV in human embryonic lung (HEL) cells, and the 
results were compared to those obtained for the reference compounds acyclovir 
and brivudin (Table 1). The antiviral activity was expressed as EC50, being the 
compound concentration required to reduce virus-plaque formation (VZV) by 
50%. 
As shown in Table 1, the N-propyl-3-acyl (4a) and N-propyl-3-piperidine methyl 
(4b) derivatives do not displayed antiviral or cytotoxic activities at 100 mM, 
while the substitution of piperidine at the 3-position by a biphenylethylamine 
group and of the propyl group at the N-1 indole by a biphenylmethyl moiety 
dramatically increased the cytotoxic activity of resultant compounds 4c and 4d, 
with CC50 values of 1.7 and 6.9 mM, respectively. Compounds 8a-c, derivatized 
at the C-5 indole position, proved less cytotoxic, but were also ineffective as 
inhibitors of VZV-induced plaque formation at similar concentrations. The most 
interesting results were obtained for the tryptamine derivatives. In this series, the 
presence of a methyl group at the N-indole position lead to weaker cytotoxicity 
(derivative 16a versus 15, CC50 20-41 versus 7.3 mM), while the acylation of the 
amine group (17a) also reduces cytotoxicity (CC50 ≈ 31-39 mM) but with an 
inhibitory effect on the anti-VZV activity. Tryptamine derivative 17a was indeed 
able to inhibit replication of TKþ and TK-VZV strains with EC50 values in the 
range of 1.7-3.6 mM (Table 1). The potency of 17a against OKA strain (EC50 ¼ 
2.5-3.6 mM) was found comparable to that of the reference drug acyclovir (EC50 
¼ 1.9-2.1 mM) but two orders of magnitude lower than that of brivudin (EC50 ¼ 
0.02-0.03 mM). However, the activity of this compound against thymidine kinase-
deficient VZV strains, both 07-1 and YS-R, was maintained in the micromolar 
range with EC50 ¼ 1.7e3.1 mM being, at least, one order of magnitude more 




Table 1. Activity of compounds 4, 8, 15, 16 and 17a against varicella-zoster virus 
(VZV) in human embryonic lung (HEL) cells. 
 




 µM)b TK+ TK- 
OKA 07-1 YS-R 
4a propyl Phenylcarbonyl >100 >100 nd >100 
4b propyl Piperidinemethyl >100 >100 nd >100 
4c propyl Biphenylethylaminemethyl >0.8 >0.8 nd 1.7 
4d biphenylmethyl Piperidinemethyl >4 >4 nd 6.9 
8a 4-Ph-NHCH2 Piperidine >4 >4 nd 15 
8b 4-Ph-NHCH2 Biphenylethylamine >4 >4 nd 9.7 
8c Ph-CO-NH Piperidine >20 >20 nd 31 
 
  
15 biphenyl methyl biphenyl ethyl Nd >4 >4 7.3 
16° Methyl biphenyl ethyl >0.8 >4 nd 20 
16b Methyl 4-(OCH3)benzyl >20 >20 nd 28 
16c Methyl 4-(Cl) benzyl >4 >4 nd 22 
16d Methyl 2-naphtyl >100 >100 nd 41 
 17a (1)c   3.6 3.1 nd 31 
17a (2)   2.5 1.7 2.1 39 
Acyclovir (1)   2.1 26  224 
Acyclovir (2)   1.9 165 nd 191 
Brivudin (1)   0.019 33  300 
Brivudin (2)   0.035 103 nd 160 
aEffective concentration required to reduce virus plaque formation by 50%. Virus input was 20 plaque 









3.2 Antiviral activity against other members of the Herpesviridae family: 1st 
series 
As shown in Table 2 none of the synthetized compounds was found active either 
towards other members of Herpesviridae family, such as cytomegalovirus 
(HCMV, AD-169 strain and Davis strain) or against herpes simplex virus-1 
(HSV-1; KOS and thymidine kinase-deficient acyclovir-resistant) (HSV-1/TK- 
KOS ACVr strains) or against herpes simplex virus-2 (HSV-2; G strain). The 
derivatives were not active against other DNA viruses such as vaccinia virus, 
adenovirus-2 and feline herpesvirus. All these compounds also lacked inhibitory 
activity against a broad variety of RNA viruses, including HIV-1 and HIV-2, 
feline coronavirus, vesicular stomatitis virus, Coxsackie virus B4 and respiratory 
syncytial virus, para-influenza-3 virus, reovirus-1, Sindbis virus, Coxsackie virus 
B4, Punta Toro virus, influenza A virus (H1N1 and H3N2 subtypes) and influenza 
B virus. 
Table 2. Activity of compounds 4, 8, 15, 16, and 17a against cytomegalovirus 
(HCMV), herpes simplex virus-1 (HSV-1) and herpes simplex virus-1 (HSV-2) in 








HMCV HSV-1 HSV-2 




4a Nd >100 >100 >100 >100 >100 
4b >4 >4 >100 >100 >100 >100 
4c Nd >0.16 >100 >100 >100 4 
4d Nd >4 >20 >20 >20 20 
8a Nd >4 >20 >20 >20 20 
8b Nd >4 >4 >4 >4 20 
8c Nd >20 >100 >100 >100 100 
15 >4 >4 >100 >100 >100 20 
16a >4 >4 >100 >100 >100 >4 
16b  >20 >20 >20 >20 >20 100 
16c  >20 >20 >20 >20 >20 20 
16d 76 100 >100 >100 >100 >100 
17a >4 >4 >100 >100 >100 20 
Ganciclovir 3.1 2.1 0.09 100 0.03 >100 
Cidofovir 0.38 0.51 0.4 1.2 0.7 >250 
Acyclovir   0.08 112 0.2 >250 
Brivudin   0.007 50 96 >250 
aEffective concentration required to reduce virus plaque formation by 50%. Virus input was 20 plaque-




1.1  Background and design: 2nd and 3rd series 
Starting from the previously obtained SAR results, we decided to further explore 
the structural requirements within the tryptamine series and to prepare two series 
of 17a analogs featuring a) a modified aromatic moiety linking the acetamide 
group (series 2) and b) a modified acyl group (series 3). (Figure 2). 
 
 

















4.2 Synthesis of 2nd  and 3rd series  
Derivatives 17d-i were synthetized according to the synthetic route 4. Treatment 
of compounds 16d-i with acetyl chloride gave the corresponding acetyl 
derivatives 17d-i (42-58% yield). 




Analogously, derivatives 18a-d were prepared applying the synthetic route shown 
in Scheme 5. Treatment of 16a with different aromatic and aliphatic acyl 
chlorides gave the corresponding acylated compounds 18a-c (48-57% yield). The 
carbamoyl derivative 18d was obtained in 58% yield by reaction of 16a with di-
tert-butyl dicarbonate in DCM/TEA. 
 








5. Antiviral activity against Varicella zoster virus 
The synthesized compounds were examined for their ability to inhibit the 
replication of VZV in human embryonic lung (HEL) cells. As shown in Table 3, 
substitution of biphenyl ethyl moiety by the more rigid naphthyl (compounds 17d, 
17e) or their superior analog naphthylmethyl groups (17f, 17g), as well as, the 
introduction of a biphenylmethyl or phenyloxybenzyl moieties (17h, 17i) led to a 
complete loss of the antiviral activity. However, compounds containing 1-naphtyl 
(17e) or 1-naphtyl methyl (17g) groups or the inferior analog biphenylmethyl 
group (17h) were less cytotoxic. On the other hand, substitution of the acylmethyl 
group by bulkier alkyl groups such as cyclohexyl, morpholinethyl and tert-
butyloxy groups (compound 18a, 18c, 18d) led to an annihilation of antiviral 
activity. In this series of compounds, only the benzoyl derivative 18b somewhat 
maintains the antiviral activity at an EC50 of 20 mM, displaying also a reduced 
cytotoxic activity (MMC >100 mM). 
Table 3. Activity of acyl analogs 17 and 18 against varicella-zoster virus (VZV) in 
human embryonic lung (HEL) cells. 
 
























































 >20 >20 100 
17i  phenyloxybenzyl
 
 >4 >4 20 
18a  Cyclohexyl >4 >4 20 
18b  Phenyl 20 20 >100 
18c   morpholinethyl >4 >4 20 
18d  t-butyloxy >4 >4 20 









aEffective concentration required to reduce virus plaque formation by 50%. Virus input was 20 
plaque forming units (PFU). bMinimum cytotoxic concentration that causes a microscopically 









This work presents the results obtained in the searching for small-molecules able 
to inhibit VZV replication. In detail the research was based on the identification of 
a new family of non-nucleoside anti-VZV agents based upon the indole scaffold. 
The results obtained from the activity and cytotoxic assays shown that the 
substitution on the tryptamine moiety strongly influences the activity/toxicity of 
these derivatives. The N-biphenylethyl acetamide derivative 17a displayed an 
interesting inhibition against VZV and was endowed with a selectivity of 10-20 
(ratio CC50/EC50). The most interesting aspect is that compound 17a showed 
similar activity against TK+ and TK- VZV strains, indicating a mechanism of 
action independent from the virus-encoded thymidine kinase. In addition 
tryptamine derivative 17a was found to have a selective inhibitory activity against 
human varicella zoster virus (VZV) replication in vitro, being inactive against a 
variety of other DNA and RNA viruses. In order to identify the structural 
requirements for anti-VZV activity we performed a structure-activity relationship 
(SAR) study, which showed that the presence of a biphenyl ethyl moiety and the 
acetylation at the amino group of tryptamine are a prerequisite for anti-VZV 
activity. The possible mechanism of action of this novel class of compounds will 













Reagents, starting materials, and solvents were purchased from Sigma-Aldrich 
(Milan, Italy) and used as received. Reactions were carried out with magnetic 
stirring in round-bottomed flasks unless otherwise noted. Moisture-sensitive 
reactions were conducted in oven-dried glassware under a positive pressure of dry 
nitrogen, using pre-dried, freshly distilled solvents. Microwave assisted reactions 
were performed in a Biotage Initiator + reactor. Analytical thin layer 
chromatography (TLC) was performed on pre-coated glass silica gel plates 60 
(F254, 0.25 mm, VWR International). Purifications were performed by flash 
column chromatography on silica gel (230-400 mesh, Merck Millipore). NMR 
spectra were recorded on Varian Mercury-400 apparatus. 
1
H NMR and 
13
C NMR 
spectra were recorded with a Varian-400 spectrometer, operating at 400 and 100 
MHz, respectively. Chemical shifts are reported in δ values (ppm) relative to 
internal Me4Si, and J values are reported in hertz (Hz). The following 
abbreviations are used to describe peaks: s (singlet), d (doublet), dd (double 
double), t (triplet), q (quadruplet) and m (multiplet). ESI-MS experiments were 
performed on an Applied Biosystem API 2000 triple-quadrupole spectrometer. 
Combustion microanalyses were performed on a Carlo Erba CNH 1106 analyzer, 
and were within 0.4% of calculated values and confirmed >95% purity for the 
final products. 
General procedure for the synthesis of N-alkylated indole intermediates (2, 3, 
6, 11, 13 and 14). 
Indole (1, 1.0 eq) or 1H-indole-5-carbaldehyde (5, 1.0 eq), or N-(1H-indol-5-
yl)benzamide (10, 1.0 eq), or 3-(2-Bromoethyl)indole (13, 1.0 eq.) were dissolved 
in a mixture of anhydrous DCM/DMF (2/1 v/v) under magnetic stirring and the 
temperature was set to 0° C. To this solution, 1.5 equivalents of NaH were added 
portionwise and the mixture was allowed to react for 30 min. Then, 1.5 
equivalents of alkyl iodide [methyl iodide, or n-propyl iodide, or 4-
(phenyl)iodomethylbenzene] in DCM were added dropwise and the reaction was 
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warmed to room temperature and maintained under stirring for further 12 h. The 
reaction was then quenched by a 10% aqueous solution of citric acid and washed 
with brine. The organic layer was separated, dried over anhydrous Na2SO4, 
filtered and evaporated in vacuo. Crude products were purified by column 
chromatography using n-hexane/ethyl acetate (4:1 v:v) as mobile phase. N-
alkylated compounds were obtained in 75% yield (derivative 2); 80% yield 
(derivatives 3 and 13); 67% yield (derivative 6); 55% yield (derivative 11) and 
50% yield (derivative 14). 
Synthesis of derivative 4a. 
To a solution of 1-propyl-1H-indole (2) in dry CH3CN was added aluminium 
trichloride (15 eq) and benzoyl chloride (10 eq), the reaction was stirred at room 
temperature overnight. The resulting mixture was dried in vacuo and reconstituted 
in DCM. The organic phase was washed with water (3 X 50 mL), dried over 
anhydrous Na2SO4, filtered, concentrated and purified by column chromatography 
using n-hexane/ethyl acetate (3/2) as mobile phase. Compound 4a was obtained in 
32% yield. 
(4-chlorophenyl)(1-propyl-1H-indol-3-yl)methanone (4a). 
Overall yield 32%. 
1
H NMR (400 MHz, CDCl3) δ; 0.88-0.94 (t, 3H, J=7.8 Hz, 
CH3) 1.82-1.84 (m, 2H, CH2); 4.12 (t, 2H,  J=7.8 Hz, CH2); 7.25-7.30 (m, 3H); 
7.35 (d, 2H, J=8.0 Hz); 7.52 (s, 1H); 7.76 (d, 2H, J=8.0 Hz); 8.39 (d, 1H, J=5.2 
Hz).
 13
C NMR (100 MHz,CDCl3) δ 11.4, 22.7, 47.4, 109.6, 119.8, 119.9, 121.7, 
126.5, 127.7, 128.9, 131.8, 137.4, .138.2,181.2. ESIMS m/z calcd for 
C18H16ClNO [(M + H)
+
] 297.78; found, 297.09. 
Synthesis of derivatives 4b-d. 
A solution of formaldehyde (2 eq.), trifluoroacetic acid (2 eq.) and 2 equivalents 
of the proper amine (piperidine or bifenylethilamine) was added portionwise to a 
solution of the intermediate 2 or 3 (1 eq.) in DCM. The mixture was stirred for 3 h 
at room temperature, then was washed with water (3 X 50 mL), dried over 
anhydrous Na2SO4, filtered, concentrated and purified by column chromatography 
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using DCM/MeOH (9:1 v/v) as mobile phase. Compounds 4b-d were obtained in 
25%-38% yield. 
3-(piperidin-1-ylmethyl)-1-propyl-1H-indole (4b). 
Overall yield 25% 
1
H NMR (400 MHz, CDCl3) δ; 0.88-0.94 (t, 3H, J=7.6 Hz, 
CH3); 1.40-1.56 (m, 6H, CH2); 1.88-1.82 (m, 2H, CH2); 2.40-2.47  (m, 4H, CH2); 
3.68 (s, 2H, CH2); 4.04 (t, 2H, J=7.6 Hz, CH2); 7.18-7.12 (m, 2H); 7.28-7.22 (t, 
1H, J=8.0 Hz); 7.34 (d, 1H, J=7.6 Hz);7.68 (d, 1H, J=7.6 Hz).
 13
C NMR (100 
MHz,CDCl3) δ 11.9, 22.8, 24.5, 25.9, 47.2, 48.2, 50.8, 109.6, 119.8, 119.9, 121.7, 
126.5, 127.7, 137.4. ESIMS m/z calcd for C17H24N2 [(M + H)
+
]  256.39, found; 
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2-([1,1'-biphenyl]-4-yl)-N-((1-propyl-1H-indol-3-yl)methyl)ethanamine (4c). 
Overall yield 38% 
1
H NMR (400 MHz, CDCl3) δ; 0.90 (t, 3H, J=7.6 Hz, CH3); 
1.79-1.84 (m, 2H, CH2); 2.91-2.95 (t, 2H, J=7.6 Hz, CH2); 3.01-3.03 (t, 2H, J=7.8 
Hz, CH2); 3.98- 4.02 (t, 2H, J=7.8 Hz, CH2); 4.31 (s, 2H, CH2); 7.11-7.15 (m, 
5H); 7.23 (s,1H); 7.34 (t, 1H, J=7,2 Hz); 7.40-7.54 (m, 7H).
 13
C NMR (100 
MHz,CDCl3) δ 11.6, 22.9, 32.8, 47.3, 51.4, 109.1, 110.5, 118.7, 118.9, 121.4, 
126.9, 127.5, 127.8, 127.9, 128.8, 129.5, 137.6, 139.5, 140.4.  ES-MS m/z calcd 
for C26H28N2 [(M + H)
+
] 368.23, found 368.51. 
1-([1,1'-biphenyl]-4-ylmethyl)-3-(piperidin-1-ylmethyl)-1H-indole (4d). 
Overall yield 29% 
1
H NMR (400 MHz, CDCl3) δ; 1.26-1.37 (m, 2H, CH2); 1.50-
1.58 (m, 4H, CH2); 2.58-2.65 (m, 4H, CH2); 3.83 (s, 2H, CH2); 5.27 (s, 2H, CH2); 
7.07 (t, 1H, J=8.2 Hz); 7.10-7.15 (m, 4H); 7.23-7.26 (m, 2H); 7.28-7.33 (m, 2H); 
7.34-7.37 (m, 4H); 7.62 (d, 1H, J = 8.0 Hz). 
13
C NMR (100 MHz,CDCl3) δ 23.8, 
25.1, 29.7, 49.9, 53.7, 109.9, 119.2, 119.6, 121.9, 127.0, 127.3, 127.4, 127.5, 
128.8, 128.9, 129.0, 136.3, 136.5, 140.6, 140.7.   ES-MS m/z calcd for C27H28N2 
[(M + H)
+





Synthesis of derivatives 8a-b. 
The intermediate 7a or 7b (1.0 eq) was dissolved in a solution of 
DCM:CH3COOH (5:1 v/v) at room temperature. To this solution 2.0 equivalents 
of 4-chloroaniline was added and the mixture was warmed to reflux for 1.5 h. 
Then, 1.8 equivalents of sodium triacetoxyborohydride were added portionwise 
and the mixture was allowed to reflux for further 3-5 h. After cooling to room 
temperature, NaOH 1 N was added. The organic phase was separated and 
extracted one more time with the alkaline solution. Then it was dried over 
Na2SO4, filtered and concentrated in vacuo. The crude products were purified by 
column chromatography using mixtures of DCM/MeOH as eluent giving desired 
compounds 8a and 8b in 24% and 30% yield, respectively. 
4-chloro-N-((3-(piperidin-1-ylmethyl)-1-propyl-1H-indol-5-yl)methyl)aniline  
(8a). 
Overall yield 24%. 
1
H NMR (400 MHz, CDCl3) δ; 0.92 (t, 3H, J=7.8 Hz, CH3); 
1.40-1.56 (m, 6H, CH2); 1.82-1.88 (m, 2H, CH2); 2.42 (s, 4H, CH2); 3.68 (s, 2H, 
CH2); 4.04 (t, 2H, J=7.6 Hz, CH2); 4.36 (s, 2H, CH2); 6.59 (d, 2H, J= 7.6 Hz); 
7.04-7.08 (m, 2H); 7.19 (s, 1H); 7.26-7.30 (m, 2H); 7.65 (s, 1H).
 13
C NMR (100 
MHz,CDCl3) δ 12.2, 22.4, 24.8, 26.5, 47.8, 48.9, 50.3 51.1, 109.4, 119.7, 119.8, 
121.5, 126.4, 127.4, 127.9, 129.9 137.8, 140.2. ES-MS m/z calcd for C24H30ClN3 
[(M + H)
+
]  395.21, found 395.28. 
N-((3-(((2-([1,1'-biphenyl]-4-yl)ethyl)amino)methyl)-1-propyl-1H-indol-5-
yl)methyl)-4-chloroaniline (8b). 
Overall yield 30%. 
1
H NMR (400 MHz, CDCl3) δ; 0.90 (t, 3H, J=7.6 Hz, CH3); 
1.79-1.84 (m, 2H, CH2); 2.91-2.95 (t, 2H, J=7.6 Hz, CH2); 3.01-3.03 (t, 2H, J=7.8 
Hz, CH2); 3.71 (s, 2H, CH2); 3.98-4.02 (t, 2H, J=7.6 Hz, CH2); 4.31 (s, 2H, 5-
CH2); 6.57 (d, 2H, J=8.0 Hz); 7.31-7.56 (m, 14H); 7.61 (s, 1H).
 13
C NMR (100 
MHz, CDCl3) δ 11.5, 22.6, 32.2, 47.7, 50.5, 51.5, 109.6, 119.9, 119.5, 121.8, 
126.1, 127.3, 127.0, 129.3 137.4, 140.6. ES-MS m/z calcd for C33H34ClN3 [(M + 
H)
+
]  507.24, found 507.29.   
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Synthesis of derivative 8c. 
To a solution of 5-amino indole (9, 1.0 eq) in dichloromethane/DMF (20 mL/5 
mL) were successively added benzoic acid (1.1 eq), HBTU (1.2 eq), HOBt (1.2 
eq), and DIEA (2.4 eq), and stirring was continued at room temperature for 24 h. 
Afterward, the reaction mixture was diluted with dichloromethane (20 mL), and 
the resulting solution was washed successively with 10% citric acid (2 X 25 mL), 
10% NaHCO3 (2 X 25 mL), and water (2 X 25 mL), dried over Na2SO4, and 
evaporated to dryness. Intermediate 10 was obtained after flash chromatography 
using n-hexane/ethyl acetate 2/1 as ratio with 63% yield. Substitution with propyl 
group of indolic N1 was carried out using the same conditions described 
elsewhere, to give compound 11 with 44% yield. Mannich reaction performed on 
position 3 of intermediate 11 follows the procedure previously described yielded 
final compound 12 in 24% yield. 
N-(3-(piperidin-1-ylmethyl)-1-propyl-1H-indol-5-yl)benzamide (8c). 
Overall yield 24%. 
1
H NMR (400 MHz, CDCl3) δ; 0.94 (t, 3H, J=8.0 Hz, CH3); 
1.61-1.64 (m, 6H, CH2); 1.87-1.89 (m, 2H, CH2); 2.52 (s, 4H, CH2); 3.73 (s, 2H, 
CH2); 4.07 (t, 2H, J=8.0 Hz, CH2); 7.13 (s, 1H); 7.30 (t, 2H, J=8.0 Hz); 7.44 (d, 
1H, J=8.0 Hz); 7.50-7.56 (m, 2H); 7.93-7.98 (m, 3H).
 13
C NMR (100 
MHz,CDCl3) δ 11.5, 23.6, 24.2, 25.7, 48.1, 53.7, 54.2, 109.6, 111.8, 116.0, 127.0, 
128.7, 128.8, 128.9, 129.7, 1219.9, 131.5, 133.9, 135.4, 165.7. ES-MS m/z calcd 
for C24H29N3O [(M + H)
+
] 375.23, found 375.51. 
General procedure for the synthesis of derivatives 15 and 16a-i. 
One equivalent of intermediate 14a or 14b was dissolved in THF and 1.5 eq of the 
proper amine, 1.5 eq of TEA, 1.5 eq of NaI and 0.3 eq of (CH3COO)2Pd were 
added to this solution. The reaction was conducted under mW, at 100° C, for 20 
min. The resulting mixture was filtered through Celite, dried in vacuo and 
reconstituted in DCM. The organic phase was washed with water (3 X 50 mL), 
dried over anhydrous Na2SO4, filtered, concentrated and purified by column 
chromatography using DCM/MeOH (9:1 v/v) as mobile phase giving derivative 




yl)ethyl)amino)methyl)benzoate (15).  
Overall yield 38%. 
1
H NMR (400 MHz, CDCl3) δ 2.88 (t, 2H, J=8.2 Hz, CH2); 
3.23 (t, 2H, J=8.0 Hz, CH2); 3.68 (s, 3H, CH3); 3.81 (s, 2H, CH2); 5.30 (s, 2H, 
CH2); 6.85 (s, 1H); 7.05-7.18 (m, 5H); 7.21-7.35 (m, 6H); 7.24-7.30 (m, 3H); 
7.35-7.41 (m, 2H); 7.52 (d, 1H, J = 8.0 Hz). 
13
C NMR (100 MHz, CDCl3) δ 22.7, 
41.6, 48.7, 50.8, 57.1, 108.4, 110.9, 112.2, 119.0, 119.5, 121.8, 122.9, 123.3, 
124.6, 125.8, 126.6, 128.0, 128.3, 128.4, 130.1, 135.8, 198.7. ESIMS m/z calcd 
for C32H30N2O [(M + H)
+
]   474.23; found 474.30. 
2-([1,1'-biphenyl]-4-yl)-N-(2-(1-methyl-1H-indol-3-yl)ethyl)ethanamine (16a). 
Overall yield 75%. 
1
H NMR (400 MHz, CDCl3) δ 2.67 (t, 2H, J=7.6 Hz, CH2); 
2.99 (t, 2H, J=7.8 Hz, CH2); 3.38-3.47 (m, 4H, CH2); 3.73 (s, 3H, CH3); 6.80 (s, 
1H); 7.16-7.21 (m, 2H); 7.29-7.36 (m, 3H); 7.50 (t, 2H, J=8.0 Hz); 7.56-7.66 (m, 
4H). 
13
C NMR (100 MHz, CDCl3) δ 24.2, 32.3, 33.5, 46.2, 51.4, 109.3, 110.1, 
117.7, 118,5, 121.2, 124.5, 126.1, 127.2, 127.6, 127.3, 128.2, 129.0, 137.5, 138.5, 
140.1. ESIMS m/z calcd for C25H26N2 [(M + H)
+
] 354.21; found 354.24. 
N-(4-methoxybenzyl)-2-(1-methyl-1H-indol-3-yl)ethanamine (16b). 
Overall yield 71%. 
1
H NMR (400 MHz,CDCl3) δ 2.92 (t, 2H, J=7.6 Hz, CH2); 
3.19 (t, 2H, J=7.6 Hz, CH2); 3.49 (s, 6H, 2CH3); 3.72 (s, 2H, CH2); 6.81 (s, 1H); 
7.07-7.15 (m, 3H); 7.20 (t, 1H, J= 6.8 Hz); 7.24-7.30 (m, 3H); 7.52 (d, 1H, J=8.0 
Hz). 
13
C NMR (100 MHz, CDCl3) δ 22.7, 41.6, 50.8, 57.1, 109.1, 110.0, 112.4, 
118.6, 118.8, 121.4, 121.9, 124.2, 126.4, 128.0, 128.3, 135.3, 199.8. ESIMS m/z 
calcd for C19H22N2O [(M + H)
+
] 294.39; found 295.60. 
N-(4-chlorobenzyl)-2-(1-methyl-1H-indol-3-yl)ethanamine (16c). 
Overall yield 69%. 
1
H NMR (400 MHz,CDCl3) δ 2.93-3.00 (m, 4H, 2CH2); 3.74 
(s, 3H, CH3); 3.77 (s, 2H, CH2); 6.87 (s, 1H); 7.10 (t, 1H, J=8.0 Hz); 7.20-7.30 
(m, 6H); 7.58 (d, 1H, J=8.0 Hz). 
13
C NMR (100 MHz, CDCl3) δ 25.57, 32.56, 
49.40, 53.06, 109.2, 110.0, 112.3, 118.7, 118.9, 121.6, 126.7, 127.8, 128.4, 129.4, 
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132.5, 137.1, 138.7. ESIMS m/z calcd for C18H19ClN2 [(M + H)
+
] 299.12; found 
299.17. 
General procedure for the synthesis of derivative 17a. 
One equivalent of intermediate 16a was dissolved in DCM, then 1.5 eq of acetyl 
chloride and 1.5 eq of TEA were added to the solution. The reaction was 
conducted for 20 min at room temperature. The organic phase was washed with 
water (3 X 50 mL), dried over anhydrous Na2SO4, filtered, concentrated and 
purified by column chromatography using n-hexane/ethyl acetate (2:1 v/v) as 
mobile phase. Final derivative 17a was obtained in 42% yield. 
N-(2-([1,1’-biphenyl]-4-yl)ethyl)-N-(2-(1-methyl-1H-indol-3-
yl)ethyl)acetamide (17a). 
Overall yield 55%. (A/B  (A) 
1
H NMR (400 MHz, CDCl3) δ 2.01 (s, 3H, CH3); 
2.85 (t, 2H, J=7.6 Hz, CH2); 3.07 (t, 2H, J=7.4 Hz, CH2); 3.43-3.50 (m, 4H, CH2); 
3.77 (s, 3H, CH3); 6.84 (s, 1H); 7.14-7.19 (m, 2H); 7.24-7.39 (m, 3H); 7.46 (t, 2H, 
J=8.0 Hz); 7.54-7.62 (m, 4H). 
13
C NMR (100 MHz, CDCl3) δ 21.5, 24.8, 32.6, 
32.7, 47.1, 51.0, 109.2, 110.7, 118.4, 119.0, 121.6, 126.7, 127.0, 127.2, 127.4, 
127.9, 128.8, 129.3, 137.3, 139.2, 140.7, 170.4. (B) 
1
H NMR (400 MHz,CDCl3) δ 
2.01 (s, 3H, CH3); 2.93-3.01 (m, 4H, CH2); 3.63-3.71 (m, 4H, CH2); 3.76 (s, 3H, 
CH3); 6.92 (s, 1H); 7.14-7.19 (m, 2H); 7.24-7.39 (m, 3H); 7.46 (t, 2H, J=8.2 Hz); 
7.54-7.62 (m, 3H); 7.70 (d, 1H, J=8.0 Hz). 
13
C NMR (100 MHz, CDCl3) δ 23.6, 
24.8, 32.7, 35.0, 47.5, 50.1, 109.5, 112.0, 118.9, 119.1, 121.9, 126.9, 127.1, 127.3, 
127.5, 128.7, 129.1, 137.0, 138.5, 139.7, 140.9, 170.5. ESIMS m/z calcd for 
C29H34N2 [(M + H)
+
] 426.27; found 426.35. 
General procedure for the synthesis of derivatives 17d-i and 18a-c. 
One equivalent of intermediate 16d-i was dissolved in DCM, then 1.5 eq of the 
proper acyl chloride and 1.5 eq of TEA, were added to the solution. The reaction 
was conducted for 20 min at room temperature. The organic phase was washed 
with water (3 X 50 mL), dried over anhydrous Na2SO4, filtered, concentrated and 
purified by column chromatography using n-hexane/ethyl acetate (2:1 v/v) as 
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mobile phase. Final derivatives 17d-i and 18a-c were obtained as an atropisomer 
mixtures in 42-58% yield. 
N-(2-(1-methyl-1H-indol-3-yl)ethyl)-N-(naphthalen-2-yl)acetamide (17d). 
Overall yield 49%. 
1
H NMR (400 MHz, CDCl3) δ 1.83 (s, 3H, CH3); 2.99 (t, 2H, 
J=7.6 Hz, CH2); 3.63 (s, 3H, CH3); 4.02 (t, 2H, J=7.8 Hz, CH2); 6.80 (s, 1H); 6.97 
(t, 1H, J=8.0 Hz); 7.12 (t, 1H, J=8.0 Hz); 7.16-7.20 (m, 3H); 7.43-7.48 (m, 3H); 
7.69-7.72 (m, 1H); 7.80 (d, 2H, J=8.0 Hz). 
13
C NMR (100 MHz, CDCl3) δ 23.4, 
23.6, 32.6, 49.9, 109.0, 118.7, 119.0, 121.5, 126.0, 126.7, 126.8, 127.7, 127.9, 
129.7, 131.2, 134.5, 134.4, 171.2. ESIMS m/z calcd for C23H22N2O[(M + H)
+
]   
342.17; found 342.23.  
N-(2-(1-methyl-1H-indol-3-yl)ethyl)-N-(naphthalen-1-yl)acetamide (17e). 
Overall yield 42%. 
1
H NMR (400 MHz, CDCl3) δ 1.71 (s, 3H, CH3); 2.94-3.10 
(m, 2H, CH2); 3.51-3.58 (m, 1H, CH2); 3.62 (s, 3H, CH3); 4.43-4.52 (m, 1H, 
CH2); 6.78 (s, 1H); 6.96 (t, 1H, J= 8.0 Hz); 7.11 (t, 1H, J= 8.2 Hz); 7.17 (d, 1H, 
J= 8.0 Hz); 7.23 (d, 1H, J= 8.0 Hz); 7.43 (t, 2H, J= 8.2 Hz); 7.48 (m, 2H); 7.74-
7.77 (m, 1H); 7.78-7.80 (m, 1H); 7.81-7.84 (m, 1H). 
13
C NMR (100 MHz, CDCl3) 
δ 22.5, 23.9, 32.5, 49.7, 109.0, 111.5, 118.7, 119.0, 121.5, 122.5, 125.7, 126.3, 
126.7, 127.4, 128.6, 128.7, 134.8, 136.9, 139.4, 169.6. ESIMS m/z calcd for 
C23H22N2O [(M + H)
+
]   342.17; found 342.23.  
N-(2-(1-methyl-1H-indol-3-yl)ethyl)-N-(naphthalen-2-ylmethyl)acetamide 
(17f). 
Overall yield 42%. (A) 
1
H NMR (400 MHz, CDCl3) δ 2.23 (s, 3H, CH3); 3.10 (t, 
2H, J= 7.4 Hz, CH2); 3.74 (s, 3H, CH3); 3.78 (t, 2H, J= 7.4 Hz, CH2); 4.60 (s, 2H, 
CH2); 6.89 (s, 1H); 7.09-7.16 (m, 2H); 7.24-7.34 (m, 2H); 7.44-7.50 (m, 3H); 7.65 
(s, 1H); 7.80-7.87 (m, 3H). 
13
C NMR (100 MHz, CDCl3) δ 22.0, 24.5, 32.6, 47.5, 
48.4, 109.2, 110.7, 118.4, 118.8, 119.1, 121.8, 124.9, 126.0, 126.4, 126.7, 126.9, 
127.7, 127.9, 128.7, 133.3, 134.4, 137.0, 170.9. (B) 
1
H NMR (400 MHz,CDCl3) δ 
2.15 (s, 3H, CH3); 3.02 (t, 2H, J= 7.6 Hz, CH2); 3.58 (t, 2H, J= 7.6 Hz, CH2); 3.74 
(s, 3H, CH3); 4.84 (s, 2H, CH2); 6.80 (s, 1H); 7.09-7.16 (m, 2H); 7.24-7.34 (m, 
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2H); 7.44-7.50 (m, 3H); 7.65 (s, 1H); 7.80-7.87 (m, 3H). 
13
C NMR (100 MHz, 
CDCl3) δ 21.5, 23.5, 24.5, 48.4, 52.9, 109.3, 109.4, 111.9, 118.8, 118.9, 121.6, 
124.5, 125.8, 126.2, 126.5, 126.9, 127.4, 127.7, 128.4, 132.8, 133.4, 135.3, 137.0, 
171.1. ESIMS m/z calcd for C24H24N2O [(M + H)
+
] 356.19; found 356.24.  
N-(2-(1-methyl-1H-indol-3-yl)ethyl)-N-(naphthalen-1-ylmethyl)acetamide 
(17g). 
Overall yield 45%. (A) 
1
H NMR (400 MHz, CDCl3) δ 2.25 (s, 3H, CH3); 3.05-
3.11 (m, 2H, CH2); 3.50 (t, 2H, J=7.6 Hz, CH2); 3.65 (s, 3H, CH3); 4.51 (s, 2H, 
CH2); 6.83 (s, 1H); 7.07-7.21 (m, 4H); 7.35 (t, 2H, J=7.8 Hz); 7.44-7.53 (m, 5H). 
13
C NMR (100 MHz, CDCl3) δ 22.5, 24.2, 30.3, 47.7, 51.2, 110.2, 110.9, 120.3, 
121.5, 125.3, 137.9, 140.3, 140.6, 143.3, 171.2. (B) 
1
H NMR (400 MHz,CDCl3) δ 
2.18 (s, 3H, CH3); 2.95 (t, 2H, J=7.8 Hz, CH2); 3.58 (t, 2H, J=7.8 Hz, CH2); 3.70 
(s, 3H, CH3); 4.70 (s, 2H, CH2); 6.85 (s, 1H); 7.07-7.21 (m, 4H); 7.35 (t, 2H, 
J=8.0 Hz); 7.44-7.53 (m, 5H). 
13
C NMR (100 MHz, CDCl3) δ 21.9, 23.8, 31.5 
48.0, 50.1, 109.1, 111.2, 120.5, 122.7, 126.5, 138.1, 139.5, 142.8, 143.0, 171.2. 
ESIMS m/z calcd for C24H24N2O [(M + H)
+
] 356.19; found 356.24.  
N-([1,1'-biphenyl]-4-ylmethyl)-N-(2-(1-methyl-1H-indol-3-yl)ethyl)acetamide 
(17h). 
Overall yield 51%. (A) 
1
H NMR (400 MHz, CDCl3) δ 2.10 (s, 3H, CH3); 2.91-
2.99 (m, 2H, CH2); 3.46 (t, 2H, J=7.8 Hz, CH2); 3.63 (s, 3H, CH3); 4.38 (s, 2H, 
CH2); 6.80 (s, 1H); 6.99-7.06 (m, 2H); 7.11-7.25 (m, 4H); 7.26 (t, 2H, J=7.8 Hz); 
7.41-7.51 (m, 5H). 
13
C NMR (100 MHz, CDCl3) δ 22.0, 24.4, 29.7, 47.5, 50.8, 
109.2, 110.7, 118.4, 119.1, 127.1, 128.6, 136.8, 140.3, 140.6, 170.9. (B) 
1
H NMR 
(400 MHz,CDCl3) δ 2.01 (s, 3H, CH3); 2.91-2.99 (m, 2H, CH2); 3.60 (t, 2H, J=7.4 
Hz, CH2); 3.67 (s, 3H, CH3); 4.61 (s, 2H, CH2); 6.73 (s, 1H); 6.99-7.06 (m, 2H); 
7.11-7.25 (m, 4H); 7.26 (t, 2H, J=8.0 Hz); 7.36 (d, 1H, J= 8.0 Hz); 7.41-7.51 (m, 
4H). 
13
C NMR (100 MHz, CDCl3) 
13
C NMR (100 MHz, CDCl3) δ 21.4, 23.4, 
32.6, 48.0, 48.7, 52.5, 109.4, 111.7, 118.9, 121.9, 127.3, 136.0, 137.0, 140.5, 
140.8, 171.0. ESIMS m/z calcd for C26H26N2O [(M + H)
+





Overall yield 50%. (A) 
1
H NMR (400 MHz, CDCl3) δ 1.99 (s, 3H, CH3); 2.88-
2.96 (m, 2H, CH2); 3.43 (t, 2H, J=7.6 Hz, CH2); 3.67 (s, 3H, CH3); 4.32 (s, 2H, 
CH2); 6.80 (s, 1H); 6.89-6.91 (m, 4H); 6.93-7.02 (m, 3H); 7.04-7.17 (m, 3H); 
7.19-7.23 (m, 2H); 7.41 (d, 1H, J= 8.2 Hz). 
13
C NMR (100 MHz, CDCl3) δ 21.9, 
23.4, 32.7, 47.3, 52.2, 109.1, 118.3, 118.8, 119.0, 121.6, 123.2, 126.9, 127.5, 
128.2, 129.6, 129.8, 131.9, 132.6, 133.8, 135.4, 137.2, 169.9. (B) 
1
H NMR (400 
MHz,CDCl3) δ 2.10 (s, 3H, CH3); 2.88-2.96 (m, 2H, CH2); 3.58 (t, 2H, J=7.8 Hz, 
CH2); 3.68 (s, 3H, CH3); 4.54 (s, 2H, CH2); 6.74 (s, 1H); 6.89-6.91 (m, 4H); 6.93-
7.02 (m, 3H); 7.04-7.17 (m, 3H); 7.19-7.23 (m, 2H); 7.43 (d, 1H, J= 8.2 Hz). 
13
C 
NMR (100 MHz, CDCl3) δ 21.4, 24.4, 32.7, 47.7, 48.6, 109.4, 118.8, 118.9, 
119.1, 121.9, 123.2, 126.7, 127.9, 128.4, 129.7, 131.4, 132.3, 133.9, 135.4, 137.1, 
170.4. ESIMS m/z calcd for C26H26N2O [(M + H)
+
] 398.20; found 398.25. 
N-(2-([1,1'-biphenyl]-4-yl)ethyl)-N-(2-(1-methyl-1H-indol-3-
yl)ethyl)cyclohexanecarboxamide (18a). 
Overall yield 55%. (A) 
1
H NMR (400 MHz, CDCl3) δ 0.79-0.88 (m, 4H, CH2); 
1.36-1.45 (m, 4H, CH2); 1.62-1.77 (m, 2H, CH2); 2.14-2.20 (m, 1H, CH); 2.84 (t, 
2H, J= 7.4 Hz, CH2); 3.05 (t, 2H, J= 7.4 Hz, CH2); 3.60-3.69 (m, 4H, CH2); 3.76 
(s, 3H, CH3);  6.91 (s, 1H); 7.08-7.12 (m, 2H); 7.25-7.41 (m, 5H); 7.47 (t, 2H, J= 
8.0 Hz); 7.55-7.66 (m, 4H).  
13
C NMR (100 MHz, CDCl3) δ 23.6, 26.0, 29.4, 32.6, 
35.2, 40.9, 47.0, 49.7, 109.2, 112.0, 118.3, 118.8, 121.6, 126.8, 127.0, 127.9, 
128.7, 128.8, 129.3, 129.4, 137.0, 137.4, 139.1, 140.8, 176.3. (B) 
1
H NMR (400 
MHz,CDCl3) δ 1.09-1.27 (m, 4H, CH2); 1.47-1.56 (m, 4H, CH2); 1.62-1.77 (m, 
2H, CH2); 2.01-2.08 (m, 1H, CH); 2.93-2.97 (m, 4H, CH2); 3.43-3.49 (m, 4H, 
CH2); 3.74 (s, 3H, CH3);  6.80 (s, 1H); 7.08-7.12 (m, 2H); 7.25-7.41 (m, 5H); 7.47 
(t, 2H, J= 8.0 Hz); 7.55-7.66 (m, 3H); 7.63 (d, 1H, J= 8.0 Hz).  
13
C NMR (100 
MHz, CDCl3) δ 25.2, 25.7, 25.8, 29.5, 32.6, 33.8, 40.4, 48.0, 48.7, 109.5, 110.7, 
118.8, 119.1, 121.9, 127.1, 127.2, 127.5, 128.8, 129.3, 137.0, 137.1, 138.7, 139.1, 
139.8, 141.0, 176.6. ESIMS m/z calcd for C32H36N2O [(M + H)
+






Overall yield 57%. (A) 
1
H NMR (400 MHz, CDCl3) δ 2.77 (t, 2H, J= 7,6 Hz, 
CH2); 3.24 (t, 2H, J= 7.6 Hz, CH2); 3.26-3.40 (m, 2H, CH2); 3.71 (s, 3H, CH3); 
3.86-3.94 (m, 2H, CH2); 6.68 (s, 1H); 6.91-7.01 (m, 4H); 7.21-7.25 (m, 2H); 7.23-
7.37 (m, 8H); 7.44-7.54 (m, 4H).  
13
C NMR (100 MHz, CDCl3) δ 23.5, 33.6, 34.9, 
46.2, 51.3, 109.2, 118.4, 118.9, 121.7, 126.4, 126.6, 127.0, 127.2, 127.3, 128.3, 
128.8, 129.1, 129.4, 137.0, 171.9. (B) 
1
H NMR (400 MHz,CDCl3) δ 2.85 (t, 2H, 
J= 7.8 Hz, CH2); 3.15 (t, 2H, J= 7.6 Hz, CH2); 3.26-3.40 (m, 2H, CH2); 3.76 (s, 
3H, CH3); 3.86-3.94 (m, 2H, CH2); 6.68 (s, 1H); 6.91-7.01 (m, 4H); 7.21-7.25 (m, 
2H); 7.23-7.37 (m, 8H); 7.44-7.54 (m, 3H); 7.60 (d, 1H, J= 8.0 Hz).  
13
C NMR 
(100 MHz, CDCl3) δ 24.8, 32.6, 34.9, 47.1, 50.6, 109.2, 118.4, 118.9, 121.7, 
126.4, 126.6, 127.0, 127.2, 127.3, 128.3, 128.8, 129.1, 129.4, 137.0, 171.9. 
ESIMS m/z calcd for C32H30N2O [(M + H)
+
] 458.24; found 458.30.  
N-(2-([1,1'-biphenyl]-4-yl)ethyl)-N-(2-(1-methyl-1H-indol-3-yl)ethyl)-3-
morpholinopropan amide (18c). 
Overall yield 48%. (A) 
1
H NMR (400 MHz, CDCl3) δ 2.54 (t, 4H, J= 7.4 Hz, 
CH2); 2.89-2.95 (m, 4H, CH2); 2.98-3.06 (m, 4H, CH2); 3.53-3.59 (m, 4H, CH2); 
3.78 (s, 3H, CH3); 6.92 (s, 1H); 7.14 (t, 1H, J= 8.0 Hz); 7.18 (t, 1H, J= 8.0 Hz); 
7.20-7.26 (m, 4H); 7.28-7.31 (m, 2H); 7.36-7.62 (m, 5H). 
13
C NMR (100 MHz, 
CDCl3) δ 23.4, 27.3, 32.7, 34.3, 46.9, 47.4, 49.6, 51.6, 53.6, 63.5, 109.3, 110.3, 
11.3, 118.8, 119.4, 121.7, 126.7, 127.2, 127.5, 127.7, 128.8, 129.2, 134.0, 137.3, 
139.4, 140.1, 168.6. (B) 
1
H NMR (400 MHz,CDCl3) δ 2.66 (t, 4H, J= 7.6 Hz, 
CH2); 2.89-2.95 (m, 4H, CH2); 2.98-3.06 (m, 4H, CH2); 3.69-3.73 (m, 4H, CH2); 
3.79 (s, 3H, CH3); 6.97 (s, 1H); 7.14 (t, 1H, J= 8.0 Hz); 7.18 (t, 1H, J= 8.0 Hz); 
7.20-7.26 (m, 4H); 7.28-7.31 (m, 2H); 7.36-7.62 (m, 4H); 7.68 (d, 1H, J=8.0 Hz). 
13
C NMR (100 MHz, CDCl3) δ 24.1, 27.1, 32.9, 33.5, 47.4, 48.6, 51.6, 52.1, 53.1, 
63.5, 109.5, 111.3, 119.0, 121.7, 126.7, 127.0, 127.3, 127.6, 128.1, 129.0, 129.9, 
137.1, 137.9, 139.5, 140.8, 168.6. ESIMS m/z calcd for C32H37N3O [(M + H)
+
] 
495.29; found 495.33. 
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Synthesis of derivative 18d. 
To a mixture of 16a (1.0 eq.) in DCM, (Boc)2O (3.0 eq.) was added followed by 
TEA (1.5 eq.). The mixture was allowed to stir at room temperature for 12 h. 
Afterward, the reaction mixture was diluted with dichloromethane (20 mL), and 
the resulting solution was washed with 10% citric acid (2 X 25 mL). The organic 
phase was dried over Na2SO4, and evaporated to dryness. Compound 18d was 
obtained as atropisomer mixture after flash chromatography using n-hexane/ethyl 
acetate 2/1 in 58% yield. 
tert-butyl (2-([1,1'-biphenyl]-4-yl)ethyl)(2-(1-methyl-1H-indol-3-yl)ethyl) 
carbamate (18d). 
Overall yield 58%. (A) 
1
H NMR (400 MHz, CDCl3) δ 1.26 (s, 9H, CH3); 2.72-
2.91 (m, 4H, CH2); 3.34-3.40 (m, 4H, CH2); 3.59 (s, 3H, CH3);  6.73 (s, 1H); 7.03 
(t, 1H, J= 8.0 Hz); 7.13-7.23 (m, 6H); 7.30 (t, 2H, J= 8.0 Hz); 7.37 (d, 2H, J= 8.0 
Hz); 7.48 (d, 2H, J= 8.0 Hz).  
13
C NMR (100 MHz, CDCl3) δ 28.4, 32.6, 49.3, 
79.3, 109.2, 118.8, 121.6, 126.7, 127.0, 127.1, 127.2, 128.7, 129.3, 137.0, 138.5, 
139.2, 141.0, 155.5. (B) 
1
H NMR (400 MHz,CDCl3) δ 1.35 (s, 9H, CH3); 2.72-
2.91 (m, 4H, CH2); 3.34-3.40 (m, 4H, CH2); 3.59 (s, 3H, CH3);  6.81 (s, 1H); 7.03 
(t, 1H, J= 7.8 Hz); 7.13-7.23 (m, 6H); 7.30 (t, 2H, J= 7.8 Hz); 7.37 (d, 2H, J= 8.0 
Hz); 7.48 (d, 2H, J= 8.0 Hz).  
13
C NMR (100 MHz, CDCl3) δ 28.4, 32.6, 49.3, 
79.3, 109.2, 118.8, 121.6, 126.7, 127.0, 127.1, 127.2, 128.7, 129.3, 137.0, 138.5, 
139.2, 141.0, 155.5. ESIMS m/z calcd for C30H34N2O2, [(M + H)
+












The compounds were evaluated against different herpes viruses, including 
varicella-zoster virus (VZV) strains Oka and YS, TK VZV strains 07-1 and YS-R, 
herpes simplex virus type 1 (HSV-1) strain KOS, thymidine kinase-deficient (TK) 
HSV-1 KOS strain resistant to ACV (ACVr), herpes simplex virus type 2 (HSV-
2) strain G, human cytomegalovirus (HCMV) strains AD-169 and Davis as well 
as feline herpes virus (FHV), the poxvirus vaccinia virus (Lederle strain), 
adenovirus-2, parainfluenza-3 virus, reovirus-1, Sindbis virus, Coxsackie virus 
B4, Punta Toro virus, respiratory syncytial virus (RSV), feline coronavirus (FIPV) 
and influenza A virus subtypes H1N1 (A/PR/8), H3N2 (A/HK/7/87) and influenza 
B virus (B/HK/5/72) and human immune deficiency virus (HIV-1 (IIIB) and HIV-
2 (ROD)). The antiviral assays were based on inhibition of virus-induced 
cytopathicity (CPE) or (VZV) plaque formation in human embryonic lung (HEL) 
fibroblasts, African green monkey kidney cells (Vero), human epithelial cervix 
carcinoma cells (HeLa), human CD4
+
 T-lymphocyte cells (CEM), Crandell-Rees 
feline kidney cells (CRFK), or Madin Darby canine kidney cells (MDCK). 
Confluent cell cultures in microtiter 96-well plates were inoculated with 100 
CCID50 of virus (1 CCID50 being the virus dose to infect 50% of the cell cultures) 
or with 20 VZV plaque forming units (PFU) and the cell cultures were incubated 
in the presence of varying concentrations of the test compounds. Viral CPE or 
plaque formation (VZV) was recorded as soon as it reached completion in the 
control virus-infected cell cultures that were not treated with the test compounds. 
Antiviral activity was expressed as the EC50, the concentration required to reduce 
virus-induced cytopathicity or viral plaque formation by 50%. 
Cytotoxicity assays 
Cytotoxicity measurements were based on the inhibition of HEL cell growth. HEL 
cells were seeded at a rate of 5 X 103 cells/well into 96-well microtiter plates and 
allowed to proliferate for 24 h. Then, medium containing different concentrations 
of the test compounds was added. After 3 days of incubation at 37° C, the cell 
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number was determined with a Coulter counter. The 50% cytostatic concentration 
(CC50) was calculated as the compound concentration required to reduce cell 
growth by 50% relative to the number of cells in the untreated controls. CC50 
values were estimated from graphic plots of the number of cells (percentage of 
control) as a function of the concentration of the test compounds. Cytotoxicity 
was expressed as the minimum cytotoxic concentration (MCC) or the compound 


















































1.1 Introduction: GPCR main features 
The cellular responses to stimuli act through several control processes, which 
make cells able to prevent the uncontrolled stimulation. Mechanisms of 
attenuation include removal of agonist from the extracellular fluid and receptor 
desensitization, endocytosis and down-regulation. Receptor phosphorylation by 
specific G protein-coupled receptor kinases (GRKs) plays a key role in triggering 
rapid desensitization. The GRK-mediated phosphorylation of the agonist-occupied 
receptor promotes the binding of a member of the family of uncoupling proteins 




GPCRs are the largest superfamily of cell surface receptor proteins and transmit 
various signals across biological membranes through the binding and activation of 
heterotrimeric G proteins, which amplify the signal and activate downstream 
effectors leading to the biological responses.
127
 There are numerous different 
types of GPCRs, some 1,000 types are encoded by the human genome and they 
respond to a diverse range of stimuli, including light, hormones, amines, 
neurotransmitters, and lipids. Some examples of GPCRs include β-adrenergic 
receptors, prostaglandin E2 receptors, rhodopsin, H1 histamine receptor (H1R), 
D3 dopamine receptor (D3R), 5-hydroxytryptamine receptors (5-HT1B and 5-
HT2B), muscarinic acetylcholine receptors (M2R and M3R), three nucleoside 
receptors, including A2A adenosine receptor (A2AAR), P2Y1 purinergic receptor 
(P2Y1R) and P2Y12 purinergic receptor (P2Y12R); ten peptide receptors, 
including chemokine receptors CXCR4 and CCR5  and μ-opioid receptor (μ-
OR).
128
 They represent the wider class of drug receptors: more than half of all 
modern drugs are targeted at these receptors. 
GPCRs share a common architecture, each consisting of a single polypeptide with 
an extracellular N-terminus, an intracellular C-terminus and seven hydrophobic 
transmembrane domains (TM1-TM7) linked by three extracellular loops and three 
intracellular loops. Based on aminoacid sequence similarity within the seven-
transmembrane (7TM) helical segments, GPCRs are divided into five families: the 
rhodopsin family (class A, 701 members), the secretin family (class B, 15 
members), the adhesion family (24 members), the glutamate family (class C, 15 
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members), and the frizzled/taste family (class F, 24 members).
129
 Despite this 
great diversity of ligand types, receptor function is generally very modular. In 
general in the GPCRs, binding of an agonist causes the transition of a GPCR from 
the inactive state to an active state and this change is necessary for G-protein 
activation. Activated receptors couple to a subset of the 16 heterotrimeric G 
protein subtypes, which are functionally grouped into four broad classes: Gs, Gi, 




GPCRs interaction with heterotrimeric G proteins (composed of an α-, β- and γ-
subunit), undergoes conformational changes that lead to the exchange of GDP for 
GTP bound to the α-subunit following receptor activation. Consequently, the Gα- 
and Gβγ-subunits stimulate effector molecules, which include adenylyl and 
guanylyl cyclases, phosphodiesterases, phospholipase A2 (PLA2), phospholipase 
C (PLC) and phosphoinositide 3-kinases (PI3Ks), thereby activating or inhibiting 
the production of a variety of second messengers such as cAMP, cGMP, 
diacylglycerol, inositol (1,4,5)-trisphosphate [Ins(1,4,5)P3], phosphatidyl inositol 
(3,4,5)-trisphosphate [PtdIns(3,4,5)P3], arachidonic acid and phosphatidic acid, in 
addition to promoting increases in the intracellular concentration of Ca
2+
 and the 










Figure 1. Diversity of G-protein-coupled receptors (GPCRs). A wide variety of 
ligands, including biogenic amines, amino acids, ions, lipids, peptides and 
proteins, use GPCRs to stimulate cytoplasmic and nuclear targets through 
heterotrimeric G-protein-dependent and independent pathways. Such signaling 
pathways regulate key biological functions such as cell proliferation, cell survival 
and angiogenesis. 
 
One important mechanism for regulating GPCR responsiveness is the G protein–
coupled receptor kinase (GRK)-arrestin pathway. G protein-coupled receptor 
kinases (GRKs) initiate the homologous desensitization of activated GPCRs 
leading to signaling termination. 
GRKs play a key role in maintaining homeostasis as regulatory proteins and 
component of chemical signaling mechanisms that provide targets for important 









1.2 GRKs: main features 
Based on the sequence similarity, vertebrate GRKs have been traditionally 
divided into three subfamilies: GRK1, comprising GRK1 (rhodopsin kinase) and 
GRK7 (cone opsin kinase) which primarily regulate photoreceptors in the retina; 
GRK2, comprising GRK2 and 3, both of which are ubiquitously expressed; and 
GRK4 comprising GRK4, whose expression is primarily in the testis, cerebellum 
and kidney, 5, and 6, both of which are widely expressed. All GRKs are 
multidomain proteins
131-132
 consisting of about 30-residue N-terminal region 
specific for this family, followed by the Regulator of G protein Signaling (RGS) 
homology domain (RH),
133
 and a Ser-Thr protein kinase domain (KD) with high 
similarity to other AGC protein kinases, such as PKA, PKB, and PKC. The C-
termini of GRKs contain additional structural elements responsible for their 
membrane targeting: GRK1 and 7 carry short C-terminal prenylation sequences, 
GRK2 and 3 contain pleckstrin homology (PH) domain interacting with G protein 
bc-subunits, GRKs 4 and 6 carry palmitoylation sites, whereas GRK5 has 





Figure 2. Domain structure of the three mammalian GRK subfamilies. 
 
 
GRKs recognize activated GPCRs, which leads to catalytic activation of the 
protein kinase and results in receptor phosphorylation at specific sites on the 
intracellular loops and carboxyl-terminal tail. Phosphorylated receptors become 
substrates for binding of arrestin proteins, which prevent the receptor from 
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activating additional G proteins. This mechanism results in a cessation of G 
protein signaling, even despite the continued presence of the receptor agonist. The 
GRK-arrestin pathway also performs other functions, such as facilitating receptor 





Figure 3. In the absence of an activating agonist ligand (A), the GPCR is in an 
inactive conformation.When an appropriate agonist binds to the extracellular face of 
its receptor, it undergoes a conformational change to expose surfaces that act as a 
guanine nucleotide exchange factor for heterotrimeric G proteins. The activated 
receptor facilitates release of tightly bound GDP from an inactive G protein bound to 
the receptor; the receptor then facilitates binding of GTP to the G protein. The GTP-
bound G protein undergoes a conformational change that causes its release from the 
receptor and dissociation into activated α- and βγ-subunits, which each go on to 
activate downstream effectors (not shown). As long as the agonist remains bound to 
the receptor, this activated receptor can continue to activate G proteins. A GRK 
recognizes the activated conformation of the receptor and phosphorylate the receptor. 
GRK-phosphorylated receptor binds to an arrestin protein, which desensitizes G 




GRKs also regulate GPCR trafficking in a phosphorylation independent manner 






1.3 GRK2:  physiopathological role 
GRK2 is the most widely studied member of this family of kinases and it is 
ubiquitously expressed, with higher levels found in brain, leukocytes, heart and 
spleen, followed by lung and kidney. Such expression pattern suggests a 
particularly important role of GRK2 in neurotransmission, cardiovascular function 
and immune and in£ammatory responses.
137
 
1.3.1 GRK2 and the cardiovascular system 
GRK2 is directly involved in β-adrenergic receptor (βAR) desensitization 
mechanism and represents a point of convergence in the pathogenesis of 
cardiovascular diseases. Constant stimulation of βARs by catecholamines in heart 
failure and hypertension leads to selective βAR downregulation and an overall 
attenuation of βAR-mediated adenylyl cyclase activity. 
During the development of heart failure β1AR density and responsiveness 
becomes severely compromised as a consequence of the downregulation that takes 
place during the maladaptive response to chronic stimulation. In addition the 
dysfunction of the adenylyl cyclase system is favoured by an abnormal 
functionality of the Gi proteins and of adenylyl cyclase itself.
138
 Several studies 
confirm that mRNA levels for GRK2 as well as kinase activity are increased 
almost three-fold in the ventricles of congestive heart failure patients.
139
 
GRK2 levels are also altered in mouse models of cardiac hypertrophy and an 
increased activity has been found in patients with ischemic and idiopathic dilated 
cardiomyopathy and hypertension.
140
  Consistent with a key role for GRK2 in 
cardiac function, cardiac contractility can be decreased or enhanced in transgenic 
mice overexpressing GRK2 or GRK2 inhibitor constructs, respectively.
141
  
Moreover, genetic deletion of GRK2 results in marked myocardial hypoplasia and 
embryonic death in mice, indicating a crucial role for this kinase in cardiac cell 
growth and differentiation.
142
  Among its role in GPCRs regulation, GRK2 is the 
major kinase responsible for type 1A angiotensin II receptor (AT1A-R) 
phosphorylation, which mediates cardiovascular effects of angiotensin II, and 
accordingly for the largest fraction of β-arrestin recruitment and receptor 
internalization in HEK293 cells.
143
 These data underline the importance of GRK2 
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levels as a marker of predisposition to cardiac dysfunction and support the idea 
that GRK2 offers a potential therapeutic target. 
1.3.2 GRK2 and the immune system 
GRK2 is highly expressed in different cellular types of the immune system and 
emerges as an important regulator of cell responses during inflammation.
144
 
GRK2 phosphorylates chemokine receptors such as CCR5, CCR2, CXCR4, 
CXCR2 and chemotactic receptors for substance P, S1P or formyl-peptide, 
responsible for leukocyte trafficking to the inflammatory foci, T cell egression 
from lymphoid organs, leukocyte activation or proliferation.
145
 Consistently, 
splenocytes and T lymphocytes isolated from GRK2+/− mice display increased 
agonist-induced activation of ERK and PI3K/Akt pathways and increased 
migration when compared with wild-type littermates in response to certain 
chemokines (CCL5, CXCL12). In agreement with these data, it has been 
described that the GRK2 transcriptional down-regulation caused by activation of 
the Toll-like receptor (TLR)-4 pathway lowers chemokine receptor desensitization 
augmenting the migratory response of polymorphonuclear leukocytes (PMNs). 
The modulation of chemokine-mediated induction of ERK activity by altered 
GRK2 levels seems to involve both kinase-dependent and independent functions, 
the later related to the ability of GRK2 to interfere the MEK/ERK interface. 
Further functional interactions of GRK2 with immune cell migration remains to 
be investigated.
146
 All these data  suggest an important role for GRK2 in the 
regulation of immune cells and development of inflammatory diseases. 
1.3.3 GRK2: role in cancer 
Emerging data indicate changes in GRK2 expression in certain tumors
147
 and 
establish a complex network of functional interactions during the cell cycle. It has 
been reported that GRK2 interacts with MEK, p38, Mdm2, PI3K, or c-Src
148
  
which are known to be implicated in several phases of the cell cycle. GRK2 is up-
regulated in breast cancer cell lines, in spontaneous tumors in mice, and in a 
proportion of invasive ductal carcinoma patients. Increased GRK2 functionality 
promotes the phosphorylation and activation of the Histone Deacetylase 6 
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(HDAC6) leading to de-acetylation of the Prolyl Isomerase Pin1, a central 
modulator of tumor progression, thereby enhancing its stability and functional 
interaction with key mitotic regulators. Cancer cells where GRK2 is enhanced 
display genetic alterations in PI3KCA and PTEN pathway or hyperstimulation of 
receptors such as EGFR, HER2, ER. G protein-coupled receptor kinase 2 (GRK2) 
was recently shown to be a key element in the creation of a permissive 
microenvironment for tumor progression and necessary for vessel formation and 
stability. GRK2 modulates transforming growth factor β1 (TGFβ1)-mediated 
pathways, which are fundamental for the activation and resolution of angiogenic 
events and upregulate other key angiogenic modulators.
149,150
 However reduced 
level of GRK2 in the endothelium accelerates tumor growth in mice, in addition to 
increasing the size of intratumoral vessels, reducing pericyte coverage, and 
enhancing macrophage infiltration. 
Currently the precise contribution of GRK2 kinase activity to different aspects of 
cancer progression remains to be determined.
151 
1.3.4 GRK2 and the insuline resistance 
Insulin resistance is characterized by a reduced responsiveness to circulating 
insulin and is a common feature of obesity that predisposes to several pathological 
conditions, including hyperinsulinemia, glucose intolerance, hypertension, 
cardiovascular disease  and type 2 diabetes. Physiologically insulin promotes 
glucose transport by stimulating translocation of insulin-responsive glucose 
transporter 4 (GLUT4) proteins to the cell surface.
152
  
GRK2 overexpression is found in blood mononuclear cells from metabolic-
syndrome patients and in different models of insulin resistance, such as human 
visceral adipocytes, and in white adipose tissue (WAT) and muscle of TNFα-, 
aging- or high-fat diet (HFD)-induced murine models, suggesting that increased 
GRK2 levels may contribute to the development of this condition.
153 Recent 
evidences suggest that GRK2 inhibits the insulin-stimulated glucose transport 






These data raise the possibility that GRK2 may be an important target for 
antidiabetic therapy. Chemical inhibitors of GRK2 could act as insulin sensitizers 
with beneficial effects in a wide variety of insulin-resistant human conditions, 
























2.1 Background and design: 1st series  
Because GRK2 modulates multiple cellular responses in various physiological 
contexts its selectively targeting may represent a new therapeutic strategy to 
tackle human pathologies involving cardiovascular disorders, uncontrolled cell 
proliferation, deregulated signaling pathways. Over the past several decade a 
significant effort was made to develop selective GRK2 inhibitors. 
The natural product balanol is a potent, nonselective inhibitor of AGC kinases and 
exhibits some selectivity among GRK. It acts as a competitive inhibitor of ATP, 
inhibiting GRK2 and GRK3 at the nanomolar level, even if it also showed activity 
on other isoforms.
156
 Takeda Pharmaceutical Company developed a class of 
heterocyclic compounds, structurally related to balanol, which exhibit higher 
selectively for GRK2 versus PKA, PKC, and Rho kinase.
157
 Mayer et al. 
identified a highly specific RNA aptamer that binds to GRK2 and inhibits its 
kinase function. This RNA aptamer represents the most potent and selective 
inhibitor of GRK2 activity reported (IC50 of 4.1 nM). Furthermore, this aptamer 
might represent a starting point for the development of small molecules that 
specifically target GRK2.
158  
Another class of GRK2 inhibitors is represented by peptides which were designed 
based on the knowledge that short peptides derived from the catalytic domain of 
the kinase show inhibiting activity. Several crystallographic and mutational 
studies have pointed to HJ-G residues (HJ-loop) as being involved in substrate 
binding and in binding to upstream activators. Seven to ten amino acids of this 
fragment typically participate in substrate binding and in some cases were shown 
to determine selectivity toward substrate.
159 Starting from the HJ-loop of GRK2 
Anis et al. synthetized short peptides that closely resemble the HJ loop of 
GRK2/3, in detail two peptides, KRX-683107 and KRX-683124 modulate GRK2/3 
activity, enhancing GPCR signal transduction and result in improved glucose 
homeostasis. These sequence-based peptides have an anti-diabetogenic effect in 
three different animal models of diabetes and could be useful in the treatment of 
Type 2 diabetes.
160  
My research group has recently found that the deacylated derivatives of KRX-
683107 and KRX-683124, selectively inhibit GRK2 in vitro.
161
 Based on conformation 
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of the HJ loop within the X-ray structure of GRK2 a small library of cyclic 
peptides was synthesized. The biological evaluation of this library evidenced that 
the cyclic peptide 7 was the most active in the GRK2 inhibition (Table 1). 
Moreover peptide 7 increased the density of β-adrenergic receptors and the βAR 
stimulated cAMP production in cardiac cells, further confirming the GRK2 control 




Table 1. Structure, inhibition activities and analytical data of peptides 2-9. 
Com. Sequence 
Inhibitiona 
GRK2b                                                GRK5b 
HPLCc 
k’ 
ESI-MS (M +H) 
Calcd                 Found 
2 GLLRrHS 47.6 ± 5.5                              <5 1.70 836.97               837.66 
3 GLLRrHSI 49.6 ±  6.3                             <5 1.72 950.13               950.70 
4 [GLLRrHS] 47.8 ± 6.0                              <5 1.70 819.96               820.53 
5 [GLLRrHSI] 37.2  ±10.7                            <5 1.85 933.12               933.80 
6 [KLLRrHD] 36.3 ± 4.4                              <5 1.72 919.09               920.13 
7 [KLLRrHD]I 55.3 ± 4.6                              <5 1.75 1032.25           1033.11 
8 [KLLRGHD] 47.2 ± 4.5                              <5 1.76 819.47               820.51 
9 [KLLRGHD]I 33.7 ± 7.8                              <5 1.78 933.12               933.68 
aData represent mean values (±SD) of three independent determinations. bGRK2 and GRK5 purified proteins 
activity (50 ng) were tested on rod outer segments (ROS) in presence or absence of 1 mM inhibitors. ck0 ¼ 
[(peptide retention time solvent retention time)/solvent retention time].  
 
 
Further studies aimed to point on the structure-activity relationship of this small 
family of peptides led to the identification of the tetrapeptide LLRr as the minimal 
sequence which retains GRK2 inhibiting activity. Conformational analysis 
performed on the isolated sequence indicated that it is characterized by β-turn 
structure. In order to overcome all the limits linked to peptides administration and 
stability and, moreover, to obtain more potent and selective derivatives, we 
decided to synthetize a library of small molecules as potential GRK2 inhibitors. 
We chose thiazolidine scaffold as template for the design of this series of 




The thiazolidine core was derivatized with substituents miming the electronic and 
structural features of the aminoacids side chains of the above mentioned peptide, 
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as shown in Figure 4. The relative position of these chain into the bicyclic core 




Figure 4. Designed library of potential GRK2 inhibitors. Numbers in 












2.2 Synthesis of 1st series  
The synthesis of the new derivatives started from the Weinreb amidation as shown 
in Scheme 1. The reaction involved three different protected aminoacids (Z-L-
Leu-OH, Boc-L-Lys(Fmoc)-OH and Fmoc-L-Arg(Pbf)-OH) that were coupled 
with N,O-dimethylhydroxylamine. The following treatment of the intermediates 
with an excess of lithium aluminum hydride led to the aldehydes 1b, 2b, 3b. 
These aldehydes were reacted with L-Cys-OEt to give the thiazolidine compounds 
as mixture of cis and trans diastereoisomers. 
 




Intermediate 1c was derivatized using different aliphatic amines through ureidic 
bond formation. Treatment with triphosgene, benzylamine, 4-chlorobenzylamine, 
4-nitrobenzylamine and 4-methylbenzylamine led to derivatives 8-11, due to 
spontaneous cyclization to hydantoin promoted by the aromatic moiety. Treatment 
with N-Boc-1,3-propanediamine led to intermediate 4, while the hydantoin 5 was 
obtained by cyclization in methanol/TEA.  Deprotection by trifluoroacetic acid in 













The ureidic intermediates 4 and 7 were stereoselectively converted to the 
corresponding hydantoins, retaining their configuration during cyclization and 
leading to the pure diastereoisomer 2S 4R 1’S. The  -3 configuration was 
assigned on the basis of the NOE correlations observed in the ROESY spectrum 
of 8. The S configuration assigned to chiral centre 3 is justified by the absence of 




Figure 5. ROESY experiment of compound 8. 
 
Intermediates 2c and 3c were converted to the corresponding hydantoins using 
benzylamine and triphosgene. The selective removal of the N-protecting group of 
compound 15 and 12 led to final derivative 16 and to intermediate 13, 
respectively. Treatment of compound 13  with isovaleryl chloride gave the 
corresponding acyl derivative 14 (Scheme 3). 
 





3.1 Activity of the thiazolidine derivatives of the 1st series 
The synthesized compounds were tested at the Department of Clinical Medicine, 
Cardiovascular and Immune Sciences of University of Naples Federico II, for 
their inhibiting activity over GRK2 protein. The results obtained are summarized 
in Figure 6. All synthesized derivatives were tested at the concentration of 1 µM 
by in vitro rhodopsin phosphorylation assay and visualized by autoradiography of 
dried gels. All the synthetized compounds showed activity in reducing GRK2 






Figure 6. GRK2 purified protein (50ng) was tested on rod outer segments 
(ROS) in presence of 1 µM inhibitors. Numbers in parentheses refer to 








4.1  Background and design: 2nd series 
Starting from the results obtained from the previous series, the aim of my second 
year of PhD was to identify a more potent GRK2 inhibitor starting from the 
structure of compound 9, which showed the best activity in the phosphorylation 
assay. We thus explored different substitutions at the thiazolidine ring (Figure 7) 
designing and synthesizing new derivatives bearing different and generally 
bulkier substituents at the N-1 position. In detail the designed modification 
included: 
 Introduction of  aliphatic fragment to verify the importance of 
hydrophobic interaction 
 Increase the distance between the thiazolidine ring and the aromatic group 





Figure 7. Synthesized compounds of series 2 starting from 9. Numbers in 







4.2 Synthesis of 2nd series  
 
The designed thiazolidine derivatives (6b, 7b, 17-20) were prepared applying the 
synthetic route shown in Scheme 4. The starting ethyl 2-(1-
(((benzyloxy)carbonyl)amino)-3-methylbutyl)thiazolidine-4-carboxylate 
intermediate 1c was obtained as previously described using Z-L-Leu-OH as 
starting material (Scheme 1). Treatment of 1c with triphosgene and N-Boc-1,3-
propanediamine, 2-phenylethylamine, 2-(4-chlorophenyl)ethylamine or n-
butylamine led to compounds 4, 17-19. As displayed for the 1
st
 series of 
derivatives the presence of the aromatic group promoted the spontaneous 
cyclization to the corresponding hydantoin (17 and 18). Hydantoins 5 and 20 were 
obtained by cyclization of the corresponding ureas in methanol/TEA. 
Deprotection by trifluoroacetic acid in dichloromethane provided the amines 6 
and 7, which were treated with N N′-Di-Boc-1H-pyrazole-1-carboxamidine as 
guanidinylation reagent to allow the synthesis of protected guanidines 6a and 7a. 





































5. Activity evaluation of the 2nd series of derivatives 
 
All the synthesized derivatives are current in the process of biological assays to 
test their activity on GRK2. 
 
6. Conclusions 
GRK2 plays a key role in human health and disease, such as in pathological 
cardiovascular processes. Hence, modulation of its activity could represent a valid 
strategy for the treatment of many pathological disorders. The present work 
describes the design and synthesis of potential GRK2 inhibitors thiazolidine-
based. The preliminary activity screening evidenced that all synthetized 
compounds showed inhibitor activity against GRK2. Overall, compound 9 was the 
most active within the 1
st
 series. Aimed to obtain more potent and selective 


















Reagents, starting materials, and solvents were purchased from Sigma-Aldrich 
(Milan, Italy) and used as received. Reactions were carried out with magnetic 
stirring in round-bottomed flasks unless otherwise noted. Moisture-sensitive 
reactions were conducted in oven-dried glassware under a positive pressure of dry 
nitrogen, using predried, freshly distilled solvents. Microwave assisted reactions 
were performed in a Biotage Initiator+ reactor. Analytical thin layer 
chromatography (TLC) was performed on precoated glass silica gel plates 60 
(F254, 0.25 mm, VWR International). Purifications were performed by flash 
column chromatography on silica gel (230−400 mesh  Merck Millipore). NMR 
spectra were recorded on Varian Mercury-400 apparatus. 
1
H NMR and 
13
C NMR 
spectra were recorded with a Varian-400 spectrometer, operating at 400 and 100 
MHz, respectively. Chemical shifts are reported in δ values (ppm) relative to 
internal Me4Si, and J values are reported in hertz (Hz). The following 
abbreviations are used to describe peaks: s (singlet), d (doublet), dd (double 
double), t (triplet), q (quadruplet), and m (multiplet). ESI-MS experiments were 
performed on an Applied Biosystem API 2000 triple-quadrupole spectrometer. 
Combustion microanalyses were performed on a Carlo Erba CNH 1106 analyzer, 
and results were within 0.4% of calculated values and confirmed >95% purity for 
the final products. Analytical RP-HPLC was performed on a Phenomenex Synergi 
Fusion RP-80A (75 mm × 4.6 mm, 4 μm), with a flow rate of 1 mL/min, using a 
tunable UV detector at 254 nm. Mixtures of CH3CN and 0.05% TFA in H2O were 
used as mobile phase. 
General Procedure for the Synthesis of Derivatives 1c, 2c and 3c. 
To a solution of Z-L-Leu-OH, Boc-L-Lys(Fmoc)-OH and Fmoc-L-Arg(Pbf)-OH) 
(1, 2, 3) (1 mmol) dissolved in DCM/DMF (10/1) 1.2 eq of HOBt, 1.2 eq of 
HBTU and 2.4 eq of Dipea at room temperature were added. After 30 min 1.2 eq 
of N,O-dimethylhydroxylamine were added and the reaction was mixed at room 
temperature over night. Then the crude was washed with water (3 x 20 mL), 10% 
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aqueous solution of citric acid (3 X 20 mL) and saturated aqueous solution of 
sodium bicarbonate (3 x 20 mL). The combined organic layer was dried over 
anhydrous sodium sulfate, filtered, concentrated and purified by flash 
chromatography in 30:20 n-hexane/ethyl acetate. 
The N-methoxy-N-methylcarbamoyl derivative (1 mmol; 90 % yield) was 
dissolved in dry THF and mixed at 0°C under nitrogen atmosphere. Then 2.5 eq of 
LiAlH4 ( 1 M in THF) were added and the reaction was mixed at 0°C for 6 
minutes. The crude was washed with 10% aqueous solution of citric acid (3 X 20 
mL), the combined organic layer was dried over anhydrous sodium sulfate, 
filtered and concentrated. No further purification was performed.  
Intermediates 1b, 2b, 3b were dissolved in ethanol, then 1.2 eq of L-Cys-OEt and 
1.2 eq of NaHCO3 were added and  the reaction was mixed at room temperature 
over night. The solvent was removed in vacuo and the crude was diluted with 
DCM and washed with water (3 X 20 mL). The combined organic layer was dried 
over anhydrous sodium sulfate, filtered, concentrated and purified by flash 
chromatography in 40:10 n-hexane/ethyl acetate to obtain final compounds 1c, 2c, 
3c (70-75 % yield). 
General Procedure for the Synthesis of Derivatives 6-11. 
To 1 mmol of intermediate 1c dissolved in dichloromethane 0.4 eq of triphosgene, 
1.2 eq of TEA and 1.2 eq of proper amine (N-Boc-1,3-propanediamine, 
benzylamine, 4-chlorobenzylamine, 4-nitrobenzylamine and 4-
methylbenzylamine) were added. The reaction was mixed at room temperature for 
20 minutes. Then the solution was washed with water (3 x 20 mL). The combined 
organic layer was dried over anhydrous sodium sulfate, filtered, concentrated and 
purified by flash chromatography in in 75:25 n-hexane/ethyl acetate to obtain 6 
and 7. According to Scheme 2 final derivatives 8-11 and intermediate 4 were 
obtained. Intermediate 5 was synthetized by refluxing 4 in MeOH/TEA for 10 
minutes. The removal of the protecting group, using a solution of DCM/TFA in 
ratio 3:1 (9:3 mL), led to final derivatives 6 and 7 after treatment with saturated 




General Procedure for the Synthesis of Derivatives 14 and 16. 
To 1 mmol of intermediate 2c or 3c dissolved in dichloromethane (20 mL) 0.4 eq 
of triphosgene, 1.2 eq of TEA and 1.2 eq of benzylamine were added. The 
reaction was mixed at room temperature for 20 minutes. Then the solution was 
washed with water (3 x 20 mL). The combined organic layer was dried over 
anhydrous sodium sulfate, filtered, concentrated and purified by flash 
chromatography in in 40:10 n-hexane/ethyl acetate to give intermediates 12 and 
15. Final derivative 16 and intermediate 13 were obtained removing the protecting 
group in a mixture 2/1 and 3/1 DCM/TFA, respectively. To 13 dissolved in 
dichloromethane 1.2 eq of isovaleryl chloride and 1.2 eq of TEA were added. The 
reaction was mixed at room temperature for 20 minutes. Then the solution was 
washed with saturated aqueous solution of sodium bicarbonate (3 x 20 mL) and 
water (3 x 20 mL). The combined organic layer was dried over anhydrous sodium 
sulfate, filtered, concentrated and purified by flash chromatography in in 45:5 n-
hexane/ethyl acetate to give final derivative 14. 
General Procedure for the Synthesis of Derivatives 6b and 7b, 17-20. 
To 1 mmol of intermediate 1c dissolved in dichloromethane 0.4 eq of triphosgene, 
1.2 eq of TEA and 1.2 eq of proper amine (N-Boc-1,3-propanediamine, 2-
phenylethylamine, 2-(4-chlorophenyl)ethylamine or n-butylamine) were added. 
The reaction was mixed at room temperature for 20 minutes. Then the solution 
was washed with water (3 x 20 mL). The combined organic layer was dried over 
anhydrous sodium sulfate, filtered, concentrated and purified by flash 
chromatography in in 70:30 n-hexane/ethyl acetate. According to Scheme 4 final 
derivatives 17-18 and intermediates 4 and 19 were obtained. Intermediate 5 and 
final compound 20 were synthetized by refluxing 4 and 19, respectively, in 
MeOH/TEA for 10 minutes. The removal of the protecting group, using a solution 
of DCM/TFA in ratio 3:1 (9:3 mL), led to intermediates 6 and 7 after treatment 
with saturated aqueous solution of sodium bicarbonate (3 x 20 mL). The amino 
free compounds were dissolved in dichloromethane and 1 eq of BPCA, 0.1 eq of 
DMAP and 1 eq of TEA were added. The reaction was mixed at room 
temperature for 3 hours. Then the solution was washed with water (3 x 20 mL). 
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The combined organic layer was dried over anhydrous sodium sulfate, filtered, 
concentrated and purified by flash chromatography using n-hexane/ethyl acetate 
(80:20 ratio) as mobile phase. The final reaction step was the deprotection of the 
N-tert-butoxycarbonyl group of intermediates 6a and 7a, using a solution of 
DCM/TFA in ratio 3:1 (9:3 mL). Derivatives 6b and 7b were obtained  with no 
further purification. 
(2S,4R, 1’S) ethyl 3-((3-aminopropyl)carbamoyl)-2-(1-
(((benzyloxy)carbonyl)amino)-3-methylbutyl)thiazolidine-4-carboxylate (7). 
Overall Yield 65%. 
1
H NMR (400 MHz, CD3OD)0.93  (m, 6H, 3CH3); 
1.18-1.26 (m, 7H, 2CH2, CH3,); 1.63-1.68( m, 1H, CH); 3.11-3.15 (m, 4H, 2CH2); 
3.35 (d, 1H, aJ = 11.2 Hz);  3.57-3.61 (m, 1H,  b); 4.08 (q, 2H, CH2); 
4.55-4.59 ( m, 1H, H-1’); 4.75 (d  1   J = 5.6 Hz); 4.98 (d , 1H, CH2   J’ = 
12Hz); 5.11 (d, 1H, CH2); 5.27 (s, 1H, H-2); 7.25-7.38 (m, 5H, Aryl).
 13
C NMR 
(100 MHz, CD3OD) δ 20.1(2CH3); 21.8 (CH3); 25.1 (CH2); 23.0 (CH2); 26.9 
(CH); 31.0 (C-5); 38.1 (CH2); 42.2 (CH2); 50.0 (C-1’); 62.2 (CH2); 63.2 (C-4); 
67.0 (CH2 Bz); 69.1 (C-2); 128.0; 128.1; 128.4 (Aryl); 156.1; 168.8; 170.6(CO). 
ESI-MS m/z calcd per C23H36 N4O5S [(M + H)
+





H NMR (400 MHz, CD3OD)0.94  (m, 6H, 2CH3); 
1.25-1.35 (m, 4H, 2CH2,); 1.69-1.72 ( m, 1H,CH); 2.66-2.72 ( m, 4H, CH2); 2.87-
2.91 (t, 1H, a); 3.24-3.28 (t, 1H,  b); 4.10-4.14 ( m, 1H, H-1’); 4.20-4.24 
(t, 1H, a);  5.11 (dd , 2H, CH2   J’ = 12  J” = 19.8   ); 5.27 (d  1    -3, J = 
3.6 Hz); 7.25-7.34 (m, 5H, Aryl). 
13
C NMR (100 MHz, CD3OD ) δ 20.5 (2CH3);  
21.8 (CH2); 25.2 (CH2); 28.6 (CH); 34.9 (C-1); 42.7 (CH2); 44.5 (CH2); 53.4 (C-
1’); 62.3 (C-7a); 65.0 (CH2 Bz); 66.5 (C-3); 126.1; 127.3; 128.5; 136.3 (Aryl); 
157.0; 158.1; 172.9 (CO). ESI-MS m/z calcd per C21H30N4O4S[(M + H)
+






Overall Yield 72%. 
1
H NMR (400 MHz, CDCl3)  d, 6H, 2CH3, J =  8.0 Hz 
); 1.22-1.36 (m, 2H, CH2); 1.57-1.68 (m, 1H, CH); 2.86 (t, 1H, a); 3.25-3.29 
(m, 1H,  b); 4.15-4.17 ( m, 1H, H-1’); 4.30 (t  1   a); 4.55 (dd, 2H, CH2  
J’ = 12  J” = 19.8   ); 5.09 (dd   2   CH2 J’ = 12  J” = 19.8   ); 5.27 (d  1    -3, 
J = 3.6 Hz); 7.25-7.33 (m, 10H, Aryl). 
13
C NMR (100 MHz, CDCl3) δ 21.8 
(2CH3); 23.1 (CH2);  24.6 (CH); 32.8 (C-1); 53.6 (C-1’); 63.3 (C-7a); 66.1 (CH2 
Bz); 67.5 (C-3); 124.7; 127.0; 127.0;127.6;127.7; 128.1; 128.6 (Aryl); 155.8; 
157.8; 170.6; (CO). ESI-MS m/z calcd per C25H29N3O4S [(M + H)
+




Overall Yield 72%. 
1
H NMR (400 MHz, CDCl3)  d, 6H, 2CH3, J = 8.0 Hz 
); 1.22-1.36 (m, 2H, CH2,); 1.57-1.68 (m, 1H, CH,); 2.84 (t, 1H, H-1a ); 3.25-3.29 
(m, 1H,  b); 4.15-4.17 ( m, 1H, H-1’);4.28 (t  1   a, ); 4.56 (dd, 2H, CH2, 
J’ = 12  J” = 19.8   ); 5.09 (dd 2   CH2 J’ = 12  J” = 19.8   ); 5.27 (d  1    -3, 
J = 3.6 Hz); 7.25-7.33 (m, 9H, Aryl).
 13
C NMR (100 MHz, CDCl3) δ 20.8 (2CH3); 
23.8 (CH2);  26.6 (CH); 32.8 (C-1); 42.2 (CH2); 55.6 (C-1’); 65.3 (C-7a); 67.1 
(CH2 Bz); 67.3 (C-3); 128.1; 128.5; 128.9;130.1; ( Aryl); 157.8; 159.8; 171.6; 
(CO). ESI-MS m/z calcd per C25H28ClN3O4S [(M + H)
+
]  502. 15; found, 502.50. 
(3S,7aR,1’S)-benzyl (-3-methyl-1-(6-(4-methylbenzyl)-5,7-
dioxohexahydroimidazo[1,5-c]thiazol-3-yl)butyl)carbamate (11). 
Overall Yield 73%. 
1
H NMR (400 MHz, CDCl3) d, 6H, 2CH3, J= 8.0 Hz 
); 1.22-1.36 (m, 2H, CH2); 1.57-1.68 (m, 1H, CH); 2.32 (s, 3H, CH3);  2.84 (t, 1H, 
H.1a ); 3.24-3.29 (m, 1H, H.1b); 4.14-4.17 ( m, 1H, H-1’);4.27 (t  1   a,); 
4.54 (dd, 2H, CH2 J’ = 12  J” = 19.8   ); 5.09 (dd  2   CH2   J’ = 12  J” = 19.8 
Hz); 5.27 (d, 1H, H-3, J = 3.6 Hz); 7.13 ( d, 2H, H-3, Aryl J = 8.0 Hz); 7.24 (d, 
2H, Aryl, J = 8.0 Hz ); 7.33-7-38 (m, 5H, Aryl). 
13
C NMR (100 MHz, CDCl3) δ 
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22.1 (2CH3); 21.8 (CH3); 23.2 (CH2);  24.7 (CH); 32.7 (C-1); 42.6 (CH2); 53.6 (C-
1’); 65.4 (C-7a); 67.0 (CH2 Bz); 67.3 (C-3); 128.1; 128.3; 128.5; 128.6; 128.9; 
129.4; (C Aryl); 154.3; 155.9; 173.9; (CO). ESI-MS m/z calcd per C26H31N3O4S 
[(M + H)
+
] 481.2; found, 482.20. 
(3S,7aR,1’S)-Benzyl (-3-methyl-1-(6-(4-nitrobenzyl)-5,7-
dioxohexahydroimidazo[1,5-c]thiazol-3-yl)butyl)carbamate (10). 
Overall Yield 69%. 
1
H NMR (400 MHz, CDCl3)  d, 6H, 2CH3, J= 12.0 Hz 
); 1.28-1.36 (m, 2H, CH2); 1.66-1.72 (m, 1H, CH); 2.90 (t, 1H, H-1a ); 3.32-3.35 
(m, 1H, H-1b); 4.19-4.22 ( m, 1H, H-1’); 4.35 (t  1   a,); 4.71 (dd, 2H, CH2 
J’=24  J’’=36   ); 5.10 (dd  2   CH2   J’= 12  J” =24   ); 5.33 (d  1    -3, J = 
12.0 Hz); 7.36-7.40 ( m, 5H, Aryl ); 7.54 (d, 2H, H-2,H-6, Aryl, J = 6.0 Hz ); 8.22 
(d, 2H, H-5,H-3, Aryl, J =12.0 Hz).
 13
C NMR (100 MHz, CDCl3) δ 20.8 (2CH3); 
23.8 (CH2);  26.6 (CH); 32.8 (C-1); 55.6 (C-1’); 65.3 (C-7a); 67.1 (CH2 Bz); 
67.33 (C-3); 128.1; 128.5; 128.9; 135.6; 145.1; 147.8;  (C Aryl); 157.8; 159.8; 
171.6; (CO). ESI-MS m/z calcd per C25H28N4O6S [(M + H)
+





Overall Yield 62%. 
1
H NMR (400 MHz, CDCl3)  d, 6H, 2CH3, J = 12 Hz); 
1.24-1.27 (m, 2H, CH2); 1.59-1.64 (m, 4H, 2CH2,); 1.71-1.75( m, 1H, CH);  2.10-
2.14 (m, 2H, CH2); 2.99-3.04 (m, 3H, CH2,  a); 3.28-3.34 (m, 1H,  b); 
4.07-4.10 ( m, 1H, H-1’); 4.32 (t  1   a); 4.39 (t, 1H, CH Fmoc); 4.51 (dd, 
2H, CH2  J’ = 12  J” = 19.8   ); 4.73-4.80 (m , 3H, CH2 Fmoc, CH2); 5.20 (d, 1H, 
H-3, J = 3.6 Hz); 7.27-7.34 (m, 7H, Aryl); 7.45-7.61 (m, 6H, Aryl) .
 13
C NMR 
(100 MHz, CDCl3) δ 22.2 (2CH3); 25.8 (CH2); 26.1 (CH2); 29.9(CH2);  36.8 (C-
1); 40.8 (CH2); 42.5 (CH2); 47.0 (CH2); 54.0 (C-1’); 64.3 (C-7a); 67.1 (CH2 ); 
69.0 (C-3); 120.5; 125.2; 126.2; 126.9; 128.5; 136.7; 142.6; 143.6 (Aryl); 155.6; 
156.4; 170.0; 172.6 (CO);  ESI-MS m/z calcd per C32H34N6O4S [(M + H)
+
] 





Overall Yield 59%. 
1
H NMR (400 MHz, CD3OD) m, 4H, 2CH2); 
2.59 (t, 2H, CH2,); 2.85 (t, 1H, a, J = 19.6 Hz ); 3.27-3.31 (m, 1H,  b); 
4.11-4.13 (m, 1H, H-1’);4.29 (t  1   a, J = 8.0Hz); 4.37 (t, 1H, CH Fmoc); 
4.48 (dd, 2H, CH2  J’ = 12  J” = 19.8   ); 4.77-4.84 (dd , 2H, CH2 Fmoc, CH2); 
5.24- (d, 1H, H-3, J = 3.6 Hz); 7.25-7.33 (m, 7H, Aryl); 7.48-7.59 (m, 6H, Aryl). 
13
C NMR (100 MHz, CD3OD) δ 25.8 (CH2); 26.1 (CH2);  34.8 (C-1); 41.8 (CH2); 
43.5 (CH2); 47.0 (CH); 53.5 (C-1’); 64.3 (C-7a); 67.1 (CH2 ); 68.56 (C-3); 120.5; 
125.2; 126.2; 126.9; 128.5; 136.7; 142.6; 143.6 (Aryl); 155.6; 156.4; 172.6 (CO); 
158.2 (CNH). ESI-MS m/z calcd per C37H42N4O5S [(M + H)
+
] 654.29; found, 
654.50. 
(2S,4R,1’S)ethyl 2-(1-(((benzyloxy)carbonyl)amino)-3-methylbutyl)-3-((3 
guanidinopropyl) carbamoyl) thiazolidine-4-carboxylate (7b). 
Overall Yield 61%. 
1
H NMR (400 MHz, CD3OD)0.96 (m, 6H, 3CH3); 
1.20-1.29 (m, 5H, CH2, CH3,); 1.55-1.68( m, 1H, CH); 1.78 (t, 2H, CH2); 3.23-
3.30 (m, 1H, a);  3.33-3.44 (m, 4H, 2CH2); 3.46- 3.50 (m, 1H,  b); 4.14- 
4.25 ( m, 3H, H-1’ CH2 ); 4.75 (t, 1H, ); 5.08- 5.15 (m , 1H, CH2 ); 5.18 (d, 
1H, H-2, J= 8 Hz); 7.13-7.30 (m, 5H, Aryl).
 13
C NMR (100 MHz, CD3OD) δ 20.6 
(2CH3); 22.5 (CH3);  24.9 (CH2); 26.0 (CH2); 31.9 (CH); 37.0 (C-5); 38.3 (CH2); 
41.1 (CH2); 51.0 (C-1’); 61.4 (CH2); 65.1 (C-4); 66.1 (CH2 Bz); 68.6 (C-2); 127.3; 
127.4; 127.9 (Aryl); 152.1; 167.8; 170.6(CO); 160.4 (CNH).  ESI-MS m/z calcd 
per C24H38 N6O5S [(M + H)
+





H NMR (400 MHz, CD3OD)0.93  (m, 6H, 2CH3); 
1.36-1.41 (m, 2H, CH2,); 1.61-1.67 ( m, 1H, CH); 1.79 ( t, 2H, CH2); 3.10  (t, 1H, 
a); 3.14-3.28 (t, 2H, CH2); 3.30 (t, 1H,  b);  3.50  (t, 2H, CH2); 3.90-3.97 
( m, 1H, H-1’); 4.40  (t  1   a); 5.01- 5.14 (dd , 2H, CH2   J’ = 12  J” = 24 
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Hz); 5.19 (d, 1H, H-3, J = 6.0 Hz); 7.28-7.32 (m, 5H, Aryl). 
13
C NMR (100 MHz, 
CD3OD) δ  20.5 (2CH3);  22.3 (CH2); 24.6 (CH2); 26.9 (CH); 35.7(CH-1); 38.3 
(CH2);  40. 3 (CH2);   53.6 (C-1’); 65.1 (C-7a); 66.1 (CH2 Bz); 67.7 (C-3); 127.2; 
127.6; 128.0;  (Aryl); 156.1; 156.9; 172.3 (CO); 158.7 (CNH).  ESI-MS m/z calcd 
per C22H32N6O4S [(M + H)
+
] 476.22; found, 476.35. 
3S,7aR,1’S)-Benzyl (1-(6-(4-chlorophenethyl)-5,7-
dioxohexahydroimidazo[1,5-c]thiazol-3-yl)-3-methylbutyl)carbamate (17). 
Overall Yield 76%. 
1
H NMR (400 MHz, CDCl3)d, 6H, 2CH3, J= 6 Hz ); 
1.21-1.33 (m, 2H, CH2); 1.65-1.69  (m, 1H, CH);  2.65-2.70 (m, 1H, H-1a ); 2.88-
2.91 (t, 2H, CH2); 3.21-3.24 (m, 1H, H.1b); 3.65-3.68 (t, 2H, CH2 ); 4.12-4.23 (m, 
2H, a, H-1’); 4.84 -5.10 (m ,2H, CH2 ); 5.24 (d, 1H, H-3, J = 4.0 Hz); 7.11 (d, 
2H, H-2   5 Aryl  J’= 12 ); 7.24-7.37(m, 7H, H-3,H-5, Aryl,). 
13
C NMR (100 
MHz, CDCl3) δ 21.88 (2CH3); 22.89 (CH2);  27.90 (CH); 37.26 (C-1); 41.65 
(CH2); 46.38 (CH2); 53.72 (C-1’); 65.19 (C-7a); 67.46 (CH2 Bz); 67.08 (C-3); 
128.14; 128.33; 128.59; 128.72; 130.30 (Aryl); 152.39; 155. 41; 170. 97 (CO); 
ESI-MS m/z calcd per C26H30ClN3O4S [(M + H)
+
] 515.16; found, 515.27. 
(3S,7aR,1’S)-Benzyl (1-(5,7-dioxo-6-phenethylhexahydroimidazo[1,5-
c]thiazol-3-yl)-3-methylbutyl)carbamate (18). 
Overall Yield 78%. 
1
H NMR (400 MHz, CDCl3)d, 6H, 2CH3, J=6.0 
Hz ); 1.27-1.34 (m, 2H, CH2); 1.67-1.69  (m, 1H, CH);  2.62-2.69 (t, 1H, H.1a ); 
2.93-2.98 (t, 2H, CH2  J’ = 6.0   ); 3.17-3.20 (m, 1H, H,1b); 3.67-3.77 (m, 2H, 
CH2 ); 4.13-4.25 (m, 2H, a, H-1’); 5.13 (s  2   CH2 ); 5.27- 5.31 (d, 1H, H-3, 
J = 12.0 Hz); 7.20- 7.37 ( m, 10H, Aryl,). ,). 
13
C NMR (100 MHz, CDCl3) δ 21.89 
(2CH3); 22.89 (CH2);  28.90 (CH); 38.26 (C-1); 41.40 (CH2); 46.1 (CH2); 54.72 
(C-1’); 65.19 (C-7a); 67.46 (CH2 Bz); 67.08 (C-3); 128.14; 128.33; 128.59; 
129.72; 132.30 (Aryl); 152.39; 155. 41; 172. 1 (CO); ESI-MS m/z calcd per 
C26H31N3O4S [(M + H)
+






Overall Yield 70%. 
1
H NMR (400 MHz, CDCl3)0.92  (m, 11H, 3CH3, 
CH2); 1.22 (t, 3H, CH3); 1.29-1.66 (m, 4H, 2CH2,); 1.63-1.68 ( m, 5H, CH2, CH); 
3.11-3.22 (m, 3H, CH2, H-5a); 3.40-3.43 (m, 1H,b);  4.10-4.15 (m, 3H, CH2, 
H-1’); 4.55-4.59 ( m, 1H, H-1’); 4.64-4.67 (m, 1H, ); 5.02 (d , 1H, CH2 , J = 
12Hz); 5.13 (d, 1H, CH2); 5.38 (s, 1H, H-2); 7.26-7.38 (m, 5H, Aryl).
 13
C NMR 
(100 MHz, CDCl3) δ 18.2 (2CH3); 19.04 (CH3); 20.02(CH3); 21.9 (CH2); 23.29 
(CH2); 25.05 (CH); 31.93 (CH2); 32.34 (C-5); 40.73 (CH2);  52.06 (C-1’); 62.18 
(CH2); 63.77 (C-4); 66.60 (CH2 Bz); 68.62 (C-2); 128.01; 128.07; 128.41; 136.55 
(Aryl); 156.19; 167.8; 170.99 (CO).  ESI-MS m/z calcd per C24H37N3O5S [(M + 
H)
+
] 479.25; found, 479.80. 
(3S,7aR,1’S)-Benzyl ((S)-1-(6-butyl-5,7-dioxohexahydroimidazo[1,5-c]thiazol-
3-yl)-3-methylbutyl)carbamate (20). 
Overall Yield 75%. 
1
H NMR (400 MHz, CDCl3)0.94  (m, 9H, 3CH3); 
1.25-1.35 (m, 4H, 2CH2,);1.41-1.58 (m, 2H, CH2); 1.65-1.68 ( m, 1H,CH); 2.85-
2.90 (t, 1H, a); 3.26-3.31 (t, 1H,  b); 3.42-3.46 (t, 2H, CH2); 4.12-4.15 ( 
m, 1H, H-1’); 4.17-4.28 (t, 1H, a); 5.09 (dd , 2H, CH2   J’ = 12  J” = 19.8   ); 
5.28 (d, 1H, H-3, J = 3.6 Hz); 7.25-7.33 (m, 10H, Aryl). 
13
C NMR (100 MHz, 
CDCl3) δ 20.1 (2CH3); 20.88 (CH3);  21.87 (CH2); 23.27 (CH2); 24.71 (CH2); 
29.91 (CH); 32.91 (C-1); 41.66 (CH2);  53.42 (C-1’); 65.30 (C-7a); 67.04 (CH2 
Bz); 67.42 (C-3); 128.14; 128.31; 128.56; 136.30 (Aryl); 156.01; 156.19; 171.99 
(CO).  ESI-MS m/z calcd per C22H31N3O4S [(M + H)
+








7.2 Pharmacology: GRK2 activity in rhodopsin phosphorylation assay 
To evaluate the effect of all synthesized derivatives on GRK2 activity we assessed 
GRK2 purified proteins by light-dependent phosphorylation of rhodopsin-
enriched rod outer segment membranes (ROS) using [g-
32
P]-ATP. Briefly, 50 ng 
of active GRK2 were incubated with ROS membranes in presence or absence of 
inhibitor molecules in reaction buffer (25 ml) containing 10 mM MgCl2, 20mM 
TriseCl, 2 mM EDTA, 5 mM EGTA, and 0.1 mM ATP and 10 mCi of [
32
P]g-
ATP. After incubation with white light for 15 min at room temperature, the 
reaction was quenched with ice-cold lysis buffer and centrifuged for 15 min at 
13000g. The pelleted material was resuspended in 35 mL protein gel loading dye, 
electrophoresed and resolved on SDSPAGE 4-12% gradient (Invitrogen), stained 
with Coomassie blue, destained, vacuum dried, and exposed for autoradiography. 
Phosphorylated rhodopsin was visualized by autoradiography of dried gels and 
quantified using a PhosphorImager (Molecular Dynamics). Alternatively, the ROS 
pellet was washed twice in ice-cold lysis buffer to remove the unbound [g
32
P]-
ATP and then resuspended in 100 mL of buffer and the level of [g
32
P]-ATP 
































A continuos flow procedure for the 



















The synthesis of organofluorine compounds has flourished because of the wide 
scope of their applications in biological and material sciences in recent 
years.
165,166
 Currently, the selective incorporation of fluorine atoms or fluorine-
containing moieties into organic molecules to modulate their biological properties 
has become a routine and powerful strategy in drug design. 
Difluoromethyl fuctionalized compounds in particular are employed because of 
their significantly increased lipophilicity, membrane permeability, aqueous 
solubility, and metabolic stability, as exemplified by the anesthetic Desflurane, 
anticancer Gemcitabine, lung desease drug Roflumilast, antiulcer Pantoprazole, 










Additionally the difluoromethyl group is known to be isosteric to a carbinol unit, 
which can act as a lipophilic hydrogen donor through weak hydrogen bonding 






The difluoromethyl compounds thus obtained are biologically and chemically 
important and, therefore, the introduction of the difluoromethyl functionality into 
organic compounds is of vital importance, as typically shown in difluoromethyl 
analogues of α-amino acids.
170
  
The difluoromethylornithine (DFMO), eflornithine is a mechanism-based 
inhibitor of ornithine decarboxylase, a pyridoxal-dependent key enzyme of the 
polyamines biosynthesis from ornithine. Fluorine atoms are essential for the 
inhibition process. Despite its very low bioavailability, eflornithine is the best 
therapy for sleeeping sickness (trypanosomiasis) in particular, at the cerebral stage 
due to Trypanosoma brucei gambiense parasite.
171
 Eflornithine is explored as 
anticancer agent, and it is in clinical use for the treatment of Pneumocystis carinii 
pneumonia, the most frequent opportunistic infection associated with the acquired 
immune deficiency syndrome (AIDS). 
172
 
Among the cheapest and most versatile reagents for direct CHF2-transfer is 
chlorodifluoromethane (CHF2Cl, Freon 22). Chlorodifluoromethane is produced 
on a massive scale, particularly for the production of fluoropolymers, and it is 
available at relatively little cost. With sufficiently strong bases, CHF2Cl can be 
deprotonated. The so-formed carbanion, chlorodifluoromethanide (CF2Cl-), 
immediately loses chloride to generate an electrophilic singlet difluorocarbene 
(CF2Cl- → CF2 + Cl-). The short-lived difluorocarbene can then be trapped with a 
suitably reactive nucleophilic species to produce the difluoromethylated product 




















However, CHF2Cl is a strong ozone depleting gas and its production and usage 
has become limited and expensive. Thus, the development of suitable methods for 
the generation of CHF2 group is of great practical significance. 
It is well known that the fluorine released in the form of fluorine radical and 
fluoride ion from stratospheric decomposition of fluorocarbons, such as CFCs, 
HCFCs and HFCs is entirely and rapidly converted to hydrogen fluoride and 
becomes inert to ozone.
176
 Many of the substitute HCFCs and HFCs contain 
trifluoromethyl groups and it was postulated that the trifluoromethyl radical (CF3), 
formed from decomposition of fluorocarbons is rapidly removed by oxidation 
processes and forms carbonyl difluoride and hydrogen fluoride, both of which are 
inert as far as ozone depletion is concerned.
177
 
For this reasons, recently, the use of fluoroform, a non ozone depleting gas, as 
source of difluorocarbene group was investigated. Fluoroform is a byproduct of 
Teflon manufacture, but if desired, it could readily be manufactured as a 
commodity chemical by fluorine/chlorine exchange of chloroform. Recently it had 
attracted little interest as a synthetic fluorinated building block reagent, in spite of 








2. Aim of the study 
During my PhD research semester abroad, at the University of Graz in the 
research group of Professor Oliver Kappe,  ’ve been involved in a project based 
on the use of fluoroform as source of difluorocarbene in the continuous flow 
synthesis of difluoromethyl compounds. Recent papers reported the fluoroform 
activation with alkali metal bases. Mikami and co-workers demostrated that 
fluoroform can be utilized for the direct difluoromethylation of lithium enolates 




The mechanism of the difluoromethylation reaction is believed to resemble that of 
the corresponding reaction with CHF2Cl. The direct α-difluoromethylation of 1 
with lithium enolates was recently demonstrated via C−F bond activation of 1 
(Figure 2). The proposed SN2 reaction involves the lithium enolate attacking a 
trifluoromethyl lithium species formed by the deprotonation of fluoroform. This 
may be possible because the interaction of the enolate lithium with the lithium 
carbenoid C-F bond is stronger than with the neutral fluoroform C-F bond. The 
leaving fluoride from the lithium carbenoid may be the driving force for SN2-











The research aim was to establish a scalable, continuous flow synthesis route to 
Cα-difluoromethyl amino acids using fluoroform as the reagent. Continuous 
processing techniques have had a significant impact in the development of more 
sustainable manufacturing routes for several pharmaceuticals.
183
 For gas-liquid 
reactions several specific advantages exist: high pressures operation and fast gas-
liquid mass transfer enhances availability of the gaseous reagent in the liquid 
phase.
184
 In addition, the gaseous reagent can be dosed into the liquid phase with 
precise stoichiometry using mass flow controllers. 
Cα-Difluoromethyl amino acids are potent and selective irreversible inhibitors of 
their respective α-amino acid decarboxylases.
185
 Representatives of this class of 
compounds exhibit a broad spectrum of biological activities, such as antibacterial, 
antihypertensive, cancerostatic, and cytotoxic activity. Two different strategies 
can be employed for the generation of Cα-difluoromethyl amino acids: 
195 
 
construction of the amino acid from fluorine-containing building blocks (e.g. α-
difluoromethyl malonates)
170b
, or direct substitution of the α-hydrogen of amino 
acids with a CHF2 moiety (Scheme 2). The direct Cα-difluoromethylation of 
Schiff base-protected α-amino acid methyl esters with CHF2Cl as the reagent has 
been demonstrated by Bey and others.
186
 
α-Difluoromethylation of protected amino acids with CHF3 is currently not 
reported. Indeed, the protocol described herein is, to the best of our knowledge, 
the first example where fluoroform is utilized for the preparation of  α-
difluoromethyl aminoacids starting from the parent one. 
 
 



















The first preliminary batch experiments were performed using diethyl 
phenylmalonate (1a) as starting material (Table 1). The malonate was dissolved in 
THF and the base was added. After stirring the mixture for a few minutes at the 
indicated temperatures (t1, T1 in Table 1), fluoroform was slowly passed through 
the reaction mixture under vigorous stirring (t2, T2 in Table 1). Using 
phenylmalonate 1a as substrate, no product was obtained with nBuLi, LDA or 
tBuOK as base (entries 1 to 5 in Table 1). We observed no difluoromethylated 
product using Dolbier and co-workers method (entry 7 in Table 1) 
187
. According 
to Dolbier’s procedure  the phenylmalonate 1a is stirred in aqueous KOH for 30 
min at room temperature. MeCN or dioxane is then added and fluoroform is 
bubbled through the solution. Small amounts of the desired product were formed 
using LiHMDS as base (entry 6 in Table 1). Mikami and co-workers have already 
shown that fluoroform in combination with LiHMDS can be utilized for the direct 
difluoromethylation of cyclic amides, cyclic and open esters, and certain simple 
malonates. According to the authors, the reaction proceeds best with 2 equiv of 
base and 5 equiv of CHF3. Reaction times of 6 to 48 h at temperatures of 0 to 25 































































30 25 120 25 32d 0 
  
a Conditions: 0.5 mmol diethyl phenylmalonate 1a in 0.5 mL 
THF, base, CHF3 (balloon). 
b analyzed by HPLC-UV/VIS at 215 
nm. c method B in ref 9a. d 20% ethyl phenylacetate (by 
hydrolysis and decarboxylation). 
 
Encouraged by this result, a continuous flow protocol was developed. The initial 
flow setup consisted of two continuous syringe pumps to introduce (i) a 0.5 M 
solution of  substrate in THF (Feed A, Table 2), and (ii) a commercial solution of 
LiHMDS (Feed B, Table 2). The two feeds were mixed in a Y-shaped connector 
in a cooling bath. The substrate was deprotonated in a 2 mL residence loop 
(reactor 1), before the mixture was combined with fluoroform in a second Y-
shaped connector in a second cooling bath. The flow rate of the fluoroform stream 
was controlled using a calibrated mass flow controller (MFC). The combined 
mixture then went through a second cooled residence loop (reactor 2) and left the 
flow system through a third residence loop at room temperature (reactor 3) and an 
adjustable back pressure regulator. With pressures of ~5 bar and temperatures 
below ~ 25 °C for reactor 2, the fluoroform dissolved completely in the liquid 
feed. At higher temperatures at this pressure, distinct gas-liquid segments 
wereevidenced. The processed reaction mixture was finally collected in a quench 




F-NMR. Methyl diphenylacetate 1b was used as the model substrate for the 
initial optimization. With flow rates of 300 µL/min for Feed A, 200 µL/min for 
Feed B and 8.3 mL/min for fluoroform, a stoichiometry of 1:1.3:2.5 for 
substrate/LiHMDS/CHF3 and a total residence time of ~20 min was obtained. The 
flow reactions clearly revealed that the conversion increased with decreasing 
temperature and increasing pressure (Table 2). Also the selectivity increased 
slightly with decreasing temperatures (Table 2). As already observed by Mikami 
and co-workers, the best results are obtained with 2 equiv of base. Also, for 
fluoroform, 2 to 3 equiv were identified as the ideal amount. 
 















1 40 5 63 81 
2 25 5 65 80 
3 -10 5 82 88 
4 -15 10 86 91 
5 -15 12 92 91 
 
a Conditions: Feed A: 0.5 M diethyl phenylmalonate 1b in THF; Feed B: 1 
M LiHMDS in THF; with flow rates for Feed A/Feed B/CHF3 = 0.30 : 0.20 : 
8.3 mL/min, respectively, the following conditions were obtained: LiHMDS 
(1.33 equiv); CHF3 (2.5 equiv). 
b analyzed by GC-FID. 
 
The general reaction conditions were suitable for a variety of substrates (Figure 
2). Malonates with sterically benign alkyl groups in the α-position performed 
particularly well (1d to 1f in Figure 2), while the phenyl derivative 1a resulted in 
low conversion. The reaction was remarkably clean, with unreacted substrate and 
tris(trimethylsilyl)amine being the only contamination in the crude mixture after 
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washing with water. The analytically pure compounds were isolated by 
preparative thin-layer chromatography (TLC). The yield for the diethyl 
methylmalonate 2e was the same as previously reported for the batch protocol, 
even though the reaction time for the present procedure was significantly shorter 
(20 min vs 20 h for the batch procedure). The yield for product 2b was lower than 
that reported for the batch procedure (39% vs 78% according 
19
F-NMR). The 
other difluoromethylated compounds prepared in this work have not been 
previously reported. 
Based on the obtained results we decided to investigate the application of this 
procedure to Schiff base-protected α-amino acid methyl esters. The N-
benzylidene-protected α-amino acid methyl esters were readily available from the 
parent amino esters using literature procedures 
188
. Gratifyingly, when the N-
benzylidene-protected α-amino acid methyl esters 1g to 1k was subjected to the 
general reaction conditions resulted in >95% conversion to the desired product. 
Indeed, the reaction was remarkably clean with only one CHF2-moiety (two 
doublets of doublets) detectable in the 
19
F-NMR spectra of the crude reaction 
mixtures. Difluoromethylation on the imine carbon, a side reaction typically 
encountered in reactions with CHF2Cl as reagent, was not observed. Due to the 
instability of the Schiff base to hydrolysis, isolation of the intermediate products 
was not attempted. Instead, the N-benzylidene- and the O-methyl- protecting 
group were directly removed by heating the crude product in 6N HCl in a 
microwave batch autoclave (150 °C for 45 min). The released benzaldehyde was 
removed by extracting with ether and the aqueous phase was concentrated. After 
recrystallization from MeOH/EtOH, the Cα-difluoromethyl amino acids were 
obtained as their monohydrochloride salts (dihydrochloride salt for product 2k). 
The yields were above 70% for all tested amino acids over the two reaction steps, 
i.e. difluoromethylation and deprotection (Figure 3). 
Importantly, eflornithine (2g) was isolated in 76% yield after the two reaction 
steps. The yield of eflornithine for the present chromatography-free method is 
significantly higher than that previously reported for the less desirable process 



























F-NMR yields (trifluorotoluene as internal 
standard); isolated yields (TLC) in parentheses.  
b
 isolation was not attempted.
 c
 isolated yields after 2 steps 
(C
α
















During my PhD course I spent a semester at the University of Graz laboratories, 
where I took part to a research project concerning the use of fluoroform as source 
of difluorocarbene in the continuous flow synthesis of difluoromethyl compounds. 
In detail, the project concerned the design of a gas–liquid continuous flow 
difluoromethylation protocol employing fluoroform as a reagent. The developed 
protocol allows this reaction to be performed within very short reaction times. 
Importantly, the protocol allows the direct Cα-difluoromethylation of  protected  
α-amino acids. These compounds are highly selective and potent inhibitors of 
pyridoxal phosphate-dependent decarboxylases. The starting materials are 
conveniently obtained from the commercially available α-amino acid methyl 
esters, and the final products are synthesized in excellent yields and high purities 
after hydrolysis and precipitation. The developed process appears to be especially 
appealing for industrial applications, where atom economy, sustainability, reagent 





















C NMR spectra were recorded on a 300 MHz instrument. Chemical 
shifts (δ) are expressed in ppm downfield from TMS as an internal standard. The 
letters s, d, t, q, and m are used to indicate singlet, doublet, triplet, quadruplet, and 
multiplet, respectively. Analytical HPLC analysis were carried out on a Shimadzu 
LC20-AD chromatograph equipped with a C18 reversed-phase (RP) analytical 
column (150 x 4.6mm, particle size 5 μm) at 37 °C using a mobile phase A 
(water/acetonitrile 90:10 (v/v) + 0.1% TFA) and B (acetonitrile + 0.1% TFA) at a 
flow rate of 1.5 mL/min. The following gradient was applied: linear increase from 
solution 3% B to 25% in 9 minutes, 25% B to 80% in 7 min hold at 80% B for 1 
minute. Low resolution mass spectra were obtained on a LC-MS instrument using 
electrospray ionization (ESI) in positive or negative mode (Shimadzu LCMS-
2020). All chemicals, solvents, catalysts, and ligands were obtained from known 
commercial suppliers and were used without any further purification. Microwave 
reactions were carried out in a Biotage Initiator+ single-mode microwave 
instrument. Reaction times refer to hold times at the temperatures indicated, not to 
total irradiation times. The temperature was measured with an IR sensor on the 
outside of the reaction vessel. Thin-layer chromatography was performed on tlc 











General procedure for continuous flow difluoromethylation of malonates 
derivatives (2a-2f). 
 




The flow setup consisted of two continuous syringe pumps (Asia Syrris) to 
introduce (i) a solution of  substrate in THF (Feed A), and (ii) a commercial 
solution of LiHMDS (1.0 M in THF, Sigma-Aldrich); Feed B). Injection loops 
(perfluoroalkoxy alkanes (PFA), 0.8 mm i.d., 1.59 mm o.d.; internal volume: 2.0 
mL (Feed A) and 2.5 mL (Feed B)) were used to deliver the two feeds. To start 
the experiment, the complete reactor setup was flushed by pumping dry THF with 
flow rates of Feed A = 250 μL/min and Feed B = 250 μL/min. Fluoroform was 
introduced into the reactor with a flow rate of 8.3 mL/min using a calibrated 
Bronkhorst mass flow controller (MFC). The internal pressure of the reactor 
reached the target pressure of 12 bar after approximately 10 min. Substrate (1.00 
mmol) was dissolved in neat THF and diluted to 2.00 mL in a volumetric flask 
with THF (Feed A). A LiHMDS solution (1.0 M, 2.5 mL) in THF was used as 
Feed B. Both solutions were loaded into their corresponding injection loops. Feed 
A and Feed B were pumped from the injection loops in a Y-shaped connector (Y 
Assembly PEEK 1/4-28 0.040in) in a cooling bath (-30 °C). The combined 
mixture went through a first residence loop at -30 °C (1/16 in. o.d.; 0.8 mm i.d.; 
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residence volume V1 = 2.0 mL), before the mixture was combined with 
fluoroform in a second Y-shaped connector (Y Assembly PEEK 1/4-28 .040in) in 
a second cooling bath (-15 °C). The combined mixture then went through a 
second residence loop (1/16 in. o.d.; 0.8 mm i.d.; residence volume V2 = 6.1 mL) 
and left the flow system through a third residence loop at room temperature (1/8 
in. o.d.; 1.6 mm i.d.; residence volume V3 = 2.0 mL) and an adjustable back 
pressure regulator (Swagelok KCB1H0A2A5P60000, 0–26 bar). The product 
mixtures were collected and the solvent removed in vacuo. The products were 
isolated by thin layer chromatography using dichloromethane/hexane as eluent. 
Methyl 3,3-(difluoro)-2,2-diphenylpropanoate (2a). 
Yield: 173 mg (0.62 mmol, 62%); 93% by 
19
F NMR; light yellow viscous liquid. 
1
H NMR (300 MHz, D2O): δ = 7.45 – 7.19 (m, 10H), 6.90 (t, 
2
JHF = 55.0 Hz, 1H), 
3.79 (s, 3H). 
13
C NMR (75 MHz, D2O): δ = 171.1, 136.3, 129.8, 128.3, 128.2, 
115.6 (t, 
1
JCF = 246.2 Hz), 64.7, 53.1.
19
F NMR (282 MHz, D2O):δ = -123.0 (d, 
2
JHF = 55.0 Hz). 
Diethyl 2-(difluoromethyl)-2-phenylmalonate (2b). 
Yield: 21 mg (0.07 mmol, 7%); 7% by 
19
F NMR; light yellow viscous liquid. 
1
H 
NMR (300 MHz, D2O): δ = 7.45 – 7.31 (m, 5H), 6.56 (t, 
2
JHF = 54.9 Hz, 1H), 
4.44 – 4.32 (m, 4H), 1.33 (t, 
3
JHH = 7.1 Hz, 6H).
13
C NMR (75 MHz, D2O): 
δ = 166.2, 129.5, 128.8, 128.3, 114.2 (t, 
1
JCF = 251.6 Hz), 62.8, 14.1.
19
F NMR 
(282 MHz, D2O):δ = -123.57 (d, 
2
JHF = 55.0 Hz). 
Diethyl 2-(difluoromethyl)-2-phenylmalonate (2c). 




H NMR (300 MHz, D2O): δ = 7.42 – 7.31 (m, 5H), 
6.38 (dd, 
2
JHF = 56.0, 55.4 Hz, 1H), 3.75 (s, 3H), 1.71 (s, 3H). 
13
C NMR (75 MHz, 
D2O): δ = 136.6, 129.0, 128.3, 126.7, 116.7 (dd, 
1
JCF = 247.1, 245.5 Hz), 54.8, 
52.8, 14.7.
19
F NMR (282 MHz, D2O): δ = -124.48 (dd, 
2
JFF = 277.0, 
2
JHF = 55.3 
Hz), -129.91 (dd, 
2
JFF = 277.1, 
2




Dimethyl 2-(difluoromethyl)-2-ethylmalonate (2d). 
Yield: 172 mg (0.82 mmol, 82%); 93% by 
19
F NMR ;light yellow viscous liquid. 
1
H NMR (300 MHz, D2O): δ = 6.28 (t, 
2
JHF = 54.6 Hz, 1H), 3.79 (s, 6H), 2.14 (q, 
3
JHH = 7.5 Hz, 2H), 1.01 (t, 
3
JHH = 7.5 Hz, 3H).
13
C NMR (75 MHz, 
D2O):δ = 167.3 (t, 
3
JCF = 4.4 Hz), 115.1 (t, 
1
JCF = 247.9 Hz), 62.0 (t, 
2
JCF = 21.2 
Hz), 53.2, 23.0 (t, 
3
JCF = 2.9 Hz), 9.4 (t, 
3
JCF = 1.6 Hz).
19
F NMR (282 MHz, 
D2O):δ = -126.18 (d, 
2
JHF = 54.6 Hz). 
Diethyl 2-(difluoromethyl)-2-methylmalonate (2e). 
Yield: 82% by 
19
F NMR; light yellow viscous liquid. 
1
H NMR (300 MHz, D2O): 
δ = 6.32 (t, 
2
JHF = 55.4 Hz, 1H), 4.21 (q, 
3
JHH = 7.1 Hz, 4H), 1.50 (s, 3H), 1.24 (t, 
3
JHH = 7.1 Hz, 6H).
13
C NMR (75 MHz, D2O):δ = 167.0 (t, 
3
JCF = 4.9 Hz), 114.6 
(t, 
1
JCF = 246.2 Hz), 62.4, 58.3 (t, 
2
JCF = 22.7 Hz), 13.9, 12.1 (t, 
3
JCF = 4.0 Hz).
19
F 
NMR (282 MHz, D2O): δ = -128.32 (d, 
2
JHF = 55.4 Hz). 
Diethyl 2-(difluoromethyl)-2-propylmalonate (2f).  




H NMR (300 MHz, D2O): δ = 6.27 (t, 
2
JHF = 54.7 Hz, 
1H), 4.25 (q, 
3
JHH = 7.1 Hz, 4H), 2.07 – 1.98 (m, 2H), 1.49 – 1.33 (m, 2H), 1.27 
(t, 
3
JHH = 7.1 Hz, 6H), 0.95 (t, 
3
JHH = 7.3 Hz, 3H). 
13
C NMR (75 MHz, D2O): 
δ = 166.8 (t, 
3
JCF = 4.5 Hz), 115.1 (t, 
1
JCF = 247.7 Hz), 62.0, 61.6, 31.4 (t, 
3
JCF = 2.4 Hz), 18.0, 14.6, 14.0.
19
F NMR (282 MHz, D2O):δ = -126.10 (d, 
2
JHF = 54.7 Hz). 
General procedure for continuous flow difluoromethylation of aminoacid 
derivatives (2g-2k). 
The aminoacid derivatives were synthesized according to Scheme 3. Then the 
reaction mixture was concentrated in vacuo and diluted with 10 mL Et2O. After 
filtration the filtrate was concentrated in vacuo and treated with 10 mL 6N HCl. 
The reaction mixture was heated to 150 °C for 45 min in a microwave reactor and 
washed with Et2O (2x20 mL). The aqueous layer was mixed with activated carbon 
which was subsequently filtered off. After concentrating the crude product in 




Yield: 151 mg (0.86 mmol, 86%); colourless powder. mp 272 °C; 
1
H NMR 
(300 MHz, D2O): δ =  6.32 (t, 
2
JHF = 53.1 Hz, 1H), 1.60 (s, 3H).
13
C NMR 
(75 MHz, D2O): δ =  169.2 (d, 
3
JCF = 6.2 Hz), 114.3 (dd, 
1
JCF = 249.1 Hz,
1
JCF = 246.0 Hz), 61.4 (dd, 
2
JCF = 20.9 Hz, 
2
JCF = 19.3 Hz), 16.8 
(dd, 
3
JCF = 4.6 Hz, 
3
JCF = 2.1 Hz).
19
F NMR (282 MHz, D2O):δ = -126.77 (dd, 
2
JFF = 281.4, 
2
JHF = 52.7 Hz), -133.44 (dd, 
2
JFF = 281.6, 
2
JHF = 53.4 Hz). 
α-Difluoromethylvaline hydrochloride (2h). 
Yield: 155 mg (0.76 mmol, 76%);colourless powder. mp 272-282 °C; 
1
HNMR 
(300 MHz, D2O): δ =  6.47 (t, 
2
JHF = 52.8 Hz, 1H), 2.33 (h, 
3
JHH = 6.9 Hz, 1H), 
1.07 (d, 
3
JHH = 6.9 Hz, 3H), 1.02 (d, 
3
JHH = 6.9 Hz, 3H).
13
C NMR (75 MHz, 
D2O): δ =  168.7, 114.8 (dd, 
1
JCF = 249.0 Hz, 
2
JCF = 244.3 Hz), 68.5 (t, 
2
JCF = 17.5 Hz), 30.30 (d, 
3
JCF = 4.3 Hz), 16.6, 15.9.
19
F NMR (282 MHz, 
D2O):δ = -126.46 (dd, 
2
JFF = 283.9, 
2
JHF = 52.3 Hz), -130.72 (dd, 
2
JFF = 281.6, 
2
JHF = 53.3 Hz). 
α-Difluoromethylleucine hydrochloride (2i). 
Yield: 189 mg (0.87 mmol, 87%); colourless powder. mp 242-243 °C; 
1
HNMR 
(300 MHz, D2O): δ =  6.21 (t, 
2
JHF = 53.4 Hz, 1H), 1.97-1.84 (m, 1H), 1.07 (m, 
2H), 0.93(d, 
3
JHH = 6.5 Hz, 3H), 0.89(d, 
3
JHH = 6.5 Hz, 3H).
13
C NMR (75 MHz, 
D2O): δ = 170.0 (d, 
3
JCF = 5.0 Hz), 115.3 (dd, 
1
JCF = 249.1 Hz, 
1
JCF = 246.3 Hz), 
65.3 (dd,
2
JCF = 20.3 Hz,
2
JCF = 16.2 Hz), 38.7 (d, 
3
JCF = 2.3 Hz), 23.5, 22.9, 21.4. 
19
F NMR (282 MHz, D2O):δ = -127.14 (dd, 
2
JFF = 277.9, 
2
JHF = 53.0 Hz), -132.73 
(dd, 
2
JFF = 277.9, 
2
JHF = 53.9 Hz). 
α-Difluoromethylphenylalaninehydrochloride (2j). 
Yield: 216 mg (0.86 mmol, 86%); colourless powder. mp 245 °C; 
1
HNMR 
(300.36 MHz, D2O): δ =  7.40-7.32 (m, 3H), 7.26-7.20 (m, 2H), 6.39 (t, 
2
JHF = 53.1 Hz, 1H), 3.44 (d, 
2
JHH = 14.3 Hz, 1H)), 3.06 (d, 
2
JHH = 14.3 Hz, 
1H).
13
C NMR (75 MHz, D2O):δ = 168.6 (d, 
3
JCF = 5.9 Hz), 131.5 130.1, 129.2, 
128.4, 114.8 (dd, 
1
JCF = 249.0 Hz, 
1





JCF = 20.3 Hz,
2
JCF = 16.9 Hz), 36.5 (d, 
3
JCF = 2.8 Hz).
19
F NMR (282 MHz, 
D2O): δ = -127.01 (dd, 
2
JFF = 280.8, 
2
JHF = 52.6 Hz), -132.02 (dd, 
2
JFF = 280.8, 
2
JHF = 53.6 Hz).  
α-Difluoromethylornithinedihydrochloride (2k). 
Yield: 194 mg (0.76 mmol, 76%) colourless powder. mp 228 °C; 
1
H-NMR 
(300.36 MHz, D2O): δ = 6.33 (t, 
2
JHF = 53.2 Hz, 1H), 3.02 (t,
3
JHH = 7.6 Hz, 2H), 
2.16-1.53 (m, 4H).
13
C NMR (75 MHz, D2O): δ = 168.8 (d, 
3
JCF = 5.9 Hz), 114.9 
(dd, 
1
JCF = 248.4 Hz, 
1
JCF = 246.0 Hz), 65.1 (dd, 
2
JCF = 21.3 Hz, 
2
JCF = 16.6 Hz), 
38.7, 27.7 (d, 
3
JCF = 5.0 Hz), 20.9.
19
F NMR (282 MHz, D2O): δ = 126.83 (dd, 
2
JFF = 281.6 Hz, 
2
JHF = 52.6 Hz), -132.39 (dd, 
2
JFF = 281.6 Hz, 
2
JHF = 53.8 Hz). 





A dry 20 mL vessel with magnetic stirring bar was charged with 1 eq of amino 
acid ester hydrochloride (1g to 1k), sealed and flushed with argon three times. 
CHCl3 was added to afford a 1 M solution followed by the addition of 
0.99 eq (1.99 eq in case of ornithine (1k)) of benzaldehyde. The resulting stirred 
solution was cooled to 0 °C. After adding 1.1 eq (2.2 eq in case of ornithine (1k)) 
of triethylamine over 10 min, the mixture was gradually warmed to room 
temperature and stirred for 24 h. The reaction mixture was filtered through 
Na2SO4 and the obtained light yellow filtrate was concentrated under vacuo and 
treated with Et2O to precipitate Et3N∙ Cl. The formed colourless precipitate was 
filtered off and the obtained filtrate was concentrated in vacuo to give the 




Methyl (S)-2-(benzylideneamino)propanoate (1g). 
970 mg (6.95 mmol, 1.0 eq) L-Alanine methyl ester hydrochloride, 700 µL 
(6.88 mmol, 0.99 eq) benzaldehyde, 1.06 mL (7.65 mmol, 1.1 eq) triethylamine 
and 7 mL CHCl3. Yield: 1.289 g (6.74 mmol, 97%), yellow viscous oil. 
1
H-NMR 
(300 MHz, CDCl3): δ = 8.31 (s, 1H), 7.81-7.74 (m, 2H), 7.48-7.38 (m, 3H), 4.16 
(q, 
3
JHH = 6.8 Hz, 1H), 3.75 (s, 3H), 1.53 (d, 
3
JHH = 6.8 Hz, 3H). 
13
C NMR 
(75 MHz, CDCl3): δ = 173.1, 163.1, 135.8, 131.3, 128.7, 128.6, 68.2, 52.4, 19.6. 
Methyl (S)-2-(benzylideneamino)-3-methylbutanoate (1h). 
1.165 g (6.95 mmol, 1.0 eq) L-Valine methyl ester hydrochloride, 700 µL 
(6.88 mmol, 0.99 eq) benzaldehyde, 1.06 mL (7.65 mmol, 1.1 eq) triethylamine 
and 7 mL CHCl3. Yield: 1.4925 g (6.80 mmol, 98%), yellow viscous oil. 
1
H-NMR 
(300 MHz, CDCl3): δ = 8.24 (s, 1H), 7.83 – 7.74 (m, 2H), 7.46 – 7.36 (m, 3H), 
3.75 (s, 3H), 3.67 (d, 
3
JHH = 7.3 Hz, 1H), 2.39 (dq, 
3
JHH = 13.7, 
3
JHH = 6.8 Hz, 
1H), 0.95 (dd, 
3
JHH = 8.9, 6.8 Hz, 6H).
13
C NMR (75 MHz, CDCl3): δ =  172.6, 
163.4, 135.8, 131.2, 128.7, 128.7, 80.6, 52.1, 31.9, 19.6, 18.8. 
Methyl (S)-2-(benzylideneamino)-4-methylpentanoate (1i). 
1.271 g (7.00 mmol, 1.0 eq) L-Leucine methyl ester hydrochloride, 706 µL 
(6.93 mmol, 0.99 eq) benzaldehyde, 1.07 mL (7.70 mmol, 1.2 eq) triethylamine 
and 7 mL CHCl3. Yield: 1.609 g (6.90 mmol, 99%), yellow viscous oil. 
1
H-NMR 
(300 MHz, CDCl3): δ = 8.23 (s, 1H), 7.76 – 7.70 (m, 2H), 7.36 – 7.29 (m, 3H), 
4.05 (dd, 
3
JHH = 8.5, 5.9 Hz, 1H), 3.65 (s, 3H), 1.90 - 1.73 (m, 2H), 1.61 – 1.46 
(m, 1H), 0.87 (dd, 
3
JHH = 14.1, 6.6 Hz, 6H).
13
C NMR (75 MHz, CDCl3): 
δ = 172.5, 162.9, 135.5, 130.9, 128.4, 128.3, 71.3, 51.8, 41.9, 24.2, 23.0, 21.2. 
Methyl (S)-2-(benzylideneamino)-3-phenylpropanoate (1j). 
1.500 g (6.95 mmol, 1.0 eq) L-Phenylalanine methyl ester hydrochloride, 700 µL 
(6.88 mmol, 0.99 eq) benzaldehyde, 1.06 mL (7.65 mmol, 1.1 eq) triethylamine 
and 7 mL CHCl3. Yield: 1.7831 g (6.67 mmol, 96%), yellow viscous oil. 
1
H-NMR 
(300 MHz, CDCl3): δ = 7.92 (s, 1H), 7.72-7.66 (m, 2H), 7.45-7.35 (m, 3H), 
7.28-7.14 (m, 5H), 4.18 (dd, 
3




JHH = 13.5, 
3
JHH = 5.1 Hz, 1H), 3.16 (dd, 
2
JHH = 13.5, 
3
JHH = 8.9 Hz, 1H).
13
C 
NMR (75 MHz, CDCl3): δ = 172.2, 163.9, 137.5, 135.6, 131.2, 129.9, 128.6, 
128.6, 128.4, 126.7, 75.2, 52.4, 39.9. 
Methyl (S)-2,5-bis((benzylidene)amino)pentanoate (1k). 
1.530 g (7.00 mmol, 1.0 eq) L-Ornithine methyl ester dihydrochloride, 1.42 mL 
(13.93 mmol, 1.99 eq) benzaldehyde, 2.13 mL (15.4 mmol, 2.2 eq) triethylamine 
and 7 mL CHCl3. Yield: 2.2136 g (6.87 mmol, 98%), yellow viscous oil. 
1
H-NMR 
(300 MHz, CDCl3): δ = 7.68-7.56 (m, 4H), 7.47-7.29 (m, 12H), 7.20-7.08 (m, 
4H), 4.10 (dd,
3
JHH = 8.0 Hz, 
3
JHH = 5.2 Hz, 1H), 3.71 (s, 3H), 3.33 (t, 
3
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